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Abstract  
Author: Elizabeth Gargon 
Thesis title: Developing the agenda for core outcome set development  
Introduction and aims 
A core outcome set (COS) is defined as an agreed standardised set of outcomes that should be 
measured and reported, as a minimum, in all clinical trials in specific areas of health or health care. 
Their use allows research to be compared and combined as appropriate, and may ensure that all 
studies provide usable information. There is currently no accepted gold standard method for COS 
development and further work was necessary to explore choices about methods, and what the 
priorities are for guidance and further research in this area. This thesis aimed to investigate what is 
currently known about COS development, and explore developers’ experiences of developing COS.  
 
Methods 
A systematic review of studies reporting the development of a COS was undertaken, and the 
methodological techniques used in these studies was described.  A mixed methods approach was 
undertaken to explore COS development, drawing on qualitative interviews with, and an online web-
based survey of, COS developers.  This thesis used a Triangulation Design to obtain different but 
complementary data on the same topic for comprehensiveness.  
 
Results  
The systematic review identified 198 published studies that described the development of COS for 
clinical trials. The systematic review demonstrated variability in the ways that COS had been 
developed, particularly the methods used and the stakeholders included as participants in the 
process. Patient participants had infrequently been included in the development of COS (18%). Key 
aspects of the process were frequently not reported.  
Eighty-one (48%) developers completed the survey. The majority of survey respondents (73%) felt 
that there is a need for methodological guidance or research to inform future activity to develop 
COS. Areas for future guidance or research included: stakeholder involvement, patient involvement 
in particular; choice of methodology, and consensus formation. 
32 interviews were conducted with COS developers (18 with published, and 14 with ongoing, COS 
projects). Developers found the process of COS development to be a challenging process, in part due 
to the nature of COS development being an emerging field of research, but also in part to not always 
considering important methodological details from the outset, for example their choice of methods 
and stakeholders. There was a variety of influences on developers’ choice of methods, which 
included the previous literature on COS development, expert advice, developers’ own experience 
with methods and the resources available to developers. The absence of guidance in COS 
development, and the prominence of uncertainties, dominated developers’ accounts. 
 
Conclusions  
The work in this thesis has brought COS together in one place for the first time, summarises key 
characteristics of COS and their development, and provides the first comprehensive account of COS 
development. It will inform the development of much needed guidance in this area and help to 
improve COS development methodology. Guidance needs to determine commonalities across 
different disease areas, and promote awareness of important issues; encourage COS developers to 
think about their own contexts and circumstances, and enable COS developers to make decisions 
about methods that best suit their needs and resources. Guidance seems to be needed for all 
aspects of COS development, but it was particularly felt that guidance around the systematic review 
process, conduct of Delphi, and conduct of consensus meetings, are high priority. 
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Chapter 1: Introduction   
 
1.1 Clinical trials  
Clinical trials are research studies undertaken for the purpose of assessing the safety and 
efficacy of interventions, treatments or care procedures. The focus of the work in this 
thesis is clinical trials with human beings.  Randomised controlled trials (RCTs) are seen as 
the gold standard in evaluating the effects of treatments [1], largely due to the 
randomisation of treatment allocation in an RCT. This prevents selection bias by 
distributing the characteristics of patients that may influence assessment of treatment 
between groups, hence allowing an unbiased assessment of treatment effect [2]. Clinical 
trial data has many uses, including to inform clinical guidelines and shared decision making 
practices; labeling to provide information that is most useful to prescribes in treating 
patients [3], and in the development of health policies such as those by The National 
Institute for Health and Clinical Excellence (NICE) [4].  
 
Researchers, clinicians and policymakers often distinguish between the efficacy and the 
effectiveness of an intervention. Whereas efficacy trials (also described as explanatory 
trials) determine whether an intervention can have a beneficial effect in an ideal situation 
under optimum conditions [5], effectiveness trials (also described as pragmatic trials) 
measure the degree of beneficial effect under “real world” clinical settings. In contrast to 
an efficacy trial, an effectiveness trial will usually be conducted following as close to clinical 
practice as possible [6]. Design of effectiveness trials are therefore based on conditions of, 
and with consideration to, routine clinical practice and clinical decision making. Efficacy 
trials tend to precede effectiveness trials,  and although it is preferential to distinguish 
between efficacy and effectiveness trials, in reality they exist on a continuum [1], often 
making it difficult to separate the two as distinct phases of research. The focus of this thesis 
hereon in will be effectiveness trials.     
 
1.2 Outcomes in trials  
There are three basic components of RCTs [7]: 
1. at least one test treatment and a comparator treatment; 
2 
 
2. randomisation of persons to treatment,  
3. outcome measure(s). 
 
It is the third component that is the focus of this thesis. Broadly, in the context of clinical 
trials, an outcome is defined to be a measurement or observation used to capture and 
assess the effect of treatment, such as assessment of side effects (risk) or benefits. When 
designing a clinical trial, the PICO format is often used to formulate a research question. A 
‘well-built’ question should include four parts; that is identifying the patient problem or 
population (P), the intervention (I), the comparator (C) and the outcomes of interest (O) 
[8]. In a randomised trial, differences between the groups in outcomes can be inferred to 
be as a result of the differing interventions. Therefore the selection, measurement and 
reporting of important, relevant and appropriate outcomes are critical.  
 
Clinical trials will usually include multiple outcomes of interest, and the main outcomes are 
usually those essential for decision making. Some outcomes will be of more interest than 
others. The primary outcome should be the outcome deemed most capable of providing 
clinically relevant evidence directly related to the objective of the trial [9]. The primary 
outcome is the outcome considered to be of greatest importance to relevant stakeholders 
(such as patients, clinicians, policy makers, funders, researchers). It often represents the 
greatest therapeutic benefit [10], is an integral component of the research question under 
investigation and is usually the one used in the sample size calculation [11]. Sometimes 
researchers propose more than one primary outcome if they are thought to be of equal 
therapeutic importance and relevance to the research question. This can also be useful if it 
is unclear which single primary outcome will best answer the question. However, 
consideration should be given to the effect on the type 1 error (the incorrect rejection of a 
true null hypothesis) because of the potential for multiplicity problems, for example the 
extent of intercorrelation among the proposed primary outcomes [9].  
 
Secondary outcomes evaluate other beneficial or harmful effects of secondary importance 
or are useful for explaining additional effects of the intervention [12]. Secondary outcomes 
may also be exploratory in nature. Harmful effects should always be viewed as important 
regardless of their primary or secondary outcome label [11]. 
 
3 
 
 A variety of different types of outcomes can be measured in trials, and researchers must 
decide which of these to measure. As well as the importance of an outcome to relevant 
stakeholders, researchers must consider an array of information including how responsive 
it is to the interventions being compared and the appropriateness to the trial, for example 
the financial cost associated with that outcome. The decision is made more complex by the 
numerous types of outcomes that exist, and researchers must decide which of these types 
of outcomes is most appropriate for both the question under investigation and the specific 
context of the clinical trial. For example, a clinical outcome describes a medical event(s) 
that occurs as a result of disease or treatment [13], and relates to a patient’s symptoms, 
overall mental state or how the patient functions. In contrast, a surrogate end point is used 
as a substitute for a clinical outcome [14] and has been defined as a biomarker intended to 
substitute for a clinical outcome [15]; an example would be prostatic specific antigen (PSA) 
in prostate cancer. A biomarker is a medical sign, typically used in earlier phase trials, used 
to predict biological processes.  Examples of biomarkers include everything from pulse and 
blood pressure through basic chemistries to more complex laboratory tests of blood and 
other tissues [16].  
 
In addition to deciding what to measure, Zarin et al (Figure 1) describe that a fully specified 
outcome measure includes information about the following [17]: domain (e.g. anxiety), 
that is what to measure; specific measurement (e.g. Hamilton Anxiety Rating Scale), that is 
how to measure that outcome/domain; the specific metric used to characterise each 
participant’s results (e.g. change from baseline at specified time), and method of 
aggregation (e.g. a categorical measure such as proportion of participants with a decrease 
greater than 50%).  
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Figure 1: An example of the four levels of specification in reporting outcome measures 
 
Reproduced with permission from Zarin, D. A., T. Tse, et al. (2011). "The ClinicalTrials.gov results database-
update and key issues." N Engl J Med 364(9): 852-860., Copyright Massachusetts Medical Society. 
 
Furthermore, outcomes can also be measured in different ways. Some clinical outcomes 
are composed of a combination of items, and are referred to as composite outcomes. A 
composite outcome combines two or more components into a single measure [18]. 
Outcomes can be objective, that is not subject to a large degree of individual 
interpretation, and these are likely to be reliably measured across patients in a study, by 
different health care providers, and over time. Laboratory tests may be considered 
objective measures in most cases. Outcomes may also be considered to be subjective. Most 
clinical outcomes involve varying degrees of subjectivity, for example a diagnosis or 
assessment by a health care provider, carer or the patient themselves. A clinician reported 
outcome is an assessment that is determined by an observer with some recognised 
professional training that is relevant to the measurement being made. In contrast, an 
observer reported outcome is an assessment that is determined by an observer who does 
not have a background of professional training that is relevant to the measurement being 
made, i.e., a non-clinician observer such as a teacher or caregiver. This type of assessment 
is often used when the patient is unable to self-report (e.g., infants, young children). 
Finally, a patient reported outcome is a measurement based on a report that comes 
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directly from the patient (i.e., the study participant) about the status of particular aspects 
of, or events related to, a patient’s health condition [13]. 
 
 
1.3 Outcome domains  
Outcome domains are constructs which can be used to classify broad aspects of the effects 
of interventions e.g. functional status. Outcomes from multiple domains may be important 
to measure in trials, and several outcomes within a domain may be relevant or important. 
Outcome domain models or frameworks exist to attempt to provide essential structure to 
the conceptualisation of domains [19], and have been used to classify outcomes that have 
been measured in clinical trials in particular conditions. Despite their intended use to 
provide a framework, there has not always been consistency between the different 
models. In a review of Health Related Quality of Life (HRQOL) models, Bakas et al. found 
that there were wide variations in terminology for analogous HRQOL concepts [19]. There 
have been several frameworks to classify health, disease and outcomes to date,, some of 
which are described below.  
 
1.3.1 Outcome-related frameworks  
World Health Organisation (WHO) 
The WHO definition of health, although strictly a definition of health, can be considered a 
framework as it includes three broad health domains [20]: physical, mental and social well-
being. This definition has not been amended since 1948 but is a useful starting place to 
study health. In a scoping review of conceptual frameworks, Idzerda et al. point out that 
although the three domains are clearly outlined, no further information about what should 
be included within each domain is provided [21].  
 
Patient-Reported Outcomes Measurement Information System (PROMIS)  
The PROMIS domain framework builds on the WHO definition of health to provide 
subordinate domains beneath the broad headings stated above [22]:  physical (symptoms 
and functions), mental (affect, behaviour, and cognition) and social well-being 
(relationships and function). It was developed for adult and paediatric measures as a way 
of organising outcome measurement tools.  
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World Health Organization International Classification of Functioning Disability and 
Health (WHO ICF) 
The International classification of Functioning, Disability and Health (ICF) offers a 
framework to describe functioning, disability and health in a range of conditions. The ICF 
focuses on the assessment of an individual’s functioning in day-to-day life. It provides a 
framework for body functions, activity levels and participation levels in basic areas and 
roles of social life; providing domains of biological, psychological, social and environmental 
aspects of functioning [23]. In many clinical areas, ICF core sets have been developed. 
These core sets identify the most relevant ICF domains for a particular health condition. 
Further discussion about ICF core sets can be found in Chapter 3. 
  
5Ds  
The 5Ds is presented as a systematic structure for representation of patient outcomes and 
includes five ‘dimensions’: death, discomfort, disability, drug or therapeutic toxicity, and 
dollar cost [24]. This representation of patient outcome was developed specifically for 
rheumatic diseases, and the authors claim that each dimension represents a patient 
outcome directly related to patient welfare; for example they describe a patient with 
arthritis may want to be alive, free of pain, functioning normally, experiencing minimal side 
effects and be financially solvent. This framework assumes that outcomes are 
multidimensional, and it is critical that the ‘concept of outcome’ is orientated to patient 
values.  
 
Wilson and Cleary  
Wilson and Cleary [25] propose a taxonomy or classification for different measures of 
health outcome. They suggest that one problem with other models is the lack of 
specification about how outcomes interrelate. They divide outcomes into five levels: 
biological and physiological factors, symptoms, functioning, general health perceptions, 
and overall quality of life. In addition to classifying these outcome measures, they propose 
specific causal relationships between them that link traditional clinical outcomes to 
measures of health related quality of life. For example, ‘Characteristics of the environment’ 
are related to ‘Social and psychological supports’ which in turn relates to ‘Overall quality of 
life.’  Ferrans and colleagues [26] revised the Wilson and Cleary model to further clarify and 
develop individual and environmental factors.  
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Outcome Measures in Rheumatology (OMERACT) Filter 2.0  
The OMERACT Filter 2.0 [27] is a conceptual framework that the authors claim 
encompasses ‘the complete content of what is measurable in a trial.’ That is, a conceptual 
framework of measurement of health conditions in the setting of interventions. It 
comprises three core areas: death, life impact and pathophysiologic manifestations; it also 
comprises one strongly recommended, resource use. These core areas are then further 
categorised into core domains. They liken the areas to ‘large containers’ for the concepts of 
interests (domains and subdomains). They recommend that the ICF domains are also 
considered under life impact (ICF domains: activity and participation) and pathophysiologic 
manifestations (ICF domains: body function and structure).  
 
Outcome Measures Framework (OMF) 
The Outcome Measures Framework (OMF) project was funded by the Agency for 
Healthcare Research and Quality (a branch of the U.S. Department of Health and Human 
Services) to create a conceptual framework for development of standard outcome 
measures used in patient registries [28]. The OMF has three top level broad domains: 
characteristics, treatments and outcomes. There are six subcategories within the outcomes 
domain: survival; disease response; events of interest; patient/caregiver reported 
outcomes; clinician reported outcomes, and health system utilisation. The model was 
designed so that it can be used to define outcome measures in a standard way across 
medical conditions. Gliklich et al conclude that ‘as the availability of healthcare data grows, 
opportunities to measure outcomes and to use these data to support clinical research and 
drive process improvement will increase.’ 
 
Survey of Cochrane reviews 
Rather than attempting to define outcome domains as others have done, Smith et al 
performed a review of outcomes from Cochrane reviews to see whether there were similar 
outcomes across different disease categories, in an attempt to manage and organise data 
[29]. Fifteen categories of outcomes emerged as being prominent across Cochrane Review 
Groups and encompassed person-level outcomes, resource-based outcomes, and 
research/study-related outcomes. The 15 categories are: adverse events or effects (AE), 
mortality/survival, infection, pain, other physiological or clinical, psychosocial, quality of 
life, activities of daily living (ADL), medication, economic, hospital, operative, compliance 
(with treatment), withdrawal (from treatment or study), and satisfaction (patient, clinician, 
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or other health care provider). The authors recognise that these 15 categories might 
collapse further and could be ‘mapped’ to the ‘core’ areas identified by Boers et al. in the 
OMERACT framework (described above).  
 
1.4 Problems with outcomes  
Clinical trials seek to evaluate whether an intervention is effective and safe by comparing 
the effects of interventions on outcomes, and by measuring differences in patient 
outcomes between groups. Clinical decisions about the care of individual patients are made 
on the basis of these outcomes, so clearly the selection of outcomes to be measured and 
reported in trials is critical. The chosen outcomes need to be relevant to health service 
users and others involved in making decisions and choices about health care.  However, a 
lack of adequate attention to the choice of outcomes in clinical trials has led to avoidable 
waste in both the production and reporting of research, and the outcomes included in 
research have not always been those that patients regard as most important or relevant 
[30]. 
 
It has been widely shown that inconsistencies in outcomes cause problems for people 
trying to use healthcare research. One such example is a cross-sectional study of oncology 
research that found that more than 25,000 outcomes had appeared only once or twice in 
oncology trials [31]. Furthermore, key outcomes may go unmeasured or unreported, and a 
review of missing data in Cochrane Reviews found that 102/143 (71%) reviews were unable 
to obtain the findings for key outcomes in the included trials, and 26 (18%) were missing 
data for more than half the patients on the review’s pre-specified primary outcome [32]. 
There are also often differences in how outcomes are defined and measured making it 
difficult, sometimes impossible, to synthesise the results of different research studies and 
apply them in a meaningful way. This was epitomised in a survey of trials involving people 
with schizophrenia, where it was found that 2194 different scales had been used in 10,000 
controlled trials, meaning that, on average a new instrument had been introduced for 
every fifth trial [33]. 
 
Alongside this inconsistency in the measurement of outcomes, outcome reporting bias 
adds further to the problems faced by users of research. Outcome reporting bias has been 
defined as the selection of a subset of the original recorded outcomes, on the basis of the 
results, for inclusion in the published reports of trials and other research [34]. Publication 
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of complete trial results is important to clinicians, consumers, and policy makers who wish 
to make well-informed decisions about health care. However, this does not always happen 
and outcomes that are statistically significant are more likely to be fully reported [35]. 
Furthermore, in a sensitivity analysis that sought to account for outcome reporting bias in 
systematic reviews with a statistically significant result, it was found that 19% would not 
have remained significant and 26% would have overestimated the treatment effect by 
more than 20% [36].  Selective reporting of outcomes means that fully informed decisions 
cannot be made about the care of patients, resource allocation, research priorities, and 
study design. This can lead to the use of ineffective or even harmful interventions, and to 
the waste of health care resources that are already limited [37]. 
 
1.5 Standardising outcomes 
1.5.1 Core outcome sets (COS)  
These issues of inconsistency and outcome reporting bias could be reduced with the 
development and application of agreed standardised sets of outcomes, known as core 
outcome sets (COS), that should be measured and reported in all trials for a specific clinical 
area [38]. These sets represent the minimum that should be measured and reported in all 
clinical trials of a specific condition and could also be suitable for use in other types of 
research and clinical audit [39]. The expectation is that the core outcomes will always be 
collected and reported and that researchers might also include other outcomes of 
particular relevance or interest to their specific study. The first step in the process is 
typically identifying ‘what’ to measure. Once it has been agreed what should be measured, 
the ‘how’ can be determined; that it is how the outcomes included in the core set should 
be defined and measured, as well as the timing of such measurements.  
 
The use of COS will make it easier for the results of trials to be compared, contrasted and 
combined as appropriate, thereby reducing waste in research [40]. This approach would 
reduce heterogeneity between trials because all trials would measure and report the 
agreed important outcomes, lead to research that is more likely to have measured relevant 
outcomes due to the involvement of relevant stakeholders in the process of determining 
what is core, and be of potential value to use in clinical audit. Importantly, it would 
enhance the value of evidence synthesis by reducing the risk of outcome reporting bias and 
ensuring that all trials contribute usable information.  
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1.5.2 COS initiatives  
One of the earliest examples of an attempt to standardise outcomes is an initiative by the 
World Health Organisation (WHO) in the 1970s, relating to cancer trials [41]. More than 30 
representatives from groups doing trials in cancer came together, the result of which was a 
WHO handbook of guidelines recommending the minimum requirements for data 
collection in cancer trials. The most notable work to date relating to outcome 
standardisation since has been conducted by the Outcome Measures in Rheumatology 
(OMERACT) collaboration, which advocates the use of COS, designed using consensus 
techniques, in clinical trials in rheumatology. This, and other relevant initiatives, is 
described below.  
 
OMERACT (www.omeract.org) is an independent initiative of international health 
professionals interested in outcome measures in rheumatology. The first OMERACT 
conference on rheumatoid arthritis was held in Maastricht, in the Netherlands in 1992 [42]. 
The motivation for this was discussions between two of the executive members, comparing 
the outcomes for patients with rheumatoid arthritis in European clinical trials with that of 
North American clinical trials, and noting that they used different outcomes. This made it 
extremely difficult to compare and combine in meta-analyses. Over the last 20 years, 
OMERACT has served a critical role in the development and validation of clinical and 
radiographic outcome measures in rheumatoid arthritis, osteoarthritis, psoriatic arthritis, 
fibromyalgia, and other rheumatic diseases. OMERACT strives to improve outcome 
measurement in Rheumatology through a ‘data driven’, iterative consensus process 
involving relevant stakeholder groups [43].  
 
An important aspect of OMERACT now is the integration of patients at each stage of the 
OMERACT process, but this was not always the case. Initially, OMERACT did not include 
patients in the process of developing COS. The patient perspective workshop at OMERACT 
6 in 2002 addressed the question of looking at outcomes from the patient perspective. 
Fatigue emerged as a major outcome in rheumatoid arthritis, and it was agreed that this 
should be considered for inclusion in the core set [44-46].    This patient input along with 
clinical trialist insight, epidemiologist assessment, and industry perspective, has led 
OMERACT to be a prominent decision making group in developing outcome measures for 
all types of clinical trials and observational research in rheumatology. OMERACT have now 
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developed COS for many rheumatologic conditions, and have described a conceptual 
framework for developing core sets in rheumatology (described in section 1.3.1) [27]. 
 
Since OMERACT there have been other examples of similar COS initiatives to develop 
recommendations about the outcomes that should be measured in clinical trials. One 
example is the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT, www.immpact.org), whose aim is to develop consensus reviews and 
recommendations for improving the design, execution, and interpretation of clinical trials 
of treatments for pain. The first IMMPACT meeting was held in November 2002, and there 
have been a total of seventeen consensus meetings on clinical trials of treatments for acute 
and chronic pain in adults and children. Another exemplar is the Harmonising Outcome 
Measures for Eczema (HOME, www.nottingham.ac.uk/homeforeczema) Initiative. This is an 
international group working to develop core outcomes to include in all eczema trials. 
 
1.5.3 The COMET Initiative  
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative (www.comet-
initiative.org) brings together people interested in the development and application of COS. 
COMET aims to collate and stimulate relevant resources, both applied and methodological, 
to facilitate exchange of ideas and information, and to foster methodological research in 
this area. Specific objectives include: 
 
1. to raise awareness of current problems with outcomes in clinical trials;  
2. to encourage COS development and uptake; 
3. to promote patient and public involvement in COS development;  
4. to provide resources to facilitate these aims;  
5. to avoid unnecessary duplication of effort,  
6. to encourage evidence-based COS development. 
 
The COMET Initiative was launched at a meeting in Liverpool in January 2010, funded by 
the Medical Research Council (MRC) North West Hub for Trials Methodology (NWHTMR). 
More than 110 people attended, with representatives from trialists, systematic reviewers, 
health service users, clinical teams, journal editors, trial funders, policy makers, trials 
registries and regulators. The feedback was uniformly supportive, indicating a strong 
consensus that the time was right for such an initiative. The meeting was followed by a 
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second meeting in Bristol in July 2011, which reinforced the need for COS across a wide 
range of areas of health and the role of COMET in helping to coordinate information about 
these. COMET has gone on to have subsequent successful international meetings in 
Manchester (2013), Rome (2014) and Calgary (2015) to affirm this.  
 
1.5.4 Other relevant initiatives  
While the initiatives described in Section 1.5.2 are specific to the development of COS for 
trials in particular areas of health, there are a few other recent initiatives relevant to the 
improvement of outcome measurement. One such initiative is the Core Outcomes in 
Women’s health (CROWN) initiative. CROWN is an international group, led by journal 
editors, to harmonise outcome reporting in women’s health research [47]. This consortium 
aims to promote COS in the specialty, encourage researchers to develop COS and facilitate 
reporting of the development of COS.  
 
The International Consortium for Health Outcomes Measurement (ICHOM) organises global 
teams of physician leaders, outcomes researchers and patient advocates to define core sets 
of outcomes per medical condition for use in clinical practice rather than clinical trials. 
Health care is very complex and medical knowledge is changing fast. Reliable outcomes 
data enable physicians and patients to make better decisions about what treatments are 
best for them and who should provide them. ICHOM provides a structured process to 
achieve consensus for a global standard [48]. This is a new initiative, and they aim to 
publish 50 standard sets by 2017. A list of completed sets, in progress and conditions under 
consideration can be viewed at: http://www.ichom.org/medical-conditions/. One such 
example is the recently published localised prostate cancer ‘standard set’ [49]. The 
publication provides limited methodological detail that would be valuable to know, such as 
how patients and other stakeholders were identified and selected, the weighting of those 
stakeholder groups and the processes of how an outcome is finally included in the standard 
set [50]. In addition, it is also important to know how the measuring tools were selected 
and substantiated as multiple definitions exist. Ultimately, the work being done by ICHOM 
to develop standard sets for clinical care should be complementary to work being done to 
develop COS for trials and research.  
 
The US National Institutes of Health (NIH) encourages the use of common data elements 
(CDEs) in NIH supported research projects or registries. The NIH provide a resource portal 
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(http://www.nlm.nih.gov/cde/) that includes databases and repositories of data elements 
and case report forms that may assist investigators in identifying and selecting data 
elements for use in their projects. PROMIS (http://www.nihpromis.org/) is another NIH 
initiative and is part of the NIH goal to develop systems to support NIH-funded research 
supported by all of its institutes and centres. PROMIS provides a system of measures of 
patient-reported health status for physical, mental, and social health which can be used 
across chronic conditions (see description in section 1.3.1). Once it has been decided what 
outcomes should be measured, PROMIS is a source of information regarding how those 
outcomes could be measured.  
 
Once a COS has been agreed, it is then important to determine how the outcomes included 
in the set should be defined and measured. Several measurement instruments may exist to 
measure a given outcome, usually with varying psychometric properties (e.g. reliability and 
validity). Important sources of information for selecting a measurement instrument for a 
COS are systematic reviews of measurement instruments. The COnsensus-based Standards 
for the selection of health Measurement INstruments (COSMIN) initiative collates 
systematic reviews of measurement properties of available measurement instruments that 
intend to measure (aspects of) health status or (health-related) quality of life. An overview 
of these reviews and guidelines for performing such reviews can be found on the COSMIN 
website (http://www.cosmin.nl/systematic-reviews-of-measurement-properties-
_5_0.html.) They have also developed a checklist about which measurement properties are 
important and standards for how to evaluate their measurement properties [51]. The 
COSMIN checklist will facilitate the selection of the most appropriate PRO measure among 
competing instruments. A collaboration between COSMIN and COMET has recently 
resulted in the development of a guideline on how to select outcome measurement 
instruments for outcomes included in a COS [52]. 
 
The Clinical Outcome Assessments (COA) Staff at the US Food and Drug Administration 
(FDA), previously known as the Study Endpoints and Labeling Development (SEALD) Study 
Endpoints Team, aim to encourage the development and application of patient-focused 
endpoint measures in medical product development to describe clinical benefit in labelling. 
The COA Staff engage with stakeholders to improve clinical outcome measurement 
standards and policy development, by providing guidance on COA development, validation, 
and interpretation of clinical benefit endpoints in clinical trials. The FDA defines a COA as a 
‘measure of patient’s symptoms, overall mental state, or the effects of a disease or 
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condition on how the patient functions.’ Put simply, the COA Staff work to ensure that the 
evidence provided about an outcome instrument can be relied upon in the context of drug 
development and regulatory decision making.  
 
The Clinical Data Interchange Standards Consortium (CDISC) is a global Standards 
Development Organization (SDO) ‘to develop and support global, platform-independent 
data standards that enable information system interoperability to improve medical 
research and related areas of healthcare,’ http://www.cdisc.org.  CDISC aims to establish 
worldwide industry standards to support the electronic acquisition, exchange, submission 
and archiving of clinical research data and metadata to improve data quality and streamline 
medical and biopharmaceutical product development and research processes. The 
Coalition for Accelerating Standards and Therapies (CFAST) Initiative is a CDISC partnership, 
set up to accelerate clinical research and medical product development by creating and 
maintaining data standards, tools and methods for conducting research in therapeutic 
areas that are important to public health (http://www.cdisc.org/cfast-0). One of their 
objectives is to identify common standards for representing clinical data for drug studies in 
priority therapeutic areas. This includes standardising definitions of outcomes, and the way 
in which outcomes are described.  
 
1.6 The need for research to improve methodological standards for COS 
development 
1.6.1 Health research guidelines  
Science has been described as a ‘heterogeneous endeavour’ [53], and health research 
guidelines can help improve the quality of science and research. Over recent years there 
has been a surge of guidelines to help researchers produce and report better research: 
“The time has come for all stakeholders to develop and implement policies that increase 
accessibility of health research, and promote its unbiased translations to the best possible 
care of patients [37].”  
 
The Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network was 
set up to tackle problems of inadequate reporting of health research. The EQUATOR 
Network website (www.equator-network.org) provides a resource for a collection of 
guidelines to help researchers publish their research [54]. The Consolidated Standards of 
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Reporting Trials (CONSORT) statement is one such guideline. It is an evidence based 
minimum set of recommendations and items for reporting clinical trials [55], and facilitates 
complete and transparent reporting. It states that trial reports should include a completely 
defined pre-specified primary and secondary outcome measure(s), including how and when 
they were assessed. The Standard Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) initiative is another guideline with the aim of improving the quality of clinical 
trial protocols [56]. The SPIRIT Statement provides guidance in the form of a checklist of 
recommended items to include in a clinical trial protocol. It includes a statement 
encouraging trial investigators to ascertain whether a COS exists relevant to their trial, and 
if so, to include those outcomes in their trial. Therefore, COS need to be readily found by 
potential users and be developed in a methodologically rigorous way. Health research 
guidelines have a greater chance of success if funders support, and journals more actively 
endorse and implement, these initiatives to improve the usefulness of research [57].  
 
1.6.2 Recent work  
Accumulating work in this area has identified the need for general guidance on the 
development of COS. There is currently little guidance on the development of COS. Sinha 
and colleagues conducted a systematic review of studies that determined outcomes for 
paediatric trials [58]. They found that studies were of variable quality, used variable 
methods and few had involved parents or children in assessing which outcomes should be 
measured. They concluded that there were recurring features of the methodology and 
reporting quality of the studies that may have compromised the scientific validity of the 
studies identified.  
 
They went on to conduct a review of studies that had used the Delphi Technique to 
determine outcomes for trials [59]. Again, they identified studies of variable methodology 
and reporting quality. They recommended that “Methodological decisions should be clearly 
described in the main publication in order to enable appraisal of the study.” Furthermore, 
they recommended a checklist that should be reported in studies using this method to 
determine outcomes to measure in trials.   
 
Williamson et al suggest key issues to consider in the development of a COS including its 
scope, the stakeholder groups to involve, choice of consensus method and the 
achievement of a consensus [38]. They suggest a checklist of items that groups should 
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consider when reporting the general development of a COS. Although the issues to 
consider are described, it is not a formal COS reporting guideline nor is there one available 
to date.  
 
1.6.3 Rationale for work in this thesis  
There is an increasing awareness of the need for greater attention to be given to the 
outcomes measured in clinical trials, in terms of standardisation and reporting. 
Furthermore, methodological issues such as the lack of patients in OMERACT originally and 
their subsequent inclusion leading to the identification of different outcomes, suggests that 
there is a need for research to determine how best to develop COS. There is currently no 
accepted gold standard method for COS development and further work is necessary to 
explore which methods are better or more appropriate than others, and what the priorities 
are for guidance and further research in this area. As highlighted in this chapter, it is 
important to identify both what to measure and how to measure outcomes once they have 
been included in a COS. The focus of this thesis in on the first part of the process, that is 
identifying what to measure. For COS to be successfully implemented, they need to be 
easily accessible to researchers and other key groups.  They are currently scattered across 
the health literature. A systematic review of COS is needed to bring these resources 
together in one place, as well as to elucidate the methods COS developers have used to 
date. 
  
The focus of the work undertaken for this thesis is to investigate COS development. In 
particular, the following questions will be explored: 
 What is currently known about COS development?  
 What influences COS developers’ choice of methodology and approach? 
 What are the priorities for guidance and further research in this area? 
 
1.7 Structure of this thesis  
The remainder of this thesis is structured as follows. 
 
Chapter 2 outlines the methodological approach taken to develop a search strategy for a 
systematic review of COS. The aim was to compare the contribution of databases to the 
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identification of included studies, and to find the best combination of methods to retrieve 
all included studies.  
 
Chapter 3 provides a detailed description of the systematic review methods used and the 
results. The aim of the systematic review was to identify studies which had the aim of 
determining which outcomes or domains to measure in all clinical trials in a specific 
condition, and to identify and describe the methodological techniques used in these 
studies. 
 
Chapter 4 provides additional information from the systematic review about the COS 
development methods most commonly used presently in COS development; specifically 
systematic reviews, the Delphi technique and consensus meetings.  
 
Chapters 5 to 7 present a mixed methods approach to explore COS development.  
 
Chapter 5 focusses on a web based survey conducted to provide quantifiable information 
about published COS developers’ experiences of the COS development process. Contact 
authors of the COS publications identified in the systematic review were contacted and 
asked to answer a few short questions about their COS work.  
 
The work described in chapters 6 and 7 involved undertaking in-depth qualitative 
interviews with COS developers to further methodological understanding of COS 
development processes.  The aim was to generate a detailed description of COS 
developers’ choice of methodological approach, including the factors that have informed 
the ways in which researchers have developed COS; and to identify priority areas for future 
methodological research. Interviews were conducted with both published and ongoing COS 
developers. 
 
Chapter 8 concludes with a summary of the main findings, further developments and 
recommendations for future work.  
 
1.7.1 Language and style 
As a mixed methods thesis, the language and style used throughout this thesis are 
consistent with the predominant style used for the methodology of the corresponding 
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chapter. Chapters 2 to 5 are written in the third person; and chapters 6 and 7 use the first 
person as the dominant style consistent with qualitative inquiry [60].  
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Chapter 2: Developing an appropriate 
search strategy  
 
2.1 Background 
Clinical trials seek to evaluate whether interventions are effective and safe for patients by 
comparing their relative effects on outcomes chosen to identify benefits and harms. 
Decision makers can then use this information to make well-informed healthcare choices. 
Therefore, it is critical that the outcomes measured and reported in trials are those that are 
needed by decision makers. However a lack of adequate attention to the choice of 
outcomes in clinical trials has led to avoidable waste in both the production and reporting 
of research, and the outcomes included in research have not always been those that 
patients regard as most important or relevant [30]. The COMET Initiative brings together 
people interested in the development and application of core outcome sets (COS). COMET 
aims to collate and stimulate relevant resources, both applied and methodological, to 
facilitate exchange of ideas and information, and to foster methodological research in this 
area. The importance of COS is increasingly recognised by research funders. For instance, 
the National Institute for Health Research’s Health Technology Assessment programme in 
the UK, the Health Research Board in Ireland and the charity Arthritis Research UK, are all 
highlighting this to researchers seeking funding for new studies. However, the identification 
of existing COS is not easy.  
 
For core outcome sets to be an effective solution, they need to be easily accessible to 
researchers and other key groups.  They are currently scattered across the health 
literature, so we have set out to bring these resources together in one place. This is the first 
known attempt to do this. As part of the COMET Initiative, we are developing a publicly 
accessible internet-based resource to collate the knowledge base for COS development and 
the applied work that has already been done according to disease area. This will be a useful 
resource for trial funders to refer to, for researchers to see what work has been done in 
their area of interest and for research funders wishing to avoid unnecessary duplication of 
effort when supporting new activities. It will include planned and ongoing work, as well as 
published accounts of COS development. Prior to the completion of the systematic review 
outlined here, 130 relevant studies had been identified through known research networks, 
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but creating a comprehensive database and keeping the database up to date is key to its 
value for users and requires a more structured and transparent approach than the ad hoc 
inclusion of studies as they come to light.  
 
This requires the development and application of an optimal, multi-faceted search strategy 
to identify work related to the development of COS. It builds on a review of studies that 
addressed which outcomes to measure in clinical trials in children that was conducted in 
2006, which identified work in 17 different paediatric conditions [58]. This, and studies that 
had been identified in ad hoc ways, was the starting point. However, in order for the 
database to be comprehensive and up to date, a systematic approach is needed to identify 
relevant material.  
 
This chapter outlines the methodological approach taken to develop the search strategy for 
a systematic review to identify studies which sought to determine which outcomes or 
domains to measure in all clinical trials in a specific condition, and, in turn, to establish a 
comprehensive database of COS.  
 
2.2 Aims  
To develop an appropriate search strategy to identify as many relevant studies as possible 
within the available resources, and then investigate the performance characteristics of this 
strategy.  
 
We aimed to compare the contribution of databases towards identifying included studies, 
and identify the best combination of methods to retrieve all included studies.  
 
2.3 Methods  
2.3.1 Developing an appropriate search strategy  
We developed a multi-faceted search strategy to search electronic databases using a 
combination of text words and index terms, adapting the search strategy as appropriate for 
each database.  This process began with an appraisal of the searches from previous reviews 
of studies that had (a) sought to determine which outcomes to measure in clinical trials in 
children [58], (b) used the Delphi technique to determine which outcomes to measure in 
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clinical trials [59], and (c) explored patients’ priorities regarding outcomes [61]. The 
relevant concepts from these searches were brought together to develop a search for use 
in MEDLINE via Ovid. The combined set of search terms generated 66,954 hits (searched 01 
February 2012). This was an unmanageable number of hits, given the resources available 
for the project. We needed to reduce the number of hits, without losing precision of the 
search. Testing was done, removing individual search terms and checking that eligible 
studies from the previous reviews were still being identified. This allowed the removal of a 
series of redundant terms, and reduced the number of hits to 23,047.  
 
The next stage in the development of the search strategy was to compare the retrieved 
records with the 130 citations that had been identified over time for inclusion in the 
COMET database of COS. We also wished to retrieve similar reports in the final search 
strategy and the results of the search for development studies were checked for these 130 
citations. Ten of these citations were not indexed for MEDLINE but, of the 120 that were, 
50 had not been retrieved by the search. These papers and their MEDLINE records were 
examined, and terms and MeSH headings that were relevant and would identify those 
citations were identified. These terms were added to the search strategy, and a re-run in 
MEDLINE generated 38,579 hits (searched 10 February 2012).  Using the term lists option in 
Endnote, we analysed the keywords (i.e. subject headings), as well as words in the title and 
abstract of the relevant papers previously identified, and compared these to the terms in 
the search strategy. This led to further revisions, which reduced the number of hits slightly 
to 37,971.  
 
The next stage in the revision of the search strategy, which had originated from the earlier 
reviews, was to examine the terms used to identify reports that related to randomised 
trials. Because our main focus was on articles about methodology relevant to randomised 
trials, rather than reports of trials themselves, we reverted to MeSH heading “randomized 
controlled trials as topic” instead of the publication type “randomized controlled trial” 
(which had been used in the previous reviews). The total number of hits fell to 26,589, with 
only 17 of the 120 citations that we knew were indexed in MEDLINE not being identified. 
Using this revised search strategy, we went through the MEDLINE indexed studies and 
identified target terms for each article. All matching terms were retained in the search, all 
other terms were removed, and further terms were added to target the 17 reports that had 
been missed. This updated search generated 15,138 hits (searched 15 February 2012).  
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However, ten of the target papers continued to be missed by this search. Further 
examination revealed that two papers were being hidden by limiting the search to humans 
and switching off this limit increased the number of hits by a relatively small amount, to 
15,704. We reviewed the remaining 8 papers [62-69] and although these are suitable for the 
COMET database, we decided that they (and papers like them) were not of sufficient 
importance to extend the search further in order to retrieve them. They were not studies 
that had developed or applied methodology for determining which outcome domains or 
outcomes should be measured, or are important to measure, in clinical trials. Therefore, 
we concluded that the revised search strategy was adequate to identify all 112 previously 
identified key papers that were indexed by MEDLINE. This process is summarised in Figure 
2. The search was then modified for use in the other electronic databases that we 
considered searching for this study. The final search strategies are shown in Appendix 1 and 
combines three concepts of search terms, covering ‘randomised trial / systematic review’, 
‘methodology’ and ‘outcomes’. All terms within each concept were combined with the 
Boolean operator OR and the three concepts were then combined using the Boolean 
operator AND. Key terms were also targeted in the title and abstract fields, and these terms 
were combined with the Boolean operator OR. Truncation and wildcards were used to 
improve the sensitivity of the search, account for spelling variations and to identify 
different derivations of search terms. This search, which was developed for MEDLINE via 
Ovid, was modified subsequently for use in other electronic databases (see Appendix 1). 
 
 
 
 
 
 
 
 
23 
 
Figure 2: Developing an appropriate search strategy   
 
 
The tables and figures in this chapter are reproduced with permission from Gargon, E., P. R. Williamson, et al. 
(2015). "Collating the knowledge base for core outcome set development: developing and appraising the search 
strategy for a systematic review." BMC Med Res Methodol 15(1): 26. 
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2.3.2 Confirming the need for such a large search  
As noted above, the final search was still retrieving a large number of records and our next 
step was to determine if this was because there were many eligible papers for the 
systematic review or because we were continuing to retrieve an overwhelming proportion 
of irrelevant material. We also wished to develop an estimate of the likely number of COS 
in the literature. Therefore, we examined the potential relevance of 1% of the hits (n=157). 
A random number generator (R) was used to select records, and their titles and abstracts 
were read to identify potentially relevant studies.  
  
2.3.3 Electronic databases  
This high yield of eligible studies from MEDLINE and evidence that no single database is 
likely to be sufficient for identifying research across health care [70-72], led to further work 
to select the sources to be searched. A variety of electronic databases were considered for 
searching: 
1. MEDLINE via Ovid  
2. The Cochrane Library (excluding categories ‘Trials’ and ‘Cochrane Groups’)  
3. Cumulative Index of Nursing and Allied Health Literature (CINAHL) plus  
4. Scopus 
 
Medline via OVID  
MEDLINE is the U.S. National Library of Medicine's (NLM) premier bibliographic database 
that contains over 19 million references to journal articles in life sciences with a 
concentration on biomedicine. Time coverage is generally 1946 to the present, with some 
older material. Currently it offers citations from approximately 5,600 worldwide journals 
(4,800 current biomedical journals) in 39 languages. The subject scope of MEDLINE is 
biomedicine and health, broadly defined to encompass those areas of the life sciences, 
behavioural sciences, chemical sciences, and bioengineering needed by health 
professionals and others engaged in basic research and clinical care, public health, health 
policy development, or related educational activities. MEDLINE also covers life sciences 
vital to biomedical practitioners, researchers, and educators, including aspects of biology, 
environmental science, marine biology, plant and animal science as well as biophysics and 
chemistry. Increased coverage of life sciences began in 2000. 
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The Cochrane Methodology Register   
The Cochrane Library is a collection of six databases that contain different types of 
research: Cochrane Database of Systematic Reviews; Cochrane Central Register of 
Controlled Trials; Cochrane Methodology Register; Database of Abstracts of Reviews of 
Effects; Heath Technology Assessment Database, and NHS Economic Evaluation Database. 
Each of these has a different focus, with the Cochrane Methodology Register being most 
relevant to this project, but it should be noted that work on the development and 
maintenance of the Register was suspended by the UK Cochrane Centre in May 2012 and it 
has not been updated since July 2012. The Cochrane Methodology Register (CMR) is a 
database of studies relevant to the methods of systematic reviews of healthcare and social 
interventions. The register includes journal articles, book chapters, conference 
proceedings, conference abstracts and reports of ongoing methodological research. 
Relevant records are identified primarily through a programme of hand searching 
undertaken by the UK Cochrane Centre. The register aims to include all published reports 
of empirical methodological studies that could be relevant for inclusion in a Cochrane 
methodology review, along with comparative and descriptive studies relevant to the 
conduct of systematic reviews of healthcare interventions. In Issue 3, 2011 of The Cochrane 
Library, CMR contains 14,761 records. 
 
Cumulative Index of Nursing and Allied Health Literature (CINAHL) plus  
This is the world's most comprehensive nursing & allied health research database, indexing 
for more than 5,000 journals. Offering complete coverage of English-language nursing 
journals and publications from the National League for Nursing and the American Nurses' 
Association, CINAHL covers nursing, biomedicine, health sciences librarianship, 
alternative/complementary medicine, consumer health and 17 allied health 
disciplines. Full-text coverage dates back to 1937. 
 
Scopus  
Scopus, launched in November 2004, is the largest abstract and citation database of peer-
reviewed research literature. With over 19,000 titles from more than 5,000 international 
publishers (18,500 peer-reviewed journals including 1,800 Open Access journals), SciVerse 
Scopus offers researchers a quick, easy and comprehensive resource to support their 
research needs in the scientific, technical, medical and social sciences fields and, more 
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recently, also in the arts and humanities. Scopus includes all Embase and PubMed Journals 
from 1996 onwards.  
 
Deciding which databases to search   
MEDLINE focuses on biomedical journal literature, CINAHL on nursing and allied health 
literature, and Scopus covers medical and scientific literature, so we thought each had a 
sufficiently different focus to consider including in the search. Previous work that has been 
done to consider the coverage between CINAHL and Scopus to determine whether Scopus 
alone provides sufficient coverage of the literature concluded that only partial duplicate 
coverage of nursing and allied health literature was offered by CINAHL [70]. While 
SCOPUS’s significantly larger coverage may offer many unique titles in these subject areas, 
it is not possible to say that these titles would be an adequate substitute for CINAHL’s 
coverage of this literature. As its relevance to COS work was not yet known, it warranted 
further exploration. EMBASE was also considered for inclusion. We decided to include 
SCOPUS as opposed to EMBASE as it is a larger database and offers more coverage of 
scientific, technical, medical and social science literature[35]. Furthermore, SCOPUS 
indexes all EMBASE journals. The relevant modified search strategy was applied to each of 
these databases and each was considered in turn for suitability for inclusion in the final 
strategy.  
 
2.3.4 Hand searching  
In addition to the electronic database searching, we decided to complete a range of hand 
searching activities, in keeping with research evidence showing the added benefits of hand 
searching alongside electronic searching [73]. We identified and reviewed funded projects 
that included the development of a COS, including National Institute for Health Research 
(NIHR) programme grant scheme reports and Health Technology Assessment (HTA) reports; 
searched for known key authors and citations to key papers, for example, the work of the 
OMERACT group; examined references cited in eligible studies and in other studies that 
referred to or used a COS. We also contacted the Cochrane Review Groups (CRGs) to 
request information on COS that they were aware of (described in more detail in Chapter 
3). 
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2.3.5 Sensitivity, precision and numbers needed to read (NNR)  
We recorded whether each included study was:  
i. retrieved by the search strategy developed for each database  
ii. indexed on each database (regardless of whether or not it was retrieved by the 
search of the database)  
 
The sensitivity (or recall), precision and numbers needed to read (NNR) for the final 
searches in each of the databases were calculated using the following definitions [74]:     
 
Sensitivity (%) = 100 x (Number of included records retrieved/ Total number of included 
records)  
 
Precision (%) = 100 x (Number of included records retrieved/ Total number of records 
retrieved) 
 
NNR = 1/precision 
 
Unique yield = number of studies retrieved only by this database  
 
In addition, sensitivity*precision was calculated to allow a balance between sensitivity and 
precision to be assessed.  
 
2.4 Results  
The results of the search strategy development process are shown in Figure 2. When one 
author examined 1% (n=157) of the large number of retrieved records (n=15,704), 30 (19%) 
were identified as being potentially relevant, including three that we had previously 
identified as eligible studies. It was determined that 8 of the other 27 records were eligible 
following an assessment of their full papers. This confirmed that the search strategy was 
identifying relevant studies, that the likely yield of such studies was likely to be high and 
that a formal, systematic review was necessary to identify papers that were not yet known 
to COMET if we were to create a comprehensive resource that others could use to 
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determine whether or not a COS had already been developed in an area of interest to 
them. 
 
The search strategy was modified as appropriate for each database. The combined results 
(searched 29 May 2012) generated a total of 47,225 records (MEDLINE n=14,520, Cochrane 
Library n=4122, CINAHL n=16,700, Scopus n=11,883), which fell to 37,132 after removal of 
duplicates (duplicates accounted for approximately 22% of total). We therefore needed to 
consider each of the additional databases that we were planning to search more carefully 
to estimate their likely added yield over MEDLINE.  For example, the Cochrane 
Methodology Register includes articles that are relevant to the methods for systematic 
reviews, trials and other evaluations of health and social care and, as such, would be the 
most relevant component of The Cochrane Library for reports on the development of COS. 
With this in mind, the search strategy that was developed for The Cochrane Library as a 
whole was then limited to the Cochrane Methodology Register. It is recognised that The 
Cochrane Methodology Register has a unique controlled vocabulary but a decision was 
made to use the generic approach typically used when searching the whole Cochrane 
Library as this had already been developed for this search. For Scopus and CINAHL, two of 
the authors (EG and PW) independently reviewed a sample of abstracts from each. Fifty 
abstracts from Scopus yielded three eligible records that were not retrieved by MEDLINE or 
CINAHL. For CINAHL, a review of 100 abstracts excluded 91 as ineligible based on the 
abstract and the remaining nine potentially eligible studies were all identified by MEDLINE, 
Scopus or both. As a consequence, it was agreed that CINAHL would not be used, at least in 
this first round for the systematic review. Therefore, the following electronic databases 
were searched (August 2013):  
1. MEDLINE via Ovid  
2. SCOPUS 
3. Cochrane Methodology Register  
 
This updated search identified 34,398 potentially relevant records, all of which were 
checked and 220 eligible records were found (the process for selecting studies for inclusion 
in the review is fully described in Chapter 3). Fifty-nine (27%) were already known to us, so 
the search identified an additional 161 records. In addition to the database search, 30 
additional records that had not been previously identified were deemed eligible after being 
identified through hand searching. A full list of the 250 included records is provided in 
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Appendix 2.   Sensitivity of the search strategies ranged from 4% to 86%, and precision 
from 0.8% to 1.1% (Table 1). MEDLINE via Ovid performed best in terms of sensitivity, 
retrieving 216 (86%) of the 250 included records, followed by Scopus (44%). The search of 
the CMR identified just 4% of the included records, and all of these were found in at least 
one of the other databases. MEDLINE via Ovid was also the database with the highest 
precision. The number needed to read varied between 89 (MEDLINE via OVID) and 130 
(SCOPUS). If our searches had been limited to MEDLINE alone, only 3 included records 
unique to SCOPUS would not have been retrieved.    
 
Table 1: Sensitivity, precision and NNR for each strategy  
Database Number 
of 
records 
retrieved 
Number 
of 
included 
records 
Unique 
yield
^
 
Sensitivi
ty (%) 
(n=250) 
Precision 
(%) 
Number 
Needed 
to Read 
(NNR) 
Sensitivity
*Precision 
MEDLINE via 
OVID 
19058 216 109 86 1.1 89 98.3 
SCOPUS 14258 109 3 44 0.8 130 33.9 
CMR  1082 9 0 
 
 
4 0.8 121 3.3 
 
^ 
Unique yield relates to the number of studies retrieved by one database only. 
 
Through examining references cited in eligible studies and in other studies that referred to 
or used a COS, 30 additional records were identified and included in the systematic review. 
No additional studies were identified through the survey of Cochrane Review Groups. Of 
the 30 records identified via hand searching and not retrieved by the search strategy, we 
found that two were not indexed on any database, 25 were indexed on both Medline and 
Scopus, two on Scopus only, and one was in all three databases. On closer inspection, we 
found that the reasons for non-retrieval of the 28 studies by the database searches was the 
wide variety of free text and index terms used in their records. As has been shown in other 
contexts, modifications to the search to retrieve all these records would have produced 
searches with unmanageably large numbers of records [75]. Furthermore, the absence of 
two of the reports from the searched databases highlights that even such extensive 
searching would not have retrieved all the studies that we identified. However, one of 
these was not a journal article, and the other was an editorial which provided additional 
methodological information on a study that had been retrieved in its own right.  
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2.5 Discussion  
COS are increasingly recognised as important for the design, conduct and reporting of 
randomised trials, systematic reviews and other forms of research. However, as I have 
shown in this chapter, the development of a search strategy to identify them is challenging. 
A search for COS in any specific area could combine the approach we have taken with 
search terms for specific conditions or interventions, but it is still likely to require a large 
number of records to be checked to identify the few that are eligible. We hope therefore 
that this comprehensive approach to searching a major database such as MEDLINE for all 
reports of studies developing COS, regardless of the setting, and the subsequent inclusion 
of identified studies in the COMET database will make it much easier for researchers in the 
future. This is akin to the work of The Cochrane Collaboration in identifying reports of 
randomised trials regardless of topic area for inclusion in the Cochrane Central Register of 
Controlled Trials [76, 77].  
 
In undertaking this comprehensive approach to identifying COS, similar challenges were 
encountered to those faced by healthcare researchers in the past. For example, variability 
in the use of free text terms and index terms on reports of randomised trials of portal vein 
infusion chemotherapy in colorectal cancer meant that a search to identify all articles that 
had been identified for a systematic review would have had to rely solely on the terms for 
colorectal cancer, which retrieved 18,450 records [75].  On a larger scale, when The 
Cochrane Collaboration was established in 1993, although tens of thousands of reports of 
randomised trials could be found easily in MEDLINE, there were many more than had not 
been appropriately indexed and could not be found so easily. The development of highly 
sensitive search strategies and subsequent work within the Collaboration to find these 
“hidden” reports, led to the identification of an additional 70,000 records that were re-
tagged as randomised controlled trials or controlled clinical trials in MEDLINE and can now 
be found using those terms [76, 77]. In a similar way, this comprehensive searching for COS 
regardless of any particular healthcare condition and their inclusion in the COMET database 
makes it much easier for users to access these studies. 
 
Although work on the development of COS goes back at least 30 years [41], the term itself 
has not been widely used until relatively recently and there are currently no MeSH 
headings in MEDLINE or index terms in other bibliographic databases for identifying COS 
papers, and they do not appear to be categorised consistently across different databases. 
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Furthermore, no single database specialises in this type of methodological research and it is 
likely to be found across a wide range of literature. For example, MEDLINE and EMBASE 
focus on biomedical journal literature, CINAHL on nursing and allied health literature, and 
Scopus covers medical and scientific literature. Each database has a different focus but 
each could include studies of the development of COS. Furthermore, no single database is 
likely to be adequate. For instance, a comparison of the coverage between CINAHL and 
Scopus to determine whether Scopus alone provides sufficient coverage of the literature 
found that Scopus can only partially duplicate the coverage of nursing and allied health 
literature offered by CINAHL [70]. The work in this chapter did not identify any unique yield 
in the sample checked for CINAHL, so it was agreed that CINAHL would not be used, at least 
in this first round for the systematic review. However, due to the reasons listed here, 
further appraisal of CINAHL could be considered in any future updates of this search.  
 
Other comparisons, of other combinations of databases, have also shown how systematic 
reviews are likely to benefit from searching for potentially eligible studies in several 
databases [71, 72].  
 
The search strategy developed for COS has been designed to be highly sensitive, so that as 
many potentially relevant studies as possible will be retrieved. The final effective search 
strategy combines keywords, index terms and free-text terms and phrases, using 
combinations of Boolean operators. As no MeSH headings or index terms currently exist for 
COS papers and these papers do not appear to be indexed in a consistent way, key search 
terms were also targeted and no limits were applied to the search. A consequence of a 
highly sensitive search is usually that a large number of irrelevant records will be retrieved, 
the majority of which will likely not meet the inclusion criteria for the review, and this 
appears to be the case here. 
 
I found that two databases and hand searching were required to locate all of the studies 
that were included in this review. MEDLINE via Ovid alone retrieved 86% of the included 
studies, but actually 97% of the included studies were indexed on MEDLINE. The search of 
the Cochrane Methodology Register did not identify any records that were not found in the 
other databases. I identified retrospectively that the search in The Cochrane Library used 
an implied ‘AND’ in some of the lines which could affect the sensitivity and precision of this 
search. Given that its development and maintenance was suspended in July 2012, it will not 
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be included in future searches to identify studies developing COS. However, this decision 
will be reviewed and the search strategy evaluated should work on the Register resume. 
SCOPUS had the lowest precision rate (0.8) and highest number needed to read (130), 
which is a particularly high number of records to check in order to find one relevant record. 
Therefore, with such a low unique yield from SCOPUS (3 studies identified with the search 
strategy, increasing to 5 actually indexed); it might not be worth searching SCOPUS, given 
the low precision and high NNR.  Furthermore, the decision to search SCOPUS may have 
increased the de-duplication burden due to the lack of flexibility in its interface, for 
example de-duplicating against MEDLINE within OVID. This could be an added advantage of 
searching EMBASE and may be considered in any future updates to this search.  
 
2.6 Conclusions  
In considering how this analysis might inform future decisions about the COMET searches 
for COS, a balance needs to be struck between the work involved in screening large 
numbers of records, the frequency of the searching and the likelihood that eligible studies 
will be identified by means other than the database searches. One possibility is that the 
comprehensive searching is limited to MEDLINE, perhaps with further appraisal of the 
unretrieved records to seek ways to modify the search to target these papers. The search 
might also continue to include SCOPUS, but consideration could be given to other 
databases that were not included in this project, such as EMBASE. In keeping with the 
research evidence, it would seem there is an added benefit to hand searching, so this 
should accompany any electronic searching in the future. This would help to identify 
relevant studies that are missed by the database searching, either because they are not 
indexed in the databases or are indexed but cannot be retrieved without using a search 
strategy that would yield an unmanageable number of records to check. To keep the 
database current, COMET aims to complete an annual search of MEDLINE and SCOPUS as a 
minimum. Finally, to supplement this annual search, the COMET database will continue to 
be populated with studies, both ongoing and completed, that are identified by ad hoc 
means and sent directly to the COMET team.  
 
The full methods and results of this systematic review are presented and discussed in 
Chapter 3.  
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Chapter 3: A systematic review of 
core outcome sets  
 
3.1      Background  
For COS to be an effective solution to problems of inconsistency and outcome reporting 
bias in trials, they need to be accessible to researchers and other key groups.  COS are 
currently scattered across the health literature, which means the identification of existing 
COS is not easy. This chapter describes a systematic review to attempt to bring together 
existing COS together for the first time. The development of the search strategy was 
described in Chapter 2. This chapter provides a detailed description of the methods used 
and the results of the systematic review.  
 
3.2      Aims  
To identify studies which had the aim of determining which outcomes or domains to 
measure in all clinical trials in a specific condition, and to identify and describe the 
methodological techniques used in these studies. 
 
3.3      Methods of the review  
The protocol is available at http://www.comet-initiative.org/about/researchprojects.  
 
3.3.1 Inclusion and exclusion criteria  
Studies were eligible for inclusion in the review if they had developed or applied 
methodology for determining which outcome domains or outcomes should be measured, 
or are important to measure, in clinical trials or other forms of health research.  
 
Studies were ineligible if they did not do this but were related to how, rather than which, 
outcomes should be measured; reported the design or rationale for a single trial or for 
preclinical or early phase trials only; reported the use of a core outcome set*; were a 
systematic review of clinical trials; were studies or systematic reviews of studies of 
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prognosis; were studies (including systematic reviews and surveys) of outcomes measured 
in clinical trials** or quantitative descriptions (e.g. frequency) of outcomes**; were based 
on the opinion of a single author only**or focussed on one domain/outcome only**.  
 
* reports relating to COS but not meeting inclusion criteria (e.g. where a COS had been 
used) were retrieved, and their references checked for potentially eligible studies.  
 
**   although these were not included in the systematic review, they were eligible for 
inclusion in the COMET database.  
 
3.3.2 Types of participants and interventions 
Studies relating to participants of any age, with any health condition in any setting and 
assessing the effect of any intervention were eligible for inclusion.  
 
3.3.3 Identification of relevant studies  
In order to optimise the identification of relevant studies, the following databases were 
searched in August 2013: 
1. MEDLINE via Ovid  
2. SCOPUS 
3. Cochrane Methodology Register  
 
We developed a multi-faceted search strategy to search these databases using a 
combination of text words and index terms, adapting the search strategy as appropriate for 
each database. The process of developing an appropriate search strategy was described in 
Chapter 2.  For full details of the search strategy see Appendix 1. 
 
In addition to the electronic database searching, we completed a range of hand searching 
activities, in keeping with research evidence showing the benefits of adding hand searching 
to electronic searching [73]. We identified and reviewed funded projects that included the 
development of a COS, including NIHR programme grant scheme reports and HTA reports; 
searched for known key authors and citations to key papers, for example, the work of the 
OMERACT (Outcome Measures in Rheumatology) group; examined references cited in 
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eligible studies, and examined references cited in other reports relating to COS that were 
not eligible for this review (e.g. where a COS had been used or referred to).  
 
We contacted the 50 Cochrane Review Groups (CRG) as of 2011 across all areas of health 
care to request information on COS that they are aware of (by asking “Are you aware of any 
other work already done/being done attempting to develop a core outcome set for 
conditions covered by your CRG?”). Full details of the methods used for that study can be 
found in Kirkham et al 2013 [32].  
 
3.3.4 Selecting studies for inclusion in the review  
The records retrieved from searching were combined, and duplicate records removed.  
Their titles and abstracts were then read to assess eligibility (stage 1) and the full texts of 
potentially relevant articles were obtained and assessed for inclusion (stage 2).  
 
Stage 1a 
The title and abstract of each citation was initially read by one reviewer (EG). Each citation 
was categorised as include, unsure, exclude, exclude-references to be checked, or exclude-
suitable for COMET database.  
 
Stage 1b 
Those categorised as include or unsure were then checked independently by a second 
reviewer (BG) and categorised as above.  The assessments of the two reviewers were 
compared, and the records were categorised again following discussion. If agreement could 
not be achieved, the citation was categorised as unsure and retained for future checking.  
Where there was agreement to exclude, the citation was excluded at this stage. Full papers 
were retrieved for all records categorised as include, unsure, or references to be checked 
after this screening of the title and abstract.  
 
Stage 2 
Each full paper was checked by one of three reviewers (EG, BG, or NM) and categorised as 
above. Citations categorised as unsure were checked by a second reviewer and discussion 
took place between the reviewers to reach consensus on eligibility. An additional reviewer 
was consulted if agreement could not be achieved (PW). Reasons for exclusion were 
documented for each article judged to be ineligible in stage 2.  
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Full papers were obtained for all records categorised as relating to COS based on the title 
and abstract but which do not appear to meet the inclusion criteria (e.g. where a core 
outcome set had been used in a research study). Reference lists were checked, and 
relevant citations retrieved and assessed for inclusion. The reference lists in the reports of 
all included studies were also checked, and relevant citations were retrieved and assessed 
for inclusion. 
 
3.3.5 Checking for agreement between reviewers  
 At stage 1 (stage 1a done by EG for all records and using all the categories, and stage 1b 
when BG checked records that had been categorised as include or unsure), reviewers 
independently assessed batches of 10 abstracts (EG and BG) to check for agreement before 
independently assessing records. Results were then compared and discussed. This was 
repeated in batches of 10 until complete agreement was reached. Following this, a further 
50 abstracts were reviewed and compared to confirm agreement between the two 
reviewers, who then went on to assess all abstracts that had been initially recorded as 
include or unsure.  
 
At stage 2, reviewers independently assessed batches of 10 full papers (EG, BG, NM). These 
were then compared and discussed with the lead reviewer (EG). This was repeated until full 
agreement was achieved in three consecutive batches. Reviewers then assessed papers 
individually.  
 
3.3.6 Checking for correct exclusion  
Full papers were obtained for a 1% sample of the records excluded on the basis of the title 
and abstract (stage 1) and checked for correct exclusion by a second reviewer (NM). If any 
studies were found to have been excluded incorrectly, additional checking would be 
performed within the other excluded records. A reviewer also assessed a minimum of 5% 
of the papers that were excluded after reading their full text, to check for correct exclusion 
at stage 2.  
 
3.3.7 Data collection and extraction  
A COS may be developed to cover all aspects of a disease or health condition, but it may 
also have been developed with a focus on a particular type of treatment only, or for a 
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specific age group or stage of disease. It is therefore important in reporting the scope of a 
COS to consider the specific area of health or healthcare to which it applies, along with 
details of health condition, population (here we focussed on age) and types of 
interventions [38]. We therefore extracted the following data as free text unless otherwise 
stated:  
 
1. Study details, including 
a. Year of publication  
b. Study aims  
c. Intended use of recommendations  
 
2. Health area  
a. Disease or health category (e.g. ‘Lungs & airways’ or ‘Pregnancy & 
childbirth’) [using a checklist] 
b. Disease name (e.g. ‘Asthma’)  
 
3. Target population 
a. Age 
b. Type of intervention 
 
4. Method of development used 
a. Rationale for choice of method(s) used  
 
5. Definition of consensus  
a. Rationale for definition used  
 
6. Rating/scoring system used  
a. Rationale for rating/scoring system used  
 
7. Stakeholders involved in the process (e.g. health professionals, patients*, industry) 
a. Geographical setting of participants  
 
8. Outcomes included in the core set  
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9. Plans for implementation  
 
10. Plans to review or update the core outcome set  
 
11. Was how to measure outcomes considered?  
 
* In using the term ‘patient’ throughout this thesis, I include patients, carers, health and 
social care service users and people from organisations who represent these groups. I 
selected the term ‘patient’ in preference to alternatives such as ‘public’ [78] as patient is 
more in keeping with the terminology used by COS developers, and with the capacity with 
which this group of participants were involved in COS development.  
 
3.3.8 Data analysis and presentation of results   
Studies were described in narrative form, and the findings provided in text and tables 
format. We did not anticipate conducting any statistical analyses to combine the findings. 
Reporting was carried out in accordance with PRISMA guidelines [79]. PRISMA stands for 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses. It is an evidence-
based minimum set of items for reporting in systematic reviews and meta-analyses. 
 
3.4 Results  
3.4.1 Description of studies  
The initial database search identified 28,371 potentially relevant records after duplicates 
had been removed. Screening at stage 1 and 2 excluded 26,025 and 2126 records 
respectively. The process of identifying studies is summarised in Figure 3. This large 
number of excluded records was expected because the search was intentionally over-
inclusive due to the lack of index terms for such studies and the likelihood that many 
records would be retrieved merely because they discussed issues around the use of 
outcomes in trials, but without the necessary emphasis on how these outcomes were 
selected. A summary of the reasons for exclusion at stage 2 is presented in Table 2.  Two-
hundred and twenty citations met the inclusion criteria. In addition to the database search, 
30 additional citations were deemed eligible after being identified through reference 
checking.  No additional studies were identified through the survey of Cochrane Review 
Groups.  In total, 250 reports relating to 198 studies were included in the review.   
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Figure 3: Identification of studies 
 
The relevant tables and figures in this chapter are reproduced with permission from Gargon, E., B. Gurung, et al. 
(2014). "Choosing important health outcomes for comparative effectiveness research: a systematic review." 
PLoS ONE 9(6): e99111. 
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Table 2: Reasons for exclusion at stage 2 (assessment of full text reports) 
Reason  N 
Review/overview/discussion only, no outcome recommendations 495  
Core outcomes/outcome recommendations not made  214  
HRQL*1 117 
How to measure outcome (including instruments, tools, scales, scores, outcome 
definition) 
123  
 
ICF core set development*2 80 
Quality indicators – included an aspect of outcomes*3 78 
Not relevant  669*5 
ICF core set validation  56 
Quality indicators – structure and/or process of care only  52  
One outcome/domain only  40 
Clinical management in practice not research (including for diagnosis) 45  
Instrument development  24 
Recommendation by single author only 21 
Registry development*4  21 
Describes features of registry  16 
Preclinical/ Early phase only (0, I, II) 18  
On-going work  11 
Duplicate  11 
Quantitative description (e.g. frequency of symptoms) 9 
Reporting the design/rationale of a single trial  22 
Oral presentation only  2 
Value attributed to outcomes  2 
TOTAL 2126 
 
*Although these studies are relevant to the development of a COS (and therefore suitable for inclusion in the 
COMET database), they did not meet the review inclusion criteria.  
 
*
1 
These studies included qualitative studies describing the impact of a treatment or condition on a patient’s 
quality of life, studies to determine particular domains of quality of life, and single patient narratives of the 
impact of a condition or treatment on their quality of life. The focus of these studies was on quality of life only.  
 
*
2
 Although the ICF is widely comprehensive, it is not all inclusive. For example, the ICF does not include 
outcomes such as death, an outcome that is often relevant to measure in clinical trials. Furthermore, as the ICF 
focuses on the individual only, caregiver outcomes would not be included. While for many health areas this may 
not be relevant, for some (e.g. dementia), caregiver outcomes may be core to measure. See inclusion and 
exclusion criteria in Section 3.3.1, and further discussion of ICF core set studies in Section 3.4.4.   
 
*
3 
These studies assessed quality or efficiency of care (clinical practice), or the performance of an individual 
institution. Indicators were often specific to that scenario/environment of care only.  
 
*
4 
These studies described the development of registries, each with its own purpose, often to evaluate 
management of patients, identify best practices or to describe therapeutic strategies.  
 
*
5 
599 of these (90%) had no abstract to assess (title only), so had to be reviewed at full paper due to potential 
eligibility based on the title alone.  
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3.4.2 Agreement between reviewers  
At stage 1, reviewers independently assessed batches of 10 abstracts (EG and BG), and the 
results were then compared and discussed. This was repeated in batches of 10 until 
complete agreement was reached. Five batches of ten were reviewed before reaching full 
agreement, with agreement of 70%, 80%, 80%, 80%; and finally 100%. Following this, a 
further 50 abstracts were reviewed and compared to confirm complete agreement 
between reviewers.  Of the 2238 abstracts reviewed at this stage, the two reviewers agreed 
98.7% of the assessments. The reviewers disagreed on 29 abstracts, so the full text for 
these were obtained and reviewed.  
 
At stage 2, reviewers independently assessed batches of 10 full papers (EG, BG, NM). These 
were then compared and discussed with the lead reviewer (EG). This was repeated until full 
agreement was achieved in three consecutive batches. The lead reviewer had full 
agreement in the first three batches with one reviewer and in the ninth, tenth and eleventh 
batches with the other. 
 
3.4.3 Checking for correct exclusion  
308 of the 26,025 (1.2%) abstracts excluded at stage 1 were reviewed by a second reviewer 
to check for correct exclusion from the review, and assessed for inclusion in the COMET 
database. None were found to have been excluded incorrectly, and no further checks were 
performed. 115 of the 2127 (5.4%) full papers excluded at stage 2 were reviewed and again 
assessed for inclusion in the COMET database. One study was found to be incorrectly 
excluded. Given this low error rate (less than 1%), it was agreed that it would not be 
efficient to undertake any further checking of the excluded full papers. 
 
3.4.4 Excluded studies  
Studies outside the scope of this review which were found in the searches include 
International classification of Functioning, Disability and Health (ICF) core set development 
papers, quality indicator studies that included an aspect of outcomes, and registry 
development. Although these studies were not eligible for inclusion in the review they 
might be relevant to COS development and they will be included in the COMET database. 
Of particular interest were the ICF development papers. ICF offers a framework to describe 
functioning, disability and health in a range of diseases. The ICF focuses on the assessment 
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of an individual’s functioning in day-to-day life. It provides a framework for body functions, 
activity levels and participation levels in basic areas and roles of social life; providing 
domains of biological, psychological, social and environmental aspects of functioning [23]. 
In many clinical areas, ICF core sets have been developed. These core sets identify the most 
relevant ICF domains for a particular health condition. We considered the inclusion of these 
core sets in this systematic review but we decided not to do so (but they will be added to 
the COMET database). Although the ICF is widely comprehensive, it is not all inclusive. For 
example, the ICF does not include outcomes such as death, an outcome that is often 
relevant to measure in clinical trials. Furthermore, as the ICF focuses on the individual only, 
caregiver outcomes would not be included. While for many clinical areas this may not be 
relevant, for some (e.g. dementia), caregiver outcomes may be core to measure. For these 
reasons, ICF core sets have not been included in the systematic review, but I provide an 
overview of the clinical areas where an ICF core set has been developed (Table 3). 
 
Table 3: ICF core sets 
Long-term context  
Chronic widespread pain  
Low back pain  
Osteoarthritis  
Osteoporosis  
Rheumatoid arthritis  
Chronic ischemic heart disease  
Diabetes Mellitus 
Obesity  
Obstructive pulmonary diseases (COPD)  
Depression  
Breast cancer  
Stroke  
Ankylosing spondylitis (AS) 
Spinal cord injury 
Systemic lupus erythematosus (SLE) 
Multiple sclerosis  
Head and neck cancer 
Sleep 
Hand conditions  
Bipolar disorders  
Traumatic brain injury  
Inflammatory bowel disease  
Amputation  
Hearing loss  
Vertigo, dizziness and balance  
Cerebral Palsy 
Situation-specific context  
Vocational rehabilitation 
Acute context  
Neurological conditions 
Musculoskeletal conditions  
Acute inflammatory arthritis 
Spinal cord injury  
Cardiopulmonary conditions  
Geriatric patients  
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3.4.5       Characteristics of included studies  
A total of 198 studies (250 reports) were included (Appendix 2). The number of reports per 
study ranged from 1 to 8. Most studies had a single report only (168/198; 85%) and 
eighteen studies had two corresponding reports. Three studies describing the work carried 
out on behalf of the Neonatal Drug Development Initiative (NDDI) were all linked with the 
same additional report that further described the methods. Three studies had three 
corresponding reports, three studies had four corresponding reports, and there were six, 
seven and eight reports for single studies. Reports were typically published in disease 
specific journals; the journal of publication is listed in Appendix 2.  
 
3.4.6       Year of publication  
The year of publication of the earliest identified report for each study is shown in Figure 4, 
which clearly shows a general increase in the number of COS over the years.  
 
Figure 4: Year of first publication of each study (N = 198) 
 
2013 Includes January to June only.  
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3.4.7       Scope of core outcome sets  
A COS may be developed to cover all aspects of a disease or health condition, but it may 
also have been developed with a focus on a particular type of treatment only, or for a 
specific age group or stage of disease. It is therefore important in reporting the scope of a 
COS to consider the specific area of health or healthcare to which it applies, along with 
details of health condition, population (age) and types of interventions [38]. The scope of 
included studies is summarised in Table 4.  This includes study aims, intended use, disease 
categories (classification according to disease name can be found in Appendix 2), 
population characteristics and intervention characteristics.  
 
Half of the studies considered outcomes whilst addressing wider clinical trial design 
decisions (51%), and half specifically considered outcome selection and measurement 
(49%).  Most studies developed recommendations intended specifically for clinical trials 
(141/198; 71%); however a further 27 studies (14%) intended their recommendations for 
health research more generally. Some studies intended their recommendations for clinical 
practice as well as trials or research generally (n=10 and n=11, respectively) and for 
regulatory purposes (n=3). Notably, one study explicitly stated they intended their 
recommendations for use in all of these situations. 
 
With regard to the age of the population that a COS was intended for, the majority of 
studies (149/198; 75%) did not specify whether their recommendations were specific to 
children, adults or both. Thirteen (7%) made an explicit statement that they intended their 
recommendations for both children and adults. Some studies made recommendations 
explicitly for one population or the other. Twenty-three studies (12%) specified they 
related to children only, and 13 (7%) to adults only, with three of these specific to ‘older 
adults’. 
 
Again, when we consider the intervention scope, the majority (115/198; 58%) did not 
specify their intentions. Only seven studies (4%) made recommendations that were clearly 
intended for all intervention types. The remaining studies (38%) specified the intervention 
type to which the COS should apply, including drugs (n=40), surgery (n=13) and vaccines 
(n=2).  
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Table 4: The Scope of included studies (N=198) 
 N (%) 
Study aims 
Considered outcomes while addressing wider clinical trial design issues (e.g. 
trial duration, ethical issues, eligibility criteria etc.)  
101 (51) 
Specifically addressed outcome selection and measurement 97 (49) 
Intended use of recommendations 
Clinical trials 141 (71) 
Clinical research 27 (14) 
Clinical research and practice  11(6) 
clinical trials and clinical practice  10 (5) 
Clinical trials and regulatory purposes 3 (2) 
Trials and observational studies  3 (2) 
Observational studies  1 (<1) 
Trials and case series 1 (<1) 
Clinical research, clinical practice and regulatory purpose  1 (<1) 
Disease Categories 
Cancer  31 (16) 
Rheumatology  28 (14) 
Neurology  24 (12)  
Heart & circulation  22 (11) 
Dentistry & oral health 12 (6)  
Infectious disease  12 (6) 
Orthopaedics & trauma 10 (5) 
Lungs & airways  8 (4) 
Gastroenterology  8 (4) 
Gynaecology  6 (3) 
Tobacco, drugs, & alcohol dependence  4 (2) 
Urology  4 (2) 
Blood disorder  3 (2) 
Anaesthesia & pain control  3 (2) 
Mental health  3 (2) 
Neonatal care  3 (2) 
Skin  3 (2) 
Others (chronic conditions, benign disease, intensive care)  3 (2) 
Kidney disease  3 (2) 
Pregnancy & childbirth  2 (1) 
Endocrine & metabolic 2 (1) 
Ear, Nose & Throat  1 (<1) 
Genetic disorders  1 (<1) 
Wounds  1 (<1) 
Health care of older people  1 (<1) 
Population characteristics  
All (adults and children stated explicitly) 13 (7) 
Children  23 (12) 
Adults  10 (5) 
Older adults  3 (2) 
Not specified  149 (75) 
Intervention characteristics 
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All intervention types 7 (4) 
Drug treatments  40 (20) 
- Drug only  34 
- Drug, and rehabilitation 1 
- Drug and delivery management  1 
- Drug and physical therapy  1 
- Drug and complementary and alternative medicine (CAM) treatment 1 
- Immunomodulatory therapies 2 
Vaccine 2 (1) 
Surgery  13 (7) 
Procedure* 5 (3) 
Device** 3 (2) 
Other*** 13 (7)  
Not specified 115 (58) 
 
*Procedure descriptions – 
Procedure - Uterine artery embolization 
Procedure - Aortic valve stenosis (AS) - transcatheter aortic valve implantation 
Procedure - Aortic valve stenosis (AS) 
Procedure - pulp treatments of primary teeth 
Procedure - drug-eluting coronary stents (DES) 
 
**Device descriptions – 
Device – Compression (n=2) 
Device - Mechanical circulatory support (MCS) 
 
***Other descriptions – 
Coronary angiogenesis 
Hip protectors 
Neuro-protective therapy (aka Neuroprotection) 
Non-surgical treatment (no other detail given) 
Operative and non-operative management 
Oral care products 
Ascorbic acid 
Exercise/physical activity 
Fall injury prevention interventions 
Behavioural therapies or other kinds of nonpharmacologic therapies 
Psychological & behavioural: Psychosocial 
Rehabilitation (vocational) 
Maternity care 
 
 
 
Studies were classified according to disease category and disease name, and the various 
disease categories for which COS have been recommended are shown in Table 4. The most 
common disease categories were cancer (n=31), rheumatology (n=28), neurology (n=24), 
heart and circulation (n=22), dentistry and oral health (n=12), and infectious disease 
(n=12); but most disease categories (63%) had less than five COS. Although the majority of 
diseases had only one COS (n=142), some diseases had more than one corresponding core 
set. These are summarised in Table 5.   
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Table 5: Number of COS per disease 
Number 
of COS 
Number 
of 
diseases 
Same 
scope 
Differences 
in scope  
Detail of differences  
1 142 0 142  
2 18 6 12 Differences in intervention (n=7), age (n=4) or 
setting (n=1). 
3 2 1 1 One core set developed specifically for 
children, but age not specified for the other 
two core outcome sets. 
4 2 1 1 One core set developed specifically for use in 
children while the other three sets did not 
appear to differ in their scope. 
6 1 0 1 One developed specifically as a patient core 
set. The remaining five sets did not differ in 
their intended scope, but one of these was 
developed specifically to address this very 
issue. 
 
3.4.8       Methods used to select outcomes  
Studies reported using a variety of methods, sometimes in combination, to select the 
outcomes for the COS. There was no description of the methods used in 16/198 (8%) 
studies. The frequency of the different methods used to select outcomes in the included 
studies is provided in Table 6. The most frequent method used was semi-structured group 
discussion (n=104, 54%), which included workshops (n=39), meetings (n=60), and round 
table discussion (n=5). A further 23 studies were classified as using an unstructured group 
discussion (12%); descriptions included task forces, work(ing) groups/parties, committees, 
boards and panels. These studies did not describe whether they had face-to-face, 
telephone or electronic discussions.  Sixty-five studies (33%) carried out a literature or 
systematic review. This was done in combination with another method in 54 of these 65 
studies (83%). Other frequently used methods included the Delphi technique (n=29, 15%), 
Consensus Development Conference (n=20, 10%), surveys (n=17, 9%) and Nominal Group 
Technique (n=15, 8%). More than one method was used in 74/198 (37%) studies. More 
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detailed description about the combination of methods used can be found in Table 6. More 
detailed information about methods is provided in Chapter 4.  
 
Table 6: The methods used to develop core outcome sets 
Main methods N (%)  
Semi-structured group discussion only 57 (29) 
- Workshop 22 
- Meeting (meeting, colloquium, conference where not described as 
consensus development conference)  
32 
- Round table discussion  3 
Unstructured group discussion only 
Descriptions include task force, work group, working group/party, committee, 
board, panel 
18 (9) 
Literature/systematic review only 11 (6) 
Consensus development conference only 12 (6) 
Delphi only 6 (3) 
Survey only 3 (2) 
NGT only 1 (1) 
No methods described  16 (8) 
 
Mixed methods – see below  74 (37) 
Delphi + another method(s) 23 (31) 
- NGT 4 
- NGT + Literature/systematic review 4 
- Semi-structured discussion (meeting& Workshop)   2 
- Systematic review + Survey  1 
- Literature/systematic review  5 
- Literature/systematic review + semi-structured group discussion 
(meeting/workshop) 
3 
- Literature/systematic review + Meeting(s) + focus group(s) + 
workshop 
1 
- Literature/systematic review + consensus conference  1 
- Literature/systematic review + survey + meeting 1 
- Meeting + survey  1 
Semi-structured group discussion (listed which method)  + another method(s) 29 (39) 
- Workshop + literature/systematic review  4 
- Meeting + literature/systematic review 13 
- Workshop and meeting  2 
- Workshop/meetings + web-based consultation  2 
- Workshop,  literature/systematic review 1 
- Workshop + survey + literature/systematic review 3 
- Round table discussion + literature/systematic review 2 
- Meeting + focus group(s) + survey  1 
- Meeting + survey  1 
Consensus development conference + another method(s) 7 (10) 
- Survey 1 
- NGT 1 
- Literature/systematic review 3 
- Meeting(s) 1 
- Literature/systematic review + survey + meeting 1 
Unstructured group discussion + Literature/systematic review 5 (7) 
NGT + another method(s) 5 (7) 
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- Survey + interview 1 
- Semi-structured discussion (workshop & meetings) 1 
- Survey 1 
- Workshop + Literature/systematic review  1 
- Literature review  1 
Survey + Literature/systematic review 1 (1) 
Focus group + rating exercise  1 (1) 
Literature/systematic review, public presentation and debate 2 (3) 
Literature/systematic review, survey and open discussion  1 (1) 
 
 
Furthermore, we found that of the 178 studies that described the methods they used to 
determine the COS, 164 (92%) did not provide an explanation regarding their choice of 
methodology. Rationale for methodological choice for the 14 studies that did provide 
explanation is provided in Error! Not a valid bookmark self-reference.. The most common 
reason provided was that the methods had been used previously to develop COS or were 
well-recognised methods for eliciting expert consensus to form guidelines. 
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Table 7: Rationale for methodological choice 
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Fried et al. 
(1993) 
NGT  
X 
  
X 
   
x x  
Sinha et al. 
(2012) 
Delphi  
         
x 
Survey  
 
x 
   
x 
   
 
Devane et al. 
(2007) 
Delphi  
X 
 
x 
   
x 
  
 
Douglas et al. 
(2009) 
Delphi, NGT  
         
x 
Khanna et al. 
(2008) 
Delphi, NGT 
         
x 
Bellomo et al. 
(2004) 
Consensus 
conference          
x 
Mease et al. 
(2005)  
Delphi  
        
x x 
Lux and 
Osborne (2004) 
Delphi  
       
x 
 
x 
Ruperto et al. 
(2003) 
Delphi, NGT  
         
x 
Schmitt et al. 
(2011) 
Delphi  
    
x 
    
 
Moniz-Cook et 
al. (2008) 
Web based 
consultation        
x 
 
x  
Cross (2005) Delphi  
        
x  
Smaïl-Faugeron 
et al. (2013) 
Delphi   
         
X 
Distler et al. 
(2008). 
Delphi  
      x    
 
 
3.4.8       Definition of consensus   
Definition of consensus was provided in 19 studies; three studies explicitly stated that this 
was decided a priori.  Agreement was typically defined as the proportion of participants in 
agreement, where the level of agreement ranged between 50% and 100% (see Table 8). In 
one study the level of agreement for the meeting part of the study was ‘less than 30% of 
the voters disagree.’ Although a definition of consensus was not specified in the remaining 
studies, there was some description about how the COS were formed in eight studies. In 
four studies this was described in terms of ‘majority’; majority vote (n=2) majority opinion 
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(n=1) and majority agreement (n=1); one study simply defined agreement as ‘unanimous 
agreement’ and the final study by ‘vote’. Two studies described an ‘iterative process’ 
leading to consensus, but this was not defined. 
 
Three studies provided a rationale for the consensus definition used. One attributed this to 
‘common sense,’ one because the threshold had been used previously, and the third 
stated: ‘We chose 66% instead of the traditional 80% as there were only nine members in 
the Steering Committee and an 80% consensus would have required agreement among 
eight of nine experts. This latter was considered an unrealistic and overly stringent 
requirement.’  
 
Ten of these nineteen studies used Likert scales to determine the importance or 
appropriateness of the outcomes (scales ranged from 5 to nine point scales) during the 
consensus process. Three studies used 100 points distribution; two studies used top three 
ranking and one study asked for top ten ranking of outcomes. No study provided a 
rationale for the choice of scale used. These 19 studies used different methods. The 
definition of consensus and rating scales used, specifically with the Delphi method and 
those that followed this with a consensus meeting, are discussed in more detail in Chapter 
4.  
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Table 8: Definition of consensus and type of rating scale (N=19 studies) 
 
Reference Method  Use of rating scales  
  
Consensus 
(value in %) 
Rationale for consensus 
definition 
Bellamy 
(1997) 
Consensus 
development 
conference  
 100 points distribution 90%  Common sense suggests 
if 90% or more 
participants agreed on a 
core set, one could claim 
a consensus, albeit 
without unanimity. 
Van Der 
Heijde 
(1997) 
NGT 100 points distribution Outcomes 
chosen by at 
least 3 out of 4 
groups  
Not reported  
Smolen 
(1999) 
NGT 100 points distribution  85%  Not reported 
Bowman 
(2001); 
Pillemer 
(2005) 
Workshop Not reported  90% Not reported 
Ruperto 
(2003) 
Delphi and 
NGT  
Rank their top 10 choices (in order 
of importance) – Delphi.  
Minimum of 
80% (NGT at 
meeting)  
Not reported  
Cross (2005) Delphi  Ranked as: Should be omitted, Not 
useful, Neutral,  
Useful and Essential 
70%  Not reported 
Mease 
(2005) 
Mease 
(2007) 
Workshop  Asked to rank which domains they 
thought were most important, and 
second and third most important 
to measure.  
50%  
 
70% 
Not reported  
Devane 
(2007) 
Delphi  5 point Likert scale: 1 = of no 
importance; 
2 = of some importance; 3 = of 
moderate importance; 4 = very 
important, and 5 = extremely 
important 
70%  Not reported 
Gladman 
(2007) 
Meeting  
 
 Not reported  72.30% Not reported  
Dent (2008) Delphi and 
meeting  
6 point scale: 1= agree strongly 
(A+);  
2=agree moderately (A); 3=just 
agree (A)); 4=just disagree (D)); 
5=disagree moderately (D); 6= 
disagree strongly (D+) 
75%; a priori Not reported  
Khanna 
(2008) 
Delphi  9 point scale: Median score 1-3 
inappropriate (complete lack of 
consensus), 4–6 uncertain (some 
consensus), 7–9 appropriate (good 
to excellent consensus). 
66%; a priori We chose 66% instead of 
the traditional 80% as 
there were only nine 
members in the Steering 
Committee and an 80% 
consensus would have 
required agreement 
among eight of nine 
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experts. This latter was 
considered an unrealistic 
and overly stringent 
requirement. 
Taylor 
(2008)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schumacher 
(2009) 
Delphi  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Workshop  
Seven point scale: 1=definitely 
necessary to 7=definitely not 
necessary 
UCLA/RAND 
disagreement 
index, whereby 
values of less 
than 1 
indicated 
agreement. 
This 
index is 
essentially 
calculated from 
the 30th and 
70th percentile 
of the 
respondents’ 
ratings, 
adjusted for 
symmetry 
between the 
central point of 
the 
interpercentile 
range and the 
mid-point of 
the rating scale. 
 
 
70% 
Not reported  
Douglas 
(2009) 
Delphi and 
NGT  
Score from 1 (least appropriate) to 
9 (most appropriate Delphi. 
Outcomes with a score of 6 or 
greater were considered in the 
committee meeting (NGT).  
80% (NGT)  Not reported 
Schmitt 
(2011)  
 
 
 
 
 
Schmitt 
(2012) 
 
 
Delphi  
 
 
 
 
 
Meeting  
9 point scale: 1–3 = not important; 
4–6 = equivocal; and 7–9 = 
important. 
60% of all 
members of at 
least 3 
stakeholder 
groups; a priori 
 
Less than 30% 
of the voters 
disagree; a 
priori 
Not reported  
Bennett 
(2012) 
Delphi  Rank top three outcomes Two or more of 
nine 
stakeholders 
ranked it 
among top 3 
outcomes  
Not reported  
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Heiligenhaus 
(2012) 
Delphi and 
meeting  
5 point scale, 1 highest 
importance and 5 lowest 
importance 
100% Not reported  
Salaffi 
(2012) 
Delphi Likert 3 point scale (patients): 
1=not relevant, not important; 
2=not very relevant, not very 
important;  
3=very relevant, very important 
 
Likert Four point scale (clinicians): 
1=not relevant, unimportant; 
2=not very relevant, not very 
important; 3=very relevant, very 
important; 4=highly relevant, 
extremely important 
70% Not reported 
Lynch (2013) Survey  5 options: Primary importance, 
Secondary importance, Not 
important/do not use, Indifferent, 
Unfamiliar with measure. ‘Primary 
Importance’ and 
‘Secondary Importance’ were 
operationally defined as positive.' 
Not Important/Do Not Use’ was 
operationally defined as negative. 
‘Indifferent’ was operationally 
defined as having no impact on 
the overall value of a measure.  
80% An 80% threshold has 
been used previously to 
identify consensus in 
surveys of orthopaedic 
surgeons with a different 
rating scale. 
Smaïl-
Faugeron 
(2013) 
Delphi 5 point scale: 1, no importance;  
2, some importance; 3, moderate 
importance; 4, very important; 
and  
5, extremely important 
70%  Not reported  
 
 
3.4.9       People involved in selecting outcomes  
Table 9 shows the participant groups that were included in these studies. The types of 
people who are regarded as (or determined to be) key to developing a COS will likely vary 
between clinical areas, but two stakeholder groups that are likely to be important to all 
COS are clinical experts and patients. Where the types of people involved were described in 
the studies in this review, almost all COS included clinical experts (173/174 studies), but 
only 18% (31/174) included patients in the process.  
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Table 9: Participant groups involved in selecting outcomes 
Participants category Sub-category N 
Clinical experts (n=171) Clinical experts* 88 
 Clinical research expertise** 67 
 Clinical trialists/Members of a clinical 
trial network 
10 
 Others with assumptions*** 52 
Patient representatives (n=31) Patients 20 
 Carers 7 
 Patient support group representatives 9 
 Service Users 2 
Non-clinical research experts 
(n=54) 
Researchers 26 
 Statisticians 20 
 Epidemiologists 11 
 Academic research representatives 4 
 Methodologists 6 
 Economists 3 
Authorities (n=40) Regulatory agency representatives 31 
 Governmental agencies 12 
 Policy makers 4 
 Charities  1 
Industry Representatives (n=32) Pharmaceutical industry 
representatives 
29 
 Device manufacturers 2 
 Biotechnology company representatives 1 
Others (n=70) Ethicists 1 
 Journal editors 2 
 Others**** (with known participants) 15 
 Others with assumptions*** 52 
No details given (n=26)  26 
 
* Clinical experts includes multiple descriptions 
 
**16 studies, participants described as 'researchers/investigators' or 'academic researchers' 
 
*** 52 studies with clinical input but unclear about involvement of others 
 
**** Workshop/meeting participants (*5), subcommittee/committee (*2), guidelines panel, military personnel, 
moderator and audience, representatives from EORTC, members with expertise in information technologies, 
informatics, clinical registries, data-standards development, expertise in vaccine safety, malaria control and 
representatives from funding agencies/registration authorities, and donor organisation, members of the 
Rheumatology Section of the American Academy of Pediatrics, the Pediatric Section of the ACR, and the Arthritis 
Foundation, the diagnostic radiology and basic science communities, and from individuals conversant with 
functional and quality of life (QOL) assessments, comparative effectiveness research, and cost/ benefit analysis 
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Patient representatives were identified most commonly via medical institutions (n=10), and 
four of these studies also used a charity or support group to identify patient participants. 
However, the majority of studies that included patient representatives did not describe 
how they were identified (18/31 studies, 58%). The number of patients that they included 
was not reported in 11 studies. A description of the methods used, the number of patients 
included and the proportion of the total participants this represents is given in Table 10 
(n=20). It was not always clear what part of the COS development process patients were 
included in (12/31 studies, 39%). In 12 studies, patients were included in generating a list of 
outcomes and prioritisation of outcomes, and the remaining seven studies included 
patients in the prioritisation of outcomes stage only. Only three studies provided some 
description of how the material for explaining outcomes was developed for this group of 
stakeholders. In two studies, clinicians explained verbally what was meant. One of these 
studies, and an additional study, also carried out a pilot phase where patient 
representatives were asked whether the questions or items were easy to understand and 
appropriate, and the wording was then refined accordingly.  
 
Table 10: Patient participation detail 
 Method  Total number of 
participants n 
Number of patient 
representatives n 
% patient 
1 Delphi (mixed panel) - Number of rounds 
not clear, all took part in all rounds  
10 1 10% 
2 Consensus Process (guidelines for trials) - 
review of RCTs and open discussion  
6 2 33% 
 
Survey (mixed)  461 Not reported Unknown - Of 335 
suggestions, 68% 
were from patients 
3* Workshops  (mixed)  OMERACT 6: 57  
OMERACT 7: 
179 
OMERACT 6: 11 
OMERACT 7: 19 
OMERACT 6: 19% 
OMERACT 7: 11% 
 
Meeting (mixed)  OMERACT 8: 80 OMERACT 8: 20 OMERACT 8: 25% 
4** Interviews (patient only) 23 23 100% 
 
Nominal Group Technique (patient only)  26 26 100% 
 
Postal survey (patient only) 254 254 100% 
5 Focus groups (mixed) 27 12 45% 
 
Rating exercise (mixed) 38 19 50% 
6 Surveys (parents and children) and Delphi 
(clinicians)  - same study  
Round 1: 95 
Round 2: 93 
Round 1: 49  
Round 2: 50 
Round 1: 52% 
Round 2: 54% 
7 SR and survey (mixed) 12 6 50% 
 
Delphi (mixed)  46 6 13% (same for all 3 
rounds) 
 Meeting(mixed)  
43 5 12% 
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8 Delphi (mixed)  Round 1: 83 
Round 2: 75 
Round 3: 68 
Round 1: 44 
Round 2: 38  
Round 3: 32 
Round 1: 53% 
Round 2: 51% 
Round 3: 47% 
9*** Focus groups (patient only)  31 31 100% 
 
Survey(patient only)   959 959 100% 
10 Focus groups (patient only)  48 48 100% 
 
Delphi (patient only)   
Did separate patient and researcher 
Delphi 
Pretest: 100  
Round 1: 73 
Round 2: 84 
Pretest: 100 
Round 1: 73 
Round 2: 84 
100% 
 
OMERACT 9 module (mixed)  not clear not clear Unknown 
11 Rating exercise (mixed) 13 3 23% 
12 Delphi (mixed)  Round 1: 218  
Round 2: 173 
Round 3: 152 
Round 1: 9  
Round 2: Not 
reported    
Round 3: 5 
Round 1: 4% 
Round 2: Unknown 
Round 3:  3% 
13 Advisory panel meeting (mixed) 11 2 18% 
14 Step 4 - survey and meeting (mixed)  
 
Step 6 - Delphi (mixed - round 3 only 
related to outcomes - previous rounds 
related to priority research questions)  
Step 4 - 6  
Step 6 - 9 
2 Step 4 (33%)  
step 6 (22%) 
15 Delphi (mixed)  - rounds not reported 338 86 25% 
16 Consensus conference (mixed) 36 2 6% 
17 Survey (mixed)  136 5 4% 
18 Workshop (mixed)  39 2 5% 
19 Workshop (mixed)  23 1 4% 
20 Workshop (mixed)  23 2 9% 
 
*COS had already been developed without patient input, so this work done to elicit patient opinion 
** Patient core set 
***COS had already been developed without patient input, so this work done to elicit patient opinion 
 
 
 
Table 11 shows the participants’ geographical location according to continent, as reported 
in the articles, as well as the median and range of number of countries included. In 34 
studies, locations for participants other than the lead contact/participating authors were 
not provided. The geographic locations of participants were predominantly North America 
(n=164; 83%) and Europe (n=150; 76%). The remaining continents were represented in less 
than a quarter of studies; Australasia (n=47; 24%), Asia (n=40; 20%), South America (n=23; 
12%) and Africa (n=13; 7%). The number of countries involved in the development of a COS 
ranged from 1 to 46 (a median of 4). 
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Table 11: Participants’ geographical location 
Continents  N (%) Median and range of 
number of countries 
North America and Europe 1 * 56 (28) 4, 2-25 
North America 2 44 (22) 1, 1-2 
Europe 3 32 (16) 2, 1-14 
North America, Europe and Australasia 4 * 13 (7) 7, 3-25 
North America, Europe and Asia 5 11 (6) 9, 5-14 
North America, Europe, Australasia, Asia 4 10 (5) 11, 6-15 
North America, South America, Europe, Australasia and 
Asia 4 * 
10 (5) 16, 5-21 
North America, South America, Europe, Australasia, Asia 
and Africa * 
4 (2) 26, 8-46 
North America, Europe, Australasia and Africa 5 ** 3 (2) 8, 3-17 
North America and Australasia  2 (1) 3, 3 
North America, South America and Europe  2 (1) 10, 9-11 
North America, South America, Europe and Asia  2 (1) 11, 7-15 
Australasia 1 (<1) 2 
North America, Europe and Africa  1 (<1) 10 
North America, South America, Asia and Africa  1 (<1) 5 
North America, South America, Europe and Australasia 1 (<1) 11 
North America, South America, Europe and Africa  1 (<1) 7 
North America, Europe, Australasia, Asia and Africa  1 (<1) 15 
North America, South America, Europe, Australasia and 
Africa   
1 (<1) 8 
North America, South America, Europe, Asia and Africa 1 (<1) 18 
Europe and Australasia  1 (<1) 2 
 
Besides the lead contact or participating authors, other participants' locations were not stated/known (
1
 – 15 
studies, 
2
 - 9 studies, 
3
 - 7 studies, 
4
 - 2 studies, 
5
 - 1 study) 
 
* In 6 studies, OMERACT participants' information was extracted from the introductory paper 
 
** In 1 study, participants’ location was based on where they had graduated  
 
 
3.4.10       Implementation and future updates  
Two papers explicitly suggested or discussed plans for the implementation of their 
recommendations. Giacoia [80], which is linked to three COS studies, stated that their 
proposed recommendations will be considered as a requirement by a governmental agency 
(NICH):  
“The study-design frameworks and/or end points proposed by the initial groups will 
be considered by the NICHD (National Institute of Child Health and Human 
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Development) in the requirements for BPCA (Best Pharmaceuticals for Children 
Act) contracts for the study of off-patent drugs in the newborn population.” 
 
Cranney [81] stated that the proposed core measures were being submitted to key 
international research groups in osteoporosis to promote their acceptance and 
implementation:  
“These suggested core measures are being submitted to the key international 
groups involved in osteoporosis research to comment and encourage the widest 
possible acceptance and implementation of these tools in future randomized 
clinical trials.” 
 
167/198 COS (84%) did not report plans to update their recommendations. Thirty-one 
(16%) included some information about updating their COS recommendations. In six 
studies, the reported planned update was in relation to how to measure the outcomes 
identified in the existing study, rather than reviewing the outcomes to measure. Two out of 
the 31 studies reported that it was hoped that an interested group of participants would 
keep the development of the core set ongoing, but did not provide any further detail. A 
further two studies hinted that there would be an on-going review of their 
recommendations, but did not say anything more specific; one described a “continued re-
evaluation” and the other “ongoing development” of the core set.  5/31 of the studies 
stated that their recommendations would be discussed and evaluated at future OMERACT 
conferences. Three studies reported that an International group had been founded to 
maintain and review the core set, but none of these stated specific plans or time frames for 
this. One study reported that the recommendations would be re-visited, as appropriate, as 
new evidence became available. Twelve studies reported a specific time frame to update 
their recommendations, which ranged between 1 year and 5 (Table 12).  
 
Table 12: Range of years stated to review COS 
Years to planned update  Number of studies  
1 1 
2 4 
3-4 2 
4 1 
4-5 1 
5 2 
No more than 5 1 
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As per the inclusion criteria of the review, all of the included COS (N=198) made 
recommendations about the domains and/or outcomes, in other words, what to measure. 
Of the total, 75 (38%) made additional recommendations about how to measure those 
outcomes, that is on how to measure the suggested core outcomes. 5/75 studies 
recommended outcomes and instruments in a two stage process: 1) determination of the 
domains/outcomes; and then 2) determination of the instruments/ measurements. The 
majority of studies (70/75 studies; 93%) determined the outcomes and instruments for 
measuring those outcomes together and it was difficult to separate the two processes. 
63/75 recommended specific instruments, such as SF-36, spirometry or HAQ-DI. The 
remaining 12 did not specify the instruments, rather provided general recommendations, 
such as use of a headache diary, health assessment questionnaire or visual analogue scale 
for pain. Although no recommendations were made for how to measure outcomes in the 
remaining 123 studies (62%), 54 of these (44%) did include discussion about this.  
 
3.5 Discussion  
This study provided the first complete assessment of COS that had been developed to 
standardise the outcomes being measured and reported in health research. The review 
identified 198 studies, in a range of health areas, and demonstrated that there has been a 
rapid increase in the development of COS over recent years. The studies identified in this 
review have been included in the COMET database.  
 
Although a wide range of health areas were identified in this review, it is clear that some 
are more active in this field than others. This review allows the identification of areas 
where COS may be lacking, and these gaps provide future opportunities for COS 
developers. Developers need to define the scope of the COS at the outset in terms of 
health condition, population and types of interventions [38]. This review suggests that this 
has not always been done or is not described adequately in the reports, which also 
suggests a need for better reporting of studies of COS development. Furthermore, there 
may be other important areas of scope to consider that were not included in this review, 
such as the staging of the disease. 
 
A striking aspect of the results is the infrequency with which patients have been included in 
the development of COS. Clinical trials are undertaken to establish whether interventions 
work and are safe for patients, so it is critical to include outcomes that they consider to be 
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important.  We found that only 16% of studies (31/198 studies) included patient 
representatives in the development process, highlighting a need to find ways of engaging 
this group of stakeholders in particular in future projects, as well as other stakeholder 
groups who would be relevant to the COS.  Most of the included studies included 
participants from more than one continent, but were dominated by North America and 
Europe. COS developers should consider including collaborators from other places as well; 
especially if a COS is to be applicable to, and adopted across, international settings.  
 
3.5.1       Strengths and limitations of the review  
I developed the search strategy in an iterative and methodological way to be highly 
sensitive, so that as many potentially relevant studies as possible were retrieved. Although 
every attempt was made to capture all relevant studies, a consequence of the lack of 
consistent indexing could be that some relevant studies were missed, along with studies 
that have been reported in journals and other places that were not indexed in the 
databases searched. We carried out hand-searching activities to try and minimise this. The 
search was performed in multiple databases, but these do have a bias towards research 
from North America and Europe. However, future efforts to identify COS and to minimise 
potential waste through unnecessary duplication would be for the bibliographic databases 
to introduce an indexing term to make them easier to find.   Another limitation is that we 
were unable to undertake a formal quality assessment of the included studies. This is 
because defining the quality of a COS is not straight forward, and no validated way of doing 
this has been developed to date. There is an urgent need to develop such an instrument, 
not least to help users appraise the quality and relevance of a COS to their research and 
practice. This is discussed further in Chapter 8. 
 
Finally, it is worth noting again that the first step in COS development is typically ‘what to 
measure’, which is the focus of this review; while the ‘how’ and ‘when’ usually come later. 
In this review we only included studies that addressed the first part of the process but, as 
an aside, of the 198 studies included in this review, 75 (38%) contained recommendations 
about how to measure the outcomes in the COS.   Although it is not the focus of this study, 
it is vital to note that this is an important stage of COS development. Work is currently 
ongoing to identify how to select outcome measurement instruments for outcomes 
included in a core set [52].  
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The outcomes that were included in the 198 COS included in the review were extracted. I 
intended on classifying these outcomes in a way that could be more meaningful to allow us 
to make comparisons and look for differences. However, when we attempted this exercise I 
naturally started by looking to see what current ways of classifying outcomes exist. As 
highlighted in Chapter 1, there are various ways to classify outcomes. This, combined with 
the high number of studies included in the review, meant it was too complex to categorise 
outcomes as it was unclear which of these various frameworks was most suitable. The issue 
of categorising outcomes is elaborated on further in Chapter 8. 
 
3.5.2       Implications  
This systematic review provided the foundations for an online resource (www.comet-
initiative.org). This is a freely accessible, publically available, searchable database that 
shows what work has been done in a particular health area. It will help to avoid 
unnecessary duplication of efforts and reduce waste in the production and reporting of 
research.  Studies identified through this extensive review, which were not already 
included in the COMET database, have been added and an annual search of the literature 
will take place to keep the database current. The ready availability of COS should make it 
easier for researchers to design new trials. For example, the SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials) guidance for protocols of clinical trials 
[56], includes a statement encouraging trial investigators to ascertain whether a COS exists 
relevant to their trial, and if so, to include those outcomes in their trial. The findings from 
this systematic review will help trialists to do this.  Furthermore, applicants to the NIHR 
HTA  programme in the UK, the Health Research Board in Ireland and the charity Arthritis 
Research UK, are now encouraged to consider COS when seeking funding for new trials. 
The COMET database will provide a resource for this.  
 
The implications of this review go beyond clinical trials; with developers of 11% of the COS 
identified noting that they intended their recommendations for clinical practice, as well as 
health research. Furthermore, the National Institute for Health and Care Excellence (NICE) 
in the UK develops guidelines to help health and social care professionals deliver the best 
possible care based on the available evidence and, since 2009, has used standard criteria 
(Grading of Recommendations Assessment, Development and Evaluation, GRADE) to assess 
the quality of the evidence by outcome, rather than by study. In addition to these methods, 
NICE now emphasises checking of the COMET database in their guideline development 
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process. This highlights the importance of the results of this review for the improved 
delivery of healthcare.  
 
3.5.3       Future work  
The credibility of a COS depends on both the use of sound methodology in its development 
and transparent reporting of these methods. This review has highlighted the need to 
improve the standards of reporting, and the COMET Initiative is now undertaking this task. 
Work will build on the preliminary checklist [38] based mainly on discussions among the 
COMET Management Group. It will follow the strategy proposed in EQUATOR guidelines 
[82] involving five major phases: initial steps, pre-meeting activities, face-to-face consensus 
meeting, post-meeting activities and post-publication activities.  This is discussed in more 
detail in Chapter 8. 
 
This review highlighted that COS have been developed in a range of ways and studies are of 
variable quality. There is currently no accepted gold standard method, and no way of 
determining or assessing the quality of COS studies; this review has highlighted the need 
for such an instrument. A quality assessment instrument for studies developing COS will 
need to use criteria that are valid and reliable so that COS developers and users can assess 
the quality of a COS, helping in the decision about whether a COS is good enough to be 
adopted on, in some cases, in choosing between COS. This is discussed further in Chapter 8.  
 
Categorising outcomes was a major challenge of this review. An outcome classification 
system that would allow this would also be helpful to future COS developers to help them 
think about potentially relevant outcomes. As such there is the need for a more formal 
review of the existing frameworks and schemes for doing this. An appraisal of existing 
methods would allow us to see which, if any, is most suitable for categorising outcomes. 
This is discussed further in Chapter 8.  
 
3.6 Summary 
In conclusion, this review identified 198 studies that have addressed the development of 
COS for measurement and reporting in clinical trials. I have highlighted future areas of 
research, including the need for methodological guidance for COS development, and 
methods for engaging key stakeholder groups, in particular patient representatives. Finally, 
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the review has shown that it is not always possible to identify key features of the 
development of a COS from the published report, highlighting a need for better reporting 
and indexing of COS development studies. The work done for this review has brought 
together the existing research in a single place, and provides a basis for improving 
standards for ongoing and future work to develop COS.    
 
The rationale for methodological decision making, including choice of methods, choice of 
stakeholder groups and definitions for consensus, has not been well documented to date.  
By exploring this we will better understand why COS developers have done things so far, 
enabling us to better inform how COS developers might do this work in the future. 
Furthermore, it would seem that COS developers have not reported their plans regarding 
the implementation of their recommendations, or plans to review or update them. These 
may not have been a priority for COS developers, or may have been beyond the scope of 
these papers. Further work is required to explore these important issues. Chapters 5 to 7 
describe work undertaken to understand COS developer’s experiences of COS. Firstly, 
Chapter 4 will describe additional data, from the systematic review, about the most 
commonly used methods by ongoing studies. It is important to know more about the 
methods that are being used presently in order to inform current practice.  
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Chapter 4: Methods used to develop 
core outcome sets    
4.1 Background 
The systematic review described in Chapter 2 and 3 identified 198 studies, in a range of 
health areas, and demonstrated a rapid increase in the development of COS over recent 
years. The systematic review highlighted that a range of methods had been used, in a 
variety of ways, to develop COS in these published studies. The first part of this chapter will 
provide a description of general COS methods identified in the systematic review. 
 
While the systematic review provided information about the range of methods that had 
been used to develop COS historically, we need to know more about the methods that are 
being used presently in order to inform current practice. At the end of 2014, the COMET 
database included a total of 57 studies listed as ongoing COS studies. The most common 
combination of methods used by these ongoing studies was a systematic review, together 
with a Delphi survey, and sometimes followed by a consensus meeting. This chapter will 
therefore describe additional data, from the systematic review, about studies that used 
these specific methods, so that we can learn more about how these methods have been 
used previously.    
 
4.1.1 Overview of methods used in core outcome set development  
The methods described in this section were used in studies identified in the systematic 
review of COS. A summary of the characteristics of each method is provided in Table 13.  
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Table 13: Characteristics of methods used in the development of core outcome sets 
 Group 
interaction   
Elicit individual 
responses from 
all participants  
Face to 
face  
Non face to face 
(e.g. telephone, 
internet, email) 
Participant 
anonymity  
Group discussion  X  X x 
Focus group     X x 
Consensus 
development 
conference  
 X  X x 
Delphi Technique  x     
Questionnaire 
survey 
x  x   
Nominal Group 
Technique (NGT) 
   X x 
Individual interview  x     
Systematic review  x X x X x 
 
 
Group discussion 
Unstructured group meetings, such as committees, are largely open, unstructured and 
informal with few rules, procedures or guidelines. Interaction between participants is not 
structured. These group discussions, which are often termed “free discussion” or simply 
“consensus” groups, bring together a group of people to discuss a problem with the 
ultimate aim of reaching consensus.  
 
The dynamics involved in groups may adversely impact on the decision making process and 
quality of decisions reached. These include that the desire to reach agreement may 
override the true result; and dominant individuals or social factors may affect group 
performance [83]. Furthermore, although this method would potentially allow the 
presence of multiple or different stakeholders, the lack of formal process and structure 
may not ensure that each stakeholder’s view is elicited.  
 
In semi-structured or structured group discussion, the discussion is often steered by a 
facilitator. This more formal structured process may eliminate some of the negative aspects 
of unstructured group decision making [83]. Semi-structured discussion techniques might 
include discussion at conference meetings and workshops. Focus groups are one example 
of structured group discussion.  
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Focus group 
Focus groups are a form of group interview, in which group members meet face to face 
together in one place, to discuss a particular issue under the direction of a facilitator. 
Groups are usually small, typically six to twelve people, and usually last between one and 
two hours. Each participant may also complete individual questionnaires to enable the 
researcher to compare what is said in public and private.  
 
Focus groups have the advantage of making use of group dynamics to stimulate discussion, 
gain insight and generate ideas to pursue a topic in greater depth [84]. It has been 
suggested that focus groups allow the interviewer to encourage participants to explore the 
issues of importance to them, and pursue their own priorities [85]. There are also the 
associated downsides of such group dynamics including the potential for vocal individuals 
to dominate discussion, which may limit the usefulness of the data. While this method 
allows for multiple/different stakeholders to be involved simultaneously, small group 
numbers may make it challenging to make sure that all key stakeholder groups are 
represented and representative. It may therefore be necessary to conduct multiple focus 
groups, which is likely to be time consuming and expensive.  
 
Consensus development conference 
In the 1970s,The National Institutes of Health (NIH) set up the NIH Consensus Development 
Programme in the US with the aim of bringing together people to seek general agreement 
on the safety and efficacy of use of various medical procedures, drugs and devices [86]. As 
part of this, they held consensus development conferences that they argued were 
preferable to traditional conferences. Traditional conferences address the status of 
research on a particular topic with limited discussion amongst individuals with diverse 
viewpoints, while consensus development conferences focus on the application of research 
and the objective is to provide resolution, including in situations where no clear answers 
are possible in the existing environment. One of the main reasons for initiating consensus 
development conferences in the UK was to promote change in health care policy and 
practice [87]. 
 
Key features of consensus development conferences include: 
(1) Background reports are prepared – individual experts or task forces are 
commissioned to compile summaries of current knowledge 
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(2) Audience participation is encouraged –all NIH consensus development conferences 
were free and open to the public   
(3) Panel to assess the evidence presented – panel members should be carefully 
selected to represent the range of individuals and organisations with expertise and 
interest.   
 
The conference begins with a session for individuals or representatives of task forces to 
present information. Comments by panellists may follow, and there is then time for 
questions and comments from the audience. The panel then convenes in an attempt to 
reach agreement. In the final session, the consensus statement(s) are presented to the 
audience, and there is again time for comments, and endorsement. The consensus 
statement may then be revised after the conference for publication. This may also be 
circulated to a “larger” group after the conference to seek a broader consensus.  
 
Consensus development conferences have been criticised for providing little information 
on how consensus is defined, having a lack of formal criteria for making decisions and an 
absence of formal voting, as well as variations in the process.  These variations include the 
nature of the audience and who is deemed the primary target of the consensus outputs; 
the pre-panel process including selecting the chair, panel members and preparation of 
background information; the panel meeting stage including meeting activities and the 
group process by which consensus is actually achieved [88]. In a critique of the consensus 
development conference following a conference about early melanoma, Ackerman reports 
that one subject discussed was not alluded to in the statement issued by the panel. 
Akerman goes on to suggest that the volume of information together with unreasonable 
time constraints may be problematic for the panel, no matter how competent or 
representative the composition [89]. Critics have also suggested that no new data are 
generated by consensus conferences and that innovation in research may be stifled or 
ideas restricted [87].  
 
Delphi technique  
The Delphi technique was designed as a method of improving decision-making by eliciting, 
formulating and refining group judgements. It is a method of reaching consensus, 
employing the rationale that “n heads are better than one,” when dealing with conflicting 
scientific evidence or uncertainty [90]. The Delphi technique was originally developed as a 
forecasting tool for technological developments, but its early application extended to policy 
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decisions in education, public transportation and public health [90]. Its application today 
remains diverse, but it is being increasingly used in research studies aiming to achieve 
consensus about the outcomes that should be measured in trials of specific conditions.  
 
Dalkey described three key features of the Delphi technique: 
(1) Anonymous response – opinions of the group are obtained by formal questionnaire 
(2) Iteration and controlled feedback – interaction is effected by a systematic exercise 
conducted in several iterations, with carefully controlled feedback between rounds 
(3) Statistical group response – the group opinion is defined as an appropriate 
aggregate of individual opinions on the final round.  
 
The advantages of this technique are that it helps to minimise the likelihood that the group 
is influenced by the views of dominant or senior individuals, to avoid irrelevant 
communication, and to minimise or avoid the influence of group pressure to conform. It is 
also generally fast, inexpensive and easy to understand [91]. Improvements in global 
communication (e.g. internet) have made it feasible to use the Delphi technique to involve 
geographically distant participants, and in larger numbers, and from different/multiple 
stakeholder groups, than may be possible in face to face situations [59].  
 
The Delphi technique has been subject to criticism and the validity of the technique has 
been questioned. One critique of the Delphi technique questions whether a group dilutes 
the opinion of “the real expert” on the particular question or uncertainty that is being 
considered [92]. The technique has also been criticised for being open to interpretation. 
For example, the use of the word “appropriate” in the description by Dalkey raises 
methodological questions about how “appropriate” is decided. This inevitably leads to 
variation in how the Delphi technique is conducted, and could therefore also influence the 
quality of the decisions reached. Furthermore, the question of how an “expert” is defined 
has also been criticised as this is an arbitrary term [91, 93]. The title of ‘expert’ is 
misleading, and refers to individuals who have knowledge of, or experience with, a 
particular topic, and the question of definition relates to the selection procedures used for 
selecting panellists. It has also been suggested that anonymity may lead to lack of 
accountability of the views expressed, resulting in hasty or ill-considered judgements [93], 
and that the feedback process may in fact lead participants towards superficial or 
premature conformity rather than consensus or true agreement [91]. Furthermore, the 
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existence of consensus does not mean that the “correct” answer has been found, as 
“misinformation may be aggregated into a less reliable opinion”[90]. As one of the most 
highly utilised methods, it may be that the Delphi technique has been subject to more 
critical scrutiny than the other methods described here. 
 
In a review of 150 studies using the technique for scientific and technological forecasting in 
a range of areas, such as education, communication technology and medicine, Sackman 
found that many variants existed with some departing widely from the original Delphi 
procedure, and he concluded that there was an absence of an agreed, universally accepted, 
working definition of Delphi. Despite these criticisms, the technique has continued to be 
widely used. More recently, however, the technique has also been criticised for there being 
no consistent method for reporting findings of such studies, and it is suggested that such 
standards might help readers to judge the reliability of the method and results obtained   
[94]. A systematic review of studies that used the Delphi technique to determine which 
outcomes to measure in clinical trials, similarly concluded that there was variability in both 
methodology and reporting of studies using Delphi for this purpose [59].  This resulted in 
recommendations to improve the quality of studies that use the Delphi process for 
determining outcomes to use in clinical trials, including the recommendation that patients 
and clinicians be involved, researchers and facilitators avoid imposing their views on 
participants, and attrition of participants be minimised.  
 
Questionnaire survey 
Questionnaires are often used as a means of collecting information about people’s 
knowledge, opinions and attitudes. Questionnaires can be used as the sole research 
instrument, but are often used within a mixed methodology study. Questionnaires may be 
validated or not, may use open ended or closed questions and can be presented in various 
ways [95]. They are used in face to face, postal and telephone surveys. The main strengths 
of a structured questionnaire include the ability to collect unambiguous and easy to count 
answers. The method leads to economical data collection, so large samples can often be 
included [84].  
 
Their weakness is that limited response choices may not be sufficiently comprehensive, and 
not all answers may be easily accommodated, so responders may be forced to choose an 
answer that might not fully represent their view. Furthermore, nuances and contextual 
factors are difficult to capture.  Although the advantages of a self-administered 
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questionnaire or postal questionnaire may be a reduction in social desirability and 
interviewer bias, this technique is not recommended for complex issues or long 
questionnaires as the interviewer is unable to clarify questions or to probe [84]. It is also 
noted that it might be possible for respondents to read all the questions before answering 
any, with the possibility of answering in any order they wish, which may affect their 
response.  
 
Nominal Group Technique (NGT) 
The NGT was developed in the context of committee decision making, for the purpose of 
structuring interaction within a group [96]. The purpose of NGT is to generate information 
in response to an issue that can then be prioritised through group discussion [97], and since 
its development, NGT has continued to be widely used in a range of fields including 
education and health. There have been an increasing number of health-care studies that 
use NGT, for example to develop a list of problems that people with type 2 diabetes 
associate with sleeplessness [98].  
 
Firstly, each participant records their opinion independently. Then, in a “round-robin” 
format by means of a facilitator, the ideas are listed from each individual in turn and listed 
in front of the whole group. Each idea is then discussed, in turn, by the group. Each 
member of the group is then asked to vote or rate each idea, before coming together to 
discuss. Further discussion and voting may take place, and the final group opinion is 
compiled. The key feature of NGT is structured face to face meetings. It allows disparate 
ideas to be expressed and collated, with a view to identifying areas of consensus and 
establishing priorities for change, with the collaborative nature of NGT said to increase the 
participants’ ownership and accountability  [99]. It enables participants to become fully 
involved in the decision making, and prevents groups from focussing on one particular area 
at the expense of others. 
 
One advantage of the NGT is that the process provides both quantitative data in the voted 
upon priorities to quantify variation, and qualitative data in terms of descriptive discussion 
to describe variation.  It also ensures that each participant’s view is represented, allowing 
inclusion of multiple/different stakeholders; helping to minimise the likelihood of the group 
being influenced by the views of dominant or senior individuals. Practical advantages of 
NGT include time and resource efficiency, as participants’ input is usually limited to a single 
meeting [97]. However, this may also be seen as a disadvantage as all participants must be 
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available to convene at the same time and place. The often immediate dissemination of 
results to the group involved, may also promote satisfaction with participation [97].  
 
Individual interview  
The interview is the most widely used method of producing qualitative health research 
[100]. It is directed towards the researcher’s particular needs for data. Interviews are often 
classified according to how far the researcher directs the interview. In structured 
interviews, the researcher directs the interview completely, and follows a specified set of 
questions in a particular order. These are typically used in survey designs. At the other end 
of the scale are informal interviews. These are often more conversational in nature and are 
likely to occur fortuitously, leading to a more opportunistic gathering of data. Between 
these extremes is the semi-structured interview, also referred to as narrative and in-depth. 
In this type of interview the researcher will set the topics covered and ask specific yet open 
ended questions, but the interviewee’s response directs the interview and the kinds of 
information produced [100].  
 
Advantages of individual interviews include providing the opportunity to explore topics in 
depth, allowing the interviewer to explain or clarify questions thereby increasing the 
likelihood of useful responses, and allowing the interviewer flexibility in administering the 
interview to the particular individual or circumstance. One main advantage of this method 
is that it allows each participant the opportunity to express his/her own viewpoint. 
However, there are also disadvantages to this method. Individual interviews can be both 
expensive and time consuming [84], and there are other practical challenges including 
social, environmental and cultural factors [100]; and there is also the possibility that both 
interviewer and interviewee can influence the process. Flexibility across interviews could 
also result in inconsistencies across interviews.   
 
Systematic review  
A systematic review is a way to bring together the evidence to answer a specific research 
question [12]. It will usually fit pre-specified criteria and is done by combining the results of 
several studies.  The procedure is designed in a way to minimise bias and uses transparent 
processes to find, evaluate and synthesise the relevant research.  The Cochrane 
Collaboration (www.cochrane.org) strives to produce high-quality relevant systematic 
reviews and is the benchmark for high-quality information about health care. The Cochrane 
Handbook Systematic Reviews of Interventions states the following five criteria that define 
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a systematic review. Although a systematic review of outcomes differs to a review of 
interventions, the same underlying systematic review principles apply: 
 a clearly stated set of objectives with pre-defined eligibility criteria for studies; 
 an explicit, reproducible methodology; 
 a systematic search that attempts to identify all studies that would meet the 
eligibility criteria; 
 an assessment of the validity of the findings of the included studies, for example 
through the assessment of risk of bias; and 
 a systematic presentation, and synthesis, of the characteristics and findings of the 
included studies. 
 
Systematic reviews differ from literature reviews in that literature reviews tend not to 
include a systematic search of the literature and may focus on only parts of the available 
data [101]. Although literature reviews can be informative and can provide an overview of 
the area, they may include an element of bias that systematic reviews should not.  
 
Throughout Chapter 4, I will provided details of studies identified in the systematic review 
of COS (as described in Chapter 3), that used these methods in COS development.  
 
4.2 Aims  
To provide information from published COS about those methods that are used most 
commonly in present COS development; specifically systematic reviews, the Delphi 
Technique and consensus meetings (when done in combination with Delphi).  
 
4.3 Methods  
The full systematic review methods are described in Chapter 3. The following data was 
extracted specific to these methods: 
 
Literature or systematic review:  
 
1. Topic/focus of review  
a. Did the study include a review of instruments/definitions? 
 
74 
 
2. Type of studies included  
 
3. Language of included studies 
 
4. Date range searched  
 
5. Databases searched  
 
6. How they classified/grouped outcomes 
 
7. The conclusions of the review  
 
The Delphi technique: 
 
1. Number of panels 
 
2. Number of rounds 
 
3. Administration of questionnaires  
 
4. How was the original list of outcomes generated? 
 
5. Information provided to participants before the first round 
 
6. What was asked in each round? 
 
7. Method to remove or reduce the outcomes  
 
8. Composition of the groups  
 
a. Countries and continents represented  
 
9. Level of anonymity  
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10. How consensus was reached 
 
a. Was Delphi the final method? 
b. Definition of consensus  
 
The recommended checklist of study characteristics and results that should be reported in 
studies using the Delphi technique to determine outcomes [59] was used to assess the 
quality of reporting in these studies.  
 
Consensus meeting: 
 
1. Description of what happened during the meeting (discussion, presentation, 
voting) 
 
2. Duration of meeting 
 
3. Who conducted/led the meeting 
a. Who assisted  
 
4.  Participants 
a. Number and type of participants  
b. Countries and continents represented  
 
  
5. Level of anonymity  
 
6. How consensus was reached 
a. Definition of consensus  
 
4.4       Results  
4.4.1 Literature or systematic review 
Sixty-five studies (33% of 198 included in the systematic review) carried out a literature or 
systematic review as part of their methods to develop a COS. This was done in combination 
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with another method in 54 of these 65 studies (83%). Table 14 summaries the type of 
review that was performed in each study. 
 
Table 14: The type of review that was performed  
Type of review  n 
Outcomes only  7 
Outcomes and outcome measurement instruments 23* 
Outcomes and  outcome definitions  7*1 
Outcomes,  outcome measurement instruments and outcome definitions 9 
Outcome measurement instruments  1 
Study design only  7 
Study design including outcome measurement instruments 2*1 
Study design including outcome definitions  3 
Study design including outcome measurement instruments and outcome definitions 2*1 
Methodological issues only  1 
Methodological issues  including  outcome measurement instruments 1 
Quality of reporting  including outcome definitions  1 
study design and quality of reporting including outcome measurement instruments 1 
 
* This was not explicitly stated in 4 of these studies, but assumed due to the discussion in the paper 
 
*
1
 This was not explicitly stated in 1 of these studies, but assumed due to the discussion in the paper  
 
 
The rest of this summary relates to the 46 studies that carried out a review of outcomes.  
 
Eighteen studies (39%) did not state the type of studies they included in their review. Of 
those that reported the types of studies they included,  clinical trials were the most 
frequent type of study to be included (24/28; 86%), one of which also included longitudinal, 
cohort studies, case control studies and consecutive case report series in addition to clinical 
trials. The descriptions of the included studies in the remaining four studies are provided in 
Table 15.  
 
Table 15: Descriptions of other types of included studies (n=4) 
Descriptions of included studies 
Articles relating to the use or validity of asthma indicators 
Existing data standards sources 
Articles discussing research design, cohort, case control, and cross-sectional studies 
Research cited in community acquired pneumonia  guidelines 
77 
 
Twenty of the studies (44%) did not provide information about the language of included 
studies. Eighteen of the 26 that reported language restrictions (69%) included English 
studies only, and three included other language studies in addition to English (Italian; 
German and French; German, French, Spanish and Italian). Five studies did not apply any 
language restrictions to their search.    
 
Seventeen studies (37%) did not state the date range searched. Six studies (21%) did not 
apply any date restrictions to their search. The number of years reported in the remaining 
twenty-three studies ranged between two and 59. Frequencies are provided in Table 16.   
 
Table 16: Number of years searched (n=23) 
Number of years searched  Frequency  
Less than 5  1 
5 to 9 3 
10 to 14 5 
15 to 19 2 
20 to 24 5 
25 to 29  0 
30 to 34 0 
35 to 39 4 
More than 40 3 
 
 
The number of databases searched was not reported for seventeen studies (37%). Two 
studies did not perform an electronic database search. Twenty-seven studies described 
which databases they searched (Table 17). The number of databases searched ranged 
between 1 and 8; frequencies are also provided in Table 17.  
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Table 17: Frequency of number of databases searched (n=27) 
Number of databases  n Databases searched  
1 15 Medline (n=9) 
PubMed (n=4) 
Central Register of Controlled Trials (n=2) 
2 6 Medline and Embase (n=2) 
PubMed and Central Register of Controlled Trials 
(n=1) 
Medline and CancerLit (n=1) 
Medline and Central Register of Controlled Trials (n=1) 
Medline and PubMed (n=1) 
3 1 Medline, Cinahl and Embase (n=1) 
4 0  
5 1 Medline, PreMedline, CancerLit, PubMed (National 
Library of Medicine) and Cochrane Library  
6 0  
7 2 Cochrane Oral Health Group’s Trials Register 
CENTRAL, 
Medline, Embase, Science Citation Index Expanded, 
Social 
Science Citation Index, Index to Scientific and 
Technical 
Proceedings, System for Information on Grey 
Literature in 
Europe (n=1) 
Cochrane Skin Group Specialised Register, the 
Cochrane Central Register of Controlled Trials in The 
Cochrane Library (Issue 4, 2009), Medline, Embase, 
AMED, PsycINFO, LILACS (n=1)  
8 2 CINAHL (Cumulative Index to Nursing and 
Allied Health Literature), Embase, Medline,  
National Criminal Justice Reference Service 
(NCJRS),  PsycINFO, Sociological Abstracts, The 
Cochrane Database, The Patient-reported Health 
Instruments 
(PHI) website (n=1) 
Medline, PubMed, Embase, PsycINFO, Cinahl, Web of 
Sciences, Cochrane Central Register of Controlled 
Trials, and Cochrane Database of Systematic Reviews 
(n=1) 
 
 
Ten studies provided some detail about how they classified/grouped outcomes. The level 
of detail is variable, and is provided per study in Table 18. 
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Table 18: Methods for classifying/grouping outcomes (n=10) 
Reference  Method for classifying/grouping outcomes  
Duncan (2000) Each outcome measure was classified into one of the following categories: death or, at 
the level of pathophysiological parameters (blood pressure, laboratory values, and 
recanalization), impairment, activity, or participation. Measures were classified according 
to the system used by Roberts and Counsell [102], which includes the Rankin/modified 
Rankin scale as a measure of activity rather than participation.  
Sinha (2012) Each outcome was grouped into one of the following six outcome domains, some of 
which were further divided into subdomains: disease activity, physical consequence of 
disease, functional status, social outcomes and quality of life, side effects of therapy and 
health resource utilisation. Where it was unclear which domain was appropriate, this was 
resolved by discussion between the authors. Reference given in support of this approach: 
Sinha et al 2008, ‘A systematic review of studies that aim to determine which outcomes 
to measure in clinical trials in children’  [58]. 
Broder (2000) List developed by staff at institution (but no further detail). 
Distler (2008) The results of this literature search were discussed at the first meeting of the steering 
committee. Based on this discussion, a list of 17 domains and 86 tools was set up for the 
first stage of the Delphi exercise to define outcome measures for a clinical trial in PAH-
SSc. Domains were defined as a grouping of highly related features that describe an 
organ, disease, function, or physiology (e.g., cardiac function, pulmonary function, and 
quality of life).  
Devane (2007) Outcome measures addressing similar dimensions or events were discussed by the team 
and collapsed where possible. For example, various modes of delivery/birth were 
presented as ‘‘mode of birth (e.g., spontaneous vaginal, forceps, vaginal breech, 
caesarean section, vacuum extraction).’’ This pilot tool was tested for clarity, with a 
sample of 12 participants, including 3 maternity care consumers, and subsequently 
refined. 
Smaïl-Faugeron (2013) “Because we expected a large diversity in reported outcomes, we grouped similar 
outcomes into overarching outcome categories by a small-group consensus process. The 
group of experts consisted of 6 doctors in dental surgery specialized in paediatric 
dentistry, including 3 clinical research investigators. First, the group identified outcomes 
that were identical despite different terms used across trials. Second, different but close 
outcomes (i.e., outcomes that could be compared across studies or combined in a meta-
analysis) were grouped together into outcome domains. Finally, the group, with 
consensus, determined several outcome categories and produced a reduced-outcome 
inventory.” 
Merkies (2006)  In advance of the workshop, a list of outcome measures applied in treatment trials was 
prepared including their scientific soundness, WHO and quality of life classification (WHO 
classification reference is ICF). 
Rahn (2011) From this outcome inventory, the outcomes were organized and grouped into eight 
proposed overarching outcome domains. Categories were determined based on their 
applicability to all potential interventions for abnormal uterine bleeding and the physician 
expert group’s consensus of their relevance for informing patient choices. Outcomes 
related to cost, resource use, or those determined by the review group to have limited 
relevance for assessing clinical effectiveness were excluded from categorization and 
further analyses.  
Chow (2002) Some detail but process not described -  
The endpoints employed in previous bone metastases trials of fractionation schedules 
were identified and listed in the first consensus survey under the following headings: 
1. Pain assessments; 2. Analgesic assessments and primary endpoint; 3. Endpoint 
definitions; 4. Timing, frequency and duration of follow-up assessment; 5. When to 
determine a response; 6. Progression and duration of response; 7. Radiotherapy 
techniques; 8. Co-interventions following radiotherapy; 9. Re-irradiation. 
10. Non-evaluable patients (lost follow-up) and statistics; 11. Other endpoints. 
12. Other new issues and suggestions; 13. Patient selection issues. 
Van Der Heijde (1997) Grouped into patient assessed, physician assessed or physician ordered measures.  
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The results/conclusions of the reviews were not reported for 14 studies (30%). The most 
common conclusion was a lack of consistency in the measurement or reporting of 
outcomes (n=22).  A summary of the conclusions drawn from the reviews is provided in 
Table 19.  
 
Table 19: Conclusions from reviews, provided in 32 studies (not mutually exclusive) 
Conclusion  N 
No consistency in the selection/measurement/reporting of outcomes 22 
Work is needed to develop a core set/agreement 9 
Outcomes recommended 6 
No consistency in how outcomes are measured (instrument, timing) 7 
Outcome measures used in trials have limitations (e.g. not been validated) 7 
No consistency in the definition of outcomes 4 
Measurement (instruments) recommended 1 
 
 
4.4.2 The Delphi Technique 
Twenty-nine studies (15% of the 198 included in the systematic review) included the Delphi 
technique as part of their methods to develop a COS. Six studies used the Delphi technique 
only. The various combinations of Delphi used with other methods (n=23) are provided in 
Table 6 in chapter 3. Systematic reviews (n=10) or literature reviews (n=4) were conducted 
in 14 studies prior to the Delphi exercise.  The Delphi technique was used in three studies 
to identify research questions or priorities related to trial design rather than prioritising 
outcomes, and are therefore excluded hereafter. A summary of the reporting quality of 
studies using the Delphi technique (n=26) is shown in Table 20.    
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Table 20: Reporting quality of the 26 studies using the Delphi Technique 
  Before Sinha et al’s 
guidelines  (pre 2011)
* 
After Sinha et al’s 
guidelines  (2011 or later) 
 
Broad aspect 
of reporting  
Specific items assessed  Clearly 
reported 
  
n (%) 
Not clearly 
reported 
n (%) 
Clearly 
reported 
 
n (%) 
Not clearly 
reported 
n (%) 
N/A 
 
n (%) 
Size and 
composition 
of panel  
Number of participants  19 (73) 0 (0) 7 (27) 0 (0) 0 (0) 
Types of participants (e.g. 
clinicians, patients) 
19 (73) 0 (0) 6 (23)  1 (4) 0 (0) 
Proportion of each type of 
participant  
18 (69) 1 (4) 6 (23)  1 (4) 0 (0) 
How participants were 
identified/sampled 
19 (73) 0 (0) 7 (27) 0 (0) 0 (0) 
Methodology 
of the Delphi 
Administration of 
questionnaires (e.g. postal) 
17 (65) 2 (8) 6 (23)  1 (4) 0 (0) 
How items were generated 
for first questionnaire 
14 (54) 5 (19) 7 (27) 0 (0) 0 (0) 
What was asked in each 
round  
15 (58) 4 (15) 6 (23)  1 (4) 0 (0) 
Information provided to 
participants before the first 
round  
9 (35) 10 (39) 3 (12) 4 (15) 0 (0) 
How the overall group 
response was fed back  
6 (23) 13 (50) 2 (8) 3 (12) 2 (8)
a
 
Level of anonymity  12 (46) 7 (27) 6 (23) 1 (4) 0 (0) 
A priori definition of 
‘‘consensus’’ about whether 
an outcome should be 
measured 
2 (8) 8 (31) 1 (4) 4 (15) 11 (42)
b
 
Were non-responders 
invited to subsequent 
rounds 
9 (35) 6 (23)  3 (12) 2 (8) 4 (15)
c
 
2 (8)
a
 
Results Number of respondents to 
each round  
15 (58) 4 (15) 6 (23)  1 (4) 0 (0) 
Number who completed 
every round  
13 (50) 6 (23)  4 (15) 3 (12) 0 (0) 
Results for each outcome in 
each round  
0 (0) 19 (73) 5 (19) 2 (8) 0 (0) 
Group response for each 
outcome (final round) 
11 (42) 8 (31) 6 (23)  1 (4) 0 (0) 
Distribution of response for 
each outcome in the final 
round  
5 (19) 14 (54) 2 (8) 5 (19) 0 (0) 
List of all outcomes that 
participants agreed should 
be measured  
10 (39) 0 (0) 5 (19) 0 (0) 11 (42)
b
 
*
Twelve studies were included in Sinha et al’s review of Delphi studies. The systematic review in Chapter 3 identified an 
additional 7 studies in this time period.  
a
Only one round of voting, therefore no feedback. 
b
Reaching final consensus was not the aim of the Delphi process. 
c
All participants responded to each round, so no discussion was made regarding non-responders. 
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Composition of the group 
The number of participants varied from 8 to 338 with a median of 35. Fifteen studies 
included less than 50 participants (58%), which increased to 89% for less than 100. Only 
three studies included more than 100 participants. The size and composition of the groups 
is described in Table 21.  
 
15 studies (58%) identified participants through one source only.  Participants were most 
frequently identified through health professional (n=9) or clinical trial (n=8) networks. Five 
studies included participants known to the authors/facilitators; this was the sole method in 
one study.  Other ways of identifying participants included published researchers (n=4), 
research groups (n=2) and recognised experts or professionals (n=2). Four studies identified 
participants (patients or clinical experts) via clinical settings (e.g. a clinic) and three studies 
used patient groups to identify participants.  
 
Clinicians were involved in all Delphi Studies, although the percentage of clinicians was 
unclear in two studies. Twelve studies (46%) included 100% clinicians, and the remaining 
twelve studies included between 24 and 92%. Nine studies involved patient representatives 
in the Delphi study, which ranged from 10 to 76 %. The proportion of patients was unclear 
for one study. Eight studies included additional participants including methodologists, 
FDA/NIH representatives, industry representatives and journal editors. These are described 
in Table 21.  
 
Ten studies conducted the Delphi in one Country only; eight in the US, one in the UK and 
one in Italy.  The number of countries was unclear for two studies. The remaining 14 
studies had between four and 46 countries involved, with a median of 11. A breakdown of 
these countries is provided in Table 21. Participants were involved from various continents. 
Most studies involved participants from North America (n=23; 92%) and Europe (n=16; 
64%). Participants from Asia (n=10; 40%), and Australasia (n=9; 36%) were also 
represented. The least represented continents were South America (n=6; 24%) and Africa 
(n=4; 16%).  
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Table 21: Composition of Delphi groups 
Study Method of 
identification of 
the sample of 
participants 
Number 
of 
participan
ts  
Number 
(%) of 
clinical 
professio
nals  
Number 
(%) of 
patient 
represent
atives 
Other types 
of 
participants 
included in 
the study (%) 
Number of countries 
represented: Names 
(Continents) 
White 
(1995) 
Health 
professional 
network  
12 11 (92) 0 Researcher 
n=1 (8) 
1: USA (North America) 
Broder 
(2000) 
Speciality societies 
Staff at institution  
10 9 (90) 1 (10) 0 1: USA (North America) 
Basson 
(2000) 
Specialty societies 
Key published 
researchers  
19 19 (100) 0 0 5: Canada, Denmark, 
Italy, The Netherlands, 
USA (Europe and North 
America) 
Miller 
(2001) 
Clinical trial 
network 
Patient support 
group 
70 Unclear Unclear 
0 14: USA, Hungary, Czech 
Republic, Sweden, UK, 
Israel, Mexico, France,  
Germany, The 
Netherlands, Canada, 
Guatemala, Italy, Korea 
(North America, Europe 
and Asia) 
Ruperto 
(2003) 
Clinical trial 
network 
267 267 (100) 0 
0 46: Argentina, Australia, 
Austria, Belgium, Brazil, 
Bulgaria, Canada, Chile, 
Costa Rica, Croatia, Cuba, 
Czech Republic, Denmark, 
Finland, France, Georgia, 
Germany, Greece, 
Hungary, Israel, Italy, 
Korea (South), Latvia, 
Lithuania, Luxembourg, 
Mexico, The Netherlands, 
New Zealand, Northern 
Ireland, Norway, Poland, 
Portugal, Russia, Saudi 
Arabia, Singapore, 
Slovakia, South Africa, 
Spain, Sweden, 
Switzerland, Tunisia, 
Turkey, UK, USA, 
Yugoslavia (North 
America, South America, 
Europe, Asia, Australasia, 
Africa) 
Lux 
(2004) 
Published 
researchers 
People known to 
facilitator 
42 42 (100)  0 
0 15: UK, Italy, USA, 
Argentina, Canada, Japan, 
Oman, Singapore, China, 
Philippines, Germany, 
Cuba, Switzerland, 
Malaysia, Thailand (North 
America, South America, 
Europe, Asia) 
Cross 
(2005) 
Recognized clinical 
experts  
8 8 (100) 0 0 5: Ethiopia, India, Brazil, 
USA, Nepal (Asia, Africa, 
North America) 
Lightfoot 
(2005) 
Health 
professional 
network 
35 35 (100) 0 0 1: USA (North America) 
Lightfoot Health 35 35 (100) 0 0 1: USA (North America) 
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(2005) professional 
network  
Mease 
(2005, 
2008) 
Clinical trial 
network 
Local patients 
96 23 (24) 73 (76) 
0 
1: USA (North America) 
Taylor 
(2005) Clinical trial 
network 
32 32 (100) 0 
0 10: countries not 
provided(North America, 
Europe, Australasia, 
Africa) 
Devane 
(2007) 
Health 
professional 
network 
Patient groups 
218 147 (68) 24 (11) 
Health service 
managers 
n=14 (6) 
Epidemiologis
ts n=9 (4);  
Social 
scientists and 
lactation 
specialists 
(numbers of 
each group 
unknown) n= 
24 (11) 
28: United Kingdom, 
Canada, Australia, 
Ireland, United States, 
the Netherlands, Peru, 
Sweden, Germany, 
Northern Ireland, 
Singapore, Switzerland, 
Thailand, Zimbabwe, 
Saudi Arabia, Argentina, 
Georgia, New Zealand, 
Albania, Austria, India, 
France, Afghanistan, 
Brazil, Nigeria, Iran, and 
Denmark; one country 
missing (North America, 
South America, Europe, 
Asia, Australasia, Africa) 
Dent 
(2008) 
People known to 
facilitator 
Published 
researchers 
13 12 (92) 0 
Clinical trial 
methodologis
t n=1 (8) 
9: Australia, USA, Canada, 
Denmark, UK, Japan, 
Norway, Italy, Belgium 
(North America, Europe, 
Asia, Australasia) 
Distler 
(2008) 
Clinical trial 
network 
87 87 (100) 0 
0 Unclear (North America, 
Europe, Australasia, Asia) 
Khanna 
(2008) 
Clinical trial 
network 
50 50 (100) 0 
0 15: USA, Italy, UK, 
Canada, Australia, 
Argentina, Hungary, 
France, Germany, 
Norway, Turkey, Ireland, 
The Netherlands, 
Sweden, Switzerland 
(North America, South 
America, Europe, Asia, 
Australia) 
McGrath 
(2008) 
People known to 
facilitator 
26 17 (65) 0 
FDA/NIH 
representativ
es n=5 (19) 
Industry 
representativ
es n=4 (16) 
4: Canada, USA, UK, 
Sweden (North America, 
Europe) 
Taylor 
(2008) 
Clinical trial 
network 
33 30 (91) 0 
Industry 
representativ
es n=3 (9) 
11: USA, Spain, Australia, 
Japan, Mexico, The 
Netherlands, Italy, UK, 
Russia, Thailand, China 
(North America, South 
America, Europe, Asia, 
Australasia) 
Douglas 
(2009) 
Health 
professional 
network 
92 92 (100) 0 
0 13 : USA, UK, Canada, 
Austria, Australia, Ireland, 
Demark, Spain, Turkey, 
South Korea, the 
Netherlands, Belgium and 
Iran (North America, 
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Europe, Australasia, Asia) 
Vargus-
Adams 
(2009) 
People known to 
facilitator 
Local clinics 
Health 
professional 
network  
83 39 (47) 44 (53) 0 1: USA (North America)  
Rahn 
(2011) 
Research group 25 25 (100 0 0 1: USA (North America) 
Schmitt 
(2011) 
People known to 
facilitator 
Health 
professional 
network 
Patient self-help 
group  
46 32 (70) 6 (13) Regulatory 
agency 
representativ
es n=1 (2)  
Journal 
editors n=7 
(15) 
11: Australia, Brazil, 
Denmark, France, 
Germany, Italy, 
Netherlands, Sweden, 
Switzerland, United 
Kingdom, United States 
(Australia, South 
America, Europe,  North 
America) 
Bennett 
(2012) 
Recognized 
professionals  
9 4 (45) 2 (22) Research 
funders n=2 
(22) 
Epidemiologis
ts/methodolo
gists=1 (11)  
1: USA (North America) 
Heiligenh
aus 
(2012) 
Research working 
group 
16 16 (100) 0 0 9: Germany, UK, 
Switzerland, Finland, 
Spain, Netherlands, 
Denmark, France, USA 
(Europe, North America)  
Salaffi 
(2012) 
Tertiary care unit  338 252 (75) 86 (25) 0 1: Italy (Europe) 
Sinha 
(2012) 
Health 
Professional 
Network 
Local clinics and 
hospital  
95 46 (48) 49 (52) 0 1: UK (Europe) 
Smaïl-
Faugeron 
(2013) 
Health 
professional 
network 
Published 
researchers 
Clinical trial 
network 
62 Unclear 0 Unclear: 
International 
Authors of 
primary trials 
France and international 
participants whose 
details are not provided 
(Europe, Other unknown) 
 
Anonymity  
It was unclear how three studies were conducted. Fourteen studies conducted the Delphi 
by email or internet (web-based), and three studies by post. Eight of these did not know 
the identity of other group members and were conducted anonymously. This was unclear 
in seven studies but it is assumed that they were conducted anonymously.  There were 
three studies where the Delphi process was conducted solely at face to face meetings. In 
two of these meetings voting was anonymous, but this was unclear for one study. One 
study conducted the Delphi using email, and a meeting. Participants did not meet during 
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the Delphi, did not know the identity of the group members and answered anonymously 
during the Delphi. One study conducted a web-based anonymous survey, and a clinic based 
survey that was still anonymous. The final study conducted the Delphi completely 
anonymously during interviews.  
 
Structure of the Delphi  
Number of panels and rounds 
The majority of studies included a single panel only (89%; 23/26 studies). In 13/23 studies 
the single panel comprised clinicians only. The remaining 10 studies comprised a single 
panel made up of mixed stakeholder groups.  Three studies included two panels in their 
Delphi, all with separate panels for patients and clinicians.  
The number of rounds in the Delphi studies ranged between one and six, with the majority 
including 2 or 3 rounds (73%; 19/26 studies). One of these studies included three rounds 
for clinicians and two for patients. The number of rounds was not clear in three studies. 
One study carried out a three round Delphi, but only round 3 was used for outcomes 
prioritisation. The remaining numbers of rounds conducted were one, four and six.  
 
Administration of questionnaires 
The method of administration of questionnaires is described in the Anonymity section 
above.  
 
How was the original list of outcomes generated? 
The general format of Delphi studies used to develop COS begins with identification of 
potential outcomes. It was not clearly reported how the initial list of outcomes was 
generated in five studies. In thirteen studies the initial list of outcomes was generated from 
a review of the literature; six of these combined this with something else including expert 
opinion, local stakeholders, discussion by the steering group or investigators, patient focus 
groups and a survey. One study collected information from Delphi participants prior to the 
Delphi, and another study presented existing COS recommendations and participants were 
asked to recommend others in the first round. In the remaining six studies the first round 
was used to generate the list of outcomes by asking participants to suggest outcomes.  In 
two of these participants were asked to suggest outcomes within domains suggested by 
the steering committee.  
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Information provided to participants before the first round 
The information provided to participants before the first round was not clear in 14 studies 
(54%). Twelve studies provided some description of the information provided to 
participants before the first round of the Delphi exercise. Eight of these were in relation to 
the study, including the process, the aims of the study and background information. Three 
studies provided a summary of the available literature. The final study gave both study 
information and evidence in advance of the Delphi.  
 
A description of rounds  
Table 8 in Appendix 3 3 describes each round of each study, where this information was 
provided. How outcomes were kept in between rounds is also described in Table 8 (Chapter 
3). This was not described in six studies, and the level of detail provided is variable in those 
that do report something about this.  
 
A description of round 1 was provided in 22/26 studies (85%). One study was completed 
after one round of the Delphi, which although does not satisfy the criteria of a Delphi study, 
is included in this section because it reports to use this method. Of the 25 studies that had 
more than one round, 19/25 provided a description of round 2 (76%),  12/14 provided a 
description of round 3 (86%) and the two studies that had more than three rounds 
provided a description of subsequent rounds. Rounds 1-3 are summarised in Table 22. 
 
Two studies were described as having more than three rounds. One study described having 
four rounds and in the final fourth round, the responses received from the third round 
were tabulated as the 'Draft gold standard.’ This is reported as the fourth round in the 
report. The other study that reported more than three rounds included six rounds. In round 
4, modified statements were presented requesting comments on their content and 
suitability for the proposal. They were then provided a draft paper for submission as a final 
proposal in Round 5 and asked to give final approval of the draft in Round 6. 
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Table 22: A summary of Delphi rounds 1-3 
Round  n Group score feedback n 
Round 1 (N=26) 
Outcomes rated using a 9 point numerical rating scale 2   
Outcomes rated using a 7 point numerical rating scale 1   
Outcomes rated using a 5 point numerical rating scale 4   
Outcomes rated using a 3 (patients) and 4 (clinicians) 
point numerical rating scale 
1   
Participants asked to distribute 100 points among 
domains considered important 
2   
Outcomes rated using a categorical rating scale (e.g. 
extremely important or not important) 
3   
Create the initial list of outcomes  8   
Rate outcome domains (no further information)  1   
Not described  4   
Round 2 (N=25) 
Review group and individual scores from Round 1 and 
re-rate outcomes 
7 Group mean and standard deviation 1 
Group median  1 
Group median, interquartile range, and 
total range (clinician panel); Group 
mean and total range (patient panel) 
1 
Group median and interquartile range 2 
Not specified 2 
Review the results from Round 1 and choose from 
them the outcomes that should be the core set  
1 Overall group’s percentage rating for 
each outcome 
1 
Review the most frequent responses from Round 1 and 
affirm agreement/disagreement  
2   
First rating of outcomes (where the first round was 
outcomes identification) 
6   
Continuing the list of outcomes (where the first round 
was outcomes identification) 
2   
New items, re-worded items, and items for which there 
was disagreement and/or median rating of 4 (neither 
agreement nor disagreement) were re-rated in the 
second iteration. 
1   
Not described  
 
6   
Round 3 (N=14) 
Repeat of round 2  7 Mean and standard deviation  2 
Median  1 
Unclear  1 
Group median, interquartile range, and 
total range  
1 
Median and interquartile range  2 
Rank the top three most important outcomes 2 Group median and interquartile range  
Participants asked to distribute 100 points among 
domains considered important 
1   
Asked to re-select the outcomes that should be part of 
the core set 
1   
Agreement whether outcome should be in final set 1   
Not described  2   
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How consensus was reached  
The Delphi technique was the final method used to reach consensus in 15 studies (58%).  
Eight of these (53%) did not provide a definition of consensus, or description of how it was 
reached. Five studies used the proportion of participants recommending that an outcome 
should be included as a way of determining that consensus was reached. The required 
proportion of participants in four studies was 70%, and one study 66%. One study used a 
specific score to determine when consensus was reached for inclusion of an outcome. They 
used a scale of 1-7 and used a median score to determine whether an outcome should be 
included in the core set (see Taylor 2008 in Table 8 in Chapter 3). The final study that 
included a definition of consensus stated that if two of nine national stakeholders ranked it 
among the top 3 outcomes it was included.  
 
Two other studies did not use a predefined level of consensus but provided some 
description: one simply stated that participants agreed on the overall recommendations at 
the end of the Delphi process, and the other stated that a steering group selected the 
ultimate core outcomes after the final round of the Delphi. In the latter, cluster analysis 
was performed prior to steering group discussion to further reduce the number of outcome 
domains and tools to make the number more practical for clinical trials.  Outcome domains 
suggested by the group as being most important were classed as feasible or not. 
 
The sequence of work was unclear in one study and so it is not clear whether Delphi was 
the final method to reach consensus. Furthermore, ten studies did not use the Delphi 
technique as the final method to reach consensus about outcomes, and went on to do 
additional work after the Delphi to determine the final core outcome set. In all but one 
study this further work was carried out face to face, including meeting(s), nominal group 
technique and workshop(s). In one study the recommendations underwent ‘expert panel 
review’ but it was not clear whether this was face to face. Eight of these studies (73%) did 
not provide a definition of consensus for the Delphi part of their study. Two studies used a 
proportion of participants recommending that an outcome should be included as a way of 
determining that consensus was reached, and these outcomes were then carried forward 
to the next stage of the work. The proportion of participants used was at least 60% in one 
study, and at least 75% in the other. One study stated that only outcomes with a median 
score of at least 6/9 on a Likert-type scale were considered in a subsequent consensus 
meeting, as consensus was not the aim of the Delphi.  
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4.4.3 Consensus meeting  
As stated above, ten studies carried out additional work after the Delphi method to 
determine the final COS, and in nine of these it was clear that this was conducted using a 
face to face method. Thus, the following summary will relate to the nine studies that did 
further work on determining COS in a meeting(s) after the Delphi process.  
 
Six studies held a single meeting, one study held two meetings (this study described the 
first meeting as exploratory, the second as consensus) and two held three meetings (in one 
study this was described as continuing the work in the first meeting, and in the second 
study as presenting and ratifying the core set); therefore there were a total of 14 meetings 
conducted relating to 9 COS.  These meetings were the final method to reach consensus in 
all but one study where further work was done through post-meeting consultations among 
the group using emails, and the findings were made available on a website for public 
review. Five of the nine studies applied the Nominal Group Technique to their meeting. The 
level of reporting was variable, but no meeting was conducted the same way and they 
varied widely in duration from two and a half hours to four days.  Table 23 shows a 
summary of the meeting details.  
 
Structure of meeting(s) 
Eight of the nine studies carried out a voting exercise, all of which took place after group 
discussion. The voting scale used was described in two studies; a six point scale for lists of 
statements from 1 (agree strongly) to 6 (disagree strongly) and a five point scale for lists of 
outcomes from 1 (being the least important) to 5 (being the most important). In the first 
meeting of the Mease study, priority ranking (first, second and third important domains to 
measure) was used. In the study’s second and the third meeting, participants were 
presented with three choices to choose from for the presented outcomes.  
 
Anonymity  
Anonymous voting was conducted in four studies. An electronic voting system was 
reported as being used in the second meeting of the Gladman and the Schmitt study. 
Audience response methodology (description not provided) was used in the final meeting 
of the Mease study. The remaining studies did not report whether voting was anonymous. 
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Table 23: Meeting details 
Reference What happened during the meeting (in the 
order of the event) 
Duration  Who led/assisted 
the meeting or the 
breakout groups 
McGrath et 
al. (2008)  
Discussion only 2 days Meeting - senior 
author, two co-
leaders of previous 
meeting 
Dent, et al. 
(2008) 
Anonymous voting that included discussion 
time 
 Not 
reported 
Meeting - non-voting 
chairman 
Schumacher 
et al. (2009) 
A presentation, 2 breakout groups discussion, 
combined session (feedback the results of the 
discussion), voting at a plenary session 
2 and half 
hours  
 Not reported  
Gladman 
(2005) 
Presentations, 3 breakout groups discussion 
(Nominal group process used, one group did 
anonymous voting), Combined session 
(feedback the results of the discussion) 
Not 
reported 
Each breakout group 
- a leader and a 
scribe  
Gladman et 
al. (2005) 
Presentations at a plenary session, 12 
breakout groups discussion, combined session 
(feedback the results of the discussion), 
voting, presentation of the summary in the 
second plenary session 
 Not 
reported 
Each breakout group 
had a scribe 
Gladman et 
al. (2007) 
A series of questions posed to audience, 
presentations, voting on the domains, 
breakout group discussion, voting to consider 
the domains into three categories 
Not 
reported 
 Not reported 
Mease et al. 
(2005) 
Presentations, a panel discussion. voting 
(priority ranking), results presented in the 
plenary session   
 Not 
reported 
 Not reported 
Mease et al. 
(2007) 
Presentations, breakout group discussion, 
combined session (feedback the results of 
discussion), voting at the workshop and the 
plenary session 
Not 
reported 
 Not reported 
Mease et al. 
(2009) 
Presentations, breakout group discussions, 
voting at the module and plenary session   
Not 
reported 
 Not reported 
Schmitt et al. 
(2010) 
Presentations and discussions 3 hours  Not reported 
Schmitt et al. 
(2012) 
Presentations, 2 panels structured discussion 
(NGT applied), anonymous voting  
2 days  Each group - one 
moderator and one 
rapporteur 
Heiligenhaus 
(2012) 
NGT process (discussion round, two ranking 
rounds) 
2 days  Not reported 
Douglas 
(2009) 
NGT process  (Discussion, voting) Not 
reported 
Not reported  
Ruperto 
(2003) 
NGT process Introductory lectures, three 
working group discussions, 5 NGT exercises 
carried out during the meeting including 
voting.  
4 days Three moderators 
with expertise in 
NGT 
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Participants  
The number and type of meeting participants is described in Table 24. The number of 
participants ranged from 8 to 137, although the number of participants was not always 
reported (4/14; 29%). The type of participants was also inconsistently reported, with three 
studies not reporting this information, and a further five studies reporting who was 
included but not providing the number of participants per type. Of the 11 that did report 
who the participants were, 100% included clinical experts, and 46% (5 meetings) included 
patient representatives. In 8/14 meeting reports it was unclear whether the participants 
had taken part in the previous Delphi exercise; in the remaining six meetings, some or all of 
the participants had taken part in the Delphi.  
 
How consensus was reached  
Seven studies provided a definition of consensus. The level of agreement to be reached in 
all studies was expressed in terms of the proportion of participants recommending that an 
outcome should be included. This included 100% (n=1), 80% (n=2), 75% (n=1), 70% (n=2) 
and in the first and the third meeting of the Mease study at least 50% and 70% agreement 
was required. It was clear in three studies that the level of consensus had been determined 
a priori, it was not clear in the remaining studies.  
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Table 24: The number and type of meeting participants 
Study Method of identification of the 
sample of participants 
Number of 
participants  
Number (%) of 
clinical professionals  
Number (%) of 
patient 
representatives 
Other types of 
participants involved in 
the study (%) 
Number of countries represented: Names 
(Continents) 
McGrath et 
al. (2008)  
People known to facilitator  
(same participants as the Delphi 
study) 
26 17 (65) 0 FDA/NIH representatives 
n=5 (19) 
Industry representatives 
n=4 (16) 
4: Canada, USA, UK, Sweden (North America, 
Europe) 
Dent, et al. 
(2008) 
People known to facilitator 
Published researchers 
(same participants as the Delphi 
study) 
13 (including a non-
voting chairman) 
12 (92) 0 Clinical trial 
methodologist n=1 (8) 
9: Australia, USA, Canada, Denmark, UK, Japan, 
Norway, Italy, Belgium (North America, Europe, 
Asia, Australasia) 
Schumacher 
et al. (2009) 
OMERACT conference participants  
(unclear if involved in Delphi) 
77 Unclear who was 
involved  
Unclear who was 
involved 
Unclear who was 
involved 
Not reported 
Gladman 
(2005) 
People known to facilitator (unclear 
if involved in Delphi) 
Not reported Not reported Not reported 0 Not reported 
Gladman et 
al. (2005) 
OMERACT conference participants 
(unclear if involved in Delphi) 
Not reported Not reported Not reported Unclear if any other 
groups were involved 
Not reported 
Gladman et 
al. (2007) 
OMERACT conference participants  
(unclear if involved in Delphi) 
137 Unclear who was 
involved 
Unclear who was 
involved 
Unclear who was 
involved 
Not reported 
Mease et al. 
(2005) 
OMERACT conference participants 
(unclear if involved in Delphi) 
Not reported Not reported 0 Academic and 
pharmaceutical based 
researchers n=not 
reported  
Not reported 
Mease et al. 
(2007) 
OMERACT conference participants  
(unclear if involved in Delphi) 
104 Not reported Not reported Unclear if any other 
groups were involved 
Not reported 
Mease et al. 
(2009) 
OMERACT conference participants 
(unclear if involved in Delphi) 
 
Not reported Not reported  4 (unknown) Researchers, statisticians, 
pharmaceutical 
industry representatives 
n=not reported 
Not reported 
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Schmitt et 
al. (2010) 
Conference participants, individuals 
with a known interest in eczema, 
and all those involved in Delphi 
exercise were invited to the 
meeting 
Approximately 40  Unclear who was 
involved 
Unclear who was 
involved 
Unclear who was 
involved 
Not reported 
Schmitt et 
al. (2012) 
People known to facilitator 
Published researchers 
(participants did include Delphi and 
2010 meeting participants) 
43 29 (67) 5 (12) Methodologists n=5 (12) 
and pharmaceutical 
industry representatives 
n=1 (2) 
10: UK, Netherlands, Germany, France, Sweden, 
Brazil, Israel, USA, Australia, Japan (Europe, 
South America, Asia, North America, Australia) 
Heiligenhau
s (2012) 
Research working group (all took 
part in the Delphi) 
14 14 (100) 0 0 9: Germany, UK, Switzerland, Finland, Spain, 
Netherlands, Denmark, France, USA (Europe, 
North America) 
Douglas 
(2009) 
Study steering committee members 
(all took part in the Delphi) 
8 8 (100) 0 0 2: USA and UK  
Ruperto 
(2003) 
Clinical trial networks (unclear if 
involved in Delphi) 
40 40 (100) 0 0 34: not reported  
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4.5 Discussion  
A full discussion of the strengths and limitations of the systematic review is provided in 
Chapter 3.  
 
COS developers have conducted different types of literature and systematic reviews as part 
of the process, with the majority undertaking a review of outcomes measured previously in 
clinical studies. Across studies that have done a systematic or literature review as part of 
their methods to develop a COS, the methodology differs considerably. Studies included 
different types of studies, had varying language restrictions, searched different date ranges 
and searched a variety of different databases, ranging between one and eight. Some went 
on to group outcomes, and studies that did so provided differing levels of detail about what 
was done. Furthermore, some studies excluded outcome categories such as cost and 
resource use that might be considered relevant to clinical trials. As highlighted in Chapter 3, 
it is currently unclear which of the multiple available frameworks are most suitable for 
categorising outcomes. Having an agreed framework for categorising outcomes might aid 
COS developers’ in doing so. This issue is discussed further in Chapter 8.  
 
Main features were often missing from reports. A third or more of studies did not report 
the type of studies that were included (39%), did not provide information about language 
restrictions applied (44%), the date ranges searched (37%) or the databases searched 
(37%). Furthermore, 30% did not report the results or main findings from the review. 
Further work could be done to identify the key features that should be reported by all 
studies including a literature/systematic review as part of the COS development process.  
These results also highlight the need for methodological guidance on how to design such a 
systematic review.  
 
The Delphi technique is another method that has been used in different ways in COS 
development. It was the final method for reaching consensus for just over half of the 
studies that used this method (58%), but others went on to do further work. Where the 
Delphi technique had been used, it had been done variably; across studies the composition 
of the groups was variable and the process was never the same. Less than half of the 
studies included participants outside of the EU and US, and half of the studies included 
participants from one country only (UK, US and Italy). Patient participation was relatively 
low, and their involvement in the process differed. Furthermore, the identification of one 
96 
 
study that only included one round of Delphi raises the question whether this study should 
be categorised as such. This highlights the need for a way of quality assessing COS studies 
and the methods they purport to use.  
 
The quality of reporting of key aspects as identified by Sinha et al [59] was variable. As this 
checklist was published in January 2011, I separated studies to look at reporting before and 
after the publication of this checklist. It would seem that there have been some 
improvements in the reporting of some of the recommended characteristics. However, 
other key characteristics seem to be still poorly reported, including ‘Information provided 
to participants before the first round’, ‘How the overall group response was fed back to 
participants’ and ‘A priori definition of consensus about whether an outcome should be 
measured.’ Although some studies did provide a definition of consensus, it was often 
unclear whether this was a priori. Reporting of Delphi studies seems improved but there 
are many key features still not being consistently reported.  
 
Where a consensus meeting was used as the final method to reach consensus, no meeting 
was conducted in the same way. They varied in duration, how many were held and what 
they did at each meeting. The duration of meetings was often not reported, as was who led 
the meeting and who was involved. What happened at meetings was described in varying 
levels of detail. Most meetings included a voting exercise, although the method of voting or 
scale used was often not reported. Anonymity was described in approximately half of the 
studies. A definition for consensus was provided in the majority (78%) although it was only 
clear that it was an a priori definition in three of the seven studies.  
 
4.5.1 Future work  
The uptake of COS depends on the user’s ability to be able to assess the core set for 
suitability of use. This requires an assessment to be made on the appropriateness of the 
methods used as well as the reporting of the key features of these methods. Poor reporting 
makes it hard to appraise, thus key features need to be reported.  
 
This chapter further exemplifies the variability in COS methodology. Furthermore, these 
findings corroborate the conclusion of the main systematic review (reported in Chapter 3) 
that there is a need to improve the standards of reporting in these studies. As discussed in 
Chapter 3, a generic COS reporting guideline is currently being developed, but here I 
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highlight the need for reporting guidelines specific to each type of study. The checklist 
developed by Sinha et al specifically for Delphi studies seems to have gone some way in 
helping to improve the reporting of Delphi studies. However, key characteristics were 
sometimes still missing from Delphi study reports so there is still a need to help improve 
this. One possible solution could be the promotion of these guidelines through the COMET 
Initiative to make sure COS developers are aware of them. It is not known whether more 
recent studies have used the Delphi checklist to report their studies, and indeed whether 
they have found this helpful.  
 
4.5.2 Summary  
Given the variations in methodology between studies, it would be helpful if we understood 
developers’ rationales behind their methodological decisions. There is a need to determine 
how best to develop COS.  This chapter provides more detailed information about the 
methods that we know are being used presently to develop core sets. By exploring choices 
of methodology we will better understand why developers have done things so far, 
enabling us to better inform how COS developers might do this work in the future. The 
work in this chapter affirms the need for further work to explore these issues, which is the 
focus of Chapters 5 to 7.  
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Chapter 5: A survey of core outcome 
set developers    
 
5.1 Background  
The systematic review of COS identified 250 reports relating to 198 studies. The review 
showed that a range of methods have been used, and applied in a variety of ways, to 
develop COS. Furthermore, of the 178 studies that described the methods they used to 
determine the COS, 164 (92%) did not provide an explanation regarding their choice of 
methodology. The reasons behind the methodological choices in the 14 studies that did 
provide explanation are provided in Table 7 in Chapter 3. The most common reason 
provided was that the methods had been used previously to develop COS or were well-
recognised methods for eliciting expert consensus to inform guidelines.  
 
To my knowledge, there is little guidance about how to conduct or report COS studies and 
it is currently uncertain which of the various methods reported are the most suitable, 
feasible and efficient. The methods used in the development process may have an impact 
on the conclusions derived. Consensus work undertaken by three different groups in the 
same clinical area (paediatric asthma) [103-105], but using different methodological 
approaches and involving different stakeholder groups, resulted in inconsistent outcomes 
being rated as important; although there was some overlap in the outcomes chosen. 
Research to investigate COS developers’ choice of approach may help to illuminate the 
reasons for these differences, as well as highlight areas of COS development that would 
benefit from improved guidelines and recommendations. It is important to investigate COS 
developers’ choice of approach as this is a new area of research, and we need to 
understand more about why these COS developers chose the methods that they did. 
 
The COMET Initiative Management Group published some preliminary suggestions around 
issues to consider when developing a COS [38]; these included steps to encourage the 
implementation of COS recommendations once they have been developed. To increase 
COS uptake, it is recommended that developers consider engagement with the relevant 
Cochrane Review Groups, clinical guideline developers, research funders, journal editors, 
regulators such as research ethics committees, and trial registries.  A recent series of 
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papers in the Lancet addressing waste in research also highlighted that efforts to improve 
the quality and usefulness of health research will have a greater chance of success if 
research funders and journals more actively endorse and implement these initiatives [37]. 
The systematic review of COS (discussed in Chapter 3 and 4) showed that only two papers 
explicitly suggested or discussed plans for the implementation of their recommendations. 
Giacoia’s report [80], which is linked to three COS studies, stated that their proposed 
recommendations will be considered as a requirement by a governmental agency (NICH); 
and Cranney [81] stated that the proposed core measures were being submitted to key 
international research groups in osteoporosis to promote their acceptance and 
implementation.  Implementation may not have been a priority for the majority of COS 
developers or it may have been beyond the scope of these papers; it is therefore important 
to explore this further.  
 
5.2 A mixed methods approach 
This thesis presents a mixed methods approach to explore COS development.  Mixed 
methods research is where the researcher(s) combine elements of qualitative and 
quantitative research approaches for the broad purposes of breadth and depth of 
understanding and corroboration [106]. I drew on qualitative methods (interviews) and an 
online web-based survey to provide the first comprehensive account of COS development. 
As an emerging area of research where little is known about COS development processes, 
and developers’ choices of methods in particular, mixed methods allowed me to quantify 
the current situation and COS developers’ experience, and at the same time explore the 
factors and actions that shaped those experiences [107]. In particular, this study used a 
Triangulation Design to obtain different but complementary data on the same topic for 
comprehensiveness [108]. Data was collected in parallel and received equal status in this 
study, and although these data were initially analysed separately, the interpretation of the 
findings were integrated as indicated in the final Discussion chapter (Chapter 8). The study 
design is depicted in a visual model in Figure 5. 
 
The qualitative work (interviews) aimed to examine researchers’ accounts and opinions of 
their work to develop COS, with the goal of identifying potentially important but previously 
unanticipated issues; this work is described separately in chapters 6 (methods) and 7 
(results). This chapter will outline the web based survey, the content of which was 
informed by the first 9 interviews conducted. 
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Figure 5: Visual model of mixed methods design 
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5.3 Aim  
To provide quantifiable information about COS developers’ experience; to explore 
similarities and differences in those experiences, and to further understand the COS 
development process. 
 
5.4  Methodological approach  
The survey was constructed using SelectSurvey.NET (http://www.liv.ac.uk/csd/ 
survey/index.htm), an online survey package provided by the University of Liverpool. The 
benefits of using this software included the facility to incorporate filter questions (whereby 
depending on the responses, questions are automatically skipped to the next appropriate 
question), the survey can be programmed individually for the study purposes, and the 
answers can be automatically programmed to download into a database [107]; the latter 
was particularly important because the survey asked COS developers to clarify the data 
that had been previously extracted from their paper as part of the systematic review, or 
provide additional information if this was missing. As such, SelectSurvey.NET was deemed 
more flexible to fit the purpose of the survey than using existing online survey software 
such as SurveyMonkey or SurveyGizmo. 
 
The survey was sent as a link within a personalised email inviting prospective respondents 
to visit a website where the survey could be found and completed. Adopting a personalised 
approach has been suggested to increase odds of response [109]. An example of the invite 
email can be found in Appendix 4. Odds of response have been shown to increase by more 
than a quarter when follow-up contact is made with those who do not respond to the initial 
survey [109], therefore two further mailings were sent to non-responders, two and four 
weeks after initial emails. Those who had not responded six weeks after the date of initial 
emails were recorded as non-responders overall. Other strategies suggested to increase 
response were utilised, including not using the word ‘survey’ in the subject line of the 
email, using a white background for the survey, including a deadline to reply, and keeping 
the survey short. 
 
5.4.1 Structure of the survey  
COS developers were asked to answer a few short questions about their COS work, 
including: how the COS study came about; how they decided which methods to use, and 
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whether implementation was a priority for them/their group. COS developers were asked 
to clarify or confirm the data that has been extracted from their paper as part of the 
systematic review (or provide additional information if missing), including:  target 
population age; interventions covered; and methods used to develop the COS, including 
the stakeholders included in the process.  Each COS developer received a slightly different 
version of the survey depending on the information required. The survey can be found in 
Appendix 5.  
 
5.4.2 Participants  
The contact author of the COS publications identified in the systematic review were 
contacted and asked to participate in the short survey. Where an author was involved with 
multiple COS, they were asked to complete the survey for the most recent COS only. COS 
authors who had already taken part in the qualitative study (interviews) were excluded.  
 
5.4.3 Analysis and presentation of results  
Data is described in narrative form, and the findings provided in text and table format with 
illustrative comments from responses to open questions. Responses to open questions 
were categorised into common topics.  First, free text data was read and re-read several 
times to gain a broad understanding of the topics covered. Recurring topics were identified, 
and the data was labelled. Data with the same labels were brought together and grouped 
into common themes.  Any discrepancies were resolved though discussion with my 
supervisors (PW and BY).  
 
The survey response and completion rates were calculated. The response rate refers to the 
number of people who initiated a response to the survey divided by the total number that 
the survey was sent out to. The completion rate refers to the number of surveys filled out 
and submitted. This is calculated by dividing the number of surveys filled out by the 
number of surveys started by respondents. 
 
Differences between responders and non-responders were examined by comparing the 
year of study and whether patients were involved in the development of the COS.  These 
factors were examined because it was felt that they might be associated with whether a 
response was received or not.  
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5.5 Results  
One-hundred and ninety eight COS studies were identified in the review. Twenty nine 
studies were excluded for the following reasons:  
 already interviewed (n=12) 
 invited to interview awaiting response(n=3) 
 accepted interview invite, waiting to be scheduled (n=2) 
 where there were duplicates (where the lead/contact author was the same for 
multiple COS) we asked them to complete the survey for the most recently 
published COS only (n=7)  
 author was deceased (n=1) 
 unable to find active/correct email address (n=4) 
 
The survey was therefore sent out to 169 COS developers. The study flowchart is shown in 
Figure 6. Four versions of the survey were set up, and each COS assigned a version 
depending on what information we needed about their COS development methods and 
participants.  
 
The survey had a response rate of 53% (89 of 169 invitees), and a completion rate of 85% 
(76 of 89 started). Eight of the thirteen partial responders only provided their name and 
email address, so did not provide any useful information. The remaining five answered 
some questions, meaning that there were a total of 81 responses to the survey. From this 
point forward these will be classed as responders (n=81), with all other responses classed 
as non-responders (n=88).   
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Figure 6: Flowchart showing participants in the survey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*One author responded to say it was too long ago and they could not remember enough details to complete the 
survey, one author had retired (co-author deceased), and the third made a referral to their co-author but this 
individual had already been contacted about the survey in relation to another study.  
**Unable to complete due to other commitments, sent to co-authors but no response. 
 
 
Survey sent out (N=169) 
Completed after 2 weeks (n=34) 
FIRST REMINDER SENT OUT (n=135) 
Total completed after 2 weeks (n=58) 
SECOND REMINDER SENT OUT (n=108) 
Total completed (n=76) 
Declined to complete (n=3)* 
Declined to complete (n=6)** 
Partial response (n=13) 
Answered some questions (n=5) 
Provided name and email only   
(n=8) 
Did not complete 
(n=13) 
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5.5.1 Response bias 
I looked for differences between responders and non-responders (Table 25). The year of 
publication of the earliest identified report for each study was used for comparison and 
showed that a higher percentage of responses were from 2010-2013 studies. COS 
developers were also more likely to respond if patients had been involved than not.  
 
Table 25: Differences between responders (n=81) and non-responders (n=88) 
Year of study 
 
Total Responders 
n (%) 
Non-responders 
n (%) 
1980-1984 1 1 (1.2%) 0 
1985-1989 1 1 (1.2%) 0 
1990-1994 13 6 (7.4%) 7 (8%) 
1995-1999 25 7 (8.6%) 18 (20.5%) 
2000-2004 30 15 (18.5%)  15 (17%) 
2005-2009 55 22 (27.2%) 33 (37.5%) 
2010-2013 44 29 (35.8%) 15 (17%) 
Patients involved  
Yes 24 15 (18.5%) 9 (10.2%) 
  
5.5.2 Sample characteristics  
The sample characteristics for the 81 respondent COS are presented in Table 26. Surveyed 
COS covered a broad range of disease categories, representing all those identified in the 
systematic review except endocrine and metabolic conditions, and wounds. Surveyed COS 
also covered a broad range of population and intervention characteristics and reflected all 
of the categories identified in the systematic review of COS.  
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Table 26: Sample characteristics of 81 surveyed COS 
 n (%) 
Population characteristics  
Both adults and children 10 (12) 
Adults  57 (70)  
Children (including neonates) 10 (12) 
Older adults only  4 (5) 
Intervention characteristics  
All intervention types  26 (32) 
Drug treatments  41 (51) 
Drug only  26 
Drug and devices   2 
Drug and behavioural 5 
Drug and procedure  1 
Drug and surgery 2 
Drug and device and behavioural 1 
Drug and procedure and device  1 
Drug and procedure and device and surgery  2 
Drug and procedure and surgery  1 
Surgery  5 (6) 
Surgery only 2 
Surgery and procedure and device 2 
Surgery and procedure and device and behavioural  1 
Procedure  5 (6) 
Procedure only  1 
Procedure and device 2 
Procedure and behavioural  1 
Procedure and behavioural and device  1 
Devices 1 (1) 
Other  3 (4) 
Vocational rehabilitation 1 
Models of maternity care 1 
Screening 1 
Disease category  
Neurology 12 (15) 
Rheumatology 12 (15) 
Cancer  11 (14) 
Heart & circulation  9 (11) 
Orthopaedics & trauma 7 (9)  
Infectious disease 4 (5) 
Gynaecology 3 (4) 
Urology 3 (4) 
Dentistry & oral health 2 (3) 
Kidney disease 2 (3) 
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Lungs & airways  2 (3) 
Mental Health 2 (3) 
Tobacco, drugs, & alcohol dependence 2 (3) 
Anaesthesia & pain control 1 (1) 
Blood disorders 1 (1) 
Ear, nose & throat  1 (1) 
Gastroenterology 1 (1) 
Genetic disorders 1 (1) 
Health care of older people  1 (1) 
Intensive care  1 (1) 
Neonatal care 1 (1) 
Pregnancy & child birth  1 (1) 
Skin 1 (1) 
Methods used  
Semi-structured group discussion only 25 (31) 
Workshop 7 
Meeting (meeting, colloquium, conference where not described as consensus 
development conference)  17 
Round table discussion  1 
Unstructured group discussion only 
Descriptions include task force, work group, working group/party, 
committee, board, panel 6 (7) 
Consensus development conference only  6 (7) 
Literature/systematic review only 6 (7) 
Delphi only 2 (3) 
Survey only 2 (3) 
Mixed methods (see descriptions below) 34 (42) 
Delphi + another method(s) 7 
NGT 2 
NGT + literature/systematic review 1 
Literature/systematic review  3 
Literature/systematic review + consensus conference  1 
Semi-structured group discussion (listed which method)  + another 
method(s) 
17 
Workshop + literature/systematic review  1 
Meeting + literature/systematic review 8 
Workshop and meeting  2 
Workshop/meetings + web-based consultation  1 
Workshop + survey + literature/systematic review 3 
Round table discussion + literature/systematic review 1 
Meeting + focus group(s) + survey  1 
Consensus development conference + another method(s) + 
Literature/systematic review 
1 
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Unstructured group discussion + Literature/systematic review 
3 
NGT + another method(s) 
3 
Survey + interview 1 
Semi-structured discussion (workshop & meetings) 1 
Workshop + literature/systematic review  1 
Literature/systematic review, public presentation and debate 
2 
Literature/systematic review, survey and open discussion  
1 
Participant groups involved 
Clinical experts + Research experts (only or 
Authorities/Providers/Others) 
30 (37) 
Clinical expert only  
23 (28) 
Clinical experts + patients (only or Research 
experts/Authorities/Providers/Others) 
20 (25) 
Clinical experts + Authorities (only or Providers/Others) 
5 (6) 
Clinical experts + Others  
2 (3) 
Patients only 
1 (1) 
 
5.5.3 COS motivation 
How did your core outcome set study come about? 
We asked ‘How did your come outcome set study come about?’ Response options were 
fixed, with a free text option to provide more information for those indicated with a *, and 
multiple responses were allowed.  All 81 respondents answered this question.  The 
motivations for COS development are shown in Table 27. The most frequent answers 
indicated that the drivers for the COS was the heterogeneity in what outcomes were being 
measured or reported in trials/research, or heterogeneity in the way outcomes were being 
measured, so studies were measuring the same outcomes using different 
tools/instruments/measures. COS developers indicated that there was not an existing COS 
that could be used. Nine COS developers responded that a COS did exist but they did not 
think it was good enough or suitable for use.  
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Table 27: Motivation for core outcome set development 
Response item n Illustrative comments  
There was heterogeneity in 
which outcomes were being 
measured (studies 
measuring/reporting different 
outcomes) in trials/research  
52 There are a variety of outcomes tools, clinical 
measurement tools that are used for measuring 
[disease name].  (S62) 
There was heterogeneity in the 
way outcomes were being 
measured (studies measuring 
the same outcomes using 
different 
tools/instruments/measures) in 
trials/research  
52 A variety of core OMs existed but their use in 
prehospital/EMS [Emergency Medical Services] 
research was limited or heterogeneous and few 
had been validated. (S42) 
There was significant heterogeneity in the 
definitions and measurement of outcomes in 
earlier studies. (S57) 
I/we thought there was 
something missing in the 
outcomes being 
measured/reported in research  
46 Some important outcomes were not reported in 
earlier studies. We aimed to encourage 
standardisation. (S57) 
There was no existing core 
outcome set that we could use 
for our study  
40  
I/we thought there was 
something missing in the 
outcomes being 
measured/reported in clinical 
practice  
28 Additionally, although there is a standard of 
intervention care, the treatment protocols are 
often deviated from based on individual needs. 
(S62) 
There were outcomes being 
measured but not reported in 
trials/research  
16  
It was part of a research 
prioritisation study* 
13 Prior to our trial there were no multi-site, 
combined-treatment randomized clinical trials 
Class 1 studies for treatments of this disorder. 
(S39) 
The outcomes that were being 
measured in research were not 
applicable/relevant to clinical 
practice  
13  
I/we were conducting other 
research (e.g. a systematic 
review or a trial)* 
11 We lead a clinical trials network and needed a 
standardized outcome for the interventional trials 
in [disease name]. (S21) 
We were conducting an observational trial and 
were discussing what the gold standard for success 
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should be for our subject population.  We could 
not agree on what definitely needed to be 
included, therefore we chose to survey experts in 
surgery and rehab. (S23) 
A Cochrane review of [disease name}. (S61) 
Conducting trials of potential medications to treat 
[disease name]; FDA guidance was a draft form 
and did not meet the needs of investigators or 
industry. (S79) 
A core outcome set existed but 
we did not think it was good 
enough/suitable* 
9 2 core sets were available, but they were both too 
broad. (S14) 
It had been identified that the patient voice was 
not included when the core sets had previously 
been developed and therefore there were some 
outcomes important to patients that were not 
included. (S44) 
Previous proposals were not detailed enough. 
(S45) 
I/we were motivated by work 
that had been done in another 
speciality  
8  
Other reasons provided*  5 I was requested to write the paper. (S11) 
We were developing guidelines for the American 
[disease area] Association to use in reviewing 
products for awarding the ADA Seal, and possibly 
for the FDA to use in similarly assessing products 
for treatment of [disease name].  We were not 
explicitly developing a core outcome set.(S37) 
Well established set of outcomes in the field, but 
no large trials on the specific topic. (S41) 
A commissioned study. (S49) 
The society wanted a reference document. (S63) 
 
 
 
 
111 
 
5.5.4 COS methods 
How did you decide on the methods you used? 
Table 26 shows the methods used to develop COS for the 81 studies included in the survey. 
The most frequent method was semi-structured group discussion (n=25; 31%), followed by 
mixed methods using semi-structured group discussion in combination with another 
method, most commonly a review of the literature. The consensus development 
conference, Delphi technique and literature reviews were also used.  
 
We asked COS developers “How did you decide on the methods you used?” Response 
options were fixed, with a free text option to provide more information for those indicated 
with a *, and multiple responses were allowed.  All 81 respondents answered this question 
and the results are presented in Table 28.   
 
Most respondents reported that they had based their choice of methods on the literature 
(previous work), specifically citing the OMERACT group’s work for rheumatoid arthritis and 
the HOME group for eczema as examples of previous work that had informed their COS 
development methods. Respondents also reported that expert advice informed their 
choice of methods, with 6/51 (12%) of respondents who cited this giving this answer 
exclusively. COS developers also reported that the available resources influenced the 
methods that were used; comments related to funding and personnel available to carry out 
the work. The author of one recent study also referred to the COMET website as an 
available resource that had helped in deciding on the methods to use.  
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Table 28: Rationale for choice of methodology 
Response item n Illustrative comments  
Based on the literature 
(previous work)* 
59 OMERACT, HOME for eczema, COMET 
website.(S36) 
We were aware of previous reports and the 
variability of reporting in them.(S38) 
We used Nick Black’s publication on consensus 
methods, some common sense, and developed a 
framework for doing systematic reviews of 
outcome measurement properties. (S61) 
Based on expert advice* 
51 Informally we sought advice from experts. (S38) 
Expert panel of individuals knowledgeable of prior 
work.(S43) 
[Name] was very helpful in advising and 
participating. (S70) 
Own experience with same 
methods before for core 
outcome set development  
31
†
 Many of us had done similar things before and we 
had applied for and received funding from [funding 
body] to do this in the light of recent trials. (S45) 
We used a workshop with 20-22 experts in different 
fields of the disease. This was easy to organise and 
we had previous experience with it.(S48) 
Suited our situation and 
circumstances* 
27 There was a limited group of researchers involved 
in the study. (S55) 
Since an international meeting was held, we tried 
to make use of this opportunity and held a 
workshop on outcome measurement and patient’s 
assessment. (S65) 
Based on the resources 
available* 
27 Surveys of professionals has been used previously 
in [disease area], was relatively low cost, and was 
achievable with the work of mostly one person. 
(S23) 
OMERACT, HOME for eczema, COMET 
website.(S36) 
Problems with other 
methods* 
15 No illustrative comments 
† 
Disease areas relate to: Dentistry & oral health (n=1); Health care of older people (n=1); 
Intensive care (n=1) 
Kidney disease (n=1); Mental health (n=1); Lungs & airways (n=2); Heart & circulation (n=2); 
Infectious disease (n=2); Urology (n=2); Neurology (n=5); Cancer (n=6); Rheumatology (n=7) 
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How did you decide who to include as participants in your core outcome set development 
work? 
Table 26 shows the participant groups included in the development of the COS for the 81 
studies included in the survey. We asked “How did you decide who to include as 
participants in your core outcome set development work?” Response options were fixed, 
with a free text option to provide more information for those indicated with a *, and 
multiple responses were allowed.  All 81 respondents answered this question and the 
results are presented in Table 29, cross-classified by the stakeholder groups involved. The 
most frequent answer reported by respondents was to involve stakeholder groups with 
experience of or knowledge about trials or research. Experience with clinical practice was 
the second most frequent answer. Wanting an international perspective was also a 
frequent answer.  
Experience of living with/caring for someone with a condition and being able to see things 
from the patient perspective were highest in those that had patient participation in the 
study. However, half of the COS developers who gave one of these answers did not include 
patients in the process.   
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Table 29: Rationale for choice of stakeholders 
Response item  Stakeholder groups involved  
  Clinical 
expert 
only  
 
n=23 
Clinical expert 
+ other (non-
patient) 
 
n=37 
Clinical experts + 
patients (only or 
other) 
 
 
n=20 
Patients 
only  
 
 
n=1 
Total 
Experience 
with/knowledgeable 
about trials/research 
19 34 17 0 70 
Experience 
with/knowledgeable 
about clinical practice 
16 30 15 0 61 
We wanted an 
international 
perspective 
19 24 14 0 57 
Experience of people 
who are involved in 
decision-making about 
treatment 
9 17 9 0 35 
To represent a broad 
view 
7 19 8 0 34 
To help with 
implementation and 
uptake later on 
6 9 5 0 20 
Experience of living 
with/having/caring for 
someone with the 
condition 
4 4 8 0 16 
Able to see things from 
the patient perspective 
2 6 7 1 16 
We wanted a national 
perspective 
3 6 5 0 14 
We wanted a local 
perspective 
0 1 1 0 2 
Other 1 1 0 0 2 
Total 86 151 89 1 327 
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5.5.5 Differences in the outcomes thought to be important  
We asked “Were there any differences in the outcomes thought to be important by 
different stakeholder groups?”  All 81 respondents answered this question. 24/81 COS 
developers did not look for this; 18 of these did include more than one stakeholder group 
in the process.  Twelve COS developers responded that it was not relevant to them as they 
only included one group of stakeholders in the process; however, a cross check with the 
stakeholders included indicated that 5/12 of these had involved more than one group. 
These were typically clinical and research experts which might suggest that COS developers 
saw these as sufficiently similar to combine as one group, and did not differentiate these as 
different stakeholders. Of the remaining 45, twenty-six indicated that there were no 
differences, but on further checking it would seem that four of these only included one 
stakeholder group.  Nineteen indicated that there were differences in the outcomes 
thought to be important by different stakeholders. Only one of the 19 who reported 
differences in the outcomes thought to be important by different stakeholder groups 
discussed these differences in their publication.  
 
A range of differences were reported.  Three COS developers did not specify what those 
differences were; two COS developers described differences in relation to ‘how’ outcomes 
were measured and one described international differences but not specific to particular 
stakeholder groups: 
Because of international variation in available technical and clinical resources for 
clinical trials, there were international variations in preferences for main outcome 
measures. (S57) 
2/19 described differences between clinical professionals from different parts of the world: 
Different opinions between US and European professionals due to differences in 
practice and reimbursement. (S1) 
4/19 described differences between clinical professionals when multidisciplinary groups 
were included: 
The differences were related to the profession and the interventions; audiologist 
preferred audiological measurements, psychotherapists QoL measurements. (S65) 
2/19 described differences between clinical professionals and researchers: 
116 
 
There are different measures noted as clinically relevant that are difficult to capture 
in the context of a research trial, much discussion centered on around how to best 
objectify these variables. Differences were primarily between the clinical 
researchers and clinical experts.  (S62) 
2/19 described differences between the FDA and another stakeholder group: 
FDA favored clinically meaningful outcome measures, while industry favored MRI 
outcomes. (S24) 
 
Of the 45 respondents who answered yes or no to the question about whether there were 
differences in the outcomes thought to be important by different stakeholder groups, 
seven involved patients as well as health professionals in the COS development process. Of 
the seven studies three reported differences in the outcomes deemed important by these 
groups: 
Patients have other priorities than physicians, e.g. function higher than cosmetics. 
(S26) 
Patients place more emphasis on pain. Healthcare professionals place more 
emphasis on controlling inflammation. (S60)  
  
5.5.6 COS developer experiences of the COS development process 
What do you think were the main strengths of your study? 
Respondents were asked to list up to five strengths. 76/81 respondents answered this 
question. Respondents provided a range of 1 to 5 strengths; the average (mode) was 3. A 
total of 211 strengths were listed and classified, and a total of 237 categories were assigned 
as some involved more than one category. For example, “lots of patients (compared to 
previous core outcomes projects)” was provided as one strength and therefore included as 
1/211 strengths; it was categorised as both ‘Stakeholder involvement’ and ‘Sample size’ so 
included in 2/237 categories. A list of classifications can be found in Appendix 6, and the 
frequency of categories is shown in Table 30.  
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Table 30: COS developers’ perceived strengths of their COS studies 
Domain  Category Frequency  
Stakeholders (n=66) Stakeholder involvement  57 
Sample size  7 
Patient research partners 1 
Response rate  1 
Consensus (n=60) International  25 
Consensus 15 
Standardisation   8 
Consensus 
definition/parameters 2 
Evidence based  7 
Experience based 3 
Methods (n=45) 
 
 
Process 27 
Literature review 12 
Method used  3 
Outcomes framework 2 
Scoring system  1 
Design (n=42) Wider trial design 13 
How to measure 13 
Novel 11 
Scope  2 
Starting point 2 
Resources 1 
Implementation (n=22) Endorsement  5 
Relevance to practice  5 
Relevance to research 5 
Impact 2 
Uptake 2 
Dissemination  1 
Relevance to regulators  1 
Prospective validation 1 
Other (n=2) Timely 2 
 
Stakeholder involvement was the most frequently listed strength by COS developers. 
Comments included involving a ‘broad group of experts and professionals’ (S49), 
‘involvement of multiple stakeholders – regulatory, industry, academics, patient societies’ 
(S24), as well as stakeholders with different, or ‘large  experience in the particular field’ 
(S66).  
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COS developers also described including key leaders in their field. Patients being involved 
as participants was also listed as a strength by some COS developers. One COS developer 
also described the involvement of patient research partners ‘at every stage of the study’ as 
a strength of their study (S44). The involvement of industry representatives ‘as full 
participants from the start’ was also noted as a strength of one COS developer’s study 
(S25). 
 
Another frequently listed strength was that the COS was international. This included both 
international representation in the process and achieving international consensus. 
Adopting a consensus process was also seen as another strength of these studies. 
Interestingly, some COS developers reported that this work was novel in the field and this 
was also seen as a particular strength. Two COS developers also perceived the work being 
‘timely’ as a strength (S24, S42).  
 
COS developers described endorsement of their work as one of its strengths, including 
‘potential for regulatory endorsement’ (S16) and ‘international representation and buy-in’ 
(S18). Uptake of the core outcome set was also perceived as a strength: 
Used in subsequent clinical trials, allowing meta-analyses. (S48) 
Widely adopted. (S60) 
Others wrote about impact in a more general way: 
Had a significant impact on future outcomes research in [disease area]. (S53) 
It has had an enduring impact. (S61) 
COS developers described an overall relevance to research, but also to ’clinical practice, 
trials, [and] regulatory agencies’ (S6). 
 
What do you think were the main challenges you experienced over the course of your 
study? 
Respondents were asked to list up to five challenges. 75/81 respondents answered this 
question. 5/75 stated that they did not experience any challenges in doing this work. Other 
respondents provided a range of 1 to 5 challenges; the average (mode) was 1. A total of 
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121 challenges were listed (137 categories assigned). A list of classifications can be found in 
Appendix 7, and the frequencies of categories are shown in Table 31.  
Table 31: Challenges experienced over the course of COS development 
Domain  Category Frequency 
Consensus (n=47) Lack of data to support recommendations   14 
Achieving consensus 12 
Differences in opinion 7 
Different interests  3 
Expert biases 3 
Conflict of interest  2 
Opinion vs data  2 
Prioritising outcomes 2 
Including all views  1 
Multiple domains important  1 
Design (n=36) Resources 14 
How to measure 11 
Wider trial design 4 
No experience/knowledge of COS 
development  3 
Novel 2 
Feasible vs important  2 
Methods (n=20) Process 18 
No guidance 1 
Finding relevant articles  1 
Stakeholders (n=17) Patient involvement  5 
Participants 3 
Size of the group  3 
Language [international] 2 
Response rate  1 
Accessing participants 1 
Participant burden 1 
Recruitment  1 
Implementation (n=14) Implementation 3 
Changing practice 3 
Validation of outcomes  3 
Keeping up to date  2 
Publishing 1 
Dissemination 1 
Generalisability of COS 1 
Other (n=3) General
†
 2 
Poor understanding of disease 1 
†
Heterogeneity. (S63) 
  Lack of gold standard outcome. (S45) 
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Achieving consensus was described as challenging by COS developers, and was described as 
the main challenge by one COS developer (S54). This theme was echoed in another 
challenge described by COS developers, that is differences in opinions and interests 
between experts. One COS developer described the challenge of ‘smoothing political 
differences,’ (S18) and another wrote that ‘experts are disinterested in others views’ (S60). 
Having a lack of data was seen as another challenge experienced by COS developers, and 
this was described as ’finding the balance between expert opinion and data’ (S25) with 
‘limited literature to support recommendation’ (S64).  
 
Respondents saw avoiding the potential for bias and managing conflicts of interest as 
further challenges for COS developers, sometimes in relation to the measurement  
instruments that participants’ had previously developed.  
To deal with the different (hidden) agenda’s/motivations of the professionals. (S1) 
Some participants insisted in the instruments they developed and used. (S65) 
 
COS developers described experiencing challenges associated with resources, commonly 
funding, time or technology:  
 Financial limitations for support of experts. (S47) 
 Time required to complete the work. (S61) 
 Managing Delphi process through ICT. (S7) 
One COS developer went further to write that ‘Speed meant we made a few mistakes,’ 
(S61).  
 
COS developers listed many challenges in relation to the COS development process itself. 
Challenges included uncertainties about how to structure the process, organising 
stakeholders, difficulties with arranging meetings and keeping participants motivated. One 
part of the process described as challenging was narrowing down the long list of outcomes: 
             Narrowing down the potential research outcomes to a small enough list. (S22) 
Making the work relevant- we worked hard to hone the list to a manageable 
realistic level. (S62) 
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Challenges associated with involving patients in the process were listed. Comments about 
the challenges involved included: 
How to label the outcomes important to patients - to use their own language or 
map onto existing outcomes? (S44) 
Explain outcomes and why this is important to non-clinical participants (patients). 
(S36) 
 
Implementation and dissemination was also described as a challenge. One COS developer 
described tensions with other professional bodies: 
The American Academy of [disease area] felt that our group, and the American 
[disease area] Association, were usurping its prerogative. (S37) 
Furthermore, implementation was seen as challenging because ‘changing practice is 
difficult,’ (S60), and ‘old methods [are] ingrained’ (S6). 
 
A lack of methodological guidance (S7), lack of knowledge (S40), and lack of experience of 
COS development (S25, S48) were also seen as challenges. The relative novelty of COS 
development was also described as a challenge:  
First of its kind, so everything was 'new', many things developed 'on the fly'. (S25) 
 
What do you think were the main limitations of your study?  
Respondents were asked to list up to five limitations. 78/81 respondents answered this 
question. 4/78 reported that they did not think there were any limitations to their study. 
Other respondents provided a range of 1 to 5 limitations; the average (mode) was 2. A total 
of 123 limitations were listed. A list of classifications can be found in Appendix 8, and the 
frequencies of categories are shown in Table 32. 
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Table 32: COS developer perceived limitations 
Domain  Limitation  Frequency  
Consensus (n=34) Lack of data to support 
recommendations  27 
Theoretical  3 
Expert bias 2 
Inability to recommend a COS 1 
Lack of preceding consensus 1 
Stakeholders (n=30) Stakeholder involvement  21 
Number of participants 6 
Language difficulties   2 
Response rate  1 
Implementation (n=21) Keeping up to date 7 
Implementation  7 
Endorsement 2 
Intended use (Trials vs practice ) 2 
Lack of validation of COS 2 
Non-specific results  1 
Other (n=20) How to measure  13 
Other† 5 
Size of COS 1 
Limited knowledge 1 
Methods (n=10) Process 8 
No gold standard 2 
Scope (n=8) Disease/population 3 
Narrow focus 3 
Study design 1 
Intervention 1 
† Complexity of the situations to apply the methodology. (S50) 
   It was not a study. (S53) 
   Over-emphasize drug effects. (S60) 
   Specific agendas by some experts not included in this chapter. (S79) 
   Differences between centres. (S41) 
  
 
The most frequently listed limitation was a lack of data on which to base 
recommendations: 
Evidence base lacking for some decisions. (S34) 
Limited evidence behind recommendations. (S64) 
COS developers felt that basing their recommendations on expert opinion in the absence of 
data was one of the main limitations of their work: 
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More consensus-based than evidence-based. (S27) 
At the end it is expert opinion, not evidence. (S28) 
Conclusions based more on expert view than trial data. (S45) 
Similarly, COS developers wrote about COS development as being theoretical or conceptual 
as another limitation.  
 
Lack of stakeholder involvement was often listed as the main limitation. COS developers 
most commonly described a lack of patient involvement. Other stakeholder groups listed as 
absent from their study included regulators and industry representatives. Two COS 
developers listed ‘expert bias’ as another limitation (S42 and S63). Others made more 
general comments about limitations of stakeholder involvement, including a lack of 
international perspectives and ‘only professionals [being] involved’ (S74). The number of 
participants included and the representativeness of included samples was seen as another 
limitation:  
Too few cardiologists. (S28) 
Although lots of patients replied to our project, their number was still lower than 
clinicians, hence possibly they were underrepresented. (S36) 
 
Uptake, implementation and endorsement were other limitations listed by COS developers:  
The work was sound, but the American Academy of [disease area] felt compelled to 
in essence redo and overwrite it with its own document. (S37) 
That despite firm recommendation, industry developed own outcome. (S67) 
Lack of ability to ensure that these outcomes will be used in clinical trials. (S75) 
 
COS developers also saw the need for their COS recommendations to be updated, and 
seemed to be concerned that their recommendations had quickly become out of date: 
Dynamic field where outcomes of interest change. (S15, published 2007) 
Newer outcome measures and domains have developed since then. (S21, published 
1997) 
Outdated at this point. (S51, published 1999). 
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COS developers listed many process related limitations, including not addressing all 
intended issues (S6) and not providing a forum for external input to the consensus process 
(S35). Two COS developers listed ‘no gold standard’ in relation to method for development 
as one of the main limitations (S2 and S46). COS developers also included some limitations 
regarding how to measure outcomes including that ‘not all domains had instruments 
available’ (S52), and ‘limited data about change sensitivity of instruments’ (S65).  
 
5.5.7 Resources  
Can you please list the resources you used to develop your core outcome set? 
This was a free text response, and 77/81 respondents answered this question. Resources 
largely included funding (n=50), experts (n=11), and literature (n=4). The funding received 
varied between COS developers: 
Funding for a researcher, funding for travel expenses, funding for international 
meeting, including flying people in from Australia and New Zealand. Was not 
massive, but I think around £30K for the overall thing. We were very lucky to have 
the dedicated support of a lot of people. (S61) 
WHO funding for one conference meeting - thus very limited resources. (S66) 
   
12/77 indicated that they did not have any resources. Four COS developers wrote that the 
only resource they had was their own time. Three other COS developers also noted time of 
experts as one of the resources used.  
 
How long did your study take, from planning to completion? 
Respondents were asked to enter the number of months, and 77/81 answered this 
question. 6/77 did not provide a number of months because they could not remember, did 
not feel it was applicable or because the work was still ongoing. The number of months 
ranged from 3 to 252; the median was 12 months, and the number of months taken are 
shown in Table 33. Studies that took the least amount of time tended to involve a single 
meeting, and solely considered what should be measured. This was in contrast to those 
studies that took the most amount of time that seemed to involve multiple methods and 
often considered how to measure the outcomes once they had been decided.  
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Table 33: Number of months to develop the core outcome set 
Months  Frequency (n) 
Less than 12 months  15 
12 - 23 months  28 
24-35 months  13 
36 -47 9 
48+ 6 
    
We asked COS developers to indicate whether the time taken was longer than expected, as 
expected, or shorter than expected.  54/77 recorded that this was as expected and one COS 
developer recorded this was shorter than expected; COS developers attributed this to 
efficient planning and having a deadline to meet, for example the length of a grant.  
 
22/77 recorded that the time taken to develop the COS was longer than expected and 
described ‘lack of time due to lack of funding’ (S26), difficulties with international 
participation, and difficulties with patient involvement:  
Large group of individuals and authors to provide feedback, writing and edits over 
many timezones throughout the world...all working as volunteers on this project. 
(S62) 
We underestimated the difficulty of patient accrual. (S4) 
 
One COS developer described ‘a lack of familiarity’ with the process (S23). Another COS 
developer simply wrote ‘This stuff takes time!’ (S18) and another noted “Difficult task, and 
probably not ever going to be done” (S17).  
  
5.5.8 What next?   
Was the future implementation or uptake of the core outcome set considered by your group 
at any stage? 
76/81 respondents answered this question, which had a yes/no response option. If 
respondents answered ‘No’, they were asked to explain why this was not a consideration, 
and if they answered ‘Yes’ they were asked what plans they had/have to promote the 
uptake of the core set.  
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Of the 12/76 (16%) who answered ‘No’ to this question, their responses indicated that they 
saw implementation as beyond the scope of COS development, or that funding was not 
available to support the implementation or uptake of the COS.  
One COS developer described not having a way to look at the uptake of the COS: 
We had no way of monitoring the uptake as these would be used in clinical trials 
most of which are proprietary.  We will know over the next several years when the 
studies are completed. (S75) 
 
64/76 (84%) answered ‘Yes’ to this question.  COS developers who answered yes mostly 
listed publication in a journal as addressing the issue of uptake (n=18), but some also listed 
participation in meetings (n=11), talking to relevant stakeholder groups (n=7), and 
interestingly, the involvement of prospective users in the development process who might 
influence uptake later on (n=5).  
 
Three COS developers cited uptake in guidelines as a way of implementing the COS, this 
included FDA and NICE guidelines. Two COS developers also wrote about research funders’ 
involvement in the implementation or uptake of COS: 
Federal grants have required their use in recent years. (S10) 
The major sponsoring professional society distributes, references, and promotes the 
use of the work. (S43) 
 
Do you have any plans to update or review your core outcome set? 
This question had a fixed yes/no response option and 76/81 respondents answered it. 
36/76 (47%) answered ‘No’ to this question. These respondents indicated either that they 
had not thought about the need for updates or reviews of their COS or, as with 
implementation, indicated lack of funding and resources as a barrier to updates or 
commented that updates were not part of the task.  
 
40/76 (53%) answered ‘Yes’ to this question. Reasons given for plans to review or update a 
COS varied and included: 
 To reduce size of COS. (S7) 
According to [OMERACT] Filter 2.0 all COS must have an update cycle. (S25) 
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Review in a larger European group. (S65) 
 
Some COS developers planned to update their recommendations to ensure relevance and 
‘to confirm importance of the domains to patients affected’ (S35).  
 
COS developers also suggested when planned updates might take place, typically between 
5 and 10 years, but they did not provide any explanation for their choice of time points.  
5 year update cycle based on any new scientific publications, new evidence. (S31) 
Originally planned to review in 3 years but due to poor results from recent clinical 
trials and number still underway it is best to wait until more data to review. (S45) 
They will be revised approx. every 10 years. (S67) 
Assess impact and revise in a 5 year time. (S74) 
 
5.5.9 Guidelines  
Reflecting on your experiences of developing a core outcome set, are there any areas that 
you feel would benefit from methodological guidance or research to inform future activity 
to develop core outcome sets? 
Respondents were asked to list up to five areas. 78/81 respondents answered this 
question. Three of the 78 did not think this was applicable to them, and two of the 78 
answered ‘don’t know.’ Sixteen answered ‘no’ to this question. 92 areas for guidance or 
research to inform future activity were listed by the remaining 57 COS developers, but 17 
of these were not relevant to COS development. A list of classifications can be found in 
Appendix 9, and a summary of the frequencies of categories are shown in Table 34. 
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Table 34: Areas that COS developers feel would benefit from methodological guidance or 
research to inform future activity to develop COS 
Category  Frequency (n) 
How to measure core outcomes 17 
Stakeholder involvement  16 
General  13 
Choice of methods 6 
Consensus methods  8 
Implementation  4 
Systematic review  3 
Outcome terminology  2 
Review and feedback 1 
More data  1 
Quality assessment  2 
Wording (phrasing of outcomes)  1 
Application of COS 1 
 
COS developers made general comments about the need for guidance in COS development 
(n=13): 
We've now developed OMERACT Filter 2.0 that is highly relevant to all COS 
developers. This, or something strongly like it, should be adopted by COMET ASAP. 
COS developers need concrete guidance NOW. (S25)  
Absolutely, any additional guidance possible offers best hope of developing 
appropriate guidelines (S31). 
I think guidance needs to reflect the practicalities of making decisions based on 
imperfect information. (S61) 
Guidelines for optimizing the process. (S67) 
 
COS developers felt that guidance or research to inform stakeholder involvement would be 
beneficial to inform future activity (n=16). Some made general comments about the need 
to involve multiple stakeholders and perspectives; others made specific comments about 
guidance: 
 Structured method for selection of experts and reaching consensus. (S27) 
How to identify participants. (S36) 
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Patient involvement seemed to be a particularly important area where it was felt that 
guidance or research was needed. As well as the need for their involvement, COS 
developers suggested: 
 How to better incorporate patients at an appropriate level and time. (S62) 
More discussion about including minority patient participants in the process. (S44) 
One COS developer also commented on the need for ‘guidance on wording of outcomes 
and domains when including patients in the process’ (S44). 
 
One specific area suggested by COS developers as requiring guidance was choice of 
methodology (n=6): 
Define different approaches and pros and cons of each. (S8)  
Which method to use (delphi, focus groups etc). (S36) 
 
Consensus methodology was another area where it was felt that guidance or research was 
needed (n=8). One COS developer asked ‘what is consensus?’ (S7). Specific comments 
related to how to define consensus:  
Noticed with others developing core sets - lots of confusion about consensus levels 
for Delphi/ NGT. (S44) 
 
COS developers also made general comments in relation to how to measure outcomes 
(n=17), although specific areas requiring guidance were not described.  
 
5.6 Discussion  
5.6.1 Main findings 
We found that COS have been developed for a range of different reasons, but 
predominantly because of heterogeneity in what is being measured and heterogeneity in 
how outcomes are being measured. This thesis focussed on studies that aimed to establish 
what to measure, but as we also found in the systematic review of COS, consistency about 
how outcomes are measured is also important to COS developers. This highlights a key 
message, that COS development does not stop at what should be measured.  
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The absence of a COS was an obvious rationale for core set development, but interestingly 
the survey highlighted that it is possible that a COS existed but it was not deemed good 
enough or suitable for use. This highlights two important findings. First, although a quality 
assessment tool does not currently exist for COS development studies, users are making 
some informal quality assessment and applying some criteria as to what they think makes a 
COS of good quality, such as patient involvement, and the level of methodological detail 
provided. This affirms the need for an agreed method to quality assess COS studies. As the 
systematic review in Chapter 3 highlighted, and in view of the continuing increase in the 
number of COS being developed, this needs to be a priority in COS research.   
 
The second area of COS development highlighted here is the importance of defining the 
scope of the COS. A COS may be developed rigorously but may not fit the required scope. It 
is therefore important that scope is well defined to allow users to decide whether a COS 
matches their required scope. Failure to do so could result in the COS not being used, the 
COS being used inappropriately or even duplication of work to develop a similar COS for a 
specific scope. This is therefore an important criterion that should be included in reporting 
standards and any reporting guidelines for these types of studies to allow users to make 
this kind of decision. COS developers’ comments also touched on other questions about the 
scope of COS. As one COS developer wrote: ‘Two core sets were available but they were 
both too broad.’ Whether COS should be more general or quite specific is an interesting 
area for discussion, and may have implications for the uptake and implementation of COS.  
 
In this survey, choice of methodology was most frequently attributed to the influence of 
previous work on COS development (by looking at the literature) or expert advice, partly 
confirming what was found in the systematic review of COS that COS developers have a 
propensity to use methods that have been used previously. This raises the question 
whether COS developers critically reviewed these methods when deciding which to use, 
and if not, this might not be the best way to make decisions if previous work is flawed or 
has not been methodologically rigorous.  More detail about previous work used to inform 
decisions was derived from the survey, and included work by OMERACT and HOME. The 
COS developer of one recent study also cited the COMET website as a resource to help 
them make decisions about methodology. In contrast to what people are doing presently, 
the survey informed us about how COS developers have made decisions regarding methods 
in already published work. This highlights the need to find out from current COS developers 
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how they decide what methods to use; this has been explored during the qualitative 
interviews as will be described in Chapters 6 and 7.  
 
The results of this survey show that COS developers regard patient involvement as an 
important area of COS development, but some also found this challenging. The 
involvement of different stakeholder groups is a vital part of COS development, as the 
survey showed that 42% of studies that examined outcome prioritisation by stakeholder 
groups observed between group differences. Of seven studies that had involved patients, 
three (43%) reported differences between patients’ and clinical professionals’ views. Half of 
the COS developers who selected ‘experience of living with/caring for someone with a 
condition’ and ‘being able to see things from the patient perspective’ as reasons for their 
choice of stakeholders did not include these groups in the process. These COS developers 
might have thought that clinical experts could provide that perspective without involving 
patients themselves. However, such a position is controversial and open to challenge. 
Certainty those COS developers in this survey who did involve patients described them as 
having different ‘priorities’ to other stakeholder groups, particularly clinicians, and placing 
‘more emphasis’ on different outcomes.  This exemplifies the importance of the choice of 
stakeholder groups to include in COS development, and the necessity of including patients 
in the process. These findings raise a further methodological question about how 
stakeholder group differences in outcome priorities are reconciled in the process of COS 
development, which was described as a challenge of the process by COS developers. 
 
Intriguingly, a lack of data to support expert opinion was another commonly described 
challenge, as well as being the most frequently cited limitation of COS work. Little 
explanation surrounding this was provided by COS developers and due to the nature of the 
survey method, it was not possible to explore this issue further beyond their initial 
responses. COS development is essentially opinion-based, but interestingly COS developers 
seem to be implying that it could be something other than this. In the context of COS 
development, any data that is available will inevitably compromise  different people’s 
views regarding what is important to measure. Systematic reviews of outcomes used in 
published trials might be regarded as data or evidence to support decision making, but they 
only indicate what outcomes previous researchers have felt important to measure and 
therefore cannot be an ‘opinion free’ test or gold standard of what is an important 
outcome. It would seem that COS developers in this study expressed an unease about 
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opinion-based decision-making rather than it being a limitation of COS development per se. 
Evidence versus opinion is an important methodological consideration, and one that we 
need to explore further in this area of COS development.  
 
COS developers reported being challenged by the lack of resources for their studies, which 
included limited funding, time and technology. One COS developer hinted at the 
implications of this challenge, commenting that ‘speed meant we made a few mistakes,’ 
which suggests that resource issues have very real implications for the quality and outputs 
of the process. This was echoed in responses regarding the time taken to complete the COS 
development work, as close to a third of respondents indicated that it took longer than 
expected and a lack of funding was amongst the reasons given for this.  
 
COS developers indicated that the uptake and implementation of the COS could be a 
strength, a limitation, and a challenge of the process. When asked directly about 
implementation as part of the process, however, COS developers  predominantly listed 
publication in a journal as addressing the issue of uptake, despite this likely being only one 
step in ensuring that a COS is actually used. Nevertheless, implementation was described as 
challenging because it required changes to practice that would be hard to achieve. 
Respondents also answered that there was currently ‘no way of monitoring the uptake.’  
COS developers lacked the influence ‘to ensure that these outcomes will be used in clinical 
trials.’ These are important obstacles to tackle if COS are to be successfully adopted in trials 
and research. Where COS developers had not considered implementation it seemed to be 
because funding was not available, or it was not felt to be part of the task. Overcoming 
these barriers is a priority for groups, such as the COMET Initiative, working in this area of 
COS development.  
 
5.6.2 Robustness of the study  
Strengths of the study 
The study had several strengths. University of Liverpool software was utilised which 
allowed the survey to be designed specifically for the purpose of this study. This was 
important as the software allowed the inclusion of filter questions, which, in turn, 
facilitated the inclusion of specific questions to gain detailed responses when particular 
answers were selected. The online survey was developed in line with design principles 
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suggested to increase survey response and included both closed and open questions, which 
again allowed for specific and more elaborate responses.  
 
The survey achieved a relatively high response rate (53%) for an online survey [110, 111], 
where rates of under 20% are not uncommon [112]. One possible explanation is that the 
survey involved a small specialised population [111]. As already noted, the steps taken 
when designing the survey to maximise the response rate could be another explanation for 
the high response rate achieved here.  Furthermore, it achieved a high completion rate of 
85% and the respondents were representative of the systematic review in relation to the 
disease categories, population and intervention characteristics covered.   
 
Response rates were higher for those COS developers from the subset of more recently 
published studies, meaning that the survey results reflect more recent COS development 
practices than older. Although it would seem that COS developers were more likely to 
respond if they had involved patients  than if they had not done so, this is likely related to 
response being higher for more recent studies as patient participation is more frequent in 
more recent COS. Given the survey’s overall goal of investigating how methodological 
guidance or research can inform future activity to develop COS, this might be considered a 
strength of the survey. Recall is also likely to be more accurate for recent studies.  
 
 
 Limitations of the study  
Thirteen COS developers started to respond to the survey but did not finish it, and the 
reasons for partial response are not known. There could be issues around the suitability of 
the questions, the length of the questionnaire or issues with respondents recall of the COS 
development process as some of the studies were published quite a time ago. These issues 
could also apply to non-responders, where again the reason for not responding is not 
known. Furthermore, although the results of the survey relate to studies that were 
published relatively recently, nevertheless 66/81 (82%) of the studies were published 
between 2000 and 2013, which is still some time ago. Recall bias may have affected the 
responses. Geographical location of the developers was not sought in this study, but could 
be considered as another factor that might be associated with whether a response was 
received or not. 
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A survey of this sort provides only a limited insight into participants’ opinions and does not 
allow clarification or more information to be sought. The survey relates to work that has 
already been done, and was conceived and designed several years ago. COS development 
appears to be a fast-moving field, and it is possible that things might have changed or 
moved on since these studies were conducted. As these are not the most up to date COS 
studies, one might question the relevancy of these survey findings today. However, to date 
limited methodological guidance has been published in the area of COS development; 
hence it is expected that these findings will still be relevant for studies published more 
recently, and indeed for studies underway or in the future.   
 
5.6.3 Summary  
This survey is the first to provide insight into COS developers’ methodological decision 
making, and choices of methods.  It also provides insight into their experiences’ of doing 
this type of work, including the challenges that they encountered and it gives the first 
account of COS development in a cohort of studies. The majority of respondents (73%) felt 
that there is a need for methodological guidance or research to inform future activity to 
develop COS, including: stakeholder involvement, patient involvement, choice of 
methodology, and consensus formation.  These findings raise important methodological 
questions and highlight areas that future research and discussion should focus on.  The 
main limitation is that the survey was carried out with COS developers who had already 
published this work, and as such, the results relate to work that was done several years 
ago. This highlights the need to find out from current COS developers how they decide 
what methods to use, and the challenges that they encounter. Interviews with recently 
published and ongoing COS developers, to explore these issues, are described in Chapters 6 
and 7.  
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Chapter 6: Qualitative methods to 
study researchers’ experiences of 
developing COS 
 
6.1 Background 
Investigating researchers’ experiences of developing COS and the influences on the choices 
they make over the course of their projects is important. COS development is a new area of 
research and the formulation of guidance in this area depends on understanding what 
influences the methodological choices being made. As already described in Chapter 5, this 
thesis presents a mixed methods approach to explore COS development, drawing on an 
online web-based survey (chapter 5) and qualitative methods. The qualitative work will be 
the focus of this and the subsequent chapter.  
 
6.1.1   Aims  
I carried out qualitative interviews to explore how COS developers described their choice of 
methodological approach, including the influences on how they developed the COS. This 
aimed to identify potentially important but previously unanticipated issues as well as to 
describe in detail the COS developers’ accounts of their projects. I also wanted to learn 
about COS developers’ experiences and the challenges they encountered to identify 
priority areas for future methodological research. 
 
6.1.2   Rationale for choosing qualitative methods  
I drew on qualitative methods to examine researchers’ accounts of their work to develop 
COS. Qualitative research is widely acknowledged as an appropriate method in evidence-
based healthcare for providing in-depth insights into areas of practice, particularly when 
little previous work has been conducted in a particular area [113]. For a new area of 
research where little is known about the nature of the phenomenon, or few definitive 
hypotheses exist, qualitative inquiry is a reasonable starting position because it is 
exploratory. Qualitative research focuses not only on the meanings that people attach to 
experiences, but the relationship between experience, knowledge, social factors and the 
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actions taken that shape these processes. Understanding this is paramount to the aims of 
this study to further our methodological understanding of COS development processes, as 
it is through multiple and contrasting accounts that theory and understanding develop. 
 
6.2 Reflexivity  
Within the field of qualitative research it is necessary to be reflexive about one’s role in 
that research and the influence of beliefs and behaviours on the research process. This is 
important because in qualitative work it is acknowledged that bias cannot be eliminated 
and that the researcher will inevitably influence the research findings. In this research I 
aimed to achieve an ‘empathic neutrality’, that is, to achieve a middle ground between 
becoming too involved which can cloud judgement, and remaining too distant which can, 
for example, stymie participants’ accounts and thereby reduce understanding [114]. I 
therefore strove to avoid obvious, conscious or systematic bias and to remain as neutral as 
possible throughout the design of this study, as well as the collection, interpretation and 
presentation of data [115]. However, it is important to recognise that research will be 
influenced by the researcher, so in turn, it is important to reflect on my own personal 
characteristics and how these could have influenced the current study.  
 
I recognise that my age, gender, training and qualifications will differ from many of the 
interviewees (COS developers) and may therefore have implications for the way in which 
they perceived me. I have undertaken training in qualitative research, specifically around 
conducting and analysing qualitative interviews (see Appendix 10 for a full list of relevant 
training).  I have a background in psychology and obtained a First class BSc in Psychology 
and Health Science from The University of Liverpool in 2007. After graduating, I went on to 
work for a patient reported outcomes (PRO) consultancy specialising in the development 
and use of PRO endpoints in clinical trials, before joining the University of Liverpool in 2009 
to work on a systematic review of paediatric adverse drug reactions.  
 
It seemed particularly important to consider how my current professional role might have 
influenced this study. I have been involved in the COMET Initiative, as the Project 
Coordinator, since its inception in 2010. As part of my role I have been involved in multiple 
COS publications, organised and participated in COMET conferences, and raised awareness 
about the COMET Initiative all around the world. I have been a point of contact for COMET, 
including when COS developers have registered work in the COMET database. These roles 
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could have influenced the way in which interviewees engaged with me and how I gathered 
and analysed data. For example, it is possible that interviewees perceived me as an 
authoritative figure in the area of COS research because of my association with the COMET 
Initiative, and as such could have been reluctant to share poor practices with me. In order 
to manage the potential impact of these issues on this work, I tried to position myself very 
much as the student in the interview, and the interviewee as the expert with experience in 
the field of COS development that I wanted to learn from. To facilitate this positioning, I 
included the following wording in the invite email: ‘You have been asked to take part in this 
study because you are or have been involved in research to determine the outcomes or 
domains to measure in clinical trials, and your experiences are therefore very important to 
us. We would like to learn from your experiences and incorporate what we learn into 
guidance to assist future researchers.’ I also repeated this at the start of each interview.  
 
It is also worth noting that my status as a PhD student could have been influential and 
interviewees could have withheld information that they felt I might not understand. 
Coming to this as a PhD student, it would be possible to feel overwhelmed or intimidated 
by interviewing some of the more senior figures who have led COS development in a 
number of areas. To avoid that being an issue, I tried to establish rapport with interviewees 
prior to the interview itself, through the enrolment process, thereby putting myself at ease 
prior to conducting the interviews. Furthermore, during my time as the COMET Co-
ordinator, I had gained experience of corresponding with senior figures so for me 
personally, interviewing people in senior positions was not something that I found 
concerning or intimidating. 
 
6.3  Methods  
As no previous qualitative research had been conducted on COS developers’ accounts of 
their work, in this study I adopted an interpretive approach informed by the constant 
comparative method [116]. An interpretive approach places emphasis on understanding 
rather than simply an explanation of the phenomena under investigation, which is 
imperative to the aims of the work undertaken in this thesis. In the analysis I therefore 
went beyond simply describing what participants said, to interpret their accounts and 
consider what could be learnt from how they constructed their accounts. The constant 
comparison method involved taking one piece of data (e.g. one interview or one theme) 
and comparing it with others that may be similar or different to conceptualise the data and 
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explore relations between various pieces of data [117]. These methods were particularly 
suited to topics that have not been previously explored because they help to avoid 
imposing assumptions, and allow a close connection between the data and its 
conceptualisation [107].  
 
6.3.1 Interviews  
I conducted semi structured interviews, a fairly open interview format that allows for 
focussed yet conversational communication. I felt that such interviews allowed specific 
issues to be addressed whilst at the same time this approach allowed interviewees to freely 
describe their experiences, thereby eliciting information that might not arise in a structured 
interview and giving insight about what COS developers deemed to be important. A semi 
structured interview also allows flexibility to ask new questions that follow up 
interviewee’s replies, as well as changing the order of questions to best suit each individual 
interview [107].   
 
While the interviews were therefore conversational, I used a topic guide comprising key 
issues and subtopics to be explored with interviewees. The topic guide was used as an aide 
memoir to ensure consistency in data collection. Consistency here does not mean asking 
the same questions in the same way to each interviewee, but rather steering the general 
topics for data collection in each interview. The topic guide was informed by the results of 
the systematic review. For each interview there was a list of questions and fairly specific 
topics to be covered (see version 1.0 of the interview guide in Appendix 11). To avoid 
generalised and idealised responses which might have arisen if questions focussed only on 
opinions, the topic guide focused initially on COS developers’ experiences of the processes 
involved in developing a COS. Open ended questions were designed to elicit COS 
developers’ accounts of what they did to develop a COS, what influenced their decisions 
about their approach, and what constraints they were operating under. I reviewed 
interviewees’ relevant publications prior to each interview in order to tailor questions and 
prompts to each individual being interviewed. I also avoided phrasing questions in ways 
that might have made interviewees feel their judgement was being questioned or 
challenged. For example, if interviewees did not talk about including patients as 
participants, I used an open question such as ‘Did you think about including patients in this 
work?’ as opposed to ‘Why didn’t you include patients?’ which might seem challenging to 
the interviewee.   
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By and large, all topics in the guide were explored with every interviewee. I asked 
additional questions, not included in the guide, to follow up issues as these were identified. 
The topic guide was also developed iteratively in light of the data analysis, which was 
conducted in parallel with the interviews. This iterative process allowed respondent 
validation whereby I was able to check the correspondence between the developing 
analysis and the perspectives and experiences of interviewees in subsequent interviews. 
Furthermore, iterative analysis allowed identification of unexpected or atypical issues, and 
provided the opportunity to explore these issues with subsequent interviewees. An 
example of an unexpected issue that arose during the interviews was around ethics 
requirements for COS work. This was not included in the original topic guide, but once it 
was identified, I was able to incorporate it into the guide to explore the issue in the 
interviews that followed.  
 
Interviews were conducted via telephone. Due to varied geographical locations of COS 
developers, face-to-face interviews were not feasible for this study. The benefits of face-to-
face interviews are well documented. However, there is no evidence that the nature, depth 
or quality of response is diminished in telephone interviews, when compared to face-to-
face [118]. Furthermore, telephone interviews may actually minimise socially desirable 
responses, and reduce bias or distortion due to interviewer’s characteristics [119].  
 
All interviews were conducted in English. As some participants were overseas, I ascertained 
the feasibility of doing an interview in English with the participant beforehand. Decisions 
were made on an individual basis, and if there was doubt that the interview could be 
conducted in English then the interviewee was asked to nominate another potential study 
author to interview. I asked interviewees for permission to go back to them after the initial 
interview to follow up areas that had not been covered in the interview or if new questions 
arose as analysis developed. I made field notes after each interview as an aide-memoir in 
which I recorded contextual details, my personal reflections about the interview and my 
initial analytic thoughts [107].  
 
All interviews were audio recorded, transcribed and anonymised. I carried out a small 
amount of transcription to inform the transcription protocol. The majority of the recordings 
were then transcribed by a professional transcriber, who was asked to sign a declaration of 
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confidentiality and instructed to adhere to the study protocol for data handling and 
storage.  
 
6.3.2 Participant selection and recruitment  
Purposive theoretical sampling, a form of non-probabilistic sampling, was conducted to 
discover categories relevant to the research questions [107]. Sampling in qualitative 
research is non-probabilistic because, with relatively small sample sizes, probabilistic 
samples would likely be too homogeneous to be of much use. Purposive sampling refers to 
a process where participants are selected because they meet criteria that have been 
anticipated by the researcher as relevant to addressing the research question.  
 
I used quota sampling to achieve purposive sampling. Quota sampling involves selecting a 
sample that reflects different criteria or characteristics of the population in question [107]. 
Unlike stratified sampling, it is not done randomly, rather the interviewer selects people 
who fit the chosen criteria, in this case, I sampled to reflect the different aspects of COS 
development identified through the systematic review of COS.  
 
The sampling was also iterative. This type of sampling is an ongoing process whereby the 
researcher collects and analyses data in parallel, and uses the developing analysis to inform 
the sampling with the goal of enhancing the development of themes and theory.  
 
The participant selection and recruitment process is summarised in Figure 7. I aimed to 
interview the lead author of selected studies. When this was not possible, secondary 
authors were considered for inclusion based on their level of involvement and 
responsibility for the work and publication. The final decision as to which author was 
interviewed was decided on a case-by-case basis.  
 
Sampling aimed for theoretical saturation, so I continued conducting interviews until no 
new insights were being gleaned from the data. The very nature of theoretical saturation 
means that the sample size could not be defined in advance, but given the relatively large 
number of categories in my sampling matrices, I anticipated that I would need to conduct 
between 30 and 50 interviews to achieve saturation. As 30 is considered a ‘medium’ size 
sample for a qualitative study [120], I considered this to be a realistic number of interviews 
to conduct in the time available.  
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As already noted, I aimed to conduct interviews with the lead author.  I contacted eligible 
authors by email to invite them for interview (see Appendix 12) and seek consent (see 
section 6.5.2 Informed consent). If the author declined, I asked them to nominate another 
author from the same study who was then invited by email. If an author did not respond, 
two further emails were sent out, two and four weeks after the initial email. I recorded 
authors who had not responded six weeks after the date of initial emails as non-
responders. I contacted authors who agreed to be interviewed, by email, in order to 
confirm their acceptance to participate, and to schedule a convenient time for the 
interview to take place. I also confirmed that I had all relevant publications prior to 
interview and sent a reminder one week before the scheduled interview date.  
 
Figure 7: Participant selection and recruitment process
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I devised the quota sampling matrices for this study, shown in Table 35 and Table 36, to 
inform sampling of COS.  The systematic review of COS, described in Chapter 3, enabled me 
to identify what I refer to as aspects of the COS development process. These aspects 
provided the starting point for informing the sampling of COS developers who were the 
interviewees for the qualitative study. The aspects represent features of COS development 
that I thought were important to explore in detail; how I sampled for them and why I 
thought they there were important are summarised below. Although the systematic review 
provided a starting point for the work described in this chapter, it did not constrain the 
qualitative work that was undertaken and described herein.  Furthermore, compared to the 
survey, I orientated the qualitative study to focus on COS development studies that were 
ongoing or had been published more recently, in order to understand current COS 
development. Within these categories I used random sampling to select the particular COS 
to be included in this study. The goal was not to reach saturation across all of these groups, 
rather to explore characteristics within groups.  
 
There were 86 unpublished studies listed in the COMET database* (date searched 
20/01/2015), of which 57 were listed as ‘COS’ studies. Fifteen of these had a planned 
completion date of 2014, so I targeted these as the most likely to be nearing completion 
and therefore suitable to provide insight into the current approaches to COS development. 
Studies nearing completion were particularly targeted because the COS developers would 
have experience of different stages of COS development.  I also enquired with the 
members of the COMET Management Group to obtain details of any other studies they 
knew to be near completion so that we could identify other potential COS developers to be 
interviewed. Due to the small number of ongoing COS nearing completion in 2014 to 
choose from, I invited all developers in this category to be interviewed.  
 
 
 
 
 
 
* The COMET database is described in more detail in Chapter 2, section 2.1.  
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Table 35: Sampling matrix 
Aspects of the COS development 
process 
 
Methods 
 
n= number of COS 
 
 
  Semi structured group 
discussion  
Consensus 
development 
conference    
Nominal 
group 
technique  
Unstructured 
group 
discussion† 
Delphi   Lit 
review/ 
SR   
No 
methods  
 
  Workshop Meeting Round 
table  
 
People involved           Mixed methods  
Clinical expert (no PPI) 
2-3 2-3 2-3 2-3 2-3**  2-3 2-3 
2-3 2-3  
6-9 COS using single method, 6-9 
COS using mixed methods 
PPI 
7-12*^ 1*** 
2-3 6-9 COS using single method, 6-9 
COS using mixed methods 
Aim of study  
Wider trial design issues 15-25  
Outcomes only 15-25  
 
 
 
 
 
How/what to measure 
What to measure only 9-12 
What to measure + 
discussion/consideration of how 
but no recommendation 
9-12 
What + how (done together) 9-12 
What + how (done in two stages) 3-5** 
 
† Descriptions included task force, work group, working group/party, committee, board, and panel 
^ I have grouped studies that included a face-to-face meeting (of any type) due to small numbers of studies that included patients, which made it hard to sample by each individual method 
* Only 7 studies in this category were 2010 or later, so I also included some pre 2010 studies (targeted most recent) 
** 1 or less in this category were 2010 or later, so I included pre 2010 studies (targeted most recent)  
*** Only 1 study in this category in the review 
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Table 36: Other COS aspects sampled 
Year of publication Number of COS 
 
N 
 
Pre 2010 3-5  
2010-2013 17-25  
Ongoing 10-15  
Scope  
Population characteristics – Age  
All  3-5  
Children 3-5  
Adults  3-5  
Not specified  15-30  
Intervention   
All  3-5*  
Drug  3-5  
surgery  3-5  
Specific (other)  3-5  
Not specified  12-25  
Number of COS/disease category Disease categories  
Clinical area where 
more than 5 
15-25 At least 1 COS from each category (10 categories with 
more than 5 COS) 
Clinical area where 
less than 5 
10-15 At least 1COS from 5 different categories (10 categories 
with less than 5 COS after 2010)  
Funding   
Commercial  3-5  
Non-commercial 3-5  
Commercial and non-
commercial  
3-5 
 
Not reported  15-30  
 
* 1 or less COS in this category were 2010 or later, so I included pre 2010 studies (targeted most recent)  
 
 
6.3.4     Aspects of the COS development process that informed sampling 
Methods used  
The results of the systematic review demonstrated that a variety of methods have been 
used to develop COS, and that it is currently uncertain which of these are the most suitable, 
feasible and efficient. The results suggested that the methods used in the development 
process may influence the conclusions derived.  
 
For example, consensus work was unknowingly undertaken by three different COS 
development groups in the same clinical area (paediatric asthma), but each group 
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identified different outcomes as core, suggesting that the use of different methodological 
approaches and stakeholders by COS developers may influence the outcomes included. 
Reddel et al [104] reported work undertaken by The American Thoracic Society (ATS) and 
European Respiratory Society (ERS) involving round-table discussions comprising clinical 
researchers, pharmaceutical representatives and regulatory agency representatives, with 
the aim of recommending outcomes to include in clinical trials of therapies for asthma in 
adolescents and adults. Busse et al [105] reported a workshop convened by National 
Institutes of Health (NIH) and the Agency for Healthcare Research and Quality comprising 
representatives from adult and paediatric asthma, pulmonology, and allergy/immunology; 
as well as lay voluntary organisations, biostatisticians, guideline developers and health 
policy representatives and pharmaceutical representatives in order to propose which 
asthma outcomes should be assessed in future asthma clinical research studies.  Finally, 
Sinha et al [103] carried out a survey with parents and young people with asthma and a 
Delphi survey with paediatricians and specialist nurses, to develop a method by which to 
identify outcomes of particular relevance when evaluating the effects of regular therapies 
for chronic childhood asthma.  Although there were some similarities in the outcomes 
selected as core by each of the three COS development groups (two common outcomes), 
there was variability in the other core outcomes identified. Research to investigate COS 
developers’ choices will help to illuminate the reasons for these differences in 
methodological approach, and how these lead to differences in the outcomes deemed to 
be important. In sampling COS developers to invite to take part in this study, I therefore 
sought to maximise the diversity of the different methods that developers had used in their 
work. I anticipated that maximising the diversity of the methods encompassed in my 
sample would allow me to identify and compare the reasons for choice of approach and, in 
turn, identify patterns in their rationales that could inform guidance development.   
 
Stakeholders involved  
The participants who are regarded as key to the development of all COS will likely vary 
between clinical areas, but two stakeholder groups that are always likely to be important 
are clinical experts and patients. The systematic review demonstrated that where 
developers had described the participating stakeholder groups (n=172 studies), almost all 
had included clinical experts (171/172 studies) but only 18% (31/172) included patients in 
the process. Historically, the outcomes reported for trials have not always reflected the 
endpoints most meaningful to patients. Examples exist where patients have identified an 
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outcome important to them as a group that might not have been considered important by 
practitioners on their own [103, 121]. Although it is increasingly recognised that including 
patients in the development of COS is important, their involvement has been limited to 
date. I therefore aimed to recruit a proportion of COS developers who had included patient 
participants, as well as some who had not, to explore the influences behind COS 
developers’ choices about which stakeholders to include as participants in the 
development process, and to identify the barriers and facilitators to the inclusion of 
different groups.   As few studies in the systematic review of COS included patient 
participants, I also wanted to find out about published COS developers’ experiences with 
patient participation as in some senses they could be considered as ‘innovators’; it is 
important to understand the reasons for their efforts to seek patients’ input and the 
challenges this brought, if guidelines are to facilitate patient participation in future COS 
development.   
 
COS study aims  
In the systematic review of COS, half the studies considered outcomes whilst addressing 
wider clinical trial design issues (51%), while half specifically considered outcome selection 
and measurement (49%). I included both study types in my sample of interviewees in order 
to explore the ways in which this consideration might influence the process of COS 
development and the methods used.  
 
In sampling interviewees I also took into account whether the COS developers had focussed  
only on ‘what’ outcomes to recommend for a core set, or whether they had also looked at 
‘how’ to measure outcomes, as I thought this likely to contribute to methodological 
decision making if multiple goals need to be achieved. In the systematic review (198 COS 
identified), 62% of studies made recommendations about what to measure only. Some of 
the remaining studies also made recommendations about how to measure outcomes, with 
35% of studies doing this as a single process, i.e. considering both what to measure and 
how to measure in an integrated way. The remaining 3% of studies in the systematic review 
of COS considered what to measure and then how to measure outcomes as a two stage 
demarcated process. Although the focus of the qualitative work described in this and the 
subsequent  chapter was on the process COS developers used to identify what to measure, 
I attempted to include COS developers who had used each of these approaches to explore 
any potential differences in methodological approach.  
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Scope of COS  
Disease area  
It is possible that how much COS work has been done in a particular disease area may 
affect how other COS developers in that particular area subsequently develop COS. The 
prevalence of COS work in a particular disease area might be useful in understanding 
methodological choices. I therefore aimed to include a range of disease categories with 
varying levels of COS activity to explore whether the volume of work in a given disease area 
influenced COS developers’ choices about methods. Furthermore, by sampling a range of 
disease categories, I hoped to explore issues that might apply to particular patient groups, 
and how the type of patient group (e.g. patients with dementia, brain injury, learning 
difficulties etc.) might influence COS developers’ choice of methods.  
 
Age of population 
Specific populations might pose distinctive methodological challenges. The age of the 
population is one aspect that might bring unique challenges. For example, the design and 
conduct of clinical trials in children presents different challenges when compared to trials in 
adults [122]. These include difficulties in the selection, measurement and reporting of 
outcomes. The outcomes that are important to measure and report for adults may not be 
the same for children, and there may be outcomes that are unique to adult or paediatric 
populations. Furthermore, outcome measurement instruments developed and validated in 
adults will often not be appropriate for children or babies which presents methodological 
challenges when designing research with children [123].  Examples exist where careful 
consideration has been paid to whether certain outcomes should be the same or different 
for adult and paediatric populations with the same condition. One such example is the 
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 
group, where developers carried out separate consensus work for adults and children, and 
provided distinct recommendations for each population [124, 125]. For example, the 
paediatric core set featured sleep as a core outcome but this did not feature in the adult 
core set. This demonstrates the need for clear consideration of the potential differences in 
outcomes between children and adults.  
 
Within the systematic review the majority of studies (149/198; 75%) did not specify 
whether their recommendations were specific to children, adults or both. Thirteen (7%) 
studies explicitly stated that their recommendations applied to both children and adults. 
whereas other studies made recommendations explicitly for one population or the other. 
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Twenty-three studies (12%) specified that the recommendations related to children only, 
and 13 (7%) to adults only, with three of the latter specific to ‘older adults’. Whilst there 
might be important or distinctive methodological considerations across the whole age 
spectrum, there were too few studies in the review to make older adults a specific focus in 
this study. I therefore wanted to explore whether there were different methodological 
considerations when developing a paediatric COS, and if so, what impact this had on the 
way the COS was developed. An example of a specific methodological consideration might 
be the potential challenges of involving children in the process of deciding which outcomes 
are important.  
 
Intervention characteristics  
The majority (115/198; 58%) of COS identified in the systematic review did not specify 
whether the COS was developed for all interventions or a specific intervention. Of those 
studies that did specify the type of intervention (83/198; 42%), only seven (8%) made 
recommendations that were clearly intended for all interventions. The remaining studies 
specified the intervention type to which the COS should apply, which included drugs 
(n=40), surgery (n=13) and vaccines (n=2). A recent article summarised the key problems 
with surgical trial outcomes as follows: choosing the right outcomes for the trial 
(considering design and purpose); selecting relevant outcomes to measure from a range of 
possible outcomes, and selecting outcomes with a minimal risk of bias [126]. These issues 
are similar to those faced by all trials; however, it is unknown whether the process of 
deciding which outcomes are important to measure and report are also similar across all 
trials regardless of intervention type. I therefore attempted to include COS developers who 
had not specified the intervention type as well as those who had, to try to understand 
whether and how this might influence the methodological choices made.  
 
Year of publication  
I oversampled studies published since 2010 as this was the year the COMET Initiative was 
launched, and to reduce potential problems with participants being unable to recall details 
of the COS development process, which might be a difficulty where COS had been 
developed many years earlier. Developers of COS where the study was published prior to 
2010 were considered for inclusion if studies published after 2010 were not available 
within a particular sampling category. While it is important to understand how COS have 
been developed in the past, I decided to focus this qualitative study on more recent and 
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ongoing studies (i.e. unpublished studies) as my study aimed to inform future guidelines for 
developing COS. To do that, I need to understand the current environment of COS 
development.  
 
Funding  
Funding source is a known potential bias in clinical research, including trial design and data 
analysis [127]. For this reason, I wanted to explore whether the source of funding 
influenced the methods used to develop COS.  47% of studies in the systematic review did 
not report the source of funding. Of those that did, I categorised 21% as commercially 
funded which includes studies funded by pharmaceutical companies and other for-profit 
health-related organisations; 57% were categorised as non-commercial which includes COS 
funded by universities and affiliated organisations, governmental agencies, professional 
medical societies and organisations, and charitable organisations; while 22% were 
categorised as receiving both commercial and non-commercial funding. I wanted to include 
studies from each category, including where the source of funding had not been reported, 
to explore any influence that funding source might have had on the development process.  
 
Plans to review/update COS  
Finally, the majority of studies identified in the review (167/198; 84%) did not report plans 
to update their recommendations, while 31 (16%) referred to a plan to update their COS 
recommendations. It is plausible that COS developers who had plans to continue COS work 
might differ in their methodological approach. However, due to my decision to focus the 
qualitative work on more recent and ongoing studies, I did not think it was appropriate to 
sample for variability in terms of future plans to update COS work, as it was likely that 
insufficient time would have elapsed for developers to be thinking about updating their 
COS work.  
 
6.3.3 Data analysis 
Undertaking an interpretive approach to analysis necessitates iterative data analysis, so I 
began analysis soon after initiation of data collection.  
 
I have attempted to provide an audit trail to illustrate how the data and the conclusions I 
have drawn about the data are linked [117, 128, 129]. As described in more detail below, I 
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used framework analysis to structure my approach to data analysis and management, and 
to facilitate the linkage between data and conclusions.  
 
Framework analysis  
I used framework analysis as an analytic tool to structure how I worked with the data and 
to support data management [115]. This technique includes indexing and sorting 
(described in steps 1 to 4 in Figure 8 below) that is common across many different 
qualitative approaches; this involves taking a set of descriptive themes, as well as 
subthemes identified through the data, and developing a framework that can be used for 
indexing the data. Framework analysis adds one further step to other qualitative 
approaches, namely data summary and display, whereby the framework forms a basis for 
constructing thematic matrices for presenting the data in outline. In the matrices every 
participant is allocated one row, and each column represents a separate subtheme. Data 
are then summarised by participant and by subtheme and the summary entered into the 
appropriate corresponding cell.  
 
Figure 8: Five key steps of framework analysis 
 
Figure 8 was developed based on the description of framework analysis by Ritchie and Lewis [115] 
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I selected framework analysis because it facilitated the constant comparative technique 
through the review of data across the matrix [130]. Furthermore, framework analysis 
allows both predetermined and novel ideas to come from the data. This was particularly 
useful as interview guide topics could be explored and developed without stunting the 
development of new themes or subthemes. The matrix format also facilitated sharing of 
data across a multi-disciplinary team, allowing individual team members to engage with 
summarised data and offer their perspectives without needing to read all transcripts; this 
was particularly helpful with the management of a large dataset. Finally, the framework 
approach helps to maintain links between the original data and findings. In turn, this 
facilitates transparency, adding to the rigour of the research process, and potentially, the 
validity of conclusions drawn from the data [131].  
 
In the first stage of framework analysis I read the transcripts in order to gain an overall 
impression of the data. My supervisors also read the first six transcripts to help inform the 
analysis. I checked field notes for additional contributing information and to ensure the 
quality of the analysis. The next stage involved line by line analysis and the development of 
open codes to summarise the content of the transcripts. I then grouped the data together 
through a process of identifying recurring patterns and themes, and organising these into 
categories. I identified variations in the data and paid particular attention to outlier or 
‘deviant’ cases, as these can help to ‘test’ and thereby develop the analysis. Coding was 
supported by a qualitative computer software package (NVivo version 10 [132]). I 
subsequently developed subtheme framework matrices for each theme identified. An 
example of an excerpt from a framework matrix is provided in Table 37.  I referred to field 
notes when gaps were present at a participant level in these matrices, as a first check of 
whether the theme in question had featured in a particular participant’s accounts, as well 
as to put data into the context of the full interview when clarification of their full account 
was helpful for interpretation. Furthermore, some themes or categories may only be 
identified by considering a participant’s account across the whole transcript, for example 
what they do not say relative to other participants. Finally I summarised the themes by 
comparing responses in terms of similarities and differences, and these were then 
reviewed by, and discussed with, my supervisors (BY and PW). I used excerpts from 
interviews to support the summaries. In terms of notation for displaying excerpts, I use […] 
to denote text that seemed unnecessary in interpreting excerpts and which I removed in 
the interest of brevity.  
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Table 37: An excerpt from the 'Choice of methods' framework matrix 
Identifier   The literature  Advice from others  Experience  Resources 
P1 Decided to use Delphi based on 
the literature. 'and it’s very 
frequently used in the, for 
developing core set of 
outcomes.'  
 
'Not many methods to do it' - did 
consider doing a 'consensus 
method' meeting but decided 'it 
was not very systematic.'  
   
P2  Methodology people' (also calls 
them 'methodology team') 
advised them to use GRADE 
methodology - 'If you really want 
to in a (.) in a erm (.) ((sigh)) 
scientifically robust way, you 
know, or er er a process that you 
can argue is, is, somehow more 
than just your professional 
opinion, use this GRADE working 
group erm methodology. And so 
that was their recommendation 
and they walked us through it.'  
Influence on how the Delphi was 
run. 
  
P3   They took 
approaches 
that they 
were 
'somewhat 
familiar with.' 
 
P4 I think very much influenced 
from the papers we had read 
about from OMERACT and they 
sometimes used this approach, 
so. ' Work of OMERACT 
influenced what they did - chose 
this approach because they had 
used it. So influenced choice of 
method.  
OMERACT person 'told' them 
they needed to set consensus 
rules before voting and so on. So 
influenced how they conducted 
the Delphi.  
  
P5 Looked at similar work that had 
been done, especially in 
Rheumatology 'but there were 
others as well.' 'If we use the 
Delphi technique we can you 
know, systematically solicit 
info…' Shows they looked at what 
others had done but did think 
about it.  
 
Other people had used this 
approach and been successful, 
and the rationale for it was 'very 
convincing.'  
 
Used rheumatology work as a 
guideline and then asked 'can we 
replicate that work in our area?' 
But if more explicit guidelines 
existed they would have looked 
at them - suggests there was still 
uncertainty.  
 
Read books on consensus and 
papers.  
Sought advice from others first 
who were not very helpful, then 
found a rheumatologist who 
shared their experience. 'He was 
a mentor for me. Um I met 
weekly with this guy for years.' 
HE would suggest work that had 
been done for her to look at.  
 
'Well um, well he was my mentor 
and so every step we took he 
advised.' 
 
'We talked through, well how 
might we do this, you know? Um 
what should I go read to learn 
more about this Delphi thing I 
never heard of? Um (.) you know, 
who could provide some advice 
about how this might, you know, 
how this could play out for us? 
All of that.' Talks about this as 
guidance as opposed to being 
told what to do. 
 Oh, well (.) number one 
we didn’t have very 
much money, (.) so 
even though maybe it 
would have been lovely 
to have had some sort 
of consensus 
conference or 
whatever, there was no 
way we were going to 
get this um degree of 
expertise all in one 
place.' However, went 
on to say that this 
would not have actually 
suited their patient 
population. But it 
'wasn't financially 
possible' to have done 
this for clinicians - 'if I’d 
had unlimited time and 
resources maybe that, 
we could have done 
that.'  
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6.4  Quality in qualitative research  
This study was informed by the literature on quality in qualitative research, to ensure 
appropriate procedures were followed and that analysis remained grounded in the data. 
However, it is important to note that although these quality procedures can strengthen the 
rigour and transparency of qualitative research, they do not guarantee quality [133]. 
Furthermore, quality procedures require the exercise of judgement on the part of the 
researcher. Quality in qualitative research is inseparable from the researchers themselves, 
hence it is important to document the process of reflection [129, 134, 135]. My personal 
reflections have been discussed in section 6.2 of this chapter.  
 
Quality can also be judged by what a research study contributes to an area and whether it  
offers insights that have the potential to change practice or research [136]. Sometimes 
termed ‘catalytic validity’, this refers to the usefulness of research and its potential for real 
world impact [137]. Catalytic validity is an important validity criterion given the aims of this 
study to identify priority areas for future methodological research and guidance in COS 
development.  
 
I also considered the literature on standards for reporting qualitative research. Reporting 
on research design and methods of data collection and analysis highlight distinctive 
features of the research such as approach and researcher characteristics, but it is also 
important to justify choices to ensure that assumptions and decisions are transparent to 
the reader [138]. THE EQUATOR network recommend two guidelines for reporting 
qualitative research, the 21-item Standard for Reporting Qualitative Research (SRQR) [138] 
and the 32-item Consolidated Criteria for Reporting Qualitative Studies (COREQ) [139]. The 
guidelines are largely overlapping and therefore both were considered in the reporting of 
this study. 
 
6.5 Governance, ethics and confidentiality  
6.5.1      Ethics 
This research study fully complied with the ethical practice guidelines laid out by the British 
Psychology Association. NHS ethics approval was not necessary for interviewing 
researchers who were also NHS staff. However, because it was possible that this study 
might also have included patients, if any had been found to lead COS work, I needed to 
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consider whether NHS ethics approval was required. After discussion with the Chair of the 
Institute of Psychology, Health and Society Ethics Committee, University of Liverpool, it was 
decided that the project did not require NHS ethics committee approval because I 
identified and recruited participants through published research and not through NHS 
facilities within which they may be patients or clinicians. Instead, approval was sought and 
granted through the University of Liverpool’s ethics procedures (Research Ethics 
Subcommittee for Non-Invasive Procedures reference number: RETH000624). 
 
6.5.2 Informed consent  
All interviewees gave signed, informed consent prior to proceeding with the interview, 
after first being provided with an information sheet about the study (see Appendix 13) and 
a consent form (see Appendix 14). I explained how the study aimed to assist the research 
community by informing the development of guidance standards for COS development (see 
invite email in Appendix 12). Consent was sought remotely, via email rather than face to 
face, due to distance between research location and participants. The recruitment process 
allowed interviewees time to discuss the study with myself or one of my supervisors (PW or 
BY), as well as have any questions answered. Participants were informed that they could 
withdraw their consent and leave the study up until the point of interview transcript 
anonymisation, without having to explain or provide reasoning. Consent for audio-
recording the interview was sought as part of the consent process prior to commencing the 
interview.  
 
6.5.3 Data protection and anonymity  
This research study complied with the Data Protection Act of 1998 concerning the handling, 
processing and storage of data. All data (consent forms, audio recording devices, field 
notes and interview transcripts) were kept in a secure locked filing cabinet or electronically 
in a secure filestore. Files were deleted from recording devices as soon as possible, and 
held securely (encrypted) until transcribed and transcriptions checked. On completion of 
the publication of the study, audio recordings will be destroyed. In accordance with the 
University of Liverpool Research Data Management Policy, all other research data (consent 
forms, anonymised interview transcripts, field notes, and contact details) will be kept in 
locked filing cabinets and/or password protected university computers for ten years.  
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All data included in the analysis and write-up of this study has been pseudo-anonymised, 
with the removal of identifiable features, such as place and person names. Details 
necessary for interpretation (e.g. clinical area) were retained in the transcripts as they 
could be important in explaining meaning but have been removed in the reporting of 
results (Chapter 7). The data from the interviews was transcribed as soon as possible 
following the completion of the interview. I assigned each transcript a unique identifier 
code. Published COS developer transcripts were allocated a code starting with P, followed 
by a number, and ongoing COS developer transcripts were allocated a code starting with an 
O. Myself and one of my supervisors (BY) had access to the pre-anonymised data (audio-
recordings) as necessary for BY to advise on the quality of the interview process. 
 
The results are described and discussed in Chapter 7.  
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Chapter 7: Qualitative study findings 
on researchers’ experiences of 
developing COS 
 
7.1 Introduction 
As described in Chapter 6, I carried out qualitative interviews to explore how COS 
developers described their choice of methodological approach, including the influences on 
how they developed the COS. This aimed to identify potentially important but previously 
unanticipated issues as well as to describe in detail the COS developers’ accounts of their 
projects. I also wanted to learn about COS developers’ experiences and the challenges they 
encountered to identify priority areas for future methodological research. The results of 
these interviews will be the focus of this chapter.   
 
7.2 Results  
I interviewed 32 COS developers (18 with published, and 14 with ongoing, COS projects) 
between May 2014 and June 2015. The study flowchart, showing inclusion of participants, 
is presented in Figure 9.  Published COS developer transcripts were allocated a code 
starting with P, followed by a number, and ongoing COS developer transcripts were 
allocated a code starting with an O. 
 
Interviews lasted between 33 and 120 minutes (median length 63 minutes). Published COS 
developers comprised 16 lead authors, one last (corresponding) author and one second 
author. Six were from Europe (33%), 10 from North America (56%) and two from 
Australasia (11%). Two of the published COS developers had worked on a COS previously. 
Ongoing COS developers comprised 10 principal investigators, three clinical leads, and one 
PhD supervisor. Of the ongoing developers, 12 were from Europe (86%) and two from 
North America (14%). Summary sample characteristics for the 32 COS are provided in 
Appendix 15 (N.B. as discussed in the methods in Chapter 6, the goal was not to reach 
saturation across all of these groups, rather to explore characteristics within groups)  
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Figure 9: Flowchart showing inclusion of participants  
 
 
 
 
 
 
 
 
 
*One participant did not give a reason for declining, the other participant was ‘over committed’.  
 
Participants spoke of how COS development was a particularly challenging area of research 
because it is an emerging field, without shared assumptions or an advanced knowledge 
base. As such, this chapter will focus on influences on developers’ choice of methods, the 
challenges encountered or perceived throughout the process of COS development, and the 
areas of COS development where developers emphasised an absence of guidance.   
 
7.2.1 Influences on methods  
COS developers discussed a variety of influences on their choice of methods for COS 
development. Most discussed more than one reason for the methods they used, as 
summarised by O32 who said ‘the Delphi was chosen for a bunch of different reasons.’ 
Prominent among these influences was choosing methods that previous developers had 
used in COS development, as discussed in the following section.   
 
I basically followed what other people have done  
Published and ongoing developers alike described looking at the literature to see how 
others had previously developed COS, and then deciding to use methods based on the 
Published COS Ongoing COS 
28 invited to 
interview  
15 invited to 
interview  
Declined to take part (n=2)* 
No response (n=8) 
18 completed 
interview  
No 
response 
(n=1) 
14 completed 
interview  
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literature. Developers described feeling comfortable with methods that had been reported 
in the literature, particularly if the methods had been frequently used, as described by this 
developer who used the Delphi method: 
I was aware of people who’d done similar types of work […] and I looked at, at their 
published work and they’d used the Delphi methodology and it seemed to generate 
the same sort of things, the same […] style of findings that we were looking to 
identify. So that’s basically, that’s basically why we arrived on that. (O28) 
 
Developers spoke of particular published COS that had influenced the methods they had 
chosen. For ongoing developers, this included HOME for eczema and Sinha et al.’s work in 
paediatric asthma. Only one developer reported looking at both published and ongoing 
work, and cited work ongoing in otitis media (O20). This developer remarked that their COS 
development group had ‘gained experience from that’ and were trying to learn from the 
examples they saw. Of all available specific examples of COS, both published and ongoing 
developers talked about the OMERACT work as both the most common and strongest 
influence on the methods they chose. Developers regarded OMERACT as established 
leaders in the field of COS development: 
So one thing we, err I really looked at and we all really looked at was the work that 
O-OMERACT has done, err they, they sort of seem to be leaders in the field, and 
their, their OMERACT handbook, well the 2.0 now I think […] set out as a step-by-
step guideline, that was something that we took really to heart and something that 
we really based a lot of our work on and sort of tried to follow that, and sort of the 
con-consensus and having multiple phases and their, their approach […] we sort of 
really took that to heart. (O32) 
 
In contrast to developers who used previous work to inform their methods in a direct or 
‘off the peg’ way as they ‘didn’t want to reinvent the wheel’ (P16), other developers (both 
published and ongoing) talked about using previously used methods as a starting point but 
then engaging in an evaluative decision making process about the suitability of previously 
used methods. For example, P5 described looking at previous COS work and then thinking 
about what it would mean to use the Delphi method that others had used previously in 
other clinical areas, and asking whether they could ‘replicate that work’ in their area. P5 
described using what had been done by others as a guide rather than a rule. P5 also said 
that they ‘knew that other people had been fairly successful with this sort of approach 
[Delphi] and the rationale behind it is very convincing’.  
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Describing an ongoing COS, O30 said that they ‘basically followed what other people have 
done,’ but went on to describe how they adapted the methods, suggesting that they had 
thought more about their own specific circumstances for using the methods rather than 
simply applying the methods exactly as others had done previously: 
We basically followed the eczema, um, core outcomes, […] adapted it a little bit in 
terms of the scale they used, how they, um, they progressed from one, er, round to 
another.  You know they had like, er, criteria, predefined criteria, of consensus.  Er, I 
think they had a lower threshold, and we had it higher because we thought that you 
know with so many outcomes we need to be more strict […] we should have more 
people, er er, agreeing on, er, that the outcome should go forwards from one stage 
to another. (O30) 
 
Ongoing developers also described looking at COS development guidance documents to 
inform their choices about methods. For example, O21 described using the guidance as a 
basis for their methods, but also building upon the guidance to: 
Create the methods […] we had to sort of modify a little bit, since I started off 
thinking specifically about patient reported outcomes and wanted to make sure we 
captured um, err physician assessed outcomes […] sort of modified our searches 
and added on to it as we went. (O21) 
These ongoing developers mentioned the COMET Initiative as a particular source of 
guidance, as indicated by O26 who described looking at this work and then working out 
which method would best fit their resources. Although this developer referred to published 
work from COMET, he also highlighted the absence of guidelines about the best methods 
for COS development: 
We consulted previous work done by people in our unit, err and also by published 
work from the comment, COMET err, err initiatives, like Paula Williamson’s 
publications and so on, and then we tried to work out which is the best method that 
we can fit in within the timeline and the manpower that we have. 'Cause some of 
them are a bit more, you know, time consuming and there is no consensus, to my 
knowledge, on what are the best methods. (O26) 
 
One published developer, whose COS preceded the COMET Initiative, remarked that ‘we 
went into the literature about evidence and literature about outcome, err and curious 
enough we didn’t find COMET at the time, so I didn’t see it’ (P12).  Furthermore, another 
developer described finding the COMET paper outlining the issues to consider when 
developing a COS, only after starting to plan their COS work for their grant application 
(O22). Although O22 remarked that it would have been better to know about this paper 
much earlier on, it was not yet published when this developer was planning their 
application. This illustrates the difficulty of working in a developing field of research rather 
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than necessarily a lack of awareness of the existence of guidance or problems with their 
dissemination. Furthermore, although the paper referred to above outlines the issues to be 
considered in COS development, it is not a formal guideline document.  
 
We took approaches that we were somewhat familiar with 
Both published and ongoing developers described choosing methods for COS development 
that they had previous experience with. Developers spoke of general experience with 
methods rather than experience specific to COS development, as in this example where 
P14’s experience with the Delphi method informed the team’s choice of methods for COS 
development:  
The methodology of the workshop was essentially built on the experience of 
running three other  Delphi-style workshops dating back over the previous, ooh, 10-
12 years um where I and my colleagues sort of refined the process of preparing 
statements that people could vote on, and refining those statements um so that the 
face-to-face time was as efficient as possible. (P14) 
 
One ongoing developer remarked that their previous experience with the method allowed 
them to design a ‘good’ Delphi survey for their COS project (O31), indicating a belief that 
their experience had resulted in a better quality design. Referring to the selection of 
interviews as a method, O24 described that as a team they had general experience with 
interviewing patients ‘assessing their views about a variety of things over the years,’ and ‘it 
just seemed logical to extend it to assess the views and experiences of patients […] as well 
as making sure that whatever was being measured was, was relevant to patients.’ O24 did 
not give any indication for why interviewing might be better than other methods but said 
‘it seemed the obvious thing to do.’  
 
In contrast to the developers who spoke of having general experience with methods, a few 
published developers described having previous first-hand experience of using particular 
methods to develop COS and using the same methods again in subsequent COS 
development. One developer described being involved in an earlier COS project as a 
subject matter expert, and then ‘running the show’ in the later work where the study team 
largely overlapped with the earlier study (P13). Similarly, P15 described how some of the 
study team had been involved in the development of a prior COS, so they had 'been 
through the process' and 'it seemed to have worked well.' Neither of these developers 
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showed any indication of critical evaluation, or adaptation of the methods, in light of their 
experiences.  
 
I guess largely we just took their advice 
Again, both published and ongoing developers described expert advice as another 
influence on their choice of methods, as indicated by P2 who referred to consulting with 
methodologists who had recommended using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) working group methodology, because it 
was perceived by his team to be a more robust method than ‘opinion alone’. The GRADE 
criteria were developed as a means of applying a quality assessment to evidence. The 
GRADE system classifies the quality of evidence in one of four levels—high, moderate, low, 
and very low [140]. GRADE uses symbolic, and number/letter representation for quality of 
evidence and grades of recommendation [141], but  still requires interpretation by the 
assessor . P2 said that the team ‘largely just took the methodologists’ advice: 
If you really want to in a […] scientifically robust […] process that you can argue is, 
is, somehow more than just your professional opinion, use this GRADE working 
group erm methodology. And so that was their recommendation and they walked 
us through it. (P2) 
Similarly, P5 described seeking advice from people who had more experience in the area of 
COS development, and ‘found a rheumatologist who said, you know, that’s what life was 
like for us 20 years ago but we figured a bunch of things out.’ P5 described the 
rheumatologist as a mentor and ‘so every step we took he advised’: 
It was very nice because he would say, well, you know, here are people who’ve done 
this. Here’s something to look at, these are, you know, new ways to consider your 
question. (P5) 
P5 returned to this later in the interview and elaborated:  
We talked through, well how might we do this, you know? Um what should I go 
read to learn more about this Delphi thing I never heard of? Um you know, who 
could provide some advice about how this might, you know, how this could play out 
for us? All of that. (P5)  
 
A few ongoing developers referred to ‘expert advice’ from the COMET Initiative, and 
choosing methods designed and used by one of the COMET Initiative group members. One 
developer used particular methods because they ‘had faith in the methodology because 
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[name of COMET Management Group member] had designed it and used it’ (O23).  
Similarly, O25 described being ‘very much guided’ by a member of the COMET Initiative, 
‘obviously with extensive understanding of methodology in this area’.  
 
Interestingly, a few published developers framed advice about COS development as 
instruction. P4 described how one person from OMERACT ‘told’ the team what they 
‘needed’ to do. Similarly, P8 described his group’s uncertainty about whether a face to face 
meeting was needed and how their decision to conduct a meeting was very much 
influenced by OMERACT: 
I said you know if you do a robust Delphi and whatever online, or remotely, if it’s 
robust enough do you have to meet, or can you just class that as your consensus; 
which other people have done and you know seems not unreasonable.  But their 
view from their OMERACT experience was, in fact their very words were if you don’t 
get people in a room it will never get signed off.  And so it was on their advice that 
we decided to call people together. (P8) 
 
One developer described having to make changes to their methods because of a journal’s 
influence (P9). In this instance, the COS developers had the opportunity to schedule their 
consensus meeting at an international conference because ‘most of the surveyees attend 
this meeting’ anyway. The COS developers had originally intended to ask individuals 
attending the meeting to vote on whether they would recommend the outcome measures, 
but their plan was 'derailed' because the journal 'wouldn't publish this paper if we did a 
vote […] they said we do not publish recommendations.' As such, P9 described how they 
had to 'calibrate the finality of the meeting so as not to derive recommendations, although 
that was my initial intent is to tr-… kind of provide a stronger guidance than I actually ended 
up writing’. This developers’ account suggests that they had to soften their 
recommendations in order to publish them. No other COS developer described similar 
experience but the influence of the journal in this individual’s account is particularly 
interesting because of the impact it had on P9’s choice of methods, and in turn, the 
potential impact this could have had on the outcomes included in this group’s work, and 
the strength of, the final recommendations.     
 
It was striking that only one developer described asking patients for their advice about the 
methods that they were using (O25).  This COS team, who were developing a COS to be 
used in a paediatric population, explained taking their ideas to a patient organisation to 
gain feedback from young people about whether they felt they could be involved in a COS 
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project. O25 remarked that children and parents made a 'significant contribution' to the 
'actual methodology and delivery’ of the exercise.  
 
If I’d had unlimited time and resources maybe we could have done that 
Published developers described that limited funding meant that they could not bring 
people together for face to face meetings. For example, P9 described how ‘fairly small’ 
budgets meant they were unable to hold a meeting and bring together people from all over 
the world. Another COS developer commented ‘well number one we didn’t have very much 
money, so even though maybe it would have been lovely to have had some sort of 
consensus conference or whatever, there was no way we were going to get this um degree 
of expertise all in one place’ (P5). However, P5 went on to explain that such a consensus 
conference would not have suited their patient population ‘for whom that sort of non-
synchronous, non-face-to-face communication is ideal because their lives are so very 
complicated’. Therefore, while P5 would have liked to have had a consensus conference for 
clinicians, it 'wasn't financially possible […] if I’d had unlimited time and resources maybe 
that, we could have done that.' As resources would not need to be unlimited to conduct a 
meeting, P5 is clearly speaking rhetorically here, perhaps in an attempt to justify her 
decisions. In contrast, P14 described being ‘fortunate’ that a pharmaceutical company 
provided funding for their team’s work, and as such they were able to hold a face to face 
meeting ‘within the limits of the budget available’. Although they received funding from a 
pharmaceutical company to hold a meeting, P14 remarked that the pharmaceutical 
company did not influence the choice of methods for COS development, as they ‘were at 
arm’s length from anything that Pharma might want to do about influencing our thinking.'  
 
Ongoing developers commented that as well as budgets, time limitations influenced the 
methods they chose. O27 described that their team had twelve months funding to develop 
the COS, and while they had considered conducting interviews with clinicians as an 
alternative to focus groups, they thought that time would not allow it.  O27 referred to 
focus groups as an efficient way of bringing clinicians together, as well as a way of getting 
clinicians to be very open: 
Focus groups are a really efficient way to bring clinicians together. It can be hard to 
get clinicians in a room um to do a focus group but this seemed to work best in our 
context. Um and we, we also thought a qualitative approach to garnering that 
information was really appropriate, 'cause we needed to give clinicians the 
opportunity to, to, to raise things that they thought were important rather than 
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asking them a set of fixed questions um and ticking boxes. We had to be very open 
at the focus group stage to what might emerge. (O27) 
 
Likewise, O26 described having to work out, in the absence of any guidelines, which 
methods suited their resources best: 
We tried to work out which is the best method that we can fit in within the timeline 
and the manpower that we have. 'Cause some of them are a bit more, you know, 
time consuming and there is no consensus, to my knowledge, on what are the best 
methods in, in this process. (O26) 
 
One COS developer described the impact of running out of time and funding on the choice 
of methods for COS development, which meant that the team could no longer use the 
methods they had originally decided upon: 
The funding period ran out we were in the process of getting patients together to 
do focus group as well as the [clinical experts], but we just um ran out of funding 
and ran out of time to do… the survey was essentially a, essentially a first step to 
um, to determine how the [clinical experts] and how the researchers thought about 
the domains, and then the next step would have been actually having focus groups. 
(O21) 
 
Pragmatism I suppose is the ultimate answer 
Some developers described basing their decisions about methods on pragmatism, that is, 
grounding decisions about choice of methods and their adaptation in practical and logical 
considerations.  Published and ongoing developers repeatedly used phrases like it was ‘a 
little bit pragmatic’ (P8) and ‘pragmatism I suppose is the ultimate answer’ (O23). O22 
talked about relying on ‘logic’ about what methods would make sense in the context of 
their COS development work: 
I have to say it was my own kind of logic that just kind of I used to develop the 
process. And, you know, just in writing this proposal for the grant just kind of 
thinking it through on my own in terms of what would, what would make sense. 
(O22) 
 
Some ongoing developers also talked about considering what methods to use but 
ultimately making ‘arbitrary’ decisions about these. O19 described the process of thinking 
about different methods, and although they had an expert in conducting focus groups on 
their team (who was keen for them to use this particular method), they ultimately decided 
that interviews suited their objectives, ‘to augment the list rather than find out the 
reasoning behind it’, better. O19 explained there were pros and cons to different methods 
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and the team were not aware of ‘proof’ that one method is better than the other. He 
described their choice of methods as an ‘arbitrary’ decision with ‘no proof to back it up,’ 
but O19 did suggest a reason for their choice, it better suited their objectives, and not just 
personal whim, thereby contradicting the notion that it was arbitrary. O23 similarly 
described their decision making about methods as ‘arbitrary’ and described how the team 
‘took a pragmatic view’ doing what ‘seemed sensible,’ indicating some conflation of 
arbitrariness and pragmatism in COS developers’ accounts.  
 
Similar to O19 who referred to pros and cons of different methods, one other COS 
developer described how their team used a combination of methods, in a type of 
methodological triangulation, to deal with trade-offs of advantages and disadvantages of 
different methods (P15). They did this by combining a consensus meeting with their 
systematic review and Delphi polls, which P15 felt enabled them ‘to make sure [they] 
hadn’t missed anything’.  
 
Finally, two ongoing developers also mentioned that ‘opportunity’ influenced what they 
did. In one example, there was an opportunity to develop a national survey and these 
developers decided to use that opportunity to ask about outcomes (O20). In the second 
example, the developers were invited to host a meeting at an international conference 
‘and it seemed like too good an opportunity to miss really to get their involvement, so, um, 
that consensus meeting was an open session at that conference’ (O23).  
 
7.2.2 Challenges of COS development  
All developers discussed the challenges they faced throughout the process of developing a 
COS. An overarching concern related to resources for COS development. This was already 
touched upon in the above section in relation to influences on methods chosen for COS 
development. The impact in relation to other challenges is discussed here. Generally, 
developers spoke about the difficulty of getting funding for COS development and the 
challenge of completing COS work in a timely manner. COS developers’ accounts of the 
challenges conveyed an overall sense of compromise in how they went about COS work as 
a consequence of limited funding: 
The most difficult part was um, well to combine in general, was to combine the 
resources we had with what err ideally should be done for developing a core 
outcome set. Because see, if you really want to do a systematic review of the 
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outcomes err included in clinical trials, if you want to do some qualitative research 
err to have more the patient perspective, to take more the patient perspective into 
account, and if you want to do a Delphi study like, as we did, so to focus also on 
both quantitative and qualitative perspective, um it’s err, I mean, you know, quite 
some resources are needed […]it’s not easy to get money in err, in this field. So we 
had a limited amount of money, so we really had to match err our resources with 
err, um with what we ideally wanted to do.  (O31) 
Specific examples of how COS developers compromised on methods in order to work 
within available resources are discussed throughout this section of the chapter.  
 
You can only do as much as you can do if there are no guidelines  
Published developers described being uncertain about the best way to develop a COS, but 
they did not directly attribute this to a lack of guidance in COS development. In contrast, 
ongoing developers explicitly pointed to the absence of guidance in COS development, 
suggesting that ongoing developers have become more methodologically aware as the area 
of COS development has established. Published developers had questions about what 
methods were available for COS development, which methods were most suitable in 
particular contexts and how to conduct a COS study generally. Both published and ongoing 
COS developers also talked about learning, over the course of their studies, how 
complicated COS development was; as in this instance where one developer said that his 
team was ‘a little bit naïve’ at the outset and did not realise the challenges they would face 
until they faced them (O23). O23 went on to highlight problems his team had encountered 
with the Delphi method, such as access to participants, sample sizes, response rates, how 
to feedback results and the influence of the method of feedback, whether to retain or 
discard outcomes along the way, the weight to give to different stakeholders, and whether 
to combine different stakeholder groups or keep them as separate. O23 described these as 
‘all sort of mysteries’ that no one really understands, suggesting layers of complexity to the 
COS development process that were only discovered as the project progressed.  
 
As noted above, ongoing developers referred specifically to an overall lack of 
methodological guidelines to develop COS: there is no ‘determined methodology’ (O25) and 
‘there’s no obvious guidelines about the definite ways of doing these things’ (O28). Ongoing 
developers talked about the absence of a ‘fixed template’ and had doubts about whether 
such a template was even a possibility, as even if something had worked in the context of a 
COS in one condition ‘there’s no guarantee’ that it will work for another (O19).  
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COS developers also described a general lack of understanding among researchers 
generally of the process to develop COS ‘correctly’, and doing the best they could in the 
absence of guidelines to develop a COS:  
There is a bit of, er, a lack of, I don’t know, understanding of, er, you know core 
outcomes process, and, um, why it’s actually needed.  And, er, you know, how it 
should be done correctly.  I am not saying that what I've added was 100% correct in 
everything, but […] you can do as much as you can do if there are no guidelines. 
(030) 
 
Ongoing developers’ accounts of the challenges of COS development were more specific 
than those of published developers. Only one published developer described the 
challenges specific to one method, the Delphi method, and simply stated that ‘there’s no 
standard, or even standardised way of using the Delphi process’ (P15). Ongoing developers 
described methodologically orientated challenges in some detail, as in the excerpt below 
where one COS developer described the challenges the team experienced in doing a 
systematic review of outcomes (O19). O19 was part of a group of researchers who 
considered themselves to be experts in conducting systematic reviews, and yet they still 
found the process of conducting a review in the context of COS development challenging: 
Doing the review in itself was err, was very challenging, and particularly err tedious 
err because we realised that it, it wasn’t really a quantitative type review, it’s err, 
it’s more um, you know, quant-qualitative/quantitative, semi-quantitative type 
review […] we, you know, wanted to look at the breadth and scope of outcomes 
which have been reported in trials and it was difficult to set thresholds: where do 
we stop? Do we stop at RCTs, do we stop at, you know, non- randomised 
comparative studies? Do we include case series? Err do we include commentaries or 
reviews? […] it was essent-essentially a new, new set of rules that we had to set for 
ourselves. (019) 
 
One developer who was working to produce a COS intended for use in both research and 
practice described how this added to the challenge. The team was conflicted about 
whether COS should be developed for both research and practice together, or developed 
for one specific context at a time (O22). O22 felt developing a COS for both research and 
practice was the right goal overall, and therefore developing the COS for use in both 
settings was the right approach to take. She went on to say that because they were 
successful in getting funding for this specific task, which she attributed to there being a 
need for consistency in the outcomes for both research and practice, this reinforced that 
this was indeed the right goal. 
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Other developers described being uncertain about how to define consensus, including the 
challenge of deciding cut-off points and the percentage of consensus to use, when others 
had defined consensus in various ways and there is ‘no kind of consensus’ about how to 
define or achieve consensus (030).  
 
Specific areas where developers suggested that guidance would be helpful are discussed 
further in section 7.2.3.  
 
Even if you’ve engaged them for round one, whether they’ll stay on for round two is 
another matter 
Published and ongoing developers alike described challenges in retaining participants, as 
well as sampling the ‘right’ people in the first place: 
Probably the biggest challenges are around um trying to make the broadest 
outreach and assure that um people who need to be in the room or need to know 
about will be invited to be in the room are there. (P13) 
The major challenges, you know, having all people that you need in place, you 
know, you have several people in, in the field that are in the driving position and, 
you know, you cannot always have them participating in […] war exercises, and the 
second is trying to um, you know, take into account all different opinions and all 
different approaches, and that is not always possible. (P10) 
 
COS developers discussed the management of conflicts of interest, as in this example 
where P15 described how ‘in a small field like [name of disease], if we had excluded people 
who had developed instruments, many of the um best researchers in the area would be 
out.’ As a way of managing this challenge, this group asked instrument developers not to 
vote on their own instruments. P15 also described being transparent in their paper about 
who was included in the process.  
 
The challenge of including multiple stakeholder groups was also prominent in both 
published and ongoing developers’ accounts.  There was agreement that despite the 
challenges it brought, multiple groups should be included ‘from the beginning’ and ‘very 
much integrated’ (P17), as doing so makes the COS ‘ultimately stronger’ (O25). 
Nevertheless, this brought difficulties, particularly when the groups were brought together 
and O32 described how groups tended to be quite inflexible, only taking their own 
perspectives into account: 
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One of the problems that we saw is that sometimes some groups are little and 
narrow minded and they sort of have their own view, and they don’t sort of go out 
of that specialism. So parents will be more focused on one thing, clinicians will be 
focused on another thing, where we sort of want them to, to sort of take the, the 
view of the other side into account as well.  (O32) 
 
Developers also described challenges with low participant response rates, and mentioned 
strategies they employed to improve response rates: 
The biggest challenge that we faced was err trying to get enough responses to the 
online survey. Despite [name of charity organisation] err help we, we struggled to 
get as many responses as we would have liked and we went to… We, we, we looked 
at the variety of ways around that including adverti-advertisements in the press and 
err, a-and other things. (O24) 
 
COS developers talked about having to send many reminders and ‘chasing’ participants to 
respond. This was illustrated by O26 who described chasing every participant individually 
three times, which was ‘quite a lot of chasing, quite a lot of trying, and the response rate 
was not great at all’. When probed about why they might have experienced low levels of 
response, O26 suggested possible lack of interest in COS development or ‘because of time 
commitment.’ O26 also alluded to why they might have struggled to engage industry 
representatives in particular, attributing this to an absence of pre-existing contact or links 
to industry representatives. Similarly, P4 highlighted the absence of a patient self-help 
group in one country as a reason for struggling to recruit patients in that country, in 
contrast to other countries where patient groups were established and recruitment was 
successful.  
 
O32 also referred to difficulties with response, and felt that their team’s efforts to increase 
the number of participants were successful. In part, they attributed this success not only to 
sending reminders, but to widening their pool and identifying ‘interested’ people to take 
part after initial poor response to a general email via European societies. The inclusion of 
interested people is an attractive strategy with understandable rationale, but it might work 
against representativeness:  
One problem is err, 'cause adopting the approach that we did we, we sent out 
online questionnaires, so emailing people, asking them, what do you think? Please 
answer these questions; please can you answer them by a specific date, and then 
sending many, many emails sort of reminding them yet again, could you please 
answer our questions? and so on. So that’s, that’s the one downside is that it does, 
it does take a while and not everyone was very responsive. Err you know, when 
researchers and people who are sort of leaders in the field get 50 or 100 emails a 
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day, when they’re told, could you please answer a questionnaire, even if it’s really 
going to take two minutes, they’re not super willing to, to help out quite often. So it 
took, it took some time but in the end err we had a fairly good response rate, we 
thought.... So I think that was the one sort of key issue of finding people who are 
actually interested in it and not just, you know, emailing anyone who was in the 
field.  (O32) 
 
Other developers also described low response rates as a consequence of participant 
burden, such as this example pertaining to patients: 
They found the technical side of err completing the online questionnaire very 
frustrating and eventually gave up. Quite, quite a, quite a few, I would say maybe 
another 20 to 30 actually gave up after trying. (O19) 
Some developers highlighted how the platform they used for their surveys had influenced 
response rates, as in this example where one COS developer described wanting to send 
their online survey out, as a link within an email, via a clinical society. The society ‘weren’t 
keen’ but then after ‘their initial reluctance that they didn’t want to get involved in a 
questionnaire survey’ they reached a ‘compromise’ to send it out as an attachment that 
people would complete and send back:  
That was a real faff.  And from the 200 odd people on the mailing list we got about 
50 responses.  Um, I think a load more people would have done if they’d just had to 
click a link […] I wouldn’t have done that (laughs) […] even though it’s only 20 
seconds more. (P8) 
Ironically, when asked why the clinical society was reluctant to send out the link, P8 
responded that as he recalled ‘from conversations at the time, they didn’t want to 
overburden people.’  
 
COS developers highlighted the importance of ‘who’ it is that is being included as 
participants. One COS developer expressed concern about the difficulty of achieving 
diversity in sampling patient participants and partners for COS development and how not 
achieving this could lead to overlooking outcomes that were important for less advantaged 
patients (P17). She recognised that having a diverse sample is a resource issue because it 
takes more time to recruit a diverse group, and these participants may need extra support 
to allow them to participate. 
I feel really strongly about this. It’s about this issue of um who we’re including as 
patient research partners, because the problem is, and this happened a lot in [name 
of clinical trial], um 'cause initially one patient partner was invited from each 
European country with, with their [specialist] to sit in and talk about the domains, 
um and they, they, they were all white, they all spoke English and they were a very 
particular kind of patient.  And it, it worries me a lot that  the people who are being 
involved in this way on a sort of patient research partner level, but probably as 
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participants generally, um don’t represent that diversity, and so we’re missing 
potentially priorities, you know, a different set of priorities, and we’ve, we’ve got to 
find a way of including those. (P17) 
 
Developers also described maintaining participation as a challenge, as explained by this 
developer who highlighted potential consequences, in terms of imbalances in stakeholder 
groups: 
The worry has always been um lack of um engagement from clinicians err and, and 
secondly, even if you’ve engaged them for round one whether they’ll stay on for 
round two err is another matter. So there’s a large imbalance in the two 
stakeholder groups at the moment, we’ve got about 110 patients for the patient 
group and we’ve got only 50 for err, for the clinician group.  (O19) 
 
Having a patient participate in COS development would be challenging 
Published developers spoke of including patients as participants in COS development as 
complicated and challenging, and pointed to this as a reason for not including patients in 
their studies. Published developers were also of the view that it was somewhat unusual to 
seek the opinions of patients in COS development when they undertook their COS work. 
This was in contrast to ongoing COS developers, of whom all but one had included patients 
in COS development. The impact of not including patients in COS development was 
described by P17. A COS already existed when P17’s core set was developed, and had been 
developed with clinicians only. She described how trying to get the ‘patient core set to sit 
alongside the professional one…was always going to be a big challenge.’ She remarked that 
other developers who are integrating different stakeholder opinions from the outset would 
not encounter this problem.   
 
Published COS developers were usually of the opinion that patients would lack 
understanding of the concept of outcomes and of research more generally, and that this 
would make it difficult for patients to be able to select important or appropriate outcomes.  
I am not sure I would involve patients in a final decision about endpoints.  In my 
experience, even trained researchers sometimes have difficulty grasping the 
concepts about biases in endpoints.   So, I believe patients would be similarly 
challenged, if not more so, and their involvement could make deciding upon the 
appropriate/valid/unbiased endpoints and primary endpoint more difficult. So I’m 
not sure on that one. (P7) 
 
We would have struggled um to bring a patient in, I think they would have needed 
some coaching and some background information on what the meeting’s um topic 
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was and what the discussions were […] you know, we had thematic discussions 
around research methodology, we had a nice controlled trial versus cohort trial 
versus, you know, and, and how different variables could be structured in those 
trials and I, I think having a patient participate in that would be challenging if it 
wasn’t someone who had a knowledge base, you know, to enable them um, you 
know, to contribute. (P13) 
Irrespective of these anticipated challenges, P13 commented that ‘having patients 
participate and weigh in on meaningful outcomes is, is a critical piece’ of COS development. 
This sentiment was echoed by other COS developers. For example, a developer who 
attributed their lack of patient participation to two major barriers, time and budget, 
described not realising the importance of including patients until the work was done, which 
suggests that they might not have truly considered patient participation  at the outset: 
We felt like we missed an entire dimension around [name of disease] by um not 
including patients at every level of the stakeholder engagement process. And it was 
actually only by doing the, this project that we realised that. (P6) 
 
P17 was one of the few published COS developers to describe experienced, rather than 
anticipated, challenges of involving patients in COS development. She described how 
patients found it hard to prioritise outcomes, and how the team had found it difficult to 
convey the realities of research and clinical trials and the need to narrow the outcomes 
down to a feasible number. P4 also described how patients rated everything as important, 
and as a direct result the team had to modify their methods to answer a slightly different 
question, ‘what should be included into the core set’ rather than which outcomes are 
important. Having anticipated that this could have been a problem,  P5 described how they 
spent a long time thinking about phrasing the question, emphasising the importance of 
anchoring it in the real world ‘within the realm of possibility presently’ and relating the 
question to an intervention. P5 also anticipated that when patients were asked what they 
would change about having their condition, they would answer ‘well I won’t have [name of 
disease] anymore…that kind of almost magical thinking.’ P5 seems to be attributing a lack 
of realism to patients’ view about what is important to measure, but it is entirely realistic 
for patients to want to get rid of their condition. This idea will be explored further in the 
Discussion.  
 
 
P17 described taking time to give patients an ‘explanation in a way that will make them feel 
confident enough then to contribute’. Patient participation was described as ‘resource 
heavy’ but for this published COS developer (P17) the benefits clearly outweighed the 
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challenges. She explained how it was important to ensure that patients could recognise 
that ‘their voice was there because it was different from what they [patients] would 
normally hear in their clinical setting’. This highlights that patients can use different 
language to clinicians to talk about outcomes. In this COS developer’s experience, 
‘approaching people face to face’ meant that they could ‘talk to them and explain’ the 
study and as such ‘they totally get it and they want to be involved.’ P17 also highlighted the 
importance of appropriate phrasing and terminology: 
We’re doing something right here because they’re responding to this, we’ve got the 
right phrasing, um and I think that’s a really important aspect […] in that Delphi we 
took a lot of care around the phrasing so that um the patients wouldn’t be sort of 
alienated by the terminology used. Um and at the same time not alienating the 
professionals I suppose, but they, they could understand, we sort of had a, a double 
layer, so there was sort of um the more technical term that you might get in the 
literature alongside um the wording that came from the qual-qualitative data. Um 
but err definitely more resource heavy. (P17) 
 
O19 echoed other developers in reflecting on how patients found it difficult to understand 
the nature of what they were being asked to do as participants, adding that because COS 
development is ‘fairly abstract’, ‘there’s always going to be a little bit of bias towards the 
more educated people.’ This is an important issue for COS development that will be 
considered further in the Discussion section of this chapter. There were some indications 
that one source of patients’ difficulties with understanding COS development may be the 
methods used to involve them. O19 utilised an online Delphi in contrast to P17 whose face 
to face approach seemed to be more successful. O25 also remarked that patients and 
parents did not understand the idea of core outcome sets until it was explained face to 
face, then ‘they got it’.  Interestingly, O19 described these as ‘mini-challenges rather than 
significant challenges’, suggesting that these issues were relatively easy to overcome. This 
raises questions about whether COS developers need to take more responsibility for 
making COS accessible to patients, a point picked up by O32 who questioned ‘how well 
does the person who is explaining it actually explain to the parents?’ O32 proposed 
providing more information and possibly writing participant information down, however 
more information does not always lead to better information or a more informed 
participant. 
 
Similarly, O29 commented on how a patient dropped out of the Delphi process who did not 
fully understand about outcomes in the context of a trial. Again, this could reflect a failure 
with the researchers’ explanation. It also suggests that it is a complex task to portray the 
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relevance of COS, and their value, to both research and clinical practice. This raises an 
important question about how COS developers can make COS relevant to patients and help 
them to be aware of the relevance of COS to the clinic: 
Some of the patients, um certainly I know one, when it came to the Delphi, um  at 
that point I think he grasped that it was about outcomes in trials, and I don’t think 
he was that clear about that before, even though we’d gone into some discussion 
about it and um obviously our information had all that in it. Um  and then he didn’t 
complete the second round of the Delphi and he said, well what I’m more interested 
in is outcomes in the clinic, and then he didn’t complete the second, second round of 
it. So yeah, I think it’s very important from, you know, to be very clear um about 
what it’s about. (O29) 
This particular COS developer questioned whether such problems arose because 
researchers did not communicate about COS well enough, or because ‘for some patients it 
just is beyond their grasp’ (O29), adding that ‘there will be different levels of understanding 
amongst different patients.’  
Difficulties with prioritising outcomes was not exclusive to patients, as COS developers 
described clinicians also finding ‘it hard to discriminate between outcomes’ (O20). COS 
developers explained how they tried to overcome this particular challenge, for example P5 
described being optimistic that after one survey they would have the core outcomes, but as 
it turned out, that was not the case. ‘Because the first way didn’t work’, the team 
introduced an unplanned survey to ‘give people the ability to really weigh their choices’ by  
giving participants 100 points to distribute amongst the outcomes, giving the most points 
for the most important outcomes. This was a post-hoc decision that the team made once 
they discovered that people rated everything as important, but P5 said that ‘it didn’t really 
help’ either. In contrast, P8 described asking participants to rank their top 3 outcomes, as 
the team had anticipated that ‘all the outcomes would be important to someone’. P8 
remarked that this had been ‘one of the most important methodological choices’ they 
made:  
We wanted to see whether choosing your top three requires a little bit more 
thought than ticking a list, which may not require more thought but requires 
different thought, you know lists you are prioritising.  So we thought well let’s just 
see how, um, this method can help discriminate between outcomes that, yeah are, 
you know are important, or outcomes that are the most important. (P8) 
 
 
In contrast to patients, only one COS developer described a lack of understanding of COS 
among clinicians. O32 remarked that if clinicians did not know what was being asked of 
them or if they had choices that they did not fully understand, ‘very often they are going to 
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just pick one, they’re going to guess, and then that becomes an issue.’ This might also 
suggest unease with working in an area that is fundamentally opinion based. O32 also 
suggested that clinicians might be reluctant to ‘admit it’ because ‘doctors are not always 
very happy with saying, I don’t know.’ Similarly, only one COS developer described 
challenges with researchers’ ability to grasp concepts about outcomes (P7).  
 
Ethical boundaries  
Like ongoing COS developers who did not include patients but anticipated that resources 
would be a challenge of including patient participants, ongoing COS developers who did 
include patients emphasised how the lack of resources to support patient participants was 
a significant challenge. COS developers referred to financial, that is funding, and human 
resources as the main resource needs for involving patients.  COS developers saw the 
resource intensive nature of involving patients as linked to the ethics approvals that were 
required in order for patients to participate in research. Because of the time and money 
associated with ethics approval processes, some COS developers decided not to include 
patients in COS development:  
One was time, so this was a one-year contract that we had from [name of funding 
body] um and so in order to involve patients in our process, we felt like to do it well 
we would want to get um IRB approval um to en-, engage focus groups of patients, 
and felt like we didn’t have sufficient time to do that unfortunately, or budget to 
sort of pay out incentives for that kind of thing.  And so in the end we felt very 
comfortable at the time um involving patient advocates and not patients 
themselves. (P6) 
 
O31 elaborated about why ethics applications were particularly resource intensive, 
describing how countries outside of their own had ethical approval procedures that they 
‘were not prepared for.’ As a result of the unexpected procedures, these developers were 
unable to involve patients from all countries that they wanted to: 
It was not easy to involve patients in the Delphi survey […] we wanted to do it with 
patients from different countries, but it was not easy to reach the amount because 
err in some countries we had to um go through some ethical approval procedures 
that we were not prepared err for […] in the UK for example, so we were not able to 
involve err patients from the UK, from, for this reason, because we tried to do it 
through patients’ organisations in the UK but err indeed we had um to apply [for 
ethics approval] and err we did not have err time and err resources to go through 
all this process. So in the end we had to make very practical decisions err not to 
involve patients from some countries err where we really wanted to involve patients 
and we um… so we did it only from other countries where there were not these err 
ethical boundaries let’s say. (O31) 
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O27 succinctly described the ethics procedures associated with stakeholder research in 
different countries as ‘the bureaucratic hurdles of international approvals’. Some COS 
developers also differentiated between stakeholder involvement as participants in research 
and ‘stakeholder work which isn’t classed as research’. O27 referred to COS projects which 
had been described as the latter, ‘and when that happens you don’t have the um err the 
large workload of the um ethics processes to deal with.’ One COS developer described a 
range of challenging administrative tasks associated with ethical approval for involving 
patients, and commented on how these were much more taxing in the US than in the UK, 
where this COS developer was based. O29 also described the US process as bureaucratic 
and excessively complicated: 
The US was a, was a totally different story, that was extremely, it was extremely 
slow and laborious process to get um ethical approval for the study, um I think 
there were some concerns because we were going to be discussing some issues with 
patients that um, mean we had to have a psychologist that was available that, that 
patients could refer to if there were concerns about um low mood. Um and, and just 
um, you know, the bureaucracy there is […] something else compared to here, you 
know, there’s still a lot of hoops to jump through, and it just took us ages to get it 
off the ground. (O29) 
 
Kids can’t always tell us what they’re feeling 
Published and ongoing developers perceived particular challenges with involving children in 
COS development. Remarking about involving children as participants, one COS developer 
(P1) who had not actually sought children’s input, commented that it was ‘hard to ask 
them’, and added: 
So I think we kind of know what they would say. We kind of know what they would 
say; that they wouldn’t want any pain, so I think pain would be the only outcome 
they would consider’.  
 One ongoing COS developer who had not involved patients similarly anticipated that 
children’s involvement would be challenging due to their limited language abilities, ‘which 
makes it a little bit more difficult because they can’t always tell us what they’re feeling’ 
(O32). 
 
To be, or not to be (international)?  
Both published and ongoing developers talked about the challenges of doing COS 
development internationally, particularly the linguistic challenges that global participation 
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entailed and the need to translate concepts and questionnaires. Some COS developers 
described how, having anticipated this challenge, they did not include international 
participants, while others confronted this challenge and involved international participants: 
'Cause that was the, that was one of the other difficulties, 'cause we had err 
parents in five or six different countries, so we had different language err 
questionnaires. (O32) 
 
We kept our study within the UK, um, I would have liked to have done it more 
internationally, um, but um access to participants is an issue, and, um, funding and 
various other things.  We did our Delphi on paper so posting things internationally 
was going to be tricky, and then there's language issues and all this other stuff. 
(O23) 
 
O32 went on to describe further challenges relating to participants’ understanding when 
questionnaires need to be translated into different languages: 
It’s a drawback because the question is, is the questionnaire really the same in 
every language? Is the err, do parents understand the same thing from the 
questionnaire in every country? (O32) 
 
Alternatively, COS developers described an international COS that only included English 
speaking participants, which engendered different challenges particularly for including 
patient participants: 
The main challenge was, er, the language thing, obviously that was, er, in English.  
So we, for example, okay for clinicians for example, the most of the clinician and the 
researchers, and of course journal editors, they do speak English.  But then the 
problem was to actually find patients who would be willing to take the 
questionnaire, all three stages, fill it in, and have a proper understanding of English. 
(O30) 
 
COS developers also spoke of the logistical challenges of organising an international 
meeting, and the challenge of getting the balance between what is ideal and what is 
pragmatic. O25 suggested that a kind of interim ‘clinician COS’ could be developed with 
international clinicians, and then there could be country specific work with patients 
followed by a consensus meeting to determine the final overall COS for each individual 
country. O25 thought this approach would be more suitable than running an international 
Delphi with patients across many different countries simultaneously:  
The barriers in terms of language particular, um and reaching a conse- a-and I think 
a consensus meeting is important, and I think strategically to get patients to fly 
from around the world to a consensus meeting is not really realistic, and therefore I 
appreciate that that’s, wh-what I’m suggesting is not an ideal answer, but I think 
it’s pragmatic. (O25) 
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O27 described a similar scenario whereby limited resources might mean that an 
international approach is not possible even if desired. COS developers engaged in a trade-
off between the best way of doing things within the resources available: 
It’s best if these things are international actually, but I think we have to think very 
carefully about what) we are doing the research for and whose care we might be 
improving. Um we also need to think very carefully about the resources we’ve got 
available um and that, that includes financial resources to do a piece of work err as 
well as the human resources we’ve got to do a piece of work, which of course are 
interconnected, but it might be that sometimes we just have to do work um in, in a 
single country setting for those reasons, and that, that, that’s okay. Um sometimes 
that’s a pragmatic approach to take and it makes good sense to do something in, in 
one, in one place. (O27) 
 
One COS developer differentiated between a COS that involved international participants 
and a COS that was developed to produce international recommendations (P14).  He had 
included participants from different countries but this was because there happened to be 
expertise in these particular countries. It was not because they were trying to include 
international representation to produce international recommendations: 
If you look at the geographical origin of the people in the workshop […] All the rest 
were from mainland Europe, UK and North America.  No South Americans, no 
Africans, um so some people would say it’s not an international consensus.  But we 
didn’t really (.) seek to present it as such.  We were um aiming to produce an output 
from an expert group.  When in some other workshops you want to maybe 
generate outputs that provide convincing guidance throughout the world - in that 
case you want to be as international as possible - that becomes er frequently quite 
unwieldy because of language barriers in, in discussion, in the workshop situations 
and (.) different levels of development of understanding in the particular field.  Um, 
for instance, I think the awareness of investigators involved in [name of disease] 
trials in Asia is significantly um less sophisticated as to methodology compared to 
people in, especially, Europe and North America.    So we ended up with a bias um 
to those areas for a good reason, because that’s where the expertise was, that’s 
where the critical thinking had been occurring. (P14) 
 
The issue of whether COS should be international or not was described as an ‘unanswered 
question’ by one COS developer (O25). Another COS developer saw the answer as very 
much linked to the overall goal of the work: 
I don’t know if the, if the step would be to have all stakeholders, you know, from all 
different countries in the same room, or whether there should be parallel processes 
in different countries that potentially reach very different conclusions but that 
should be sort of compared.  And so I, I think that that would need to be considered 
in terms of what the method would look like.  But the focus of our paper was, the 
goal was not to sort of get international perspective, it was to get a US perspective. 
(P6) 
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If no one uses it, you cannot really say that the development of your COS was 
successful  
Ongoing COS developers described challenges with getting their COS protocols published, 
with one even referring to the process as ‘painful’ (O19). In all instances, this was linked to 
reviewers’ and editors’ perceived lack of understanding or knowledge about COS, the 
development process and the importance thereof:  
It wasn’t really easy to publish it […] not many people are actually experienced, are 
experienced in, er, core outcomes, and they are not very experienced in how core 
outcomes should be, you know the e-Delphi kind of process.  Because (coughs) I was 
trying to publish in, er, another, er, journal before the, the one that, which I 
published it at the end.  And from their reviewer point of view you would get you 
know very funny sort of questions and critiques, which, which just wouldn’t make 
sense to someone who you know, um, who would appreciate how difficult a process 
it is. (O30) 
 
Some ongoing COS developers expressed concern that the time taken to develop COS 
might mean that the COS is ‘slightly obsolete’ when the COS is published and ready for use 
(O19), as ‘things change’ such as ‘new developments, new interventions come into the 
equation’.  COS developers felt that given that COS development ‘takes a little while to do 
these things, staying at the forefront of the evidence can be hard as well too’ (O21). 
 
Interestingly, only one published COS developer described difficulty when publishing the 
findings of their COS work. P8 remarked that he had received ‘disparaging’ comments from 
a couple of high impact journals, and had been asked ‘this is a nice idea but is it really 
science?’ (P8). This COS developer went on to say ‘the people were a bit disparaging about 
the idea that we, um, just asked people what items were important.’ P8 described two 
further challenges associated with publishing their meeting report. The first that ‘peer 
review takes forever’, and the second that the reviewers did not like one of the scales they 
had decided on, and did not ‘agree with the consensus we have made.’  
 
Published developers described uptake and implementation of the COS as a challenge of 
COS development more frequently than ongoing developers, with some published COS 
developers describing implementation of the COS as the ‘biggest challenge.’  One 
explanation of this difference is that published COS developers are more aware of the 
challenges associated with this stage of the process, while ongoing COS developers, with 
their focus on more immediate concerns, were deferring some of their efforts to promote 
implementation to a later point in the process: 
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I don’t see it too much as a challenge now, although see, again if you have limited 
resources, not that you can have a very broad implementation plan, but this might 
be a challenge after some years when our core outcome set will be developed and 
we will be seeing maybe that people don’t use it err too much. (031)  
Nevertheless, despite not regarding implementation as an immediate challenge, this COS 
developer went on to describe the importance of implementation from an early phase, 
commenting that if no one uses the COS once it is developed it can hardly be regarded as 
successful:  
You can err have the best methodology in developing a core outcome set but err, 
err if at the end of the day the, no one uses it, you cannot really say that your, the 
development of your core outcome set was successful. Implementation is not an 
easy step but it is really worth it to spend err time and energy on that because err 
again um having a core set which is not used by the clinical com-com-community 
that err it’s the target to might be er r not very successful. (031) 
He emphasised the importance of adopting ‘implementation strategies’, and went on to 
describe a dissemination strategy to aid implementation: 
So we have reached consensus on outcome domains, and um yeah, the first step of 
course we made a publication on this, but then err, err we are trying to work err on 
newsletters err of professional bodies for example, so to implement more our um, 
our message. We have presented the results of our study in err three, four different 
congresses and err we are going to present in even more err, err during this year, so 
to present the results of these different conferences in different err, err also with 
different audience possibly. (O31) 
 
Other COS developers described instances where COS implementation had been 
unsuccessful and they did not know how to resolve the situation. Linked to this, one COS 
developer described a lack of openness by gatekeepers to the uptake of their COS: 
So the FDA is, right now, studies, erm, are being planned and conducted on systemic 
treatments for [name of disease] and the FDA just doesn’t accept our core outcome 
set. They favour an outcome that is not included in the core outcome as a primary 
endpoint, and they just refuse to acknowledge our work. And we wrote them, I 
think four or five months ago, about this issue and we never got a reply. (P4) 
 
A similar challenge was echoed by another COS developer who described how the existing 
leading authority for recommendations and guidelines in their field felt ‘threatened’ by 
their COS work (P9). The COS group had planned to do further work to involve patients, but 
according to P9 the leading authority were so 'miffed' by this COS work that they created a 
'political heat storm.' As a result, the COS developers decided not to do this further work as 
they did not want to ‘antagonise’ the committee further. P9 relayed how the two groups 
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held discussions and the leading authority agreed to be more open to some of the 
discussion that arose from their COS work. He attributed this to the leading authority 
wanting to remain in control as the standard for recommendations, rather than have the 
COS group ‘derail’ them.  
 
Published developers were aware that the process of COS development could influence its 
implementation. Describing this as ‘social and political’ aspects of COS development, one 
COS developer explained that who is involved in the process of deciding what is core can 
influence the later uptake of the COS (O31). Another COS developer highlighted similar 
issues: 
Probably the biggest challenges are around um trying to make the broadest 
outreach and assure that um people who need to be in the room or need to know 
about will be invited to be in the room are there. Um I’ve seen really good 
consensus initiatives go bad um because err one individual was insulted that they 
were not invited to participate, um literally.  That was um, err a, a group I didn’t 
participate in but I, I, I know a woman who moderated a consensus um, err 
initiative recently and, you know, again she got together five or six really good 
people, put them behind a closed door, have them do all kinds of literature review 
and worked very hard to put out a document, and when they rolled it out there it 
was met with a lot of resistance among um the community of [clinical experts]; it 
was a very, it was a big challenge.  (P13) 
When asked what the solution was to involving all necessary stakeholders to avoid 
problems with implementation, P13 answered 'Magic wand?' which suggests that she saw 
implementation and uptake as something that was virtually impossible to get right. In some 
respects COS could be regarded as proposing that no one group has authority and that all 
opinion is equally important or valid. This can be extremely challenging for some groups. 
P13 went on to offer some solutions, including the planning committee ‘knowing who to 
bring into the room, and, not keep it confined to people who are similar in thought to you, 
right?’ This COS developer also described what she felt were successes with her COS 
project, such as having ‘an organisation that is perceived as non-biased’ to help oversee or 
facilitate the process and to overcome ‘the feelings of inclusive or exclusiveness.’  
 
Ongoing and published developers talked about people’s lack of understanding of COS, 
their importance and their purpose, as barriers to the uptake of COS recommendations. 
COS developers described an apparent lack of knowledge about what COS are for, along 
with a concern that COS might stifle other outcomes of interest that should be included in 
research: 
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The biggest challenge, erm, maybe to make, erm, people that are important in a 
field but not directly involved aware of the importance and of the definition of the 
development of a core set, and also of the importance to then apply to it without 
necessary having to feel restricted in their choices of like primary outcomes or 
whatever. (P4) 
Similarly, P12 talked about a general lack of awareness of COS as a challenge to 
implementation, and saw this as COMET’s responsibility to resolve: 
COMET’s problem that when you are in an area and so knowledged about it, and 
you are working full time in that, you are speaking an internal language which a lot 
of people [may] not know exactly what you mean outside, and that is one of the 
major implementation problems. You need to have this out so people can 
understand what we are talking about. (P12) 
P11 described frustration of speaking at a meeting where people disregarded the 
recommended outcomes as ‘irrelevant,’ and went on to say ‘It’s almost like people weren’t 
even listening to what you had to say.’ He added that when people have a ‘basics of 
understanding’ about outcomes and the importance of core outcome sets it is like 
'speaking the same language,' which can help with uptake and implementation of COS.  
 
O32 described that implementation of a COS might be challenging when COS 
recommendations are based on a small number of experts, asking ‘Do we trust this group 
as a sort of oversight committee over a larger group of experts, or do we need more people 
involved in this?’ O32 also suggested that the status and trustworthiness of the people 
leading the COS, as well as the numbers of participants included, might also influence 
uptake:  
Will there not be criticism that, okay well you did this but, you know, who are you? 
Why, why should we trust your core outcome set? You only asked a hundred people, 
and so on and so forth. (O32) 
O28 asked similar questions, again highlighting the importance of process issues such as 
the selection of participants in the subsequent uptake of the COS: 
How do you convey to people that who you’ve chosen is the, are the right people? 
Um you know, how do you know or how can you err how do you know, and how can 
you demonstrate if you do know, that the people you’ve chosen are the right people 
to be commenting on it? So I think that’s probably the major thing when we’ve sort 
of been talking about this amongst you know when we’ve been presenting the work 
locally that’s the thing that’s perhaps generated the most discussion. (O28) 
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7.2.3 Guidelines for COS development  
As already highlighted in section 7.2.2, COS developers emphasised the absence of 
guidelines to develop COS, and suggested areas where they felt specific guidance would 
have helped them or would be helpful for future COS developers. They also suggested 
areas of research where they felt there were methodological questions that need 
answering:  
It’s really helpful to be developing these guidelines because at the time that I was 
doing this there wasn’t really, you know, I, I felt a bit like a pioneer in a way, you 
know, trying to decide which was the best way to go about this. Um and I think 
there are some really important discussions that need to be had. (P17) 
 
One has to be careful that any kind of description of what gold standard is, is also 
tempered by a reality check 
COS developers described the need for guidance about how to develop a COS. Published 
COS developers spoke of a ‘best’ methodology, implying that they thought there could be 
one right method for COS development. P1 suggested that guidance is needed about 
‘which technique should be chosen’, and P13 similarly spoke of a need for ‘some semblance 
of guidelines […] for what is an optimal methodology for getting to a consensus,’ or ‘a 
preferred methodology’. P2 remarked that guidance for the novice investigator or for 
clinicians who do not do research full time, is needed, and went on to say that it would be 
helpful if the entire process was laid out and COS developers ‘could be aided by a concrete 
set of steps to go through.’ P2 likened this ‘set of steps’ to CONSORT, adding that ‘people 
need to be educated’. This COS developer also suggested that guidance should be a 
‘prescribed process’, suggesting that guidelines should be set down as rules, while 
commenting ‘I don’t know if you would, if a journal could mandate that you followed a 
particular order of steps.’ P2’s turn of phrase here suggests that this COS developer had 
concerns about how such prescriptive guidelines could be enforced. Nevertheless he  also 
suggested that a concrete set of steps to go through would ‘make it a more robust set of 
outcomes in the end, that people actually believe and care about,’ adding that guidelines 
about COS methodology could impact on the uptake of that COS, by allowing people to 
decide if a COS has been rigorously developed: 
People could say wow they really did not stick to what is considered a robust 
methodology for creating a core outcome set, I really have no faith in the final 
product or the converse, they did everything they could given the resources that 
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they had and I do think that future investigators should lean on that paper. Or not, 
you know. (P2) 
 
Despite suggesting the need for guidance to describe how a COS should be developed, COS 
developers offered few suggestions as to what the COS development process should entail. 
Only one COS developer made a suggestion that a combination of methods was most 
appropriate, but did not explicitly say what that combination should be. This COS developer 
did, however, say that ‘a systematic review is very important, where there’s enough 
literature to do a reasonable systematic review’ and also said that he preferred the Delphi 
poll as it means ‘you can actually get, if you’re going to do a consensus […] because it 
focuses attention’ (P15).  
 
Other COS developers similarly said that a flow diagram and set of steps like CONSORT 
would be helpful for COS developers. CONSORT offers a standardised way for authors to 
report clinical trials, and it comprises a 25-item checklist and flow diagram for trialists to 
follow [11]. P11 remarked that ‘what I really think is helpful is you can talk about all the 
theory you want but what people really want is a “how to” guide […] a step by step march 
through it.’  Guidance needs to 'lay it out for people as to that process they march through' 
because 'people don't think about these things at all.'  
Now, look, I’m a pragmatist, okay.  I’m all for laying out the conceptual foundation 
but at some point the rubber’s got to hit the road, and that’s what we’re not doing 
and needs to get done.  It’s to lay out this here’s the CONSORT type check list for 
developing outcome measures as end points in clinical   trials.  And I would even go 
beyond clinical trials – I would say clinical research in general.   It doesn’t have to be 
in the setting of a randomised trial. (P11)   
 
P12 also compared guidelines for COS development as being similar to CONSORT, adding 
that establishing guidelines for COS development would be a challenge because of the 
need to cover ‘so many areas’, but this could be overcome by identifying ‘common rules, 
[…] for all type of medical areas.’ If methodological guidelines were disease specific, ‘people 
outside might not understand it and say it’s not for us, we jump out,' so there is a need for 
‘common rules’ to be established.  Likewise, in contrast to those published COS developers 
who described the need for guidance about a best method, one published COS developer 
described the need for guidance about 'how it can be done' rather than a single, gold 
standard, way of developing a COS (P4). This COS developer suggested that a protocol 
template would be helpful for people to follow, as well as ‘a group of advisors or more 
experienced people in this field who would be available to consult new groups.’  
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Ongoing COS developers also felt that guidance was needed for how to develop a COS, but 
unlike published COS developers, they acknowledged that this could not be ‘a one size fits 
all approach’ due to the ‘nature’ of COS development (O19).  O19 spoke about a need for 
guidance to help researchers ‘think for themselves’ about how their individual 
circumstances influence how they develop their COS for their different diseases. Although 
he did not feel that a ‘one set fits all’ guideline for how to develop a COS was possible, he 
did suggest that ‘what you can do is have some guidelines on how to be flexible’ as 
‘essentially there’s no fixed template to do this.’ Likewise, O23 suggested that there is no 
fixed method for COS development, and instead proposed that COS guidance should be 
developed to prompt COS developers to think very carefully about their data sources. O23 
described how his COS had involved qualitative interviews with patients, but later found 
out that extensive qualitative research had already been published in their field. He 
therefore felt this qualitative work had been done unnecessarily. He added that such 
interviews could be useful in other clinical areas where such work has not been done 
previously. These views further support the idea that COS development is not a fixed 
process and guidance should reflect that. O27 further elaborated this point, commenting 
on the need for COS teams to make ‘considered decisions about the methods to use along 
the way,’ and illustrated this with an example of methods they considered for their 
context: 
We discussed whether to do focus groups or interviews with clinicians and working 
out what works best in a timeframe, what works best for tho-those people. All 
those have to be thought about in some detail um in order to get them right. (O27) 
 
In direct contrast to P2 who suggested that COS guidance should be prescriptive, O27 said ‘I 
think again it’s maybe about not being prescriptive and ensuring that people do have the 
chance to think about their own contexts, and work in accordance with their contexts really, 
and, to kind of respect local knowledge, I think, as well.’ Rather than being prescriptive, 
‘being aware of some of the possible hurdles, that is really important.’ Nevertheless, O27 
also highlighted the importance of guidance being practical and taking into account 
resources issues.  
 
One COS developer highlighted the importance of not only developing guidance for COS 
development, but of COS developers knowing that guidance exists and where they can find 
it (O22). When prompted about whether there were any particular guidelines that she 
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would have found helpful, O22 described how she had not learnt about the COMET papers 
until after the group had started their COS work (the COMET papers were published around 
the time that this COS team started their work). She described discovering ‘things’ from 
reading the COMET papers that their team had not done. She saw COMET as very much 
part of this process of disseminating COS development guidelines: 
When I started this whole thing I did come across COMET, but I don’t know if those 
guideline papers were out there yet or… Like I don’t know why I didn’t find them the 
first year I started this […]  I was quite far into it before I came across some of those 
other papers, then I was like, oh crap, I should have done this or that, kind of thing, 
you know? So I think just getting your stuff out there more so that when people are 
starting it that they find it. (O22) 
 
Ongoing COS developers commented that guidance around how to develop a COS would 
also have a positive impact on dissemination and uptake of the COS. For them, guidelines 
about methods would help make publishing COS work easier as they could refer to 
guidelines to justify their methodological decisions: 
Some of the very helpful guidelines and papers that are coming out, like that would 
be something that, you know, if I could refer, you know, if there was a statement 
that I could refer back to, because I think a lot of journals don’t necessarily know 
about this methodology yet either, and if I had a reference that I could point to that 
would be very helpful. (O22) 
Likewise, O30 said: 
You have the guidelines, and you can tell referees, er, you know, we actually did 
what the guidelines suggested so it, it gets you know more straightforward.  (O30) 
The particular COS developer quoted above (O22) highlighted the need for ethics approval 
as an example of something that they had not thought about during the development of 
the COS. She commented that it would be necessary to include advice about ethics 
approval in COS development guidelines. In the case of this group’s COS, the issue of 
ethical approval only arose at the publication stage when the team started to question 
‘how should ethics work with this?’. 
 
Methodological mysteries  
As touched on in section 7.2.2 above, it was almost always ongoing, rather than published 
developers who, suggested specific methods where guidance would be helpful. Two COS 
developers suggested that guidance ‘on how to run discussion meetings’ would be useful. 
P14, the only published COS developer to suggest specific methodological guidance, 
described how they did not come across any existing guidelines, and ‘20 years or so that 
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I’ve been involved in chairing discussion meetings, I’ve learnt on the job, and I don’t think 
that’s necessarily the best way it’s good to be able to benefit from other people’s 
experience.’ He elaborated that guidance should include ‘how best to organise a workshop 
like this to try and ensure that you use the expertise and time of the individuals actually face 
to face as efficiently as possible.’  P14 also suggested that planning and preliminary work is 
vital to the success of the meeting, as ‘ultimately you’ve got to have something that 
provokes people to think about a question and then to make a judgment’. Another COS 
developer (O26) remarked on the absence of guidelines for consensus meetings 
specifically, commenting that there was variability in the literature about how meetings 
were conducted; some hold an informal chat whilst others have involved more formal 
voting. O26 remarked that there was no consensus ‘on how to actually do it’:  
The functionality of the consensus meeting is very, very vague. In the, in the 
literature, there is absolutely no consensus there about how to do it and what are 
the objectives and the aims of having this consensus meeting, so that err something 
that needs to be looked at a bit further in detail. (O26) 
 
COS developers suggested specific areas of Delphi where guidance is lacking or further 
research is required. These included numbers of people for a Delphi, including number of 
patients (O29), and ‘how do you know, and how can you demonstrate if you do know, that 
the people you’ve chosen are the right people?’ (O28) and how to increase response rates – 
‘how do you motivate people to answer?’  (O32). O32 went on to ask ‘if you’re motivating 
people to answer them, is that not biased?’ Furthermore, he remarked that he did not 
know if these questions would ever be answered: 
So that was sort of the question where we sort of thought about it, okay we can tell 
the head of the department, tell the ten people in your department that we’ve 
emailed to answer it, but then we know that their answers will probably be similar 
to their boss’s because they have a similar approach to everything, and then you 
bias your own results. So that’s, that’s something that’s an issue, but I don’t know if 
there’s a, if there’s an answer to it, I don’t know if there’s a good way to try and 
increase that. (O32) 
 
O23 asked similar questions about sample size and populations in Delphi surveys, but also 
had questions about the ‘the internationalness of the population’ and the additional 
complexities that international participation brings, such as access to participants, funding 
and language issues. O23 listed multiple research questions about Delphi that need to be 
answered: 
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I don’t think anyone understands the implication of, um, response rates in Delphi 
studies, because they are different to standard surveys, so I don’t think anyone 
really understands that.  […] within Delphi, I don’t think anyone understands the 
best type of feedback to give people, um, the impact of what that feedback, um, 
you know of how that feedback affects responses.  Um  er, the issues around, um, 
whether you discard or retain outcomes, or whether you keep the whole lot in, um, 
until the end of the Delphi process, I don’t think that’s been resolved at all.  Um 
what else had problems?  Um, I guess the relative weight of different, um er, of 
different stakeholders, and do you keep them equal, do you weight one more 
heavily than the other.  Um, do you, um, combine different stakeholders, different, 
er, results at different stages, do you merge it all at the end, um, yeah these are all 
sort of mysteries to be honest with you. I could go on and on. (O23) 
O23 also referred to the systematic reviews that are often done prior to the Delphi 
exercise, and the need to have methods in place that allow ‘appropriate categorisation’ of 
outcomes prior to the Delphi exercise.  He described that domain categorisation during 
their systematic review of outcomes was 'a subjective process' that 'if you don't get that 
stage right then your Delphi just kind of doesn't matter.'  
 
The amount of involvement (and participation) that you have from patients will 
differ depending on the clinical context 
COS developers made some reference to including patients as participants in COS 
development as an area requiring guidance. This included the ‘number of patients’ that 
should be involved, as well as the ‘amount of involvement that you have from patients’ 
(O29). This COS developer remarked that ‘I guess that for every clinical context that will 
probably differ’ which suggests a belief that any guidance in this area could not provide a 
definitive answer to these questions.  
 
O27 highlighted the importance of considering the resources that will be available to COS 
developers when thinking about producing guidance. She elaborated that ‘patient 
involvement in research – a lot of groups won’t have the resources to do that properly,’ and 
so guidance needs to be realistic about what is do-able with limited resources. P17 was the 
only developer to distinguish between patient participation in contributing data and 
patient involvement as research partners. She described both as resource issues, and the 
difficulties associated with representing patient diversity with limited resources. P17 
remarked on the importance of making sure that the outcome priorities of different 
stakeholder groups are not missed, and on the need for guidance on how to represent 
diversity in both patient research partners and patient participants. P17 also acknowledged 
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the difficulties in producing such guidance ‘we’re probably not going to be able to give 
guidance’ on how best to represent patient diversity, but added ‘going forwards we need 
to think about this, I think that would be a really important contribution’.  
 
How to report your findings 
A small number of COS developers, both published and ongoing, commented that guidance 
on ‘how to report your findings’ was currently lacking and would be helpful. One COS 
developer (O26) who described using the ‘paper by Sinha et al’ to write their manuscript, 
when prompted about the usefulness of this reporting guidance, said that this was 
‘definitely helpful, and especially when you compare it to previously done previously 
published papers, you see that quite a few of the papers are missing very important points.’ 
This COS developer elaborated that reporting guidelines are important for ‘transparency of 
how you’ve done your Delphi survey.’  Despite using the Sinha checklist, he still felt that 
reporting guidelines were necessary ‘'cause I think that it’s only very few papers that 
actually highlight, you know, best practice in reporting findings for the consensus.’  
 
7.3 Discussion  
As the first in-depth description of COS developers’ choice of methodological approach, 
including the factors that have informed how researchers have developed COS, this study 
has furthered our understanding of COS development processes and enabled me to 
identify priority areas for future methodological research. A summary of the main findings, 
including these priorities, is presented below.  
 
7.3.1 Main findings  
COS development is  an emerging field and in this respect contrasts markedly with the area 
for which COS are being developed – clinical trials. There are many rules and a good 
measure of consensus about how to conduct clinical trials, and it is now a highly directed 
field with well-developed guidance to support the process [55, 56]. By contrast, COS 
development is an emerging field without shared assumptions, and COS developers are 
trying to bring order to the outcomes that are measured in trials in a specific condition, 
where currently there is considerable inconsistency in what is being measured and 
reported. The absence of a knowledge base for COS development and the lack of 
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consensus about the best way to develop a COS underpin methodological decision making 
processes. COS developers discussed a variety of factors that influenced their choice of 
methods, which included accounts in the literature of previously used COS development 
methods, expert advice, their general experience with methods and the resources 
available. Some COS developers described uncritical application of methods, for example 
using the methods they were familiar with rather than working out which methods would 
best suit their purpose and context. Other COS developers demonstrated more critical 
evaluation of methods, evidenced in the adaptation of methods before applying them. 
Experience with methods was a common influence on choice of methods, but this 
experience was general and not COS specific. Furthermore, COS developers who had 
previous COS experience did not demonstrate any critical appraisal of their methods before 
applying them to subsequent COS.  
 
Questions about resources, namely time and money constraints, also influenced COS 
developers’ choices of approach. COS developers emphasised a need to compromise in 
how they went about COS development as a consequence of limited resources, and saw 
this as one of their major challenges.  While small budgets and time limitations are likely to 
be genuine constraining factors, it is possible that in some ways these serve as justification 
of choices about methods rather than explanation. For example, COS developers who 
received generous funding still talked about their projects being compromised due to 
funding and time. Time has been widely accepted as a critical barrier to research, but could 
also be suggestive of the task in hand as being seen as lower priority than other activities 
[136].  
 
Interestingly, there were examples of advice being framed as instruction. While it is 
possible that this advice was given as instruction, it could be that COS developers saw 
certain well known figures as leaders in the field of COS development and therefore 
followed their advice without questioning it. The notion of instruction also contradicts the 
opinion of ongoing developers that there is no single way (or right way) to develop a COS. It 
is also possible that these COS developers were seeking to avoid accountability for their 
decisions, or mitigating responsibility.  
 
COS developers frequently cited OMERACT as an example of previous work that had 
informed their decisions about methods, and the OMERACT team as providers of advice. 
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While OMERACT members have years of experience in COS development, their experience 
is limited predominantly to the field of rheumatology. OMERACT have developed the 
OMERACT filter 2.0 as a template for rheumatology COS development [27, 142], and there 
have been recent similar efforts in the field of dermatology [143]. Condition specific 
guidelines certainly have their place, but as one COS developer highlighted, if guidance is 
disease specific then others might be reluctant to use it.  COS developers saw the COMET 
Initiative as having a role in guideline development and dissemination in the field of COS 
development.  
 
Ongoing COS developers referred to the available guidance in this area, albeit limited, as 
being useful in deciding what methods to use. Of note, ongoing developers were keen to 
point out that there is no consensus about an optimal method for COS development, so 
they were still required to make their own decisions about which methods to use, whether 
this be to suit their resources or their circumstances. Ongoing COS developers somewhat 
self-critically referred to having made arbitrary decisions about methods, but they seemed 
to be conflating this with the need for decision making to be influenced by pragmatic 
considerations. Developers who described their choice of methods as pragmatic conveyed 
an element of logic and thinking through their methodological choices, albeit within 
resource constraints. This is reflective of an emerging area of research where guidelines on 
which to base decisions are currently limited. The absence of guidance in this area is 
discussed further, later in this chapter. 
 
In contrast to published COS developers, ongoing COS developers described more detailed 
methodological uncertainties pertaining to the process, particularly systematic reviews of 
outcomes, defining consensus and uncertainties about the Delphi method. These more 
detailed descriptions of methodological uncertainties might reflect an overall increased 
awareness of the complexities of COS development, through the work of groups such as 
the COMET Initiative [40, 144]. One published COS developer referred to their work as 
preceding the ‘methodology movement’ implying that researchers today are more 
methodologically aware.  One other explanation is that description of more detailed 
methodological uncertainties could also be a matter of recall, as the ongoing developers 
were still very much involved in that work at the time of interview, and these issues may 
therefore be at the forefront of their minds. 
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One of the biggest challenges experienced by COS developers was around participant 
selection, access, and retention. COS developers also expressed concern about reflecting 
multiple stakeholder opinions and integrating different opinions into the process. Health 
researchers have long looked to systems and frameworks in an attempt to understand 
human endeavours and interactions, and complex adaptive systems are one such system 
[145]. Complexity here relates to the importance of interactions of parts, in relation to the 
establishment of the whole [145]. COS development could be regarded as a complex 
adaptive system, that is the collection of individual groups or agents with freedom to act in 
ways that are not always predictable yet whose actions are interconnected [146]. Many of 
the concepts of complexity apply to COS development, such as neither the system nor its 
external environment being constant, individuals within a system being independent 
decision makers, and having to manage uncertainty and paradox within the system.  For 
example, individuals within a Delphi study are making an independent decision about the 
outcomes that are important, but when feedback is given they become interconnected to 
the group as they can change their scores based on the collective. These exist not 
necessarily as problems that can be solved, but as ways of understanding COS 
development.  Furthermore, because the agents or groups within a complex system can 
change, the complex system in itself can adapt over time [147]. This adaptation can occur 
through learning or experience. The activity of COS development in its entirety can, at a 
higher level, also be considered a complex adaptive system. Through the sort of experience 
and learning such as indicated in some developers’ accounts, this complex system is likely 
to adapt in time. With different groups developing COS in different ways, their experiences 
might lead to changes in the ways COS are developed, or even to more standardised ways 
of developing COS as more evidence about methods becomes available (i.e. through 
guidance), thus creating an adaptive system.    
 
Incorporating diversity within stakeholder groups was also an issue, and is an important 
challenge to address as it may influence the outcomes ultimately defined as core. Involving 
patients in the process of COS development was a particular concern for developers and an 
area of COS development where developers felt that guidance was needed. Published 
developers particularly perceived that involving patients in COS development would be 
challenging, and as a consequence most had not included patients. However, it is worth 
considering that this might be retrospective justification for not having considered patient 
participation explicitly at the time of development.  Published developers also described 
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that including patient participants in research was not commonplace when they undertook 
their COS work, which might corroborate this suggestion. COS developers also anticipated 
difficulties with involving children in COS development. This is an area that requires further 
work to identify specific challenges with involving children, and to look for exemplar work 
where children have been successfully involved and from which COS developers might 
usefully learn.  
 
COS developers suggested that patients had trouble understanding the nature of what they 
were being asked to do, but also questioned whether the problem was really that COS 
development had not been explained sufficiently rather than understanding being an 
insurmountable issue for patients. One developer suggested that providing more 
information to patients might help with patient understanding. However, it is important to 
highlight that more information is not always better information and might not be helpful 
at all. More information could even be detrimental and lead to patients disengaging 
because it leaves them feeling overwhelmed or confused. One developer also attributed a 
lack of realism to patients’ views about what it important, referring to patients not wanting 
the disease anymore. While it is true that outcomes for trials need to be realistic and 
measurable, it is entirely realistic for patients to want to be rid of their condition. This 
arguably demonstrates the vital importance of patient participation in COS development, 
as a reminder for researchers not to lose sight of key research goals, even if these currently 
seem out of reach.  
 
Interestingly, only one COS developer highlighted the issue of researchers’ ability to grasp 
concepts about rating the importance of outcomes. Additionally, developers spoke of how 
both patients and clinicians struggle with rating outcomes. Again, one could argue that it is 
more about how the question is framed, so what it is that participants are asked to do, and 
the importance of differentiating between important outcomes and core outcomes that 
should be measured and reported in every trial, rather than participants’ inability to 
discriminate between outcomes. One also needs to question whether understanding is so 
important. If participants do not understand what is being asked of them, then one needs 
to question what this means in relation to participants’ ratings of outcome.  COS 
developers did not exclude clinicians or researchers from the process based on their 
perceived level of understanding, yet some did exclude patient participation because of it. 
However, most ongoing COS developers are now including patients in the process. 
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Increasing patient participation in current COS development provides an opportunity for 
further research with patient participants themselves to find out about their experience of 
being included in COS development. We can then learn from this to inform guidance in the 
area of patient participation in COS development. Interestingly, patient involvement did 
not feature heavily in developers’ accounts in these interviews, with only one developer 
making a clear distinction between patient participation in contributing data and patient 
involvement as research partners. The involvement of patients as research partners is an 
area of COS development that requires further attention.  
 
Some COS developers proposed including patient advocates (as participants in COS) as a 
solution to challenges of involving patient participants. Here, developers were referring to 
including individuals who can ‘represent’ the views of the wider patient community. While 
research has suggested that training patients to actively participate in the research process 
may increase confidence and ability to participate in research [148], COS developers need 
to be cautious about this and question the ‘representativeness’ of trained patient 
advocates. Patient advocates tend to be of a higher socioeconomic status [149], which 
could have implications for the outcomes they think are important. Ives et al describe the 
professionalisation paradox whereby they suggest that training patients undermines the 
very purpose of their involvement to bring a lay perspective [150], and propose that 
researchers risk being drawn into a paradox that will render patient participation and 
involvement ineffective, even tokenistic. Patient advocates likely have a place in COS 
development, for example as research partners, but probably not at the expense of 
involving patient participants providing personal perspectives. This is an area of COS 
development that requires further exploration. 
 
Interviews with COS developers also raised questions about whether the inclusion of 
patients in COS development is participation in research or consultation. The distinction 
between involvement and participation is arguably not so clear in COS development, as 
patients in a Delphi exercise or consensus meeting are in a sense being consulted as 
experts about what outcomes to include based on their knowledge and experience of a 
health condition. Furthermore, this links to the above point about professionalisation, and 
some have argued that consultation should not require the professionalisation of the 
patient to provide their experience of living with a disease or as a service user [150]. This 
issue was also raised in relation to ethics requirements, and is therefore an important 
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consideration for future COS developers. COS developers expressed that ethics 
requirements are currently unclear, or developers were lacking knowledge of the 
requirements, and there is a need for guidance around what ethics approvals are required. 
One developer felt that if COS development is classed as consultation rather than research 
then ethics approval would not be necessary. The Health Research Authority offers a 
decision tool to determine whether a study requires Research Ethics Committee review 
(http://www.hra-decisiontools.org.uk/ethics/). This tool suggests that if the aim of the 
study is to generate generalisable knowledge, which COS are, then it is research rather than 
consultation, and therefore an ethics review is required.  Of note, if COS development 
claims the status of research rather than consultation, ethics consideration would be 
required for all participants, not just patients. 
 
A particularly prominent question among developers was whether COS should be 
developed internationally. This links to the intended reach of the COS recommendations. If 
the COS is intended to be used globally then this has implications for how COS are 
developed, who is involved in that process and the resources required. Considerations 
about efficiency and heterogeneity arise with global development, as well as 
generalisability. However, heterogeneity can be as great within countries as between so 
this should not serve as a barrier to internationally developed COS. In a letter to an editor 
in reference to the international HOME for eczema COS, it was pointed out that for a 
disease with global impact there was limited representation of non-western participants 
from countries where the societal burden of the disease is high [151]. If a COS is developed 
to have international applicability then there is an issue of inclusivity that needs to be 
addressed. The question of international representation in COS development is one that 
requires further research and insight. 
 
In this study, COS developers expressed concerns about the translation of questionnaires 
when multiple language participants are included, which could, in part be addressed by the 
literature on translation of instruments. Limited work has compared different techniques 
for translation of instruments, including back translation, forward translation and use of 
multiple methods [152]. The World Health Organisation (WHO) recommend an approach 
that uses both forward and back translation, input from experts, pretesting with target 
populations and methods of suggesting alternative wording and expressions [153].  
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International Society for Pharmacoeconomics and Outcomes Research (ISPOR) have also 
developed principles of good practice for the translation and cultural adoption process for 
patient reported outcome measures [154]. Researchers can decide which method suits 
their purpose, but research could be done to see whether the same techniques could be 
applied to questionnaires and surveys, such as those used in the Delphi method, about 
outcomes in the context of COS development.  
 
Implementation of a COS was seen as a key challenge by COS developers in this study. They 
described a lack of openness by gatekeepers to adopting COS, a general lack of 
understanding within the research community about how COS function and their benefits, 
and the importance of process issues such as the selection of participants, in influencing 
uptake. The link between appropriate stakeholder participation in development and 
subsequent implementation highlights the importance of considering implementation of 
the COS earlier on in the development process. Developers felt that COMET has a role in 
raising general awareness about COS. However, there is a shared responsibility in raising 
awareness and gaining interest in COS, as developers have a role in achieving this within 
their clinical and research communities. 
 
From their accounts, it seemed that some COS developers adopted what could be regarded 
as a rather passive approach to implementation.  Some did not seem to think much beyond 
publishing the COS, while others did think about implementation but saw this as something 
to address at a later stage of the COS development process. Developers’ accounts raise a 
complexity about impact and implementation of COS. However, the success of 
implementation is not just a product of the quality of developers work and efforts to 
publicise the COS and promote impact. The readiness of the target community is of utmost 
importance to its success, as demonstrated by some of the opposition faced from 
individuals and organisations in these developers’ accounts. Precedence should be given to 
devise strategies to convey the importance of COS and encourage relevant communities to 
implement them.  It is therefore critical to discuss implementation in any future COS 
development guidelines. 
 
Integral to the development and implementation of COS are questions about how far work 
in this area is valued by developers themselves and also by the wider community. For COS 
work to be successful it needs to be valued, yet the developers’ accounts pointed to ways 
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that COS activity is currently undervalued. This could be linked to the challenges of 
promoting understanding about COS, and to the unease that developers expressed around 
opinion based nature of COS work. With developers reporting peer reviewer comments 
such as ‘is it really science?’ (P8) and encountering disparagement because they ‘just asked 
people what items were important’, thought needs to be given to how the value attributed 
to COS work can be communicated and enhanced. This will be considered in the Discussion 
in Chapter 8.  
 
The absence of guidance in COS development, and the prominence of uncertainties, 
dominated COS developers’ accounts. There was an apparent distinction between 
published and ongoing developers’ attitudes towards the nature of guidance in this area, 
from one of seeking prescribed ways of doing COS work from published developers, to one 
of seeking guidance that promoted thought and good practice by ongoing developers. 
There was recognition amongst ongoing COS developers that context was very important, 
and that what worked for one COS development might not necessarily work for another. 
Developers saw a need for guidelines that identify commonalities across disease areas, and 
aid researchers to think about their own contexts and circumstances and how this 
influences what they do, as well as being aware of potential challenges and hurdles. Whilst 
a gold standard is aspirational, guidelines need to be practical, realistic and resource 
friendly. COS developers also commented that guidance on how to report COS work was 
currently lacking and would aid future COS developers.  COS developers understood that 
answers to methodological questions and uncertainties may not be immediately 
forthcoming, but felt that raising awareness of important areas and potential pitfalls in 
itself would be a significant contribution. It was particularly felt that guidance around the 
systematic review process, conduct of Delphi, and conduct of consensus meetings, were 
high priority. Guidelines for consensus meetings may well be found in other contexts or 
specialities, such as clinical guideline development and many of the issues with using this 
method may not be unique to COS development. This should be explored before work is 
undertaken to avoid unnecessary duplication.  As the most frequently used methods in 
current COS development, there is an impetus to conduct necessary research to answer 
questions about best practices for these methods and provide guidance to COS developers.    
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7.3.2 Robustness of the study  
 
Strengths of the study 
The strength of this study lies with the conduct and analysis of qualitative interviews to 
provide insight into, and a first in-depth account of, experience of COS development. The 
use of semi-structured interviews meant that I was able to cover specific topics of interest, 
whilst remaining flexible to adjust questions and change the direction of each interview as 
they were taking place. The survey responses in Chapter 5 had to be taken at face value, 
whereas responses to the interview questions could be clarified and expanded in the 
moment.  
The iterative nature of the analysis enabled me to incorporate new topics or questions into 
subsequent interviews. Furthermore, my use of framework analysis maintained a link 
between the original data and the conclusions drawn from it, thus adding to the 
trustworthiness of the conclusions drawn from the data.   
 
Due to the broad nature of the topic guide used, this study contributed to understanding 
about the complete process of COS development, which in turn has identified aspects 
where guidance or research will help to improve future COS developers’ experience and 
improve standards of COS development. Finally, by including the most up to date COS 
studies, that is, those published after 2010, as well as ongoing COS, the findings are 
relevant to present COS development, and indeed for future studies. In terms of the 
concept of catalytic validity, which refers to the usefulness of research and its potential for 
real world impact [137], the findings from this study point to priority areas for future 
methodological research, which in turn has the potential for a direct impact on future 
practice in COS development.  
 
Limitations of the study  
This study provides insight into the experiences of only those COS developers who agreed 
to be interviewed.  Furthermore, I identified ongoing COS developers through the COMET 
database, meaning that COS developers had already been in contact with the COMET 
Initiative to register their work in the COMET database. This sample could comprise a 
particular subset of COS developers and limit the transferability of the findings. 
Nonetheless, COS developers did represent a broad range of disease categories and COS 
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characteristics (methods used, stakeholders involved), supporting the transferability of the 
findings. It is, however, possible that this group of COS developers might have different 
experiences and views to those not interviewed.  
 
Furthermore, the existence of established contact with COMET could have influenced their 
responses, for example developers’ might have been more likely to provide idealised 
responses. As discussed in Chapter 6, it is possible that my association with the COMET 
Initiative may well have influenced the data. Lastly, the length and breadth of the interview 
topic guide meant that it was not always possible to cover every topic with every 
participant. 
 
7.3.3 Summary  
This study set out to generate a detailed description of COS developers’ choice of 
methodological approach, including the factors that have informed the ways in which 
researchers have developed COS, and to identify priority areas for future methodological 
research. It is clear that the COS developers who were interviewed found the process of 
COS development to be a challenging process, in part due to the nature of COS 
development being an emerging field of research, but also in part to not always considering 
important methodological details from the outset. This study provides the first insight into 
ongoing COS developers’ methodological decision making and their experiences in COS 
development in the current COS environment. The findings raise important questions and 
highlight areas that future research should focus on to solve ‘methodological mysteries’ 
and provide guidance for COS developers. Guidance needs to promote awareness of 
important issues; encourage COS developers to think about their own contexts and 
circumstances, and enable COS developers to make decisions about methods that best suit 
their needs and resources.   
 
The findings of this study can be combined with the systematic review findings (Chapter 3 
and 4) and survey of published COS developers (Chapter 5) to establish a research agenda 
and priorities for COS development guidance. These will be discussed in Chapter 8.   
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Chapter 8: General discussion 
 
8.1 Summary of findings  
COS are increasingly recognised as important for the design, conduct and reporting of 
randomised trials, systematic reviews and other forms of research. Accumulating work in 
the area of COS development has identified the need for general guidance on the 
development of COS. My principal aim in this thesis was to explore what influences COS 
developers’ choice of methodology and approach in COS development, and identify 
priorities for guidance and further research in this area. Several conclusions can be drawn 
from the work within this thesis. A summary of each chapter is provided below.  
  
When I started working on this thesis, COS were scattered across the health literature. A 
systematic review of COS was needed to bring these resources together in one place. This 
systematic review also enabled me to describe the methods developers had used 
previously, and also to help inform the later work in this thesis. In Chapter 2 I described the 
development of a search strategy to identify COS. This was particularly challenging due to 
the variability in the use of free text terms and index terms on reports of COS development, 
the absence of MeSH headings in MEDLINE or index terms in other bibliographic databases 
for identifying COS papers, and inconsistent categorisation across different databases. The 
search strategy that I developed for identifying COS was designed to be highly sensitive, but 
as a consequence a large number of records were retrieved, mostly irrelevant, and had to 
be assessed for suitability.  
 
In the systematic review of COS described in Chapter 3, I identified 198 published studies 
(250 reports) that described the development of COS for measurement and reporting in 
clinical trials. COS development is frequently described across a series of publications. This 
was the first time COS from all medical areas had been brought together in a single place. 
This is particularly important for COS to be successfully implemented as they need to be 
easily accessible to researchers and other key groups. The systematic review highlighted 
great variability in the ways that COS had been developed, particularly the methods used 
and the stakeholders included as participants in the process. Furthermore, key aspects of 
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the process were frequently not reported. A striking aspect of the results was the 
infrequency with which patient participants had been included in the development of COS. 
While the systematic review provided information about the range of methods that had 
been used to develop COS historically, in order to inform current practice it was important 
to know more about the methods that were being used presently. At the end of 2014, the 
COMET database included a total of 57 projects listed as ongoing COS studies. The most 
common combination of methods planned or used by these ongoing studies was a 
systematic review, together with a Delphi survey, followed by a consensus meeting. In 
Chapter 4 I therefore described additional data, from the systematic review, about studies 
that had used these specific methods. This chapter further demonstrated the variability in 
COS methodology and corroborated the conclusion of the main systematic review, 
reported in Chapter 3, that there is a need to improve the standards of reporting in these 
studies. The variability demonstrated by the review, and the absence of an accepted gold 
standard method for COS development, meant that further work was needed to explore 
this variation. I anticipated that it would be helpful if we understood developers’ rationale 
behind their methodological decisions; exploring choices of methodology and subsequent 
experience of those methods seemed important to inform how developers might be able 
to do this work better in the future. 
 
I used a mixed methods approach to further explore COS development, drawing on 
qualitative methods and an online web-based survey. I conducted an online survey with 
published developers identified in the systematic review of COS. The survey provided 
quantifiable information about developers’ experience, as well as the first insight into 
developers’ methodological decision making about choices of methods.  It also provided 
insight into developers’ experiences of doing this type of work, including the challenges 
that they encountered. The majority of survey respondents (73%) felt that there is a need 
for methodological guidance or research to inform future activity to develop COS, 
including: stakeholder involvement, patient involvement in particular; choice of 
methodology, and consensus formation.  
 
I undertook semi-structured qualitative interviews with a purposive sample of developers 
of published, as well as ongoing studies, and described the methods for this in Chapter 6. I 
decided to focus the qualitative study on more recent (published) and ongoing COS studies 
(unpublished studies), as my aim was to inform future guidelines for developing COS, and 
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so it was important to try and understand the current situation. One of the main findings, 
described in Chapter 7, was the variety of influences on developers’ choice of methods, 
which included the previous literature on COS development, expert advice, developers’ 
own experience with methods and the resources available to developers. The absence of 
guidance in COS development, and the prominence of uncertainties, dominated 
developers’ accounts. By exploring developers’ experiences inductively, I was able to 
provide the first in-depth description of developers’ choice of methodological approach. It 
has furthered our methodological understanding of COS development processes and 
enabled me to identify priority areas for future methodological research and guidance, 
which will be the main focus of the rest of this chapter.  
 
8.2 Comparison of COS developer survey and interviews 
Developers’ choices about methods were a focus in both the survey and the semi-
structured interviews. In both studies, developers presented multiple reasons for the 
methods they used. The influences on the choice of methods for COS development were 
largely consistent across both studies, with the following influences featuring prominently 
in both: previous work; expert advice; experience with methods, and resources. As might 
be anticipated, the interviews provided more detail than the survey about these influences 
and how they shaped COS development. For example, it was apparent from the interviews 
that developers did not always apply critical thinking about the methods used previously in 
the literature, or as advised by experts, before using them. This has important implications 
when the methods that have been used previously are not the most suitable methods. 
Furthermore, the previous use of methods has been in other contexts (e.g. to develop a 
COS for a different disease). This knowledge would not have been gleaned from the survey 
alone.  
 
Methodological decision making about COS development, as developers described it in 
their interviews, was informed by their previous experience of the methods generally, 
rather than specifically using the methods in the context of COS development. Although 
the response option for the question in the survey that related to experience referred to 
experience with methods for COS development, developers’ comments to accompany this 
response suggested that it was their general experience with methods, rather than 
knowledge of the methods within the specific context of COS development, that influenced 
their decisions about the methods they used. This is unsurprising given that COS 
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development is an emerging field.  Written comments accompanying the survey response 
option ‘Suited our situation and circumstances’ were more analogous to the accounts of 
interviewed developers who described basing their decisions about methods on 
pragmatism and opportunity.  
 
All of the developers who were interviewed described the challenges of COS development 
and many of these matched the challenges that developers reported in the survey, such as 
involving multiple stakeholders, defining consensus, implementation of the core set and 
working within available resources. The interview findings went beyond the short survey 
responses by pinpointing the detrimental impact of some of these challenges, such as the 
need to compromise methods due to resource limitations. Survey respondents identified 
‘How to measure core outcomes’ as a challenge, but this was not highlighted by developers 
in the interview study. Rather than seeing the findings as contradictory and having to give 
precedence to one or the other set of findings in order to reach a conclusion, I considered 
how my methods might have influenced these findings. One likely explanation is that I 
highlighted to the interviewees that the focus of my interest was on identifying what to 
measure, rather than how to measure, at the start of each interview. It was necessary to 
explain the emphasis of the interviews in order to focus developers’ accounts, but in doing 
so I might have limited developers’ responses to exclude their experiences about this 
equally important part of COS development. By not limiting the focus of the survey, these 
views were still captured.  
 
Some significant challenges were discussed in the interviews that did not feature strongly 
in the survey, including difficulties with ethical application procedures and requirements, 
and the complexities of international COS development. The former challenge was 
spontaneously mentioned by one developer at interview, and then incorporated in 
subsequent interviews. The latter challenge was an area that I had anticipated and included 
in the topic guide. Interviewees suggested that if a COS is developed globally then it has 
implications for how COS are developed, who is involved in the process and the resources 
required. Considerations about efficiency of process and generalisability of the results arise 
with global development. The interview study highlighted that the question of international 
representation in COS development is one that requires further research and 
understanding. One of the limitations of the survey was that I could not prompt for topics. 
However, the question about challenges included an open response to list up to five 
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challenges. Both the interview and survey therefore helped to give a comprehensive 
picture of the challenges involved in COS development.  
 
Only one survey respondent highlighted an absence of COS development guidance as a 
challenge. Sixteen survey respondents explicitly reported that they did not think there were 
any areas where guidance or research would benefit future activity to develop COS. 
However, 92 areas for guidance or research to inform future activity were listed by the 
remaining 57 survey respondents.  ‘How to measure’ was the most frequently suggested 
area that surveyed developers wanted guidance on. How to measure core outcomes did 
not feature as an area for guidance in the interview study, but, as mentioned above, this is 
likely due to the emphasis being placed elsewhere during the interviews. A collaboration 
between COSMIN and COMET has recently resulted in the development of a guideline on 
how to select outcome measurement instruments for outcomes included in a COS [52]. 
 
The other areas where surveyed and interviewed developers felt guidance or further 
research were needed were consistent, particularly stakeholder involvement, choice of 
methods, consensus methods and implementation. The interviews generated much more 
specific information to help in identifying priorities for future research, such as the 
mechanics of the Delphi process (e.g. how to feedback results to participants, whether to 
retain or discard outcomes between rounds, whether to combine different stakeholder 
groups) beyond simply defining consensus. The interviews also highlighted the need for 
guidelines about how to report COS studies. Although this was not mentioned by survey 
respondents, it is a gap supported by the systematic review of COS that highlighted poor 
reporting of COS studies.  
 
The interviews raised some important issues that were not seen in the survey. For example, 
developers’ described problems around participants understanding the nature of what they 
were being asked to do, but also questioned whether the problem was really that COS 
development had not been explained sufficiently rather than understanding being an 
insurmountable issue. Understanding of COS by the wider community was also raised as an 
issue by interviewees, which had implications for the uptake of the COS. Furthermore, 
these findings raise the possibility that difficulties with understanding about COS might be 
linked to the value – or lack of value - that people attribute to COS. Some interviewed 
developers did not seem to value the COS work in itself, but as useful or necessary to 
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complete in order to achieve a different aim.  Also relevant here was the unease that some 
developers expressed in their interviews about working with opinion based data. Surveyed 
developers similarly described a lack of data to support expert opinion as a challenge, as 
well as being the most frequently cited limitation of COS work. Due to the nature of the 
survey method, it was not possible to explore this issue further. However, by combining the 
survey and interview data we are able to glean more insight into this important issue of 
value; that developers’ perceived that an implication of working with opinion data might be 
a subsequent lack of value being attributed to the COS. 
 
Another interesting question raised by the interview study was about whether patient 
participation in COS development is participation in research or consultation in research. 
This question applies to all stakeholders who might participate in COS development. The 
distinction between involvement and participation is arguably not so clear in COS 
development, as participants in a Delphi exercise or consensus meeting are in a sense being 
consulted as experts about what outcomes to include based on their knowledge and 
experience of a health condition. As discussed in Chapter 7, The Health Research Authority 
offers a decision tool to determine whether a study requires Research Ethics Committee 
review (http://www.hra-decisiontools.org.uk/ethics/). If the aim of a study is to generate 
generalisable knowledge, then it is regarded as research rather than consultation, and an 
ethics review is required.  If COS development claims the status of research rather than 
consultation, ethics review would be required for all stakeholder participation, not just 
patients.  
 
8.3  Strengths and limitations  
The strengths and limitations in relation to each study have been discussed in detail in the 
relevant chapters. This section will focus on the overall strengths and limitations of the 
work presented in this thesis.   
 
COS development is an emerging field of research methodology. The work undertaken in 
this thesis has contributed to knowledge and has the potential to improve methodology for 
COS development. The identification and accumulation of COS to provide the evidence 
base for the COMET database is already proving to be a valuable resource for developers. It 
is important to acknowledge that the systematic review work provided the sample 
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population for the survey, and the published COS developer population for the interviews. 
The difficulty around identifying COS work in the published literature has been discussed 
extensively, but it is worth noting here that issues around searching could mean that 
relevant papers were missed, and therefore the populations in the proceeding survey and 
interviews were limited by this. The same can be said about the ongoing (unpublished) 
population that I drew from for the interviews, as these were developers already in contact 
with COMET. Other developers, not identified in the systematic review or in contact with 
COMET, could not have been included in this work.  
 
The mixed methods approach undertaken here to explore developers’ experiences of COS 
development is the first of its kind. The mixed methods approach allowed me to draw on 
the strengths of both methodologies and to provide a broader perspective on the overall 
issues. The interviews provided nuances that could not be captured in the survey alone.  
One limitation of the inclusion of open-ended responses in the survey, and the qualitative 
interviews, is the risk of idealised responses. That is, developers might have been inclined 
to say or write what they thought I wanted to hear, specifically when prompted during the 
interviews. There might also have been a difference in how developers articulated their 
choices in the survey and interviews, and how they made those choices in practice. This 
could work either way; those that described making uncritical COS development choices 
may have been more critical in practice than they alluded to and the reverse could also be 
true. 
 
8.4 Implications 
The thesis has identified several issues that are now being addressed by the COMET 
Initiative. These are discussed throughout section 8.4.  
 
 
8.4.1       Reporting guideline for studies developing COS  
The poor reporting of COS in the systematic review of COS, coupled with interviewed 
developers who expressed the absence of guidance on how to report findings, have 
confirmed the need for a reporting guideline for studies developing COS. Interviewed 
developers suggested that the credibility and success of a COS depends on the use of sound 
methodology in its development, and clear and transparent reporting of the processes 
adopted are required to demonstrate this. There is an increasing number of COS being 
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developed which makes this reporting guideline a priority, and to date no formal reporting 
guideline exists. A COMET research project, led by Jamie Kirkham (University of Liverpool), 
is now underway to develop a reporting guideline, along with an explanatory document to 
accompany the guideline [155]. The Core Outcome Set-STAndards for Reporting (COS-
STAR) is expected to be completed in 2016. This work follows the approach proposed by 
EQUATOR [82]. It builds on a preliminary checklist of issues to consider when developing a 
COS that was based mainly on experience of the COMET Management Group members  
[38].  
 
The survey also highlighted the importance of defining the scope of the COS; even if a COS 
has been developed rigorously it might not fit the required scope of the user. Scope needs 
to be well defined in reports of COS development to allow users to decide whether a COS 
matches their required scope. Failure to do so could result in the COS not being used, COS 
being used inappropriately or duplication of work to develop a similar COS for a specific 
scope. This is therefore an important criterion that should be included in reporting 
standards and any reporting guidelines for these types of studies to allow users to make 
this kind of decision. Items specific to clearly defining the scope of the COS have been 
included in the preliminary checklist of reporting items, to be considered for inclusion in 
the reporting guideline.  
 
8.4.2       Quality assessment of COS studies  
There is currently no way of determining or assessing the quality of COS studies and this 
work has corroborated the need for such an instrument. The survey has demonstrated that 
developers and users are making their own informal quality assessments and applying 
some criteria as to what they think makes a COS of good quality, such as patient 
involvement, and the level of methodological detail provided. However, without a standard 
means of assessing quality, individual judgements can result in different estimates of 
quality. In view of the continuing increase in the number of COS being developed, the 
development of a tool to determine or asses quality is a priority in COS research. As part of 
the COMET Management Group we have plans to develop a quality assessment tool. 
Discussions are underway about how we can best approach this and how one would define 
quality in the context of COS development. While the outcomes that are included in a COS 
cannot be subject to quality assessment, it is possible and desirable to assess 
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methodological quality of the process to develop a COS. Quality would therefore relate to 
the design of the study and the methods used, not the outcomes that are being 
recommended for measurement and reporting. We need to understand the 
methodological issues before we can make judgements about quality, so the results of the 
work in this thesis will be used to provide some insight into quality issues and criteria. One 
such example would be international elements of COS development. If the goal of the COS 
work is to get an international perspective, then of course international representation 
would be a mark of quality. However, if this is not the goal, or resource limitations mean 
that COS have to be developed at a more local or national level, then it is currently unclear 
how this transposes to quality. Further methodological research is needed, to answer some 
of the questions about methods posed by this research (a research agenda is presented in 
section 8.6), before we can adequately determine quality. The interviews carried out as 
part of this thesis also demonstrated that ‘a one size fits all’ approach to methods is not 
relevant for COS development, as different populations and disease areas have specific 
considerations. This makes the assessment of quality particularly challenging. The 
development of an instrument for quality assessment of COS studies remains a priority on 
the COMET research agenda.   
 
8.4.3       Funding COS development  
Both surveyed and interviewed developers expressed an overarching concern related to 
resource limitations, particularly the difficulty with obtaining funding for COS development. 
Interviewed developers were compromised in how they went about COS work as a 
consequence of limited funding. The acquisition of funding for COS work is therefore 
critical to avoid compromise in the methodology that could ultimately impact upon the 
final core set.  As such, it is vital to raise awareness about COS and the fact that resources 
are needed to develop them amongst research funding agencies.  Work is ongoing within 
the COMET Initiative to identify representatives from different countries who are best 
placed to start such communication with funders in their country. A pilot is underway, with 
a representative in Portugal, who has started the process of engaging the relevant 
Portuguese funding agency on COS development research. COMET can then learn from this 
pilot interaction to build an effective model for engaging research funding agencies. 
Guidelines should also comment on the important issue of obtaining funding for COS 
development.  
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8.4.4       A framework for outcomes categorisation  
The extensive systematic review that was undertaken as part of this thesis demonstrated 
the difficulty with categorising outcomes. The various ways of classifying outcomes and the 
current uncertainty around which of these is most suitable, coupled with the high number 
of studies included in the review, meant that it was too complex to categorise outcomes. 
Nevertheless, classification of outcomes into an agreed framework is highly desirable to 
help future developers think about potentially relevant outcomes. The existing frameworks 
for doing this were briefly described in Chapter 1 of this thesis, and it was clear that there is 
inconsistency between the different models. I therefore recommend a more formal review 
of the existing frameworks and schemes for categorising outcomes. An appraisal of existing 
methods would help to identify which, if any, of these existing frameworks and schemes 
are suitable for categorising outcomes. This would be of benefit to developers when they 
review the outcomes used in previous research as part of the COS development process. 
 
The COMET Management Group worked with Valerie Smith [29] to compare the review of 
outcomes from Cochrane reviews, with the outcomes recommended as core in those COS 
included in the systematic review reported in this thesis. Smith et al’s classification was 
amended based on similar outcomes across different categories and The Cochrane 
Collaboration is currently trialling that classification in two Cochrane Review Groups, with 
view to adopting an agreed framework for classification of outcomes. 
    
 
8.4.5       Implementation and uptake of COS  
COS developers who were interviewed as part of this study described implementation of 
the COS as a major challenge. Implementation of a COS was also presented as a challenge 
by developers in the survey. The majority (84%) of surveyed developers, when asked 
whether implementation or uptake was considered during COS development, answered 
that it was. Those who answered ‘no’ indicated that they saw implementation as beyond 
the scope of COS development, or that funding was not available. Both studies also 
indicated that monitoring the uptake of COS will be challenging.   
 
To my knowledge only two studies have examined the impact of COS, and each have 
focussed on particular COS. Kirkham et al. [156] carried out an observational review of 
rheumatoid arthritis trials identified through the Cochrane Library, and evaluated whether 
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or not there were trends in the proportion of trials reporting the full COS over time. 
Findings indicated an upward trend in the proportion of trials reporting on the full 
rheumatoid arthritis COS. The study examined published trial reports but the method 
proved to be lengthy. Furthermore the study did not include data about recent trials, or 
indeed that were currently underway. [157]. Bautista-Molano et al. [158] carried out a 
systematic literature review to investigate how well a COS for ankylosing spondylitis had 
been implemented in clinical trials according to the type of intervention. Similarly, an 
increase over time was reported. 
 
COS have the potential to improve the evidence base for health care, but consideration 
must be given to the methods for disseminating their availability amongst the relevant 
communities. With the number of COS in development on the increase, it is timely to 
examine the level of uptake of a wider range of COS to identify an efficient and effective 
way of monitoring uptake. An MRC HTMR studentship has recently commenced to develop 
an efficient approach to assessing COS uptake with results based on up to date information 
[157].  
 
8.5 Methodological guidance for COS development  
In addition to the areas already discussed in this chapter, this work has demonstrated an 
urgent need for methodological guidance and research to inform future COS development. 
As discussed in Chapter 7, guidance needs to promote awareness of important issues, 
encouraging developers to think about their own contexts, which will in turn support 
developers to make methodological decisions that suit their needs and resources. Some of 
the issues raised might not be unique to COS development, therefore there is a need to 
look to other disciplines and applications to see what can be learnt from existing research. 
Methodological guidelines for some aspects of COS methods, such as Delphi or consensus 
meetings, may well be found in other contexts such as clinical guideline development. This 
should be explored to avoid unnecessary duplication.  
 
8.5.1       A platform for methodological guidance and research   
COS development guidance and methodological research need to be freely available and 
accessible to developers. The COMET Initiative are developing a handbook which brings 
together existing research about COS development.   The previous issues to consider as 
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highlighted by Williamson et al [38] will be expanded upon, as well as the inclusion of 
additional issues identified since their publication. This expansion will be informed by the 
work in this thesis. The work undertaken here has identified how developers have tackled 
the challenges of COS development, such as the inclusion of patient participants in the COS 
development process. This work has also shown that patient participation in COS 
development has increased, and although it was not originally commonplace, the majority 
of COS now include patient participation and there is agreement that this is an important 
component. The question is therefore no longer whether patients should participate, but 
rather the nature of that involvement (see Table 38 below). Interviewed developers’ 
experiences will be incorporated to provide examples of successful or unsuccessful 
strategies.  The handbook will serve as a resource for developers, and will be updated as 
new data, evidence and guidance emerges. Because it takes time for new evidence to be 
published, there is a need for this new information to be made immediately available.  
 
Access to the COMET Initiative website continues to increase and COS awareness is 
growing internationally [144]. The COMET website is therefore ideally placed to host a 
dynamic platform for methodological guidance and research. Similar to the existing COMET 
database that contains published and ongoing COS, a methodological database could be 
developed to include both published and ongoing material. Furthermore, known gaps in 
research or methodological uncertainties could also be listed with a contact link to enable 
individuals or groups to make suggestions or proffer assistance to address unanswered 
questions. The inclusion of work ongoing and unanswered questions would be particularly 
important, because as one COS interviewed developer commented, ‘answers to 
methodological questions and uncertainties may not be immediately forthcoming, but 
raising awareness of important areas and potential pitfalls in itself would be a significant 
contribution’.  
 
 
8.5.2       Research within research  
One way to address uncertainties about COS development may be through research within 
research. SWAT studies, a Study Within a Trial, have been suggested as a way of addressing 
uncertainty in methods for doing trials [159]. Similarly nested studies within COS 
development could answer important questions. For example, randomised controlled trials 
were nested within the development of three core sets (each including a Delphi process 
with two rounds of questionnaires completed by patients and health professionals) to 
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examine the impact of receiving feedback from different stakeholders on the subsequent 
rating of items and level of consensus between stakeholders [160]. Studies within studies 
to answer research questions will be an efficient and timely way to address research 
uncertainties. It is unlikely that the COMET Initiative will have the resources to conduct all 
of the necessary research, but it might be possible for advisors within the COMET team to 
develop protocols for priority methodology research that developers could then execute. 
These protocols could also be made available in a methodology database, minimising 
unnecessary duplication of work and facilitating collaborative efforts. The use of studies 
nested within COS projects to help resolve uncertainty will generate the evidence needed 
to support well informed decisions about COS development methods.  
 
 
8.6 Proposed research agenda and future work  
This thesis has identified areas of uncertainty in COS and provided topics for focus for 
further research to resolve these uncertainties. Taken together the findings from the 
systematic review, survey and interviews point to the following as questions where further 
research is required:  
1 Stakeholder involvement  
1.1 How can COS developers know and demonstrate that the people sampled are ‘the right’ 
people? 
1.2 How can COS developers incorporate diversity within stakeholder samples? 
1.6 Do different stakeholder groups understand the nature of COS and what they are being 
asked to do, and does this matter? 
1.3 How can response rates be improved?  
1.4 How can participation be maintained? 
1.5 
1.6 
How can COS developers reconcile different stakeholder groups’ opinions? 
Is stakeholder input in COS development participation in research or consultation in 
research? 
2 How can patient participation in COS development be improved?  
2.1 Do patient participants understand the nature of COS and what they are being asked to 
do, and does this matter?  
2.2 Should COS developers involve patient advocates, patient participants, or both?  
2.3 Is patient input in COS development participation in research or consultation in research?  
2.4 Are there specific challenges of including certain participants such as children and young 
people as participants in COS development?** 
2.5 How can participants such as children and young people be included effectively as 
participants in COS development?** 
3 Systematic review of outcomes  
3.1 What studies should be included?  
3.2 What are the rules or thresholds for this type of review? 
3.3 How should outcomes be categorised?  
4 Delphi methodology 
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4.1 How should consensus be defined?  
4.2 How should feedback be given to participants, and how does feedback affect responses?  
4.3 Should outcomes be retained or discarded between rounds?  
5 Consensus meetings  
5.1 How should consensus be defined? 
5.2 How should a consensus meeting be conducted?  
6 General  
6.1 How general or specific should the scope of a COS be? 
6.2 What ethics requirements are necessary for COS development? 
6.3 Should COS be developed internationally? 
6.4 How should questions about outcome prioritisation be framed (i.e. should the question 
asked be about which outcomes are important or which outcomes are core?)? 
 
As more developers are now including patient participants in COS development, in Table 38 
I have explored how uncertainties about patient participation and involvement might be 
addressed through further research. I have also considered how the COMET Initiative might 
actively support and facilitate this further research.    
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Table 38: Methodological uncertainties in patient participation and involvement  
 
 Research question  Research examples Example of how COMET might help 
2 How can patient participation in COS 
development be improved? 
(1) A systematic review of existing patient participation 
methodology research, not exclusive to COS 
development, to see what can be learnt from existing 
research. For example, de Wit has published work on 
patient participation in the development of PROs in the 
area of psoriatic arthritis [161]. Here, the authors 
summarise facilitators for effective involvement of 
patients in PRO development.   
(2) Interviews with patient participants who have been 
involved in COS development to understand their 
experiences of the process, and find out what they think 
was done well and what was not done well.  This would 
highlight the distinctive challenges of COS development 
in relation to patient participation.  
(3) There is intrinsic value in including the patient in health 
research, but it is important to evaluate its impact [162]. 
Case studies could address the impact PPI has in the 
design, development and dissemination of a COS study.  
 
- List the research gap/question in a methodology database with a 
contact link to enable individuals or groups to make suggestions or 
proffer assistance to address unanswered questions. 
- Develop proposals or protocols to address research questions, with 
input and advice from the COMET Initiative People and Patient 
Participation Involvement and Engagement (PoPPIE) Working Group*. 
- A repository for resources. As an example, the work in this thesis 
highlighted that recruitment was more successful when researchers 
had a way of accessing patient participants, such as through patient 
groups. ISPOR have ‘tools for patients’ including a list of patient 
organisations worldwide: 
http://www.ispor.org/Patients/PatientOrgWorldwide.asp 
This, and resources like it, should be identified and included as part of 
COMET resources. Guidance in this area might suggest that patient 
groups are useful in thinking through strategies to improve patient 
participation, but should not be considered as the only method of 
recruitment due to issues around self-selection of members and a 
potential lack of representativeness.  
2.1 Are there specific challenges of including 
children and young people as 
participants in COS development?** 
(1) Interviews with COS developers about these specific 
issues.  
(2) Qualitative work with children and young people about 
their experience of being involved in COS work, or their 
opinion about whether they think they would be able to 
participate in COS development.   
(3) A systematic review of broader literature to explore 
whether work has been done to develop consensus with 
children and young people in other areas, for example in 
social sciences or education. What lessons can be 
learned from other areas? 
- Identify published or prospective COS studies that have involved 
children and young people, and facilitate communication between 
COS developers and researchers.  
2.2 How can children and young people be 
included effectively as participants in 
COS development?** 
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2.3 Do patient participants understand the 
nature of COS and what they are being 
asked to do, and does this matter?***  
(1) Qualitative research to explore how people talk about outcomes – we 
need to understand the language that people use to talk about 
outcomes as they do not tend to use the word ‘outcome’.  This could 
potentially be addressed by exploring how people discuss outcomes in 
social media.  
(2) Jepson et al  found that when trial recruiters explained randomisation 
to patients, patients wanted to know ‘why’ they were being randomised 
above all else [163]. A survey of COS developers could be conducted, 
about how COS and instructions are given to patient participants, to 
identify how a COS as a concept is explained. A survey could also be 
carried out with corresponding patient participants to see how the 
concept of a COS was understood. This would help to highlight whether 
the focus is on patients’ understanding or developers’ ability to explain 
clearly and meaningfully to patients.  
(3) A randomised study within COS development to explore different ways 
of explaining COS to patient participants and the impact this has on 
patient participants’ understanding and participation.  
- Develop guidance about how COS should be described 
for patients. This might include materials that will help 
to facilitate researchers’ discussions of COS. The use of 
audio-visual aids (e.g. a video) for recruitment would 
mean that basic information is delivered consistently 
every time. Personalisation of information should also 
be considered and ways of responding to 
individualised questions and needs for information.  
2.4 Should COS developers include patient 
advocates, patient participants, or both?  
(1) Review the literature in more detail to identify how patient 
participation has been conducted to date, particularly in ongoing COS 
development. The ethical approval requirements for COS development 
should also be considered.  
(2) A Delphi process including COS developers and COS patient participants 
could be undertaken to agree an optimum model for involving the 
patient in COS development. This might include the stage of 
development as well as the number, or proportion, of participants that 
should be included at each stage.   
- Draw on the experience of PoPPIE group members of 
patient participation and involvement in research to 
provide guidance.  2.5 Is patient participation in COS 
development considered to be 
participation in research or consultation 
in research?  
*  PoPPIE is a Working Group set up to lead and oversee the patient participation, involvement and engagement work of the COMET Initiative. They held their inaugural meeting in November 
2015 to discuss the importance of patient and public involvement in developing and overseeing core outcome set studies and the wider activities of patient and public engagement in relation 
to the work of the COMET Initiative.   
 
** As discussed in Chapter 6, whilst there might be important or distinctive methodological considerations for adults with additional needs (e.g. older adults, people with learning disabilities) 
as well as for children, the number of studies in the review was too few to make this a specific focus of the work in this thesis. Therefore, methodological considerations for other groups is a 
necessary area of exploration for further research.  
 
*** The interviews with developers highlighted that problems with understanding outcomes and COS was not exclusive to patients. Therefore, the issue of understanding should be explored 
with other stakeholder groups as well as patients.   
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8.7 Improving the search for COS 
The COS identified in the systematic review chapter have formed the basis of an online 
searchable database. A short pop-up survey in 2015, to ascertain why people were 
searching the COMET database, showed that the most common reasons for searching the 
database were to inform decision making about developing a COS, or to inform the 
outcomes in planning a clinical trial [164]. The database was also searched by systematic 
reviewers, funders of COS and trials, and people who had been asked to take part in the 
development of a COS study. The results of the pop up survey, in particular that people 
thinking about developing a COS are checking the COMET database to see whether a COS 
exists in their area of interest to avoid duplication, emphasise the importance of keeping 
the database current. To achieve this, the search for COS needs to be performed on a 
regular basis.  
 
The challenges of performing this search have been discussed extensively in this thesis. One 
way of addressing these challenges would be the introduction of a COS MeSH term in 
MEDLINE and other bibliographic databases for identifying COS papers. However, the 
inclusion of a new MeSH term in itself might be a challenge. MeSH is the National Library of 
Medicine’s controlled vocabulary thesaurus, who state that before a new descriptor is 
introduced, consideration must be given to how much is published about that topic; if little 
is published the Library see little purpose or advantage in creating a new descriptor in a 
vocabulary which has to encompass the subject content of the entire published literature 
[165]. Although COS development is a growing area of research, it is relatively niche when 
compared to the broad nature of most medical subject headings. It is therefore probable 
that the proposal of a COS heading is unrealistic at this time.   
 
In the absence of a COS MeSH term, standards for reporting, as described in section 8.4.1, 
could help with the searching and identification of COS development studies. The use of 
standardised terms, for example ‘core outcome set’ in the title and abstract would make it 
much easier to identify appropriate COS development papers. Although under 
development, it will take some time for the production, publication and adoption of the 
reporting guideline for COS development studies to benefit the searching of these papers. 
In the interim, I therefore recommend a review of the current search strategy to see where 
improvements can be made immediately. The  systematic review of COS has already been 
updated once [164], and a second update is underway, both using the original search. As 
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with the original search, the update proved to be resource intensive due to the large 
retrieval of records that need assessing. I recommend a review of the language used in the 
COS papers identified in the updated searches, to see if there is already a trend towards 
using more consistent language to describe COS development. A comparison could then be 
performed with the search terms to see where improvements could be made. If accuracy 
could be retained whilst significantly reducing the number of hits, and therefore the 
amount of irrelevant material needed to read, this would be advantageous to maintaining 
an up to date database of COS.     
 
8.8 Wider implications  
The ‘E’ in COMET stands for effectiveness, and that has been the focus of the work 
undertaken in this thesis. However, COS should not be completely disparate to clinical 
practice. Outcomes that are important in effectiveness trials and research might be 
important for routine clinical practice and vice versa. The potential for using electronic 
health records in health research have been well documented [166], and there is a growing 
interest in e-trials using health records to collect outcome data. The inclusion of core 
outcomes in routine health records should therefore be considered to maximise efficiency 
in e-trials. Although presently very few trials run entirely based in routine health records, 
this is a vision for the future. As such, consideration of including core outcomes in routine 
health records now will help towards achieving this vision whilst avoiding future 
complications. There is also a need to critique e-trials where a COS exists, but that have 
been run from the health record alone and may not have included the most important 
outcomes. E-trial designers need to think carefully about the outcomes included in routine 
collection. For all trials, researchers should start by looking at the COMET database to see 
whether a COS exists. If there is a COS, a cross-check could be performed to see whether 
the routine health record collects data on those outcomes. If it does not, then researchers 
should consider how best to collect the missing information. There is an overall need to 
collaborate on health research and clinical practice infrastructure, working towards 
agreement about what is important to measure, collect and report routinely.  
 
The importance of COS methodology can also be seen from its potential application to 
other areas. For example, similar methodology has recently been applied to develop core 
information sets for the disclosure of information in consultations with patients before 
surgery [167]. The use of core information sets to help patients understand what to expect 
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from surgery demonstrates the significance of the methodology used to arrive at this core 
set. Methodology used to develop core information sets might be improved as direct result 
of the work described in this thesis. Additionally, future work to develop core information 
sets might also provide additional opportunities to answer methodological questions of 
relevance to COS development.  
 
The value that is placed on COS is of utmost importance to their success. There was 
evidence of some interviewees attaching little value to their COS development work, as 
well as struggling to gain acceptance of their work within their wider communities. The 
work undertaken in this thesis has suggested that value is linked to understanding about 
COS, as well as the unease that comes with working with opinion based data. Whist 
guidance and further research around methods will go some way to help increase the 
perceived value of COS; guidance alone will not foster value. To enhance the value 
attributed to COS development we might be able to learn from analogous examples, such 
as the increased emphasis on PPI in health research in the last decade. PPI has increased in 
perceived value, and it would be advantageous to consider how this has been achieved and 
if there are any lessons for COS development. One explanation is the backing that PPI 
received from important stakeholder groups, organisations and influential individuals. For 
example, a report commissioned by Cancer Research UK [168], evaluating the current state 
of research in the NHS, described the NIHR as having a central and enabling role in the 
increased involvement of patients in research. This demonstrates the importance of the 
role of research funders, such as NIHR, in the transformation of research practices. 
Furthermore, the support of individuals such as the Chief Medical Officer (Dame Sally 
Davies) has also given value to PPI in health research [169].  Funders of research are 
starting to acknowledge the importance of COS, with  the NIHR HTA  programme in the UK, 
the Health Research Board in Ireland and the charity Arthritis Research UK, now 
encouraging applicants to consider COS when seeking funding for new trials. As described 
in section 8.4.3, COMET is undertaking work to advance engagement with funders.   
Furthermore, groups like CROWN now have over 70 journals involved  that are committed 
to promoting the uptake of COS in the area of women’s health [170], are likely to add value 
to COS in that disease area. As CROWN is a new initiative, the impact will need to be 
evaluated in time; but, if successful, this might be a model that other areas could replicate. 
Understanding how the perceived value of COS can be increased will facilitate the 
development and application of COS in health research.  
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8.9 Final summary  
To make well informed decisions about healthcare, we need to be able to compare and 
contrast research findings on the basis of the same outcomes. COS represent the minimum 
important outcomes that should be measured and reported in all trials for a specific 
condition.  For COS to be successfully implemented, they need to be easily accessible to 
researchers and other key groups, developed using rigorous methods, and reported clearly. 
The work in this thesis has contributed to that goal by bringing COS together in one place 
for the first time. These results provide the first comprehensive account of COS 
development, and will inform the formulation of much needed guidance in this area, thus 
improving COS development methodology. The use of COS in research means that all trials 
in a given area of health are measuring and reporting the agreed important outcomes. This 
will improve the quality of evidence used in health care decision making, ultimately 
translating to improved health care for patients. It is therefore critical that COS are 
developed in the best possible way. The answers to the methodological questions and 
uncertainties posed by this research may not be immediately forthcoming, but by raising 
awareness of important areas and potential pitfalls, the work undertaken in this thesis will 
make a valuable contribution to COS knowledge and future research. 
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Appendix 1: Search strategies used in the systematic review of core outcome sets  
 
Search terms for MEDLINE  
 
Number of hits 
(searched 
August 2013) 
 Randomised trial and systematic review terms  
1 Health Services/ut [Utilization] 5742 
2 registries/ 45459 
3 systematic review.mp. 28277 
4 structured review.ti. 108 
5 evidence based medicine.ab. 4843 
6 exp Clinical Trials as Topic/ 258536 
7 clinical trial$.ab. 149831 
8 randomised controlled trial$.ti,ab. 16321 
9 randomised trial$.ti,ab. 9858 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 444510 
 Methodology terms  
11 workgroup$.mp. 757 
12 standard$ outcome$.mp. 519 
13 Practice Guideline/ 16919 
14 clinical database.mp. 908 
15 patient important outcome$.mp. 78 
16 (standard$ adj3 reporting).mp. 1999 
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17 congresses.pt. 57907 
18 Delphi Technique/ 2274 
19 (recommend$ adj3 outcome$).mp. 1062 
20 consensus development conference.pt. 8085 
21 outcome$ reporting.mp. 267 
22 priorit$ symptom$.mp. 23 
23 (task force adj3 outcome$).mp. 49 
24 appropriate outcome$.mp. 338 
25 research design/ 67019 
26 endpoint determination/ 3416 
27 consensus development conference/ 8085 
28 patient participation/ 16143 
29 consensus.mp. 93957 
30 workshop.mp. 17486 
31 Consensus Development Conferences, NIH as Topic/ 314 
32 focus groups/ 13711 
33 
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 
279051 
 Outcome terms   
34 outcome$.mp. 1156289 
35 end point$.mp. 32706 
36 (core adj3 set).mp. 1510 
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37 treatment emergent problem$.mp. 1 
38 exp outcome Assessment Health Care/ 593962 
39 Treatment Outcome/ 535004 
40 Quality of Life/ 101029 
41 34 or 35 or 36 or 37 or 38 or 39 or 40 1256710 
 Key terms targeted   
42 clinical-study design.mp. 82 
43 patient$ perspective$.ti. 1387 
44 outcome$.mp. and delphi.ti. 153 
45 (outcome$ and delphi).ab. 624 
46 (perspective$ adj3 outcome$).ti. 102 
47 core outcome$.ti,ab. 121 
48 core set$.ti,ab. 1124 
49 clinical trial design$.ti. 355 
50 design$ clinical trial$.ti. 72 
51 (consensus and outcome$).ti. 133 
52 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 3931 
53 10 and 33 and 41 12607 
54 52 or 53 16079 
Search terms for SCOPUS  
 
 
((((INDEXTERMS(registries)) OR (INDEXTERMS(clinical trials as topic)) OR 12286 
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(ABS("evidence based medicine")) OR (ABS("clinical trial*")) OR 
(INDEXTERMS("Health Services Utilization")) OR (TITLE-ABS-KEY("SYSTEMATIC 
REVIEW")) OR (TITLE("structured review"))) OR (TITLE OR ABS("randomised 
controlled trial*")) OR (TITLE OR ABS (randomised trial*))) AND (((TITLE-ABS-
KEY(workgroup*)) OR (TITLE-ABS-KEY(standard* outcome*)) OR 
(INDEXTERMS(practice guideline)) OR (TITLE-ABS-KEY("clinical database")) OR 
(TITLE-ABS-KEY("patient important outcome*")) OR (TITLE-ABS-KEY("standard* 
outcome*")) OR (INDEXTERMS(delphi technique))) OR ((TITLE-ABS-
KEY(recommend* W/3 outcome*)) OR (TITLE-ABS-KEY(standard* W/3 
reporting*)) OR (TITLE-ABS-KEY(task force W/3 outcome*)) OR (TITLE-ABS-
KEY("appropriate outcome*")) OR (TITLE-ABS-KEY("outcome* reporting")) OR 
(TITLE-ABS-KEY("priorit* symptom*")) OR (INDEXTERMS(focus group)) 
(INDEXTERMS(research design))) OR ((INDEXTERMS(endpoint determination)) 
OR (INDEXTERMS(consensus development conference)) OR 
(INDEXTERMS(patient participation)) OR (TITLE-ABS-KEY(consensus)) OR (TITLE-
ABS-KEY(workshop)))) AND 74) OR (((TITLE("design* clinical trials")) OR 
(TITLE(consensus AND outcome*)) OR (TITLE-ABS-KEY("clinical-study design")) 
OR (TITLE("patient* perspective*")) OR (ABS(outcome* AND delphi)) OR 
(TITLE(outcome* AND delphi)) OR (TITLE(perspective* W/3 outcome*)) OR 
(ABS("core outcome*") OR TITLE("core outcome*"))) OR ((ABS("core set*") OR 
TITLE("core set*")) OR (TITLE("clinical trial design*")))) 
 
Search terms for The Cochrane Library    
 
 
 Randomised trial and systematic review terms   
#1 (clinical trial*):ab  58990 
#2 MeSH descriptor Health services  750 
#3 MeSH descriptor registries  604 
#4 (systematic review ):ti,ab,kw  13816 
#5 (structured review ):ti  6890 
#6 (evidence based medicine ):ab  681 
#7 MeSH descriptor Clinical Trials as Topic explode all trees  1117 
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#8 (randomised controlled trial):ti or (randomised controlled trial):ab  79593 
#9 (randomised trial*):ti,ab,kw  158334 
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)  126425 
 Methodology terms   
#11 (workgroup*):ti,ab,kw  24 
#12 MeSH descriptor Practice Guideline  1221 
#13 (patient important outcome*):ti,ab,kw  3977 
#14 (clinical database):ti,ab,kw  2335 
#15 standard* NEAR/3 reporting  2310 
#16 (congresses):pt  45 
#17 MeSH descriptor Delphi Technique explode all trees  33 
#18 recommend* NEAR/3 outcome  309 
#19 (consensus development conference):pt  4 
#20 (priorit* symptom*):ti,ab,kw  964 
#21 (task force NEAR/3 outcome*):ti,ab,kw  4 
#22 (appropriate outcome*):ti,ab,kw  2528 
#23 MeSH descriptor Focus Groups explode all trees  232 
#24 MeSH descriptor Research Design  1811 
#25 MeSH descriptor endpoint determination  61 
#26 MeSH descriptor consensus development conference  570 
250 
 
#27 MeSH descriptor patient participation  354 
#28 (consensus):ti,ab,kw  2049 
#29 (workshop):ti,ab,kw  955 
#38 "standard outcome*":ti,ab,kw 27 
#39 "outcome* reporting":ti,ab,kw 191 
#37 
(#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 
OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #38 
OR #39)  
14699 
 Outcome terms   
#30 (outcome*):ti,ab,kw  143278 
#31 (end point*):ti,ab,kw  12764 
#32 (core NEAR/3 set):ti,ab,kw  82 
#33 (treatment emergent problem*):ti,ab,kw  25 
#34 MeSH descriptor Outcome Assessment (Health Care) explode all trees  81711 
#35 MeSH descriptor Treatment Outcome  1957 
#36 MeSH descriptor quality of life  1517 
#40 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36)  151831 
#41 (#10 AND #37 AND #40)  7096 
 Key terms targeted   
#42 (design* clinical trials):ti  541 
#43 (clinical-study design):ti,ab,kw  2081 
#44 (patient* perspective*):ti  161 
251 
 
#45 (outcome*):ti and (delphi):ti  0 
#46 (outcome*):ab and (delphi):ab  62 
#47 (perspective* NEAR/3 outcome*):ti  5 
#48 (core outcome*):ti or (core outcome*):ab  616 
#49 (core set):ti or (core set):ab  383 
#50 (clinical trial design*):ti  541 
#51 (outcome):ti and (consensus):ti  8 
#52 (#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51)  3674 
#53 (#41 OR #52)  10572 
#54 
(#53) 
In Methods Studies  
1082 
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Appendix 2: Studies included in the systematic review (250 reports relating to 198 
studies)  
 
Study  Disease category Disease name  Journal  
Dixon 1987 [171]** Cancer  Hodgkin's disease and 
lymphoma 
Journal of Clinical 
Oncology 
Glynne-Jones 2006 
[172]** 
Cancer Rectal cancer Annals of Oncology 
Auvinen 1996 [173]** Cancer Prostate cancer Journal of Medical 
Screening 
Denis 1997 [174]* Cancer  Prostate cancer (early 
stage) 
Urology 
Scher 2004 [175]* Cancer Prostate cancer (rising 
prostate-specific antigen) 
Journal of Clinical 
Oncology 
Dawson 1998 [176]* Cancer Prostate cancer  Journal of Clinical 
Oncology 
Middleton 1995 [177] 
Schellhammer 1997 [178] 
** 
Cancer Localized prostate cancer  Journal of Urology 
Urology 
Rajkumar 2011 [179]* Cancer Myeloma  Blood 
Chow on behalf of 
International Bone 
Metastases Consensus 
Working Party [180]* 
Chow 2002 [181] 
Cancer Bone metastases  Clinical Oncology (Royal 
College of Radiologists) 
Radiotherapy & Oncology 
Partsch 2010 [182]* Cancer Breast cancer related 
lymphedema (BCRL) 
International Angiology 
Hesketh 1998 [183]* 
Tonato 1998 [184] 
Cancer Chemotherapy-induced 
nausea and vomiting 
Supportive Care in 
Cancer 
Mcvie 1992 [185]* Cancer Chemotherapy-induced 
nausea and vomiting 
Drugs 
Pallis 2011 [186]** Cancer Solid tumours  Annals of Oncology 
Miller 1981 [41]** Cancer Cancer (not specified) Cancer 
Prorok 2010 [187]* Cancer Cancer (not specified) Seminars in Oncology 
Punt [188]** Cancer Colorectal cancer Journal of the National 
Cancer Institute 
Wils 1998 [189]** Cancer Colorectal cancer 
(advanced) 
Tumori 
Llovet 2008 [190]* Cancer Hepatocellular carcinoma Journal of the National 
Cancer Institute 
Pagliusi 2004 [191]** Cancer Human papillomavirus 
(Cervical cancer) 
Vaccine 
Lefebvre 2009 [192]* Cancer Head and neck cancer International Journal of 
Radiation Oncology, 
Biology, Physics 
Adelstein 2012 [193]* Cancer  Head and neck cancer  Head & Neck 
Gridelli 2004 [194]* Cancer Advanced non-small-cell 
lung cancer 
Annals of Oncology 
Gridelli 2012 [195]* Cancer Advanced non-small-cell 
lung cancer 
Lung Cancer 
Cheson 1999 [196]** 
Cheson 2007 [197] 
Cancer Non-Hodgkin's 
lymphoma 
Journal of Clinical 
Oncology 
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Study  Disease category Disease name  Journal  
Anderson 2008 [198]** Cancer Leukaemia  Leukemia 
Cheson 2003 [199]* Cancer  Acute Myeloid 
Leukaemia 
Journal of Clinical 
Oncology 
Kulke 2011 [200]* Cancer Neuroendocrine tumours Journal of Clinical 
Oncology 
Bellm 2002 [201]** Cancer Oral Mucositis (OM) Cancer Investigation 
Du Bois 2005 [202]* 
Stuart 2011 [203] 
Thigpen 2011 [204] 
Cancer Ovarian cancer Annals of Oncology 
International Journal of 
Gynecological Cancer x2  
Comenzo 2012 [205]* Cancer Systemic light-chain 
amyloidosis 
Leukemia 
Dorman 2009 [206]* Cancer Dyspnoea or 
Breathlessness in 
Palliative Care 
Palliative Medicine 
Renal Disease 
Subcommittee of the 
American College of 
Rheumatology Ad Hoc 
Committee on Systemic 
Lupus Erythematosus 
Response Criteria [207]* 
Rheumatology Systemic lupus 
erythematosus 
Arthritis & Rheumatism 
Bertsias 2009 [208]* 
Gordon 2009 [209] 
Rheumatology Systemic lupus 
erythematosus 
Annals of the Rheumatic 
Diseases 
Smolen 1999 [210]** Rheumatology Systemic lupus 
erythematosus 
Journal of Rheumatology 
Ruperto 2003 [211]** Rheumatology Juvenile systemic lupus 
erythematosus and 
juvenile dermatomyositis 
Rheumatology 
White 1995 [212]* Rheumatology Systemic sclerosis  Arthritis & Rheumatism 
Khanna 2008 [213]** Rheumatology Systemic sclerosis Annals of the Rheumatic 
Diseases 
Clements 2012 [214]* Rheumatology Systemic sclerosis - 
related arthritis 
Seminars in Arthritis and 
Rheumatism 
Khanna 2010 [215]* Rheumatology Systemic sclerosis-
associated interstitial 
lung disease 
Clinical & Experimental 
Rheumatology 
Merkel 2009 [216]** 
Merkel 2011 [217] 
Rheumatology Small-vessel Vasculitis/ 
ANCA-associated 
Vasculitis 
Journal of Rheumatology 
Hellmich 2007 [218]* Rheumatology Systemic vasculitis, AAV, 
anti-neutrophil 
cytoplasmic antibody-
associated vasculitis; 
Wegener’s 
granulomatosis 
Annals of the Rheumatic 
Diseases 
Felson 1993 [219]** Rheumatology Rheumatoid arthritis Journal of Rheumatology 
Fried 1993 [220]** 
Tugwell 1993 [221] 
Boers 1994 [42] 
Kirwan 2003 [45] 
Kirwan 2005 [44] 
Kirwan 2007 [46] 
Rheumatology Rheumatoid arthritis Journal of Rheumatology 
Sanderson 2010 [222]** 
Sanderson 2010 [223] 
Rheumatology Rheumatoid arthritis Arthritis care & research 
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Study  Disease category Disease name  Journal  
Bombardier 1982 [224] 
** 
Rheumatology Rheumatoid arthritis Journal of Rheumatology 
Scott 1989 [225]** Rheumatology Rheumatoid arthritis Annals of the Rheumatic 
Diseases 
Van Riel 1992 [226]** Rheumatology Rheumatoid arthritis British  Journal of  
Rheumatology 
Taylor 2005 [227]** 
Gladman 2005 [228] 
Gladman 2005 [229] 
Gladman 2007 [230] 
Rheumatology Psoriatic arthritis Annals of the Rheumatic 
Diseases x3 
Journal of Rheumatology 
Miller 2001 [231]** Rheumatology Idiopathic inflammatory 
myopathies (IIM)  
Rheumatology 
Van Der Heijde 1997 
[232]** 
Rheumatology Ankylosing spondylitis Journal of Rheumatology 
Wolfe 1999 [233]** Rheumatology Rheumatic diseases Journal of Rheumatology 
Mease 2005 [234]** 
Mease 2007 [235] 
Arnold 2008 [236] 
Mease 2008 [237] 
Carville 2008 [238] 
Choy 2009 [239] 
Mease 2009 [240] 
Rheumatology Fibromyalgia syndrome Journal of Rheumatology 
x5 
Patient Education & 
Counseling 
Arthritis & Rheumatism 
Salaffi 2012 [241]** Rheumatology Fibromyalgia syndrome Reumatismo 
Schumacher 2005 
[242]** 
Schumacher 2007 [243] 
Taylor 2008 [244] 
Schumacher 2009 [245] 
Rheumatology Gout  Journal of Rheumatology 
x 3 
Annals of the Rheumatic 
Diseases 
Giannini 1997 [246]** Rheumatology Arthritis Arthritis & Rheumatism 
Bellamy 1997 [247]** Rheumatology Knee, hip and hand 
osteoarthritis 
Journal of Rheumatology 
Heiligenhaus 2012 
[248]** 
Rheumatology idiopathic arthritis-
associated uveitis 
(juvenile) 
Arthritis care & research 
Bowman 2001 [249]** 
Pillemer 2005  [250] 
Rheumatology Sjögren's syndrome  Rheumatology 
Journal of Rheumatology 
Cranney 1997 [81]** 
Guidelines for 
osteoporosis trials[251] 
Rheumatology Osteoarthritis  Journal of Rheumatology 
Hammarlund 2012 
[252]** 
Neurology Parkinson's disease Quality of Life Research 
Vellas 2008 [253]** Neurology Alzheimer's disease Lancet Neurology 
World Federation of 
Neurology Research 
Group 1995 [254]* 
Miller 1999 [255] 
Neurology Amyotrophic lateral 
sclerosis/motor neurone 
disease 
Journal of the 
Neurological Sciences 
Leigh 2004 [256]* Neurology Amyotrophic lateral 
sclerosis/motor neurone 
disease 
Amyotrophic Lateral 
Sclerosis & Other Motor 
Neuron Disorders 
Shankaran 2003 [257]* Neurology Hypoxic-ischemic brain 
injury 
Seminars in Perinatology 
Vargus-Adams 2009 
[258]** 
Neurology Cerebral palsy Archives of Physical 
Medicine & 
Rehabilitation 
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Study  Disease category Disease name  Journal  
Katona 2007 [259]** Neurology Dementia  International 
Psychogeriatrics 
Moniz-Cook 2008 
[260]** 
Neurology Dementia Aging & Mental Health 
ILAE Commission 1998 
[261]* 
Neurology Epilepsy (newly 
diagnosed and chronic) 
Epilepsia 
LaFrance 2006 [262]* Neurology Seizures Epilepsy & Behavior 
Osborne 2001 [263]** 
Lux 2004 [264] 
Neurology Infantile spasms  
West syndrome 
(Epilepsy) 
Brain & Development 
Epilepsia 
Mindell 2006 [265]* Neurology Insomnia  Pediatrics 
Schumacher 2010 [266]* Neurology Intracranial cerebral 
atherosclerosis 
Journal of 
Neurointerventional 
Surgery 
Whitaker 1995 [267]** Neurology Multiple sclerosis Multiple Sclerosis 
Chitnis 2012 [268]* 
Chitnis 2013 [269] 
Neurology Multiple sclerosis Multiple Sclerosis 
Neurology 
Penzien 2005 [270]* 
Penzien 2005 [271] 
Andrasik 2005 [272] 
Neurology  Headache  Headache 
Tfelt-Hansen 1991[273]* 
Tfelt-Hansen 2000 [274] 
Tfelt-Hansen 2012 [275] 
Neurology Migraine  Cephalalgia 
Lipton 1995 [276]* Neurology Cluster headache  Cephalalgia 
Schoenen 1995 [277]* 
Bendtsen 2010 [278] 
Neurology Tension-type headache Cephalalgia 
Hughes 2005 [279]* Neurology Chronic Inflammatory 
Demyelinating 
Polyradiculoneuropathy 
and Multifocal 
Motor Neuropathy 
Neuromuscular Disorders 
Merkies 2006 [280]** Neurology Peripheral neuropathy Neuromuscular Disorders 
Reilly 2006 [281]* Neurology Charcot-Marie-Tooth 
disease type 1A (CMT1A) 
Neuromuscular Disorders 
Clifton 1992 [282]** Neurology  Traumatic brain injury   Neurosurgery 
Wilde 2010 [283]** Neurology Traumatic brain injury Archives of Physical 
Medicine & 
Rehabilitation 
Duncan 2000 [284]** Heart & circulation  Acute stroke  Stroke 
Schellinger 2012 [285]** Heart & circulation  Acute stroke International Journal of 
Stroke 
Hoeper 2004 [286]* Heart & circulation  Pulmonary arterial 
hypertension 
Journal of the American 
College of Cardiology 
Distler 2008 [287]** Heart & circulation  Pulmonary arterial 
hypertension relates 
Systemic Sclerosis 
Arthritis & Rheumatism 
Becker 2011 [288]** Heart & circulation  Cardiac arrest  Circulation 
Chiam 2008 [289]** Heart & circulation  Aortic valve stenosis (AS) Cardiovascular 
Interventions 
Leon 2011 [290]** 
Kappetein 2012 [291] 
Heart & circulation  Aortic stenosis (AS);  
Valvular heart disease 
European Heart Journal 
European Journal of 
Cardio-Thoracic Surgery 
Cutlip 2007 [292]** Heart & circulation  Obstructive coronary 
artery disease 
Circulation 
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Study  Disease category Disease name  Journal  
Simons 2000 [293]* Heart & circulation Ischemic heart disease Circulation 
Conte 2009 [294]** Heart & circulation  Critical limb ischemia Journal of Vascular 
Surgery 
Timaran 2011 [295]* Heart & circulation  Atherosclerosis Journal of Vascular 
Surgery 
Stout 2012 [296]* Heart & circulation  Chronic leg edema International Angiology 
Nedeltchev 2010 [297]** Heart & circulation  Obstructive disease of 
supra-aortic arteries 
Catheterization & 
Cardiovascular 
Interventions 
Anderson 2013 [298]* Heart & circulation  Cardiovascular disease Journal of the American 
College of Cardiology 
Hausenloy 2013 [299]* Heart & circulation  Coronary heart disease Cardiovascular Research 
Labs 1999 [300]* Heart & circulation  Peripheral arterial 
occlusive disease (PAOD) 
European Journal of 
Vascular & Endovascular 
Surgery 
Mitchell 2011 [301]** Heart & circulation  Deep venous thrombosis 
and pulmonary embolism 
Journal of Thrombosis & 
Haemostasis 
Steg 2011 [302]* Heart & circulation  Acute coronary 
syndrome 
European Heart Journal 
O'Connell 2009 [303]* Heart & circulation  Acute heart failure 
syndromes (AKA Acute  
decompensated heart 
failure) 
Heart Failure Reviews 
Higashida 2003 [304]* Heart & circulation  Acute 
ischemic stroke 
Stroke 
Calkins 2012 [305]* Heart & circulation  Atrial fibrillation Journal of Interventional 
Cardiac Electrophysiology 
Kirchhof 2007 [306]** Heart & circulation  Atrial fibrillation European Heart Journal 
Buser 1997 [307]* Dentistry & oral health Implants in regenerated 
bone 
Annals of Periodontology 
Page 1992 [308]* Dentistry & oral health Periodontitis Journal of Periodontal 
Research 
Imrey 1994 [309]* Dentistry & oral health Periodontitis Journal of Periodontal 
Research 
Lightfoot 2005 [310]** Dentistry & oral health Chronic periodontitis 
(Anterior teeth) 
Journal of 
Periodontology 
Lightfoot 2005 [311]** Dentistry & oral health Chronic periodontitis 
(Posterior teeth)  
Journal of 
Periodontology 
Weber 1997 [312]* Dentistry & oral health Endentulous  Annals of Periodontology 
Cochran 1998 [313]* Dentistry & oral health Endentulous Journal of 
Periodontology 
Tonetti 2012 [314]** Dentistry & oral health Endentulous Journal of Clinical 
Periodontology 
Smaïl-Faugerson 2013 
[315]** 
Dentistry & oral health Extensive tooth decay PLoS ONE 
Chilton 1986 [316]* Dentistry & oral health Plaque and gingivitis Journal of Clinical 
Periodontology 
Council on Dental 
Therapeutics 1986 [317]* 
Dentistry & oral health Supragingival dental 
plaque and gingivitis 
Journal of the American 
Dental Association  
Pitts 2004 [318]* Dentistry & oral health  Caries Journal of Dental 
Research  
Marshall 2005 [319]** Infectious disease  Sepsis and critical care  Critical Care Medicine 
Goldstein 2005 [320]* Infectious disease Sepsis and critical care Pediatric Critical Care 
Medicine 
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Study  Disease category Disease name  Journal  
Wood 1995 [321]* Infectious disease Herpes Zoster Journal of Antimicrobial 
Chemotherapy 
Barlow 2003 [322]** Infectious disease Community-acquired 
pneumonia  
The Lancet Infectious 
Diseases 
Spellberg 2008 [323]* Infectious disease Community-acquired 
pneumonia 
Clinical Infectious 
Diseases 
Powers 2010 [324]* 
Spellberg 2010 [325] 
Infectious disease Hospital-acquired 
pneumonia and 
ventilator-associated 
pneumonia 
Clinical Infectious 
Diseases 
McCracken 1992 [326]* Infectious disease Acute bacterial 
meningitis  
Clinical Infectious 
Diseases 
Alioum 2001 [327]* Infectious disease HIV Statistics in Medicine 
Kirkby 2010 [328]* Infectious disease Influenza  Journal of Alternative & 
Complementary 
Medicine 
Nystrom 1990 [329]* Infectious disease Intraabdominal infection World Journal of Surgery 
Cross 2005 [330]** Infectious disease Leprosy  International Journal of 
Leprosy & Other 
Mycobacterial Diseases 
Moorthy 2007 [331]** 
Moorthy 2009 [332] 
Infectious disease Malaria  Vaccine 
Steeves 2007 [333]** Orthopaedics & trauma Spinal cord injury  Spinal Cord 
Bombardier 2000 [334]** Orthopaedics & trauma Spinal disorders Spine 
Deyo 1998 [335]** Orthopaedics & trauma Low back pain  Spine 
Devogelaer 2003 [336]* Orthopaedics & trauma Acute low back pain  Clinical & Experimental 
Rheumatology 
Goldhahn 2008 [337]** Orthopaedics & trauma Osteoporosis Bone 
Lynch 2013 [338]** Orthopaedics & trauma ACL injury  British Journal of Sports 
Medicine 
Falder 2009 [339]** Orthopaedics & trauma Burns  Burns 
Reneman 2013 [340]** Orthopaedics & trauma Musculoskeletal pain 
(subacute and chronic) 
Journal of Occupational 
Rehabilitation 
Lamb 2005 [341]** Orthopaedics & trauma Fall injury  Journal of the American 
Geriatrics Society 
Cameron 2010 [342]* Orthopaedics & trauma Hip fracture  Osteoporosis 
International 
Smith 1996 [343]**  Lungs & airways  Asthma  Australian & New 
Zealand Journal of Public 
Health 
Reddel 2009 [104]** Lungs & airways  Asthma  American Journal of 
Respiratory Crital Care 
Medicine  
Busse 2012 [105]** 
Fuhlbrigge 2012 [344] 
Akinbami 2012 [345] 
Szefler 2012 [346] 
Tepper 2012 [347] 
Cloutier 2012 [348] 
Krishnan 2012 [349] 
Wilson 2012 [350] 
Lungs & airways  Asthma  Journal of Allergy & 
Clinical Immunology 
Sinha 2012 [103]** Lungs & airways  Asthma  Trials 
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Study  Disease category Disease name  Journal  
Keim 2004 [351]** Lungs & airways  Respiratory distress Academic Emergence 
Medicine 
 
Canonica 2007 [352]* Lungs & airways  Respiratory allergy  Allergy 
Cazzola 2008 [353]** Lungs & airways  Chronic obstructive 
pulmonary disorder 
(COPD) 
European Respiratory 
Journal 
Task Group on 
Mucoactive Drugs 1994 
[354]* 
Lungs & airways  Chronic bronchitis and 
COPD  
Chest 
Dent 2008 [355]*  Gastroenterology  Gastro-oesophageal 
reflux disease (GERD) 
Alimentary 
Pharmacology & 
Therapeutics 
Wirth 2011 [356]* Gastroenterology Chronic Hepatitis C Journal of Pediatric 
Gastroenterology & 
Nutrition 
Bajaj 2011 [357]* Gastroenterology Hepatic encephalopathy Alimentary 
Pharmacology & 
Therapeutics 
Fekety 1992 [358]* Gastroenterology Antibiotic associated 
colitis 
Clinical Infectious 
Diseases 
Griffiths 2005 [359]** Gastroenterology Crohn's disease Inflammatory Bowel 
Diseases 
Laine 2010 [360]* Gastroenterology Nonvariceal upper 
gastrointestinal bleeding 
American Journal of 
Gastroenterology 
Pimentel 2013 [361]* Gastroenterology Irritable bowel syndrome 
(IBS) 
Gastroenterology 
Sanyal 2011 [362]* Gastroenterology Nonalcoholic 
steatohepatitis 
Hepatology 
Rahn 2011 [363]** Gynaecology  Abnormal uterine 
bleeding  
Journal of Clinical 
Epidemiology 
Meuleman 2012 [364]** Gynaecology Deeply infiltrative 
endometriosis (DIE) 
Current Opinion in 
Obstetrics & Gynecology 
Vincent 2010 [365]* Gynaecology Endometriosis-related 
pain  
Fertility & Sterility 
Broder 2000 [366]* Gynaecology Uterine fibroids Journal of Vascular & 
Interventional Radiology 
Basson 2000 [367]* Gynaecology Female sexual 
dysfunction  
Journal of Urology 
Clayton 2010 [368]* Gynaecology Female sexual 
dysfunction 
Journal of Sexual 
Medicine 
Walker 2006 [369]** Tobacco, drugs, & 
alcohol dependence 
Addiction (gambling) Addiction 
Del Boca 2007 [370]* Tobacco, drugs, & 
alcohol dependence 
Addiction (substance) Addiction 
Donovan 2012 [371]** Tobacco, drugs, & 
alcohol dependence 
Drug dependence Addiction 
Vocci 1999 [372]* Tobacco, drugs, & 
alcohol dependence 
Nicotine, alcohol and 
cocaine 
abuse/dependence 
National Institute on 
Drug Abuse Medications 
Development Division 
Levine 2003 [373]** Urology Peyronie's disease International Journal of 
Impotence Research 
Djurhuus 1997 [374]** Urology Nocturnal enuresis Scandinavian Journal of 
Urology & Nephrology 
259 
 
Study  Disease category Disease name  Journal  
Toozs-Hobson 2012 
[375]** 
Urology  Pelvic organ prolapse International 
Urogynecology Journal 
Porst 2010 [376]* Urology Male sexual 
dysfunction/disorders 
Journal of Sexual 
Medicine 
Pavletic 2006 [377]** Blood disorders  Chronic graft-versus-host 
disease (GVHD) 
Biology of Blood & 
Marrow Transplantation 
Lassila 2005 [378]* Blood disorders Haemophilia and other 
bleeding disorders 
Haemophilia 
Rodeghiero 2009 [379]** Blood disorders Immune 
thrombocytopenic 
purpura 
Blood 
Turk 2003 [125]** 
Turk 2008 [380] 
Anaesthesia & pain 
control 
Chronic pain  Pain 
McGrath 2008 [124]** Anaesthesia & pain 
control 
Chronic pain/ 
recurrent pain and acute 
pain 
Journal of Pain 
Apfel 2002 [381]* Anaesthesia & pain 
control 
Post-operative nausea 
and vomiting 
Anaesth Intensivmed 
Notfallmed Schmerzther 
Anderson 1998 [382]* Endocrine & metabolic  Obesity Obesity Research 
Douglas 2009 [383]** Endocrine & metabolic Thyroid eye disease (TED) Archives of 
Ophthalmology 
Carlson 2003 [384]* Mental health  Bipolar disorder Journal of Child & 
Adolescent 
Psychopharmacology 
Rush 2006 [385]** Mental health Major depressive 
disorder 
Neuropsychopharmacolo
gy 
Fitzpatrick 2010 [386]** Mental health Forensic mental health Health Technology 
Assessment 
Finer 2006 [387]* 
Giacoia 2006 [80] 
Neonatal care  Neonatal apnea (also 
known as Apnea of 
prematurity, and 
Apnoea) 
Pediatrics 
Short 2006 [388]* 
Giacoia 2006  
Neonatal care Neonatal cardiovascular 
instability 
Pediatrics 
Clancy 2006 [389]* 
Giacoia 2006 
Neonatal care Neonatal seizures Pediatrics 
Gonzalez 2011 [390] 
Eleftheriadou 2012 
[391]* 
Skin Vitiligo Archives of Dermatology 
British Journal of 
Dermatology 
Schmitt 2007 [392]** 
Schmitt 2010 [393] 
Schmitt 2011 [394] 
Schmitt 2012 [395] 
Skin Eczema Journal of Allergy & 
Clinical Immunology 
British Journal of 
Dermatology 
Journal of Investigative 
Dermatology 
Allergy 
Olliaro 2013 [396]* Skin Cutaneous leishmaniasis PLoS Neglected Tropical 
Diseases 
Bellomo 2004 [397]* Kidney disease  Acute renal failure Critical Care 
Molitoris 2012 [398]* Kidney disease Acute kidney injury Clinical Journal of the 
American Society of 
Nephrology 
Endre 2013 [399]* Kidney disease Acute kidney injury Pediatric Nephrology 
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Study  Disease category Disease name  Journal  
Abellan van Kan 2011 
[400]* 
Health care of older 
people  
Sarcopenia Clinics in Geriatric 
Medicine 
Devane 2007 [401]** Pregnancy & child birth  Maternity care Birth 
Bennett 2012 [402]* Pregnancy & child birth Gestational diabetes 
mellitus 
Journal of Women's 
Health 
Langguth 2007 [403]** Ear, nose & throat  Tinnitus Progress in Brain 
Research 
Ramsey 1994 [404]** Genetic disorders Cystic Fibrosis Journal of Pediatrics 
Gottrup 2010 [405]** Wounds Non-healing wounds Journal of Wound Care 
van Brussel 2011 [406]* Chronic conditions JIA, OI, Achondroplasia, 
Hemophilia, Cerebral, 
Palsy, Spina Bifida, CF, 
Cancer 
Pediatric Physical 
Therapy 
Angus 2003 [407]* Intensive care Critical illness/ ICU 
disease 
Intensive Care Medicine 
Micke 2002 [408]* Benign disease Benign/ Non-malignant 
diseases 
International Journal of 
Radiation Oncology, 
Biology, Physics 
 
* Considered outcomes while addressing wider clinical trial design issues 
** Specifically considered outcome selection and measurement 
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Appendix 3: A description of rounds in studies that used the Delphi technique 
Study Number of 
rounds 
Round 1 Round 2 Round 3 Other rounds How outcomes were kept in 
between rounds  
White (1995) Unclear Number of rounds unclear  Unclear 
Broder (2000) 2 Outcomes were rated independently and 
anonymously (either “important to 
measure” or “essential to measure” or 
"do not measure"). 
The outcomes with the highest 
group rating were discussed and 
several new ones added. 
Independent rating took place. 
N/A N/A Round 2: The outcomes with 
the highest group rating were 
discussed and several new 
ones added and outcomes 
were again rated the second 
time. 41 outcomes got 
reduced to 23 outcomes  
Basson (2000) 2 Unclear Unclear N/A N/A Unclear 
Lightfoot (2005) 2 Rate outcome measures as either 
“extremely important,” “very 
important,” “moderately important,” 
“somewhat important,” or “not 
important” for successful therapy in 
relation to the scenario.  
Requested to review the most 
frequent responses to the first 
round of the survey and if they 
agreed to affirm the result or if they 
disagreed, to mark what they 
considered the most appropriate 
outcome.  
N/A N/A Round 2: The most frequent 
responses of Round 1 were 
reviewed. 
Lightfoot (2005) 2 Rate outcome measures as either 
“extremely important,” “very 
important,” “moderately important,” 
“somewhat important,” or “not 
important” for successful therapy in 
relation to the scenario.  
Requested to review the most 
frequent responses to the first 
round of the survey and if they 
agreed to affirm the result or if they 
disagreed, to mark what they 
considered the most appropriate 
outcome.  
N/A N/A Round 2: The most frequent 
responses of Round 1 were 
reviewed. 
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Sinha(2012) 2 Open questions were asked in order to 
identify a long list of outcomes. 
To identify the relative importance 
of each outcome, participants were 
asked the following question: 
“Regular treatments for children can 
have a variety of beneficial effects, 
each of which could be measured as 
an outcome in clinical trials. Please 
score how important each of the 
following outcomes are on a scale of 
0–4”. They were also asked to pick 
the three outcomes they felt were 
most important. In order to ensure 
that important outcomes were not 
missed, participants were asked to 
suggest any unlisted outcomes that 
they would have selected in their 
top 3.  
N/A N/A Round 2: To enable each 
group of participants, 
regardless of its size, to have 
equal opportunity to suggest 
outcomes for phase 2, those 
outcomes suggested by at 
least 10 % of young people 
and/or parents and/or 
clinicians were carried 
forward to the next phase. By 
censoring in this way, we 
reduced the number of 
outcomes listed on the phase 
2 questionnaire, without 
overlooking outcomes of 
potentially genuine 
importance. The reviewers 
discussed the individual 
outcomes that had not been 
suggested by sufficient 
numbers of participants, but 
were measured in at least 10 
% of RCTs identified in the 
systematic review described 
earlier. If nearly 10 % of both 
clinicians and parents 
suggested the outcome, it 
was carried forward to the 
next phase, because we felt 
that, if we had a larger 
sample size, the outcome 
may have been suggested by 
sufficient numbers of 
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participants. 
Schmitt (2011) 3 Rate outcome domains on a nine-point 
Likert scale (1-3=not important, 4-
6=Equivocal, 7-9=important) in the 
context of (a) clinical trials and (b) 
recordkeeping in daily practice. Asked to 
list additional outcome domains they 
considered potentially relevant. 
Additionally, they were asked in the first 
round to indicate how many domains 
should be included in the final core set of 
outcome domains for each context. 
In subsequent rounds, participants 
received feedback on their own 
response along with the group 
opinion for each domain (median 
and interquartile range, calculated 
using Stata 10, Stata, College 
Station, TX) from the previous 
round. Respondents could submit 
new scores or leave their scores 
unchanged.  
In the final 
round, instead 
of ranking the 
importance of 
the individual 
domains on a 
Likert scale, 
participants 
were asked 
explicitly which 
domains they 
recommend 
incorporating 
into the core 
set.  
N/A Round 3: Although the panel 
considered a broad set of 
different outcome domains as 
important, the panel 
indicated that only three 
different domains should be 
included in the core set 
(median rating by the whole 
panel). 
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Vargus-Adams 
(2009) 
3 Open question asked in order to identify 
a long list of outcomes. 
The second survey listed the 
domains that were identified from 
the first survey and asked the 
respondents to rank them in order 
of importance. Respondents were 
asked to rank every item, starting 
with 1 for the item they thought was 
most important. 
The third 
survey again 
addressed 
these domains 
and asked the 
respondents to 
demonstrate 
the relative 
value of each 
domain by 
distributing 100 
points among 
the domains. 
The ranks for 
each domain 
were examined 
for any 
patterns or 
obvious drop-
off points that 
would permit 
the elimination 
of one or more 
domains that 
were less 
valued by the 
respondents. 
This process led 
to the final list 
of important 
domains. 
Round 4 and 5 
related to how 
to measure 
those 
outcomes.  
After round 3, the ranks for 
each domain were examined 
for any patterns or obvious 
drop-off points that would 
permit the elimination of one 
or more domains that were 
less valued by the 
respondents. 
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Cross (2005) 4 Open question asked in order to identify 
a long list of criteria. 
Rating/ranking of collated criteria. Round 3: 
Further 
refinement of 
agreed criteria. 
Participants 
were required 
to again 
consider the 
criteria and 
given a concise 
description of 
outcomes. 
Round 4: On 
receipt of the 
response from 
Round 3, 
outcomes 
were tabulated 
as 'Draft gold 
standard'.  
Assurance was 
given that 
should 4 or 
more people 
request 
changes to any 
one item in the 
tables, such 
request would 
be 
implemented. 
It was re-
iterated that 
screening, 
assessment 
and outcome 
criteria were 
no longer 
negotiable.  
Each rank was given a score. 
Descending negative scores 
were given when members 
had ranked a criterion as 
either 'not useful' or 'should 
be omitted'. If a criterion was 
ranked as 'neutral' it was 
scored as O. Ascending 
positive scores were given 
where members had ranked a 
criterion as either 'useful' or 
'essential'. With nine 
members contributing the 
final score for each criterion 
represented the mean of the 
nine responses. Score>1. The 
indication was the criterion is 
not acceptable and should be 
rejected. Score >1<2 
acceptable and should 
therefore be included for 
further consideration.  
Heiligenhaus 
(2012) 
Unclear  Number of rounds unclear. 
Each domain and item was ranked on a scale from 1–5, where 1 was of highest importance and 5 lowest importance. 
Domains or items with low 
importance or redundant 
variables were eliminated.  
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Salaffi (2012) 1 Clinicians rated symptoms/domains 
using a Likert scale from 1 to 4 (4=highly 
relevant, extremely important; 3=very 
relevant, very important; 2=not very 
relevant, not very important; 1=not 
relevant, unimportant). Patients asked to 
put various domains in order of priority 
giving each one a score on the Likert 
scale from 1 to 3.  
N/A N/A N/A In order to reduce the 
number of clinical domains, 
items were excluded from the 
list if: 
a) they were related to 
gender; 
b) they required use of 
special equipment; c) they 
used terminology which was 
ambiguous or difficult to 
understand; 
d) they presented 
alternatives to other items, 
duplicated them and/or were 
similar to them.  
Smaïl-
Faugeron(2013) 
3 Rate the importance of each outcome on 
a 5-point Likert-type scale: 1, no 
importance; 2, some importance; 3, 
moderate importance; 4, very important; 
and 5, extremely important.  
The results from the first round were 
relayed back to participants. 
Participants were asked to choose 
the outcomes that should be part of 
the core set.  
Round 3 sought 
to obtain 
broader 
consensus on 
the core set of 
outcomes. The 
results from 
round 2 were 
relayed back to 
participants. 
The 
participants 
were asked to 
re-select the 
outcomes that 
should be part 
of the core set 
with 
N/A Round 2: Only outcomes or 
component outcomes rated 
very or extremely important 
by at least 50% of 
participants were carried 
forward to round 2. 
Round 3: Component 
outcome measures chosen by 
70% or more of participants 
were retained in round 3. 
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knowledge of 
the group’s 
previous 
ratings.  
Outcome 
measures 
chosen by 70% 
or more of 
participants 
were retained 
in round 3.  
Bennett (2012) 3 [only 
round 3 
for voting] 
Outcomes suggested.  Outcomes suggested.  Round 3 for 
outcomes 
prioritisation: 
From a list of 
possible 
outcomes that 
had been 
suggested in 
rounds 1-2. 
Each 
stakeholder 
ranked their 
top three 
outcomes that 
would be most 
important to 
include in a 
clinical trial 
that assessed 
medication and 
delivery 
N/A N/A. The aim was to 
prioritise, not reach 
consensus on the final set 
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management. 
Rahn (2011) Unclear Number of rounds unclear. 
The importance of each outcome was graded on a scale suggested by the GRADE working group: a 9-point scale with 
outcomes scored as ‘‘critical’’ for decision making (score: 7-9), ‘‘important but not critical’’ (score: 4-6), and ‘‘not 
important’’ for decision making (score: 1-3).  
During outcome 
categorisation: From the 
outcome inventory, the 
outcomes were organized 
and grouped into eight 
proposed overarching 
outcome domains. Outcomes 
related to cost, resource use, 
or those determined by the 
review group to have limited 
relevance for assessing 
clinical effectiveness were 
excluded from categorization 
and further analyses 
Dent (2008) 3 Unclear (between each of the three 
voting rounds, statements were revised 
based on feedback from the Working 
Group and additional literature reviews, 
and some statements were added on 
matters not addressed previously) 
Unclear  Unclear  N/A Unclear  
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Devane (2007) 3 Rate the importance of each outcome 
listed using a 5-point Likert-type scale 
rating their importance for inclusion in a 
minimum set as: 1 = of no importance, 2 
= of some importance, 3 = of moderate 
importance, 4 = very important, and 5 = 
extremely important. Participants were 
also asked to identify up to 2 ‘‘new’’ 
outcomes under each of 5 broad 
headings, which they judged to be 
relevant or important. 
Participants were asked to re-rate 
the importance of each outcome 
with knowledge of their individual 
and the group’s previous ratings. In 
addition, participants were asked to 
rate the newly identified outcomes 
from round 1. All ratings used the 
same Likert-type scale that was used 
in round 1. 
Each of the 
outcomes in 
round 3 was 
again 
presented 
together with 
the mean 
rating and 
standard 
deviation for 
the whole 
group, and 
participants 
were asked to 
re-rate the 
importance of 
each item for 
inclusion in a 
minimum data 
set using the 
same Likert-
type scale used 
in round 2. 
N/A Round 2: outcomes retained 
after analysis of responses 
from round 1, where (a) the 
overall mean score for 
inclusion for that outcome 
was greater than the mean 
score for all the outcomes 
combined and (b) the mean 
score for inclusion for that 
outcome was greater than 
the mean score for all the 
outcomes combined for those 
participants who had rated 
their perceived level of 
expertise in evaluating 
models of maternity care as 
high (i.e., 6 or 7 on the Likert 
scale).  
Round 3: Outcomes retained 
after analysis of responses 
from round 2, where (a) the 
overall mean score for 
inclusion for that outcome 
was greater than the mean 
score for all the outcomes 
combined and (b) 70 percent 
or more of study participants 
rated their importance for 
inclusion as a ‘‘4’’ or ‘‘5’’ on 
the 5-point Likert-type scale 
used in round 2. 
270 
 
Distler (2008) 3 Score each domain and tool for use as 
outcome measures in randomized 
controlled trials using a 5-point scale, 
where a score of 1 indicated “not 
important/appropriate at all” and 5 
indicated “very important/appropriate.” 
A text box of unlimited size was provided 
for free text below each domain and its 
associated measurement tools to add 
new tools. Additional domains could be 
proposed at the end of the 
questionnaire. 
Participants were asked to repeat 
the rating of the domains and tools 
based on the information from the 
group rating of stage 1.  
Participants 
were asked to 
perform 
another, and 
final, rating of 
the items 
retained from 
round 2. As in 
stage 2, 
participants 
were shown 
their own 
rating in the 
previous stage 
as well as the 
median ratings 
of the entire 
group.  
N/A A cluster analysis was 
performed on the items from 
stages 2 and 3 to differentiate 
important/appropriate from 
unimportant/inappropriate 
domains and tools. This 
reduced the number of 
domains and tools in a 
statistically significant 
manner. 
Douglas (2009) 3 To identify parameters that they 
believed could be used in a 1-year 
multicentre clinical trial. 
To rate the importance of each item. 
Each respondent rated the criteria 
on a scale of 1 (extremely 
inappropriate for a combined 
measure) to 9 (extremely 
appropriate for a combined 
measure) 
A report 
containing the 
final 
questionnaire 
was sent to 
participants 
that provided 
feedback to the 
respondents, 
reminding 
them of their 
previous 
ratings in 
Delphi 2 for 
each criterion 
N/A Round 3: Steering committee 
review and RAND/University 
of California, Los Angeles, 
appropriateness method. 
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compared with 
a group mean 
(standard 
deviation). The 
questionnaire 
requested that 
each 
participant 
again rate the 
criteria after 
they 
considered the 
mean group 
response. 
Khanna (2008) 3 List the items in the 11 domains 
suggested that could be used in 
development of a response index for a 1-
year multi-centre clinical trial. 
They were asked to rate each item 
on a scale of 1 (extremely 
inappropriate for a combined 
measure) to 9 (extremely 
appropriate for a combined 
measure).  
Round 3 [after 
NGT meeting] 
they were 
asked to 
provide their 
agreement on a 
scale of 1 
(complete 
disagreement 
on the core set 
measure for a 
combined 
measure) to 9 
(complete 
agreement on 
the core set 
measure for a 
combined 
measure). 
N/A Round 3: Steering committee 
review and RAND 
Corp./University of California, 
Los Angeles (RAND/UCLA) 
Appropriateness Method 
272 
 
Lux (2004) 6 Outcomes suggested.  Outcomes suggested.  Participants 
were invited to 
respond to 32 
statements 
that 
represented 
majority 
opinions from 
earlier rounds 
and to state 
whether they 
agree, unsure 
or would prefer 
an 
amendment. 
They also were 
asked to state 
whether they 
thought the 
statement 
should be 
included in the 
final proposal.  
Round 4: 
presented 
modified 
statements 
requesting 
comments on 
their content 
and suitability 
for the 
proposal.  
Round 5: 
consisted of a 
draft paper for 
submission as 
a final proposal 
from the West 
Delphi Group.  
Round 6: 
consisted of a 
final approval 
of the draft 
paper. 
Unclear  
273 
 
Mease (2005, 
2008) 
Clinicians: 
3  
Patient: 2 
Clinician Delphi: Participants asked to 
distribute 100 points among the 
domains, giving more points to domains 
they considered more important to 
evaluate. Patient Delphi: participants 
were asked to rank each domain as it 
applied to them and impacted their life. 
Participants were instructed to distribute 
100 points among the domains. 
Clinician Delphi: Result of previous 
round group median, interquartile 
range, and total range of the earlier 
responses were provided to reflect 
on them and revise subsequent 
scoring if they choose.  
Patients Delphi: Participants were 
asked to rank each domain as it 
applied to them and impacted their 
life. Participants were presented 
with their score on each domain 
from the previous round and the 
domain ranking results from round 1 
for all patients, which were revealed 
as the mean and total range. 
Clinician 
Delphi: Result 
of previous 
round group 
median, 
interquartile 
range, and total 
range of the 
earlier 
responses were 
provided to 
reflect on them 
and revise 
subsequent 
scoring if they 
choose.  
N/A Delphi was conducted to 
establish a prioritized list of 
key domains before a 
workshop. 
McGrath (2008) 2 Rate the outcome domains that had 
been suggested in original 
recommendations and to recommend 
others. They were also asked to suggest 
possible measures for each domain. 
Results of the first round were 
summarized and were supplied to 
participants for the repeat poll. 
N/A N/A Unclear  
Miller (2001) 2 Unclear Unclear N/A N/A Unclear  
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Ruperto (2003) 2 Indicate up to 10 variables that they 
judged as clinically most important. Any 
types of variable (e.g. laboratory tests, 
questionnaires, indices of disease 
activity) could be chosen. 
Variables indicated by at least 10 
responders in the first round and 
additional variables used in 
published therapeutic trials or 
observational studies were listed in 
alphabetical order. Among these 
variables, physicians were asked to 
select, in order of importance, their 
top 10 choices. They were also asked 
to define the minimum and 
maximum number of variables that 
should be included in the core set. 
N/A N/A Round 2: Variables indicated 
by at least 10 responders in 
the first round and additional 
variables used in published in 
therapeutic trials or 
observational studies were 
listed in Round 2. 
Taylor (2005) 3 Distribute 100 points amongst the 
domains. Respondents were free to 
assign points to as many or as few 
domains as they wished.  
Participants were given their own 
response and the group opinion for 
each domain (median and 
interquartile range) from the 
previous round. Respondents were 
able to submit new scores or leave 
their scores unchanged.  
Participants 
were given 
their own 
response and 
the group 
opinion for 
each domain 
(median and 
interquartile 
range) from the 
previous round. 
Respondents 
were able to 
submit new 
scores or leave 
their scores 
unchanged.  
N/A Using structured consensus 
methods, this exercise 
reduced the number of 
potential domains for 
consideration in a core set 
from 26 to around a dozen 
before the consensus 
meetings. Outcomes were 
not removed rather divided 
into higher and lower scoring 
domains. 
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Taylor (2008) 3 Rate the importance of domains on a 
seven-point scale (1 = definitely 
necessary to 7 = definitely not 
necessary). Additional domains felt to be 
of importance could be added.  
New items, re-worded items, and 
items for which there was 
disagreement and/or median rating 
of 4 (neither agreement nor 
disagreement) were re-rated in the 
second iteration.  
In the final 
(third) 
iteration, no 
new items 
were 
introduced and 
only items for 
which there 
was 
disagreement 
and/or median 
rating of 4 were 
re-rated. 
N/A Rating of 5-7=should not be 
included 
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Appendix 4: Invite to take part in the COS developer survey  
From: Gargon, Liz  
Sent: 08 October 2014 11:57 
To:  
Subject: Re your study: [Study title] 
 
Dear [Name] 
We have recently completed a systematic review to identify studies that sought to 
determine which outcomes or domains to measure in all clinical trials in a specific 
condition. Your study [Title] was identified in our search and included in the review. You 
can view the systematic review at 
 http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099111 
As part of a follow up study from this review we are writing to ask if you’d be willing to 
answer a few short questions about your study. We have prepared a short questionnaire to 
help with this and would be very grateful if you’d be willing to fill this in. Our follow up 
study will contribute to a larger research project that is aiming to develop methodological 
guidance for core outcome set development. In order to develop this guidance we need to 
try to understand what factors have informed the ways in which researchers have 
developed core outcome sets.  We would like to learn from your experience of doing this 
and incorporate what we learn from you into guidance to assist future researchers. We will 
acknowledge your contribution in the publication of the results, but all responses will 
remain confidential and data will be aggregated. 
The questionnaire can be accessed online Survey.liv.ac.uk/version1 and should take around 
15 minutes to complete. Your progress can be saved and returned to at any point via the 
'save’ button at the bottom of each page.   We ask that you please complete the 
questionnaire within two weeks of receiving this email.  
Thank you very much for taking the time to consider this request.  
With best wishes 
Liz Gargon  
 
277 
 
Appendix 5: COS developer survey  
 
Page 1  
Welcome to the Core Outcome Sets questionnaire  
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative (www.comet-
initiative.org) is bringing together people interested in the development and application of 
core outcome sets (COS). COMET aims to collate and stimulate relevant resources, both 
applied and methodological, to facilitate exchange of ideas and information, and to foster 
methodological research in the area of COS. We have recently completed a systematic 
review to identify studies which sought to determine which outcomes or domains to 
measure in all clinical trials in a specific condition. Using this approach we have identified 
198 studies. Your study was identified in our search and we have included it in the review 
and the COMET database.  
 
We would like to learn from real life experiences and incorporate what we learn into 
guidance to assist future researchers. As such, I would like to ask you to answer a few short 
questions about your work. The survey will take around 15 minutes to complete. You can 
save the questionnaire and return to it at any point.  
 
Please click 'next' to complete the questionnaire. 
 
Thank you 
Liz Gargon, COMET Project Coordinator 
  
Page 2  
Your details  
1. Please enter your name: 
 
  
278 
 
 
2. Please enter your email address:  
  
 
 
Page 3  
Core outcome set details  
With regard to the core outcome set (COS) study that we referred to in the email we sent 
you, please clarify the below details about your COS. 
 
3. This core outcome set is intended to be applied to studies involving: [dropdown] 
Both adults and children 
Adults  
Children (including neonates) 
Older adults only  
 
4. This core outcome set is intended to be applied to studies involving the following 
interventions: [check list –tick all that apply]  
Devices  
Procedures  
Surgery  
Vaccines 
Drug treatments 
Behavioural  
All intervention types 
Other, please specify [free text to specify]  
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5. Please indicate which methods you used to develop the core outcome set [check 
list –tick all that apply] 
  
 
     
 
Literature/systematic review  
 
Nominal Group Technique  
 
Non Delphi survey (e.g. in a questionnaire)  
 
Delphi (a structured technique to reach consensus)  
 
Meeting (an assembly of people for a particular purpose, particularly for discussion)  
 
Consensus development conference (key features include summaries of current 
knowledge, audience participation and a panel to assess the evidence presented 
Other, please specify 
 
 
 
6. Please indicate which participants you included in the development of this core 
outcome set [check list –tick all that apply] 
  
 
Clinical professionals (e.g. physicians, nurses, physiotherapists, counsellors, 
occupational therapists)  
 
Patients  
 
Caregivers (informal e.g. family, friends)  
 
Patient/support group representatives  
 
Researchers - non clinical  
 
Researchers - clinical  
 
Industry representatives  
 
Charity representatives  
 
Governmental agencies (e.g. NIH) 
 
Policy makers (e.g. technology assessment and health policy)  
 
Regulatory agency representatives (e.g. FDA, EMA) 
Other, please specify 
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Page 4  
Methods  
 7. How did your core outcome set study come about?  
Why did you/your group decide to develop the core outcome set? (Please tick all 
that apply) 
  
  
 
It was part of a research prioritisation study*  
 
I/we thought there was something missing in the outcomes being 
measured/reported in research  
 
I/we thought there was something missing in the outcomes being 
measured/reported in clinical practice  
 
The outcomes that were being measured in research were not applicable/relevant 
to clinical practice  
 
I/we were motivated by work that had been done in another speciality  
 
There was no existing core outcome set that we could use for our study  
 
A core outcome set existed but we did not think it was good enough/suitable*  
 
There was heterogeneity in which outcomes were being measured (studies 
measuring/reporting different outcomes) in trials/research  
 
There was heterogeneity in the way outcomes were being measured (studies 
measuring the same outcomes using different tools/instruments/measures) in 
trials/research  
 
There were outcomes being measured but not reported in trials/research  
 
I/we were conducting other research (e.g. a systematic review or a trial)*  
Other, please specify     
 
 
 8. How did you decide on the methods you used? 
(Please tick all that apply) 
 
   
Based on the literature (previous work)*  
 
Problems with other methods*  
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Suited our situation and circumstances*  
 
Based on the resources available* 
 
Based on expert advice*  
 
Own experience with same methods before for core outcome set development  
Other, please specify 
     
 
  
 
A conditional question is set up, so that when each answer marked with a * is ticked, an 
additional box appears below asking to provide more information about those responses.  
 
 9. How did you decide who to include as participants in your core outcome set 
development work? 
(Please tick all that apply) 
 
Experience with/knowledgeable about clinical practice  
 
Experience with/knowledgeable about trials/research  
 
Experience of living with/having/caring for someone with 
the condition  
 
Able to see things from the patient perspective  
 
Experience of people who are involved in decision-making 
about treatment  
 
To help with implementation and uptake later on  
 
To represent a broad view  
 
We wanted a local perspective  
 
We wanted a national perspective  
 
We wanted an international perspective  
Other, please specify 
     
 
Page 5  
Methods  
282 
 
10. Were there any differences in the outcomes thought to be important by different 
stakeholder groups? [dropdown] 
 
Yes 
No 
We did not look at this  
N/A – only one group of stakeholders included  
 
A conditional question is set up, so if yes is selected, another box appears below asking for 
more information. 
 
Page 6  
Your experiences  
 
11. What do you think were the main strengths of your study? (Please list up to 5) 
1) 
2)  
 3) 
 4) 
 5)  
 
12. What do you think were the main challenges you experienced over the course of your 
study? (Please list up to 5) 
1) 
2)  
 3) 
 4) 
 5)  
 
13. What do you think were the main limitations of your study? (Please list up to 5) 
1) 
2)  
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 3) 
 4) 
 5)  
 
14. Reflecting on your experiences of developing a core outcome set, are there any areas 
that you feel would benefit from methodological guidance or research to inform future 
activity to develop core outcome sets? (Please list up to 5) 
1) 
2)  
 3) 
 4) 
 5)  
 
Page 7  
Resources 
15. Can you please list the resources you used to develop your core outcome set?   
Resources available (e.g. funding for salary of researcher, travel expenses for meeting 
participants) 
 
 
 
 
16. How long did this work take, from planning to completion?  
Please enter the number of months 
 
  
17. Was the time taken: [dropdown] 
Longer than expected  
As expected  
Shorter than expected  
FREE TEXT BOX  
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A conditional question is set up for the answer selected to ask ‘Why do you think that was?’ 
 
Page 8  
What next? 
18. Was the future implementation or uptake of the core outcome set considered by your 
group at any stage? [dropdown] 
Yes   
No   
 
A conditional question is set up for the answer selected to ask ‘If not, could you please 
explain why this wasn't a consideration by your group?’ Or ‘If yes, what plans did/do you 
have to promote the uptake of the core outcome set?’ 
 
19. Do you have any plans to update or review your core outcome set? [dropdown] 
Yes   
No   
 
A conditional question is set up for the answer selected to ask ‘If not, could you please 
explain why your group doesn't have any plans to update or review the core outcome set?’ 
Or ‘If yes, what plans did/do you have?’ 
END OF SURVEY 
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Appendix 6: COS developers’ responses to the survey question ‘What do you think were 
the main strengths of your study?’  
 
Respondent Strength listed Category 
S29 consensus of experts Consensus 
S35 Consensus was strong Consensus 
S25 
development and application of small group 
consensus process, at that time (1992) innovative Consensus 
S52 consensus process Consensus 
S30 
All participants agreed on the terms by which 
consensus would be met Consensus 
S27 overall consensus Consensus 
S26 structured consensus finding Consensus 
S4 that we achieved some degree of consensus Consensus 
S45 
High level of agreement with proposals on 
outcomes that should be considered Consensus 
S5 international consensus Consensus 
S51 international consensus Consensus 
S12 international consensus Consensus 
S25 in the end, world-wide consensus reached Consensus 
S42 
study design (systematic review, consensus 
panel) Consensus 
S65 first consensus in the field Consensus 
S28 unbiased, statistic based definition of cut offs 
Consensus 
definition/parameters 
S50 clear definitions of parameters 
Consensus 
definition/parameters 
S35 Wide dissemination and update Dissemination 
S75 
Supported and published by the International 
Society of [disease area] Endorsement 
S47 endorsement by major national organization Endorsement 
S16 Potential for regulatory endorsement Endorsement 
S60 Generally accepted Endorsement 
S18 International representation and buy-in Endorsement  
S62 
Provides evidence-based rationale for the 
necessity of the variables in our recommended 
core Evidence based 
S20 based on review of literature Evidence based 
S44 
Conceptual framework from the initial qualitative 
research Evidence based 
S39 
rigorous, systematic, hypothesis driven, evidence 
based study Evidence based 
S61 Based on robust reviews of the evidence Evidence based 
S54 own experience was compared to published data Evidence based 
S78 
Developed based on own experience and 
literature Evidence based 
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S78 
Developed based on own experience and 
literature Experience based 
S67 based on clinical trial experience Experience based 
S11 
The experience I had had with coordinating 
clinical trials Experience based 
S14 applying validated measures to the constructs How to measure  
S72 
Agreed on uniform criteria to assess response to 
therapy How to measure  
S75 Only using objective outcome measures How to measure  
S79 
Analysis of baseline data to assess confluence of 
measures and outlier/poor measures How to measure  
S79 
Looking at additional factors:  patient reported 
outcomes, clinically meaningful change vs. 
statistically significant change How to measure  
S79 
Documented diagnostic strengths and 
weaknesses, representative sample selection 
needs, which PRO measures were appropriate for 
endpoints  How to measure  
S65 focus on feasibility How to measure  
S60 Robust measures How to measure  
S2 uniformity in endpoint definition How to measure  
S5 
recommendations for directions to pursue for 
more sensitive and specific outcomes measures How to measure  
S70 
We highlighted that many endpoints are poorly 
defined and have different definitions How to measure  
S81 
recognition that consensus definitions of [disease 
name] are the beginning not the end of the 
(re)definition pathway 
How to measure 
(definitions) 
S77 Clear definitions 
How to measure 
(definitions)  
S53 
Had a significant impact on future outcomes 
research in [disease name] Impact  
S61 It has had an enduring impact Impact  
S36 international experts International 
S36 international patients International 
S64 International International 
S61 
International - very large group of stakeholders 
and considered international variations in 
language and definition International 
S5 international consensus International 
S51 international consensus International 
S3 International expertise International 
S24 International in representation International 
S18 International representation and buy-in International 
S7 International International 
S73 Pan European International Perspective International 
S12 international consensus International 
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S38 
Reflects an international view of researchers in 
the area. International 
S23 
Breadth of participants (North Am, Europe, PTs, 
MDs) International 
S62 Representative body of international experts International  
S75 Agreement by international experts International  
S1 based on many discussions with international International  
S66 International perspective (WHO) International  
S48 
International agreement on core outcome 
measures International  
S25 in the end, world-wide consensus reached International  
S8 international perspective International  
S65 international International  
S28 International participation International  
S30 
Only surgeons and therapists of established 
international repute were recruited for the study International  
S6 Representation by international experts International  
S73 Comprehensive review of existing evidence Lit review 
S76 review of the literature Lit review 
S56 
two recent systematic reviews of outcome 
measures Lit review 
S70 We partly knew the literature Lit review 
S73 
Comprehensive review of existing outcome 
measure classifications Lit review 
S42 
study design (systematic review, consensus 
panel) Lit review 
S9 comprehensive review Lit review 
S54 
Leading experts performed a search of the 
literature Lit review 
S13 Literature data Lit review 
S52 literature review Lit review 
S55 Wide literature review Lit review 
S69 
Complete review of the whole field (Clinical trials 
in male sexual dysfunction-MSD) Lit review 
S30 Method circumvented negative group dynamics  Method 
S42 
study design (systematic review, consensus 
panel) Method 
S21 used formal nominal group technique Method 
S25 
development and application of small group 
consensus process, at that time (1992) innovative Novel 
S48 First attempt in the field Novel 
S39 
first study of its kind: multi-site, multiple 
modalities Novel 
S53 
First comprehensive summary of the state of the 
art Novel 
S5 
first effort to systematically review and critique 
[disease name] trials outcomes Novel 
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S65 first consensus in the field Novel 
S67 new Novel 
S70 
no-one had addressed the topic before in 
[disease name] Novel 
S33 novel Novel 
S71 Novelty in the particular field Novel 
S39 first Class 1 level study Novel 
S14 ICF as framework Outcomes framework 
S10 
attempt to map to other disease Common Data 
Elements Outcomes framework 
S44 
Patient research partners were involved at every 
stage of the study 
Patient research 
partners 
S62 Strong methodological process Process 
S1 
based on statistical methods the most valid 
variables were chosen  Process 
S1 
variables were based on large database with 
reliable clinical practice data; Process 
S35 Open discussion and debate among all present Process 
S63 lengthy consultation  Process 
S63 number of revisions (22) Process 
S25 mix of quantitative and qualitative input Process 
S25 
exercises at conference to develop responder 
index Process 
S61 Modified nominal group technique was rich Process 
S61 It was completed efficiently, and cheaply Process 
S51 listed pros and cons of each approach Process 
S18 Kept list of domains and tools short Process 
S41 Good coordination Process 
S22 Delphi panel process Process 
S78 Based on CONSORT recommendations Process 
S10 
significant amount of discussion was involved, 
high degree of active participation Process 
S50 full statistical model Process 
S26 scientific approach Process 
S9 assessment of many domains Process 
S47 balanced and fair Process 
S24 Addressed practical questions Process 
S41 
Well prepared procedures for outcome 
assessment Process 
S6 Incorporated most current technology Process 
S21 
used longitudinal actual data on potential 
outcome measures  Process 
S47 comprehensive 
Process - 
Comprehensive 
S74 objective Process - objective 
S7 Robust process Process - Robust 
S62 Addressing an important health issue Relevance to practice  
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S30 
It did establish what the optimal method for 
[disease area] correction is Relevance to practice  
S74 relevance of outcomes to clinical practice Relevance to practice  
S6 
More relevant to clinical practice, trials, 
regulatory agencies Relevance to practice  
S27 Reflection of the clinical relevance Relevance to practice  
S6 
More relevant to clinical practice, trials, 
regulatory agencies 
Relevance to 
regulators  
S6 
More relevant to clinical practice, trials, 
regulatory agencies Relevance to research 
S15 Relevance to important clinical research studies Relevance to research 
S47 fills critical research gap Relevance to research 
S47 facilitates research excellence Relevance to research 
S50 application to various studies and contexts Relevance to research 
S45 
Recognition that not all trials will use same 
outcome measures as depends on objective of 
drug being tested Relevance to research 
S61 It was completed efficiently, and cheaply Resources 
S36 
high response rate in all three rounds of our e 
Delphi Response rate  
S28 large number of participants Sample size 
S41 Large size, sufficient statistical power Sample size 
S19 large writing group Sample size 
S10 
relatively large group of experts from different 
training backgrounds Sample size 
S23 Sample Size Sample size 
S61 
International - very large group of stakeholders 
and considered international variations in 
language and definition Sample size  
S36 
lots of patients (compared to previous core 
outcomes projects) Sample size  
S14 tailored for specific target group Scope 
S45 
Need for research on most appropriate outcome 
measures to be used in different situations Scope  
S77 An internationally known scoring system Scoring system  
S64 All key academic players involved 
Stakeholder 
involvement - 
academic 
S23 
Breadth of participants (North Am, Europe, PTs, 
MDs) 
Stakeholder 
involvement - broad 
S66 Broad group of professionals/researchers 
Stakeholder 
involvement - broad  
S49 Broad range of experts and professionals  
Stakeholder 
involvement - broad  
S15 Broad representation of stakeholders 
Stakeholder 
involvement - broad  
S44 
A national survey captured a broader patient 
perspective 
Stakeholder 
involvement - broad  
290 
 
S35 
Diverse group of clinical investigators 
participated 
Stakeholder 
involvement - broad  
S34 wide participation - academia, industry, NCI, FDA 
Stakeholder 
involvement - broad  
S53 Included a broad perspective 
Stakeholder 
involvement - broad  
S41 
Multidisciplinary team of scientists working 
closely together 
Stakeholder 
involvement - broad  
S55 Multidisciplinary involvement of authors 
Stakeholder 
involvement - broad  
S22 Multidisciplinary panel 
Stakeholder 
involvement - broad  
S7 Multiprofessional 
Stakeholder 
involvement - broad  
S26 different perspectives included 
Stakeholder 
involvement - broad  
S10 
relatively large group of experts from different 
training backgrounds 
Stakeholder 
involvement - expertise 
S17 the multidisciplinary team that reviewed the data 
Stakeholder 
involvement - expertise  
S79 
Strong committee members/author who brought 
different skills and focus 
Stakeholder 
involvement - expertise  
S20 expertise of panel members 
Stakeholder 
involvement - expertise  
S66 
Experts with large experience in the particular 
field 
Stakeholder 
involvement - expertise  
S9 update with experienced reviewers 
Stakeholder 
involvement - expertise  
S34 experienced group 
Stakeholder 
involvement - expertise  
S8 Inclusion of different specialists 
Stakeholder 
involvement - expertise  
S8 inclusion of experts in the field 
Stakeholder 
involvement - expertise  
S51 subject matter world experts participating 
Stakeholder 
involvement - expertise  
S3 Multidisciplinary 
Stakeholder 
involvement - expertise  
S24 Key experts involved 
Stakeholder 
involvement - expertise  
S37 
Involvement of a deeply knowledgeable group 
combining major academic [disease area] 
researchers and expert clinical research 
methodologists. 
Stakeholder 
involvement - expertise  
S19 experienced writing group 
Stakeholder 
involvement - expertise  
S13 Panellists skills and experience 
Stakeholder 
involvement - expertise  
S56 
group of experts with research and clinical 
experience 
Stakeholder 
involvement - expertise  
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S56 mixed qualitative and quantitative researchers 
Stakeholder 
involvement - expertise  
S21 
panel of experts all had experience both in 
treating [disease name] but also in doing 
interventional studies in [disease name] 
Stakeholder 
involvement - expertise  
S14 stakeholder involvement 
Stakeholder 
involvement - general  
S40 A strong group of authors 
Stakeholder 
involvement - general  
S43 Collaboration with bioinformatics groups. 
Stakeholder 
involvement - general  
S25 
inclusion of industry scientists as full participants 
from the start 
Stakeholder 
involvement - industry 
S37 
The study reflected input from leading industry 
representatives. 
Stakeholder 
involvement - industry 
S70 
We had someone from the pharmaceutical 
industry who also have an interest in endpoints 
Stakeholder 
involvement - industry 
S66 Broad group of professionals/researchers 
Stakeholder 
involvement - multiple 
stakeholder groups   
S49 Broad range of experts and professionals  
Stakeholder 
involvement - multiple 
stakeholder groups   
S34 wide participation - academia, industry, NCI, FDA 
Stakeholder 
involvement - multiple 
stakeholder groups   
S37 
Involvement of a deeply knowledgeable group 
combining major academic [disease name] 
researchers and expert clinical research 
methodologists. 
Stakeholder 
involvement - multiple 
stakeholder groups   
S56 
group of experts with research and clinical 
experience 
Stakeholder 
involvement - multiple 
stakeholder groups   
S21 
panel of experts all had experience both in 
treating [disease name] but also in doing 
interventional studies in [disease name] 
Stakeholder 
involvement - multiple 
stakeholder groups   
S36 different stakeholders groups 
Stakeholder 
involvement - multiple 
stakeholder groups   
S24 
Involvement of multiple stakeholders -regulatory, 
industry, academics, patient societies 
Stakeholder 
involvement - multiple 
stakeholder groups   
S65 different perspectives included 
Stakeholder 
involvement - multiple 
stakeholder groups   
S44 
The methods chosen allowed a patient-centred 
approach throughout 
Stakeholder 
involvement - patients  
S62 Representative body of international experts 
Stakeholder 
involvement - 
representative 
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S24 Key experts involved 
Stakeholder 
involvement - KOL 
S28 key opinion leaders involved 
Stakeholder 
involvement - KOL 
S44 
Prioritisation was systematically undertaken with 
patients 
Stakeholder 
involvement - patients  
S36 
lots of patients (compared to previous core 
outcomes projects) 
Stakeholder 
involvement - patients  
S48 patients involved 
Stakeholder 
involvement - patients  
S63 experts involved 
Stakeholder 
involvement - expertise  
S68 Everyone in the field participated 
Stakeholder 
involvement - general  
S37 
The study reflected input from a wider 
conference called to address the specific issues 
covered. 
Stakeholder 
involvement - general  
S47 facilitates research excellence Standardisation  
S31 Attempt to define a standard of measurement Standardisation 
S9 proposal of core assessment Standardisation 
S78 Proposed set of clinical outcome indicators Standardisation 
S10 
attempt to come up with a battery that could be 
done in a feasible time frame Standardisation 
S50 standardization Standardisation 
S27 Standardization Standardisation 
S72 
Agreed on the based metrics of success and 
failure that need to be reported Standardisation 
S14 
2 existing high profile core sets as basis for 
development Starting point 
S43 Refinement and extension of prior work. Starting point 
S24 Timely report Timely  
S42 timeliness Timely  
S48 
used in subsequent clinical trials, allowing 
metanalyses Uptake 
S60 Widely adopted Uptake 
S12 prospective validation Validation 
S72 
Agreed on how specific patient populations are 
defined Wider trial design  
S79 
Suggested change to duration of trial - initial 
response followed by maintenance of effect Wider trial design  
S45 
To raise awareness about all the issues that 
should be considered when planning trials in 
[disease area] Wider trial design  
S46 
We established a definition of who to include in 
child and adolescent [disease name] studies Wider trial design  
S39 
manualized therapy that was disseminated to 
other sites Wider trial design  
S39 
demonstrated significant effect size of therapy, 
despite small sample size Wider trial design  
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S81 
recognition of the empiricist vs rationalist basis 
for intervention (and trial) strategies Wider trial design  
S81 
recognition that [disease name] trials are never 
targeted to an individual’s phase of stage of 
injury Wider trial design  
S81 
recognition that RCTs were not the only useful 
trial strategy Wider trial design  
S74 measurable in large scale studies Wider trial design  
S50 consideration of the long-term exposure and risk Wider trial design  
S45 
High agreement with criteria to consider for 
eligibility and management of other drugs during 
trials Wider trial design  
S79 
Documented diagnostic strengths and 
weaknesses, representative sample selection 
needs, which PRO measures were appropriate for 
endpoints  Wider trial design   
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Appendix 7: COS developers’ responses to the survey question ‘What do you think were 
the main challenges of your study?’  
 
Respondent Challenge Category  
S7 Accessing participants; Accessing participants 
S4 achieving that consensus Achieving consensus 
S35 
Balancing the size of the group involved with 
achieving consensus in brief time available Achieving consensus 
S9 consensus inbetween authors Achieving consensus 
S5 developing consensus Achieving consensus 
S25 
no experience in consensus processes of this 
scope and sensitivity; Achieving consensus 
S14 getting consensus Achieving consensus 
S24 
lack of agreement between different regulatory 
agencies; Achieving consensus  
S68 reaching consensus Achieving consensus  
S43 Reaching consensus. Achieving consensus  
S37 
The guidelines included an efficacy effect size 
criterion, for which consensus proved difficult to 
achieve. Achieving consensus  
S54 
the main challenge was to reach a consensus on 
standards and definitions Achieving consensus  
S42 reaching consensus Achieving consensus  
S65 
some participants insisted in the instruments 
they developed and used Bias 
S63 expert biases Bias 
S1 
to deal with the different 
(hidden)agenda's/motivations of the 
professionals  Bias 
S6 Old methods ingrained Changing practice 
S60 Changing practice is difficult Changing practice 
S65 established routines in some centers Changing practice 
S65 
some participants insisted in the instruments 
they developed and used Conflict of interest 
S1 
to deal with the different 
(hidden)agenda's/motivations of the 
professionals  COI  
S6 Differences in opinions among the main authors Differences in opinion 
S31 Disagreement among experts Differences in opinion 
S72 Some disagreement among experts Differences in opinion 
S24 
lack of agreement between different regulatory 
agencies; Differences in opinion 
S18 Smoothing political differences Differences in opinion 
S51 differing opinions Differences in opinion 
S60 Experts are disinterested in others views Differences in opinion 
S62 Collaboration among international colleagues Different interests  
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with diverse interests 
S67 
different interests between industry and 
clinicians Different interests  
S20 
individuals who focus in biological versus 
behavioural measures of drug use Different interests  
S48 Dissemination  Dissemination 
S35 
Balancing what is important with what is feasible 
in a trial - patient, investigator burden feasible vs important  
S62 
Making the work relevant- we worked hard to 
hone the list to a manageable  realistic' level feasible vs important  
S9 find all relevant articles 
Finding relevant 
articles  
S63 heterogeneity General 
S45 Lack of gold standard outcome; General 
S60 
Conclusions are too general - overlook minority 
views Generalisability  
S74 patient reported outcomes How to measure 
S50 uncertainties of some of the laboratory methods How to measure 
S76 
Upon literature review it was clear there were 
minimal validated studies/outcomes How to measure  
S10 
the same kinds of measures do not uniformly 
apply to injury severity or chronicity or age across 
the spectrum, so this was addressed in later 
efforts; How to measure  
S10 
Versions of measures change over time (e.g., 
WAIS, etc.) which may necessitate substitution. 
Validation/evidence base vs availability/latest; How to measure  
S10 
The same kinds of measures were not always 
used across different populations (e.g., military vs 
civilian, sports-related versus other, etc.); How to measure  
S10 
considerations pertaining to international use 
(availability of measures in different languages, 
cultures, settings) How to measure  
S73 
heterogeneity in ascertainment of outcomes 
across studies; How to measure  
S45 
Relative Lack of trials with validated instruments 
to discuss; How to measure  
S45 
Lack of experience of some participants with 
some potential outcome measures ; How to measure  
S70 
Difficult to access the protocols of randomised 
trials to find how endpoints were actually defined 
and they were not always defined in the papers 
How to measure 
(definitions) 
S28 implementation Implementation 
S24 timing of implementation Implementation 
S37 
The American Academy of Periodontology felt 
that our group, and the American Dental 
Association, were usurping its prerogative. Implementation 
S15 Organizing stakeholders and including all views Including all views  
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S5 lack of available data Lack of data 
S71 Lack of data Lack of data 
S13 No full data available Lack of data 
S8 expert opinion with little data Lack of data  
S73 
lack of solid long term mortality data to correlate 
to nonfatal outcomes Lack of data  
S34 insufficient data in many areas Lack of data  
S70 Lack of data from randomised trials Lack of data  
S72 Lack of good data for some metrics; Lack of data  
S75 Lack of published evidence to validate outcomes Lack of data  
S24 
Lack of sufficient longitudinal/natural history data 
for all outcomes discussed; Lack of data  
S64 Limited literature to support recommendations Lack of data  
S51 weak evidence base; Lack of data  
S49 Weakness of primary research Lack of data  
S79 
Weaknesses in the literature, especially bias for 
specific theoretical models; Lack of data  
S23 Language difficulty; Language  
S61 Understanding across borders; Language  
S48 Multiple domains involved in disability 
Multiple domains 
important  
S25 
no experience in consensus processes of this 
scope and sensitivity; 
No 
experience/knowledge 
of COS development  
S48 No previous experience in the field 
No 
experience/knowledge 
of COS development  
S40 limited knowledge in the field 
No 
experience/knowledge 
of COS development 
S7 Absence of methodological guidance No guidance 
S67 never done before in this disorder Novel 
S25 
first of its kind, so everything was 'new', many 
things developed 'on the fly'; Novel 
S8 expert opinion with little data Opinion vs data  
S25 
finding the balance between expert opinion and 
data Opinion vs data  
S35 
Balancing what is important with what is feasible 
in a trial - patient, investigator burden Participant burden 
S65 heterogeneity of participants Participants 
S45 
Role of comorbidities confounding physician and 
patient related outcomes Participants 
S36 
keep participants motivated and chase them up 
to reply on questionnaires 
Participants - 
motivation  
S44 
How to label the outcomes important to patients 
- to use their own language or map onto existing 
outcomes? Patient involvement  
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S36 
explain outcomes and why this is important to 
non clinical participants (patients) Patient involvement  
S70 we did not have patient perspective Patient involvement  
S16 No patients involved Patient involvement  
S39 
patients with seizures cannot drive and may have 
to come from a distance for treatment Patient involvement  
S40 poor understanding of biology of disease 
Poor understanding of 
disease 
S44 
Some patients found it difficult to prioritise a 
large number of outcomes Prioritising outcomes 
S22 
Narrowing down the potential research 
outcomes to a small enough list  Prioritising outcomes 
S12 
data collection in a large number of centres 
(>100) Process 
S41 
Differences between trial sites in an international 
multicentre study Process 
S36 
keep participants motivated and chase them up 
to reply on questionnaires Process 
S23 
Ensuring that professional organizations 
distributed the survey to their members Process 
S18 
Teaching participating investigators about 
methods; Process 
S26 to structure the process; Process 
S30 valid interpretation of responses ; Process 
S30 
limiting responses to concise statements 
disallowed complex  discussion Process 
S42 volume of effort/review  Process 
S55 
Open ended question so no limit to the studies 
that could be included - difficult to know what to 
include and what not to Process  
S15 Organizing stakeholders and including all views Process  
S63 difficulty arranging meetings (annual) 
Process - Arranging 
meetings  
S62 
Making the work relevant- we worked hard to 
hone the list to a manageable  realistic' level Process - list  
S22 
Narrowing down the potential research 
outcomes to a small enough list  Process - list  
S79 
initial and final work done at a distance - 
collaborative meeting sponsored by ICSM led to 
specific recommendations from our discussions 
over 4 days; Process - remotely  
S27 Definition of critical questions Process - Wording  
S44 
How to label the outcomes important to patients 
- to use their own language or map onto existing 
outcomes? Process - wording  
S81 simplifying the outcomes 
Process (simplifying 
outcomes) 
S66 
Limited space to present the review (in 
conference proceedings) Publishing 
298 
 
S59 Getting subjects early in their disease course Recruitment 
S29 quick development of treatment options Keeping up to date  
S11 Covering more recent treatment areas Keeping up to date   
S21 
Y2K wiped out our longitudinal database of 
clinical measures Resources - IT  
S26 funding Resources - funding  
S3 Insufficient resources for systematic review Resources - general 
S66 Limited time/resources to undertake the review Resources - general  
S7 Managing Delphi process through ICT; Resources - IT  
S47 financial limitations for support of experts; Resources - money  
S35 
Balancing the size of the group involved with 
achieving consensus in brief time available Resources - time  
S47 time/availability of experts Resources - time  
S66 Limited time/resources to undertake the review Resources - time  
S43 Time required to complete the work. Resources - Time  
S56 staff time Resources - time  
S26 lengthy process; Resources - Time  
S61 Speed meant we made a few mistakes Resources - Time  
S10 
we did not have the time to do an EXHAUSTIVE 
literature review or coding of evidence base level; Resources - Time  
S23 Response rate; Response rate  
S35 
Balancing the size of the group involved with 
achieving consensus in brief time available Size of the group  
S79 
Small number of contributors - each had a lot of 
work to do Size of the group  
S36 
ensure the balance of clinicians and patients in 
the study is the same  Size of the group(s)  
S28 further validation Validation 
S44 
Some outcomes e.g. activities of daily living and 
independence may have a strong degree of 
overlap - testing required to create a robust core 
set Validation 
S53 
We realized that most outcomes had not been 
validated at that time. Validation 
S46 
Defining the age of onset and the definition of 
mania Wider trial design 
S45 
Variety of types of trials that could be done in 
this single disease; Wider trial design 
S78 
use CONSORT guidelines for outcomes in surgical 
trials Wider trial design 
S17 
we were to develop protocols to study drugs that 
had not had appropriate studies done in 
newborns Wider trial design 
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Appendix 8: COS developers’ responses to the survey question ‘What do you think were 
the main limitations of your study?’  
 
Respondent Limitation  Category  
S42 expert panels always have limitations (bias) Bias 
S63 expert biases Bias 
S5 
the heterogeneity of [disease name] and the need 
for different outcomes at different times and for 
different phenotypes of the disease Disease/population 
S24 
Lack of accurate estimate of pediatric [disease 
name] population Disease/population  
S77 The complexity of the particular patient group Disease/population  
S54 
the proposed definitions have not been backed up 
by the corresponding scientific societies Endorsement 
S61 
We have not canvassed the research community to 
see what they have thought about the consensus, 
although it is widely quoted  Endorsement 
S10 
the initial publication acknowledged a weakness in 
pediatric measures, so this was addressed in future 
efforts How to measure  
S21 PROs were in very early stage of development How to measure  
S21 
we went for response measure and should have 
also developed a state measure at the same time How to measure  
S45 
Lack of instruments validated in clinical trials to use 
in future trials ; How to measure  
S45 
Most outcome measures validated in observational 
studies; How to measure  
S48 Low responsiveness due to slow disease evolution How to measure  
S52 not all domains had instruments available How to measure  
S65 limited data about change sensitivity of instruments How to measure  
S10 
the project considered the application of these 
measures in populations of patients, but not 
necessarily in the selection of control groups for 
these How to measure  
S15 
Limited to endpoint definitions and did not include 
analysis methods How to measure  
S17 
no known norms for blood pressure in the very 
premature infant, that had not been determined How to measure  
S41 Statistical power to address subgroup analyses; How to measure  
S41 
Limited attention to rigorous assessment of patient-
centered outcomes How to measure  
S4 feasibility remains an unanswered question Implementation  
S38 
The recommendations will not necessarily be 
followed. Implementation  
S44 
Following on from 1) - this means that it is harder to 
get researchers and clinicians using the patient core 
set; Implementation  
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S67 
that despite firm recommendation industry 
developed own outcome Implementation  
S72 
A pre and post analysis has not been done to 
determine success of our guideline; Implementation  
S75 
Lack of ability to ensure that these outcomes will be 
used in clinical trials Implementation  
S37 
The work was sound, but the American Academy of 
[disease area] felt compelled to in essence redo and 
overwrite it with its own document. Implementation  
S5 
maintaining the difference between needs for trials 
outcomes (i.e. research) versus practice outcomes 
(i.e., monitoring disease in daily practice) 
Intended use (Trials 
vs practice ) 
S21 
performance of the core set and calculation of 
response not easily adapted to routine clinical care 
Intended use (Trials 
vs practice ) 
S5 lack of data to serve as an initial resource Lack of data 
S9 not confronted with studies Lack of data 
S12 lack of performance in other data set Lack of data 
S12 
lack of clinical trials in juvenile dermatomyositis and 
lupus Lack of data 
S13 Lack of comparative trials among some drugs Lack of data 
S29 missing randomized studies Lack of data 
S34 insufficient data in many areas; Lack of data 
S34 evidence base lacking for some decisions Lack of data 
S41 Limited breadth of data on risk factors; Lack of data 
S45 
Heterogeneity of previous trials that influenced 
discussions; Lack of data 
S3 Lack of systematic review Lack of data  
S6 Not always data driven Lack of data  
S6 
Unable to include data in development not 
validated Lack of data  
S24 
Lack of sufficient longitudinal/natural history data 
for all outcomes discussed; Lack of data  
S43 Only a portion of the knowledge base included. Lack of data  
S64 Limited evidence behind recommendations Lack of data  
S66 
Seen in a historic perspective, the underlying 
literature search was limited; Lack of data  
S70 Lack of data from randomised trials   ; Lack of data  
S70 Randomised trials were not mature; Lack of data  
S70 
randomised trials were historical and contemporary  
treatment  had improved; Lack of data  
S76 
Upon literature review it was clear there were 
minimal validated studies/outcomes Lack of data  
S11 
It was based upon my experience - as indicated it 
was not a study, but a review 
Lack of data (based 
on 
experience/opinion) 
S27 More consensus-based than evidence-based 
Lack of data (based 
on 
experience/opinion) 
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S28 at the end it is expert opinion, not evidence 
Lack of data (based 
on 
experience/opinion) 
S45 
Conclusions based more on expert view than trial 
data; 
Lack of data (based 
on 
experience/opinion) 
S68 Expert consensus approach 
Lack of data (based 
on 
experience/opinion) 
S56 
it was not designed as a study, rather a consensus 
from a group of experts - pragmatic approach 
Lack of data (based 
on 
experience/opinion) 
S30 
Some eminent surgeons and therapists could not 
participate due to language difficulties Language difficulties 
S23 Language difficulties Language difficulties  
S40 limited knowledge in the field Limited knowledge 
S60 Too focused on inflammation; Narrow focus 
S61 
We left out head injury when we should have 
included it and will update the measures; Narrow focus  
S62 The findings are applicable to our population Narrow focus  
S2 no golden standard available No gold standard  
S46 There is no gold standard to define those things No gold standard  
S45 
Results were not very specific but raised awareness 
about points to consider in trial design and  use of 
outcome measures that are validated Non-specific results  
S59 could have enrolled more subjects 
Number of 
participants 
S28 too few cardiologists; 
Number of 
participants  
S39 small sample size 
Number of 
participants  
S65 relative small number of experts; 
Number of 
participants  
S36 
although lots of patients replied to our project, their 
number was still lower than clinicians, hence 
possibly they were underrepresented 
Number of 
participants/Represe
ntativeness  
S44 
Despite efforts to recruit from minority groups, 
these were not well represented 
Number of 
participants/Represe
ntativeness  
S50 
complexity of the situations to apply the 
methodology Other 
S53 It was not a study Other 
S60 Over-emphasize drug effects; Other 
S79 
Specific agendas by some experts not included in 
this chapter; Other 
S5 
ultimately, the inability to recommend  a core 
outcome set, but rather limited to critiquing those 
commonly used outcomes at the time (1994/5) 
Inability to 
recommend a COS 
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S20 
rather than a single core set of measures to use 
across studies, aspects of  the study will determine 
which core measures from among a larger set will 
be used  Scope (study design)   
S31 Clinically unproven 
Lack of validation of 
COS 
S33 lack of preceding consensus 
Lack of preceding 
consensus 
S41 Differences between centres; Others 
S9 new studies have new challenges 
Out of date (keeping 
current/updated) 
S15 Dynamic field where outcomes of interest change 
Out of date (keeping 
current/updated) 
S21 
newer outcome measures and domains have 
developed since then 
Out of date (keeping 
current/updated) 
S48 Need to update ; 
Out of date (keeping 
current/updated) 
S51 outdated at this point; 
Out of date (keeping 
current/updated) 
S51 needs an update 
Out of date (keeping 
current/updated) 
S73 ever changing standard of care 
Out of date (keeping 
current/updated) 
S6 Did not address all of the intended issues Process 
S30 It did not allow for innovation; Process 
S35 
Did not provide a forum for external input to the 
consensus process Process 
S55 
Each study was not reviewed in a standardised 
way,; Process 
S55 Only English language literature Process 
S70 
Not sure we captured as many studies as we should 
in our searches because of different nomenclature Process 
S71 Nominal group methodology Process 
S79 
Much of the work was done while authors 
continued to do their full time work Process 
S23 Response rate; Response rate  
S22 
we were not able to consider procedures other than 
UAE Scope (intervention)  
S7 We need to reduce size of COS Size of COS 
S26 
even more perspectives needed, e.g. health 
authorities 
Stakeholders 
(general) 
S74  only professionals involved 
stakeholders 
(general)  
S47 
some experts who might have facilitated had other 
commitments 
Stakeholders 
(general)  
S72 Did not include representatives from industry 
stakeholders 
(Industry 
involvement)  
S78 view of other international experts also needed; stakeholders 
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(international)  
S1 limited patient involvement 
stakeholders (Patient 
involvement)  
S8 lack of patient input 
stakeholders (Patient 
involvement)  
S16 no patients involved 
stakeholders (Patient 
involvement)  
S18 
Lack of direct patient input (we are addressing that 
now) 
stakeholders (Patient 
involvement)  
S25 no patient involvement (solved in 2002); 
stakeholders (Patient 
involvement)  
S35 Did not include patient advocates; 
stakeholders (Patient 
involvement)  
S36 
although lots of patients replied to our project, their 
number was still lower than clinicians, hence 
possibly they were underrepresented 
stakeholders (Patient 
involvement)  
S44 
It would have been preferable to include the patient 
perspective at the time of the original development 
of the core set rather than later; 
stakeholders (Patient 
involvement)  
S44 
Following on from 1) - this means that it is harder to 
get researchers and clinicians using the patient core 
set; 
stakeholders (Patient 
involvement)  
S49 
Unable to include forensic mental health service 
users 
stakeholders (Patient 
involvement)  
S56 
if designed as a study would include a greater range 
of stakeholders including patients and families 
stakeholders (Patient 
involvement)  
S60 Overlook important benefits to patients 
Stakeholders (Patient 
involvement)  
 
S61 
We did not have a multi-layered patient 
involvement process, we selected measures that 
had been developed through patient involvement; 
stakeholders (Patient 
involvement)  
S66 No patient representative; 
stakeholders (Patient 
involvement)  
S70 No patient perspective; 
stakeholders (Patient 
involvement)  
S25 limited regulatory involvement 
stakeholders 
(Regulatory 
involvement)  
S9 theoretical proposition 
Theoretical - discuss 
with lack of data? 
S66 
A theoretical overview and not an empirical study of 
papers/reports 
Theoretical - discuss 
with lack of data? 
S81 conceptual not a trial 
Theoretical - discuss 
with lack of data? 
S74 no validation of outcomes data set Validation 
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Appendix 9: COS developers’ responses to the survey question ‘Reflecting on your 
experiences of developing a core outcome set, are there any areas that you feel would 
benefit from methodological guidance or research to inform future activity to develop 
core outcome sets?’  
 
Respondent  Guideline requirements  Category  
S64 The ability to deliver international registries Application of COS  
S7 what is consensus Consensus methods  
S12 consensus formation techniques Consensus methods 
S44 
Noticed with others developing core sets - lots of 
confusion about consensus levels for Delphi/ NGT Consensus methods 
S27 
Structured method for selection of experts and 
reaching consensus Consensus methods 
S25 
We've now developed OMERACT Filter 2.0 that is 
highly relevant to all COS developers. This, or 
something strongly like it, should be adopted by 
COMET ASAP. COS developers need concrete 
guidance NOW Consensus methods   
S7 homogenous versus heterogeneous samples; Consensus methods 
S23 Selecting potential outcomes Consensus methods 
S42 
including other methodology experts to observe 
for potential bias; Consensus methods  
S18 
Better definitions of what domains and sub-
domains are in this context Outcome terminology  
S38 
There could be general guidelines about defining 
types of outcomes. Outcome terminology  
S7 All aspects; General  
S31 
Absolutely, any additional guidance possible offers 
best hope of developing appropriate guidelines General  
S36 systematic approach; General  
S37 
The guidelines development effort was led by 
research methodologists, most specifically myself, 
and had ample external methodological advice 
available General  
S54 
probably, this is not my main focus of expertise 
anymore General  
S61 
I don't think it is rocket science, but guidance 
would be good; General  
S61 
I think guidance needs to reflect the practicalities 
of making decisions based on imperfect 
information; General  
S61 
I don't think that guidance should be too 
constraining, there are many ways to skin a cat; General  
S63 probably General  
S66 
This field is to me a moving target with constant 
need of overview and deliberations; General  
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S67 guidelines for optimizing the process General  
S65 
for a next step methodological guidance might be 
useful General  
S10 use of evidence-based guidelines General  
S4 
we don't know what a clinically meaningful effect 
size will be How to measure  
S5 
there still (nearly 20 years later) needs to be 
informative and useful data on such issues as 
biomarkers (lab-based and imaging) How to measure  
S5 
more data still needed on interface between MRI 
and clinical outcomes How to measure  
S5 
more flexibility on the part of regulators on 
surrogacy and use of MRI as a surrogate outcome How to measure  
S6 More quantitative than qualitative assessments How to measure  
S21 
response measure versus status measure choice in 
design stage How to measure  
S45 
Having more clinical trial data to assess how 
individual outcome measures and composite 
indices worked would help; How to measure  
S60 Better generic health status measures; How to measure  
S60 Simpler ways to capture cost-effectiveness How to measure  
S70 PROMS How to measure  
S74 
integrating clinic and patient perspectives into 
composite outcomes How to measure  
S76 The outcome measures need to be validated first,; How to measure  
S76 
Then you might be able to develop a composite 
outcome How to measure  
S77 There are several severity scores in use; How to measure  
S77 The outcome death/survival may be same  How to measure  
S77 but risk predictions may differ and level of risk; How to measure  
S77 
may be consequence of the particular severity 
score. How to measure  
S48 
Advice on how to make regulatory agencies use 
the core set Implementation  
S66 
The relation/balance between (masses of) core 
outcomes and specific results related to the 
hypothesis tested sometimes difficult Implementation  
S72 Pre and post analysis  Implementation  
S47 
ensure endorsement mechanism is in place in 
advance Implementation   
S8 
define different approaches and pros and cons of 
each Methods 
S48 Advice on choice of method; Methods 
S51 gleaning methods from other diseases Methods 
S62 Focus group methods; Methods 
S78 
Yes. Methodology recommendations, like those 
available for guideline development Methods 
S36 which method to use ( Delphi, focus groups etc); Methods  
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S34 more data More data  
S36 
what are the criteria for consideration of a core 
outcomes project as valid Quality assessment 
S35 
Need to demonstrate the validity and utility of the 
recommendations; Quality assessment  
S43 Constant review, refinement, and updating. Review and feedback  
S3 Systematic review SR 
 
include other librarian to shoot literature search 
separately and look for degree of agreement SR 
S55 
Guidance on developing a clear rationale for study 
inclusion SR 
S23 
Inviting participants to act as stakeholders in the 
development of the recommendations. 
Stakeholder 
involvement  
S27 
Structured method for selection of experts and 
reaching consensus 
Stakeholder 
involvement  
S30 
The choice of participants for a Delphi study 
should be made by a group of independent 
observers ; 
Stakeholder 
involvement  
 
Independent observers that should be tasked to 
choose Delphi participants should be guided by 
patients 
Stakeholder 
involvement  
S32 Input from multiple perspectives 
Stakeholder 
involvement  
S35 
Involvement of external groups to increase 
acceptance 
Stakeholder 
involvement  
S36 how to identify participants; 
Stakeholder 
involvement  
S38 
There could be general guidelines about defining 
participant populations and recording of 
sociodemographic factors. 
Stakeholder 
involvement  
S39 
having a patient group that discusses relevant 
outcomes 
Stakeholder 
involvement  
S44 
More discussion about including minority patient 
participants in the process; 
Stakeholder 
involvement  
S45 
Need international panel from worldwide 
research community with relevant experience of 
undertaking and analysing trial data 
Stakeholder 
involvement  
S48 Advice on choice of participants and stakeholders; 
Stakeholder 
involvement  
S51 
increase input from patients and patient advocacy 
organizations 
Stakeholder 
involvement  
S62 
How to better incorporate patients at an 
appropriate level and time 
Stakeholder 
involvement  
S73 need to incorporate patient perspective 
Stakeholder 
involvement  
S79 
Include individuals from interested agencies 
FDA/EMA, NIH 
Stakeholder 
involvement  
S44 
Guidance on wording of outcomes and domains 
when including patients in the process; Wording 
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Appendix 10: Relevant qualitative training  
 
Introduction to Qualitative Interviewing course; completed 2012 (University of Oxford) 
Analysing Qualitative Interviews course; completed 11-12 April 2013 (University of Oxford)  
MEDR628: Epistemological and Methodological Approaches to Qualitative Research on 
Medicine, Health & Society 12 week lecture series; completed 2013 (University of 
Liverpool)   
MEDR629: Qualitative Research Methods – Methods workshops; completed July 2013 
(University of Liverpool)   
Introduction to NVivo for qualitative data analysis; completed March 2014 (University of 
Liverpool)  
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Appendix 11: Version 1.0 of the interview topic guide 
 
Topic Guide for interviewing researchers  
This topic guide outlines the questions and prompts that may be used during the 
interviews. It may be adapted as the study proceeds according to participant’s needs and 
responses, as well as the emerging analysis.  
 
Introduction 
Explanation of the context of the study and terminology being used (emphasise that the 
focus is on ‘what’ part of core outcome set development not ‘how’)  
Explain that all q’s in relation to study/project [title] 
 
Main discussion  
Background 
 
1. Tell me about your role in the development of this core outcome set  
 How did you become interested in developing a core outcome set in [clinical 
area] 
 Had you worked on a core outcome set previously?  
 
2. Tell me about your research [title] 
 What were the main objective/aims? 
 Were there any secondary aims?  
 If so, what were they  
 
3. How did this study come about?  
 What was the motivation  
 What was your motivation for getting involved  
 What was the current situation/environment  
 What was already known  
 Did anything else influence your initial thinking  
 
4. What role did each individual have in the planning of this work   
 Your role in the planning of this work  
 Who else was involved, and what were their roles  
 Were any patient or public research partners involved in the planning of the 
work? 
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 If so, tell me about it  
 
Choice of methods  
5. Can you talk me through the planning of this project  
 Was there a protocol? 
 Did you consider the scope of the core outcome set (e.g. all interventions, 
specific intervention etc.)? 
 Was this at the planning stage or come later? 
 How did you make the final decisions on what scope to cover? 
 
6. Was the study funded? 
 
 Who funded the project? 
 Tell me about the funding 
 How easy/difficult was it to obtain funding for this work? 
 Did any funders turn the proposal down?  
 Did you receive any advice about how to get funding? What? Who from? Was 
this useful?  
 How did you decide where to apply?  
 Did you use other resources to get the project done? 
 If so, what were they?  
 
7. Can you tell me about the methods you used? 
 How did you decide on the methods to use – why this/these method? 
 Any pilot work?  
 Did the methods differ by stakeholder group?  
 What influenced this approach? 
 Previous work  
 Clinical area 
 Experience of methods  
 Who influenced this  
 Who made the final decision on the methods?  
 Did you consider using any other methods? 
 If not, why? 
 If so, which ones? Why did you decide not to use them?  
 
8. Do you think that the available resources influenced the methods you used?  
 If so, how? 
 If not, why?  
 
9. Did the methods change throughout the process? 
 If so, how? 
 Why do you think that was/wasn’t? 
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10. Did you experience any difficulties in maintaining interest in the process? 
 E.g. if it was lengthy, required input on more than one occasion 
 Consider patient involvement   
 
 
Choice of stakeholders to include  
 
11. Who was included in the development of this core outcome set? 
- Be clear they understand as participants not as members of research team   
 
12. How did you decide who to include in this work?  
 E.g. important, resources etc.  
 Was this easy/ difficult?  
 
13. How did you decide how many and the proportions of different types of people to 
include? 
 What was the response rate to the research team's invitation to participate? 
(Different for different groups)?  
 
14. Did you end up including the numbers and proportions you intended? 
 
15. How did you explain the study to different groups? 
 Did you have to explain things differently to patients? 
 Were there misunderstandings and how were these dealt with?  
 
16. Did you think about including any groups that you didn’t end up including? 
 Key stakeholder groups e.g. patients/PPI, clinical experts, industry 
representatives, authorities (e.g. governmental, regulatory).  
 Why were they not included?  
 Did you try to include them but they declined, or did you decide not to 
include them? 
 
17. How did you decide to integrate opinions from different stakeholders?  
 If used a single heterogeneous panel, did you examine differences of opinions 
between groups?  
 Was this considered?  
 
 Had you included strategies to cope with disagreements when planning the 
project? 
 If not, why not? 
 If yes, what strategies did you include? 
 
 Were there any disagreements? 
 If so, how was this handled?  
 If you got differences what did you do? 
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 Did these considerations influence the methods you used then?  
 
Process and methods of analysis  
18. How did you decide what information (if any) to give to participants before the 
process?  
 
19. How did you decide on how outcomes would be scored or rated during the consensus 
exercise or at each stage in the process?   
 
20. Did you adopt a particular definition for consensus?  
 
 If not, was this considered?  
 If yes, when was the definition decided (for example at the protocol stage, 
during the rating/scoring or analysis stage?)  
 And what was the rationale behind that definition?  
 
21. How did you decide the procedure for determining how outcomes would be included 
or excluded from consideration at each stage of the consensus process?  
 
22. How did the researchers ask the question(s) about outcomes?  
 
 What was the specific wording? 
 Did you do this differently for different stakeholder groups?  
Results  
23. What did you think about the content of the core outcome set at the end of the study? 
 Were the final outcomes in the COS anticipated by you? 
 Why/why not?  
 Were the final outcomes in the COS anticipated by others involved in initiating 
the project? 
 Why/why not? 
 Can you tell me about one outcome that was included and you were confident 
it would be at the outset? 
 Can you tell me about one outcome that was included and you were confident 
that it would not be at the outset? 
 Can you tell me about one outcome that was not included but which you were 
confident would be included at the outset? 
 Why do you think these three examples went the way they did? 
 
 
24. What influenced the final choice of outcomes to include in the final core outcome set? 
 Did you consider having short term and long term and Patient Reported 
Outcomes all within a COS? 
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 Do you think it is possible to include these in the same core outcome 
set? 
 
25. Were there differences in the outcomes identified and thought to be important by 
different groups? 
 What outcomes did patients identify as important that clinicians didn't?  
 What was the same?  
 What did clinicians say was important that patients didn't? 
 
26. Did the development of this core outcome set change anything? 
 Influence the research community in this area 
 If so, how? 
 If not, why? 
 If definitive yes or no given, what’s your evidence source for this?  
 
 
27. Did the results influence your thinking? 
 If so, how? 
 If not, why not?  
Publication 
We want to find out about your experience of getting this work published so that we can 
help others with getting this type of study published.  
28. Can you tell me about the publication process for this project  
 Did you use any reporting guidance?  
 How was the decision made regarding choice of journal?  
 Were any problems encountered?  
 Was the paper accepted by first journal?  
 If not, which journal(s)? 
 If not, what reasons were given for this?  
 Did the reviewers/editors have any influence on the final format/content of 
the paper?  
 If so, how? 
 
General  
29. What (if any) have you experienced to be the challenges of this work? 
 
30. What (if any) have you experienced to be the benefits of this work? 
 What do you think they will be? 
 
31. Would you do anything differently?  
 (Additional stakeholders, different choice of methods...) 
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32. Were there any areas particularly that you felt would benefit from methodological 
research?  
 Do you think you would have benefited from guidance in developing a COS?   
 If so, what? 
 If not, why? 
 
33. Did you go as far as to consider the implementation of your core outcome set? 
 Can you tell me about it 
 What did you do? 
 What was successful? 
 Have you experienced/anticipate potential barriers to implementation? 
 
34. Do you think there were any limitations to your work?  
 (E.g. stakeholders included, geographical coverage, lack of anonymity etc.)  
 
35. What do you think are the implications for future research?  
 Do you have plans to review the COS?  
 If so, how? 
 Funding  
 Who – individuals, organisations?  
 What would make you decide to start the updating? 
 If not, why not?  
 
36. What impact do you think this work will have? 
 Who are the key groups that should benefit from this work? 
 What do you consider its relevance to these key groups? 
 E.g. patients and the public, healthcare providers, researchers, 
pharmaceutical companies, device manufactures, policy makers  
 Will you assess this?  
 If so, how? 
 If not, why not?  
  
37. What is it intended the core outcome set is used for? 
a. Do you consider the results of this study to be applicable beyond use in clinical 
trials? E.g. systematic reviews, clinical practice, clinical guidelines  
 
  If so, what?  
 If not, why not?  
 
 
38. Do you think there were any conflicts of interest within the study team?  
 (e.g. researchers who have developed an outcome measurement instrument 
applicable to the scope of the COS) 
 Or industry wanting shorter term outcomes to be included rather than longer 
term outcomes (because cheaper?)  
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39. Do you plan to work on another core outcome set? 
 If you did work on another core outcome set (whether or not you plan to), can 
you tell me about anything that you would definitely want to do in the same 
way? 
 And about anything that you would definitely want to do in a different way? 
 
 
Other issues 
 
40. Are you still in touch with the patients or members of the public included in the study?  
 
41. Would you like to receive a copy of the publication?  
 
That’s the end of my questions.  
42. Is there anything else that is important to you that we haven’t talked about today? 
 
43. Is there anything else you’d like to say? 
 
………………………………………………………………………………………… 
Close interview 
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Appendix 12: Invite email 
Date  
Dear [lead author] 
I am a PhD student working with Professor Paula Williamson (Department of Biostatistics) and 
Professor Bridget Young (Department of Psychological Sciences) at the University of Liverpool, UK. I 
am based within the Medical Research Council Network of Hubs for Trials Methodology Research, 
and I’m also the Project Coordinator for the COMET (Core Outcome Measures in Effectiveness Trials) 
Initiative. The COMET Initiative brings together researchers interested in the development and 
application of agreed standardised sets of outcomes, known as a ‘core outcome set.’ More 
information about the COMET Initiative can be found from http://www.comet-initiative.org/.    
I’m conducting a study that aims to assist the research community by informing the development of 
guidance standards for core outcome set development. We have recently completed a systematic 
review to identify studies that have been conducted to determine the outcomes or domains to 
measure in clinical trials. The major focus of my study is to improve our methodological 
understanding by exploring researchers’ experiences and views of core outcome set development 
and implementation.  
We read with interest your study [title] published in [journal title] which was included in our 
systematic review. You have been asked to take part in this study because you are or have been 
involved in research to determine the outcomes or domains to measure in clinical trials, and your 
experiences are therefore very important to us. We would like to learn from your experiences and 
incorporate what we learn into guidance to assist future researchers.  
I would be grateful if you would be willing to be interviewed by telephone about your experiences. If 
you would like more information about the project one of my supervisors or myself would be happy 
to talk by phone or email. If you are happy to participate, any information you provide would remain 
anonymous and would be combined with information provided by other researchers who also take 
part.  
Please can you let me know if you would be willing to be interviewed? I will then contact you again, 
to arrange a convenient time to carry out the interview.  
I am most appreciative of your help and I look forward to hearing from you soon.  
Yours sincerely  
Elizabeth Gargon 
*************************************************** 
Elizabeth Gargon 
COMET Project Coordinator 
Department of Biostatistics, University of Liverpool, 1
st
 floor Duncan Building, Daulby Street, 
Liverpool, L69 3GA 
e-mail: e.gargon@liv.ac.uk 
Tel:  +44(0) 151 706 5955 
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Appendix 13: Participant information sheet 
 
 
Exploring researchers’ experiences and views of core outcome set development and 
implementation 
 
You are being invited to take part in a research study 
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully, and ask if you would 
like more information or if there is anything unclear or you don’t fully understand. Feel free 
to discuss this with colleagues or others if you wish.  
 
Who is doing the research? 
Elizabeth Gargon, PhD student in the Department of Biostatistics at the University of 
Liverpool, will be carrying out the interviews.  
I am a PhD student funded by the Medical Research Council Network of Hubs for Trials 
Methodology Research.  My supervisors are Professor Paula Williamson, Department of 
Biostatistics at the University of Liverpool, and Professor Bridget Young, Department of 
Psychological Sciences also at the University of Liverpool.  
What is the purpose of the study? 
This study will contribute to a larger research project that is aiming to develop 
methodological guidance for core outcome set development. In order to formulate 
guidance in this area we need to try to understand what factors have informed the ways in 
which researchers have developed core outcome sets.  We would like to learn from your 
experiences and incorporate what we learn into guidance to assist future researchers. 
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Why have I been chosen to take part? 
You have been asked to take part in this study because you are or have been involved in 
research to determine what outcomes or domains to measure in clinical trials. Your 
experiences are therefore very important to us.  
Do I have to take part? 
No. Your participation is entirely voluntary. If you decide to take part, you will be asked to 
sign a consent form. If you decide later on that you wish to withdraw from the study then 
you can leave up until the point of interview transcript anonymisation, and you do not 
need to give a reason.  
What will happen if I take part? 
The interview will involve you speaking to the researcher about your experiences of 
conducting research to determine what outcomes or domains to measure in clinical trials. 
The interview will last approximately 45 minutes to an hour. With your permission, the 
interview will be audio-recorded. You can stop the interview at any time, and you do not 
have to answer a particular question if you don’t want to.  
Where will the interview take place?  
The interview will be conducted by telephone, at a time and date convenient to you.  
Are there any risks in taking part? 
We do not expect there to be any risks or discomfort to be associated in this research 
study. However, if you feel uncomfortable then you can stop the interview at any given 
time and without providing a reason.  
Are there any benefits in taking part? 
You will be helping with a new area of research. Your experiences will help us to learn 
about what methods are most helpful in determining which outcomes or domains to 
measure in clinical trials. We hope this study will help to improve this process in the future.  
What if there is a problem? 
If you have a concern about any aspect of this study, please feel free to let us know by 
contacting the lead researcher, Elizabeth Gargon, who will try to help and answer your 
318 
 
questions. If you remain unhappy or have a complaint which you feel we cannot deal with, 
then you can contact the Research Governance Officer at the University of Liverpool 
ethics@liv.ac.uk, 0151 794 8290. When contacting the Research Governance Officer, please 
provide details of the name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
Will my participation be kept confidential? 
All of the information that you give us will be kept strictly confidential. Only Elizabeth 
Gargon will have access to any information about you. My supervisor, Bridget Young, may 
listen to a recording of the interview to advise on my interview technique. The audio-
recordings of the interviews will be marked with a number only. These audio recordings will 
be transcribed but identifying details such as place and person names will be removed from 
the transcripts. Only details necessary for interpretation (e.g. clinical area) will be kept in. 
We may use brief quotes from your interview in the write-up of the study. We will ensure 
that identifiable details (e.g. person and place  names) have been removed, although it will 
be necessary to indicate the general clinical areas in which core outcome set work has 
taken place. All the information that you provide during the study will be stored in locked 
filling cabinets and/or password protected computers.  
At the end of the study, audio recordings will be destroyed. All other research data 
(consent forms, anonymised interview transcripts, field notes, and contact details) will be 
kept in locked filing cabinets and/or password protected university computers for ten 
years.  
 
Will my taking part be covered by an insurance scheme? 
 
Participants taking part in a University of Liverpool ethically approved study will have cover. 
 
What will happen to the results of the study? 
The results will be written up as part of Elizabeth Gargon’s postgraduate research thesis 
and submitted for examination. The findings will also be published in academic journals 
and presented at conferences. If you wish, you will be provided with a summary of the 
findings at the end of the study and a copy of the final research report.  
319 
 
What will happen if I want to stop taking part? 
If you decide that you no longer want to take part, then you can stop up until the point of 
interview transcript anonymisation and do not need to give a reason for doing so. Results 
up to the period of withdrawal may still be used. Otherwise you can ask for your data to be 
removed from the study and destroyed.   
How can I find out more? 
Get in touch with the researcher, Elizabeth Gargon:  
Elizabeth Gargon 
Department of Biostatistics, University of Liverpool, 1st floor Duncan Building, Daulby 
Street, Liverpool, L69 3GA 
e-mail: e.gargon@liv.ac.uk 
Tel:  +44(0) 151 706 5955 
 
The contact details of my supervisor are: 
Paula Williamson  
Department of Biostatistics, University of Liverpool, 1st floor Duncan Building, Daulby 
Street, Liverpool, L69 3GA 
e-mail: prw@liv.ac.uk  
Tel:  +44(0) 151 706 4958 
 
 
Thank you for reading this information sheet. 
This is your copy to keep; please retain for your records. 
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Appendix 14: Consent form 
 
 
Exploring researchers’ experiences and views of core outcome set development and 
implementation 
Researcher: Elizabeth Gargon 
 
          
Participant Name                                                             Date                          Signature 
 
      
     Researcher                                                               Date                       Signature 
 Please 
initial box 
1. I confirm that I have read and have understood the information sheet dated 
[DATE] for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw up 
until the point of interview transcript anonymisation without giving any 
reason, without my rights being affected.   
 
3. I understand that, under the Data Protection Act,  I can at any time ask for access 
to the information I provide and I can also request the destruction of that 
information if I wish. 
 
4. I understand that quotes from what I say during the study may be used where 
necessary, on the condition that my identity remains anonymous.   
5. I agree to the interview being audio-recorded.  
 
6. I agree to take part in the above study.    
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Please complete this form and return it to e.gargon@liv.ac.uk. The researcher will then sign 
the form, and a copy of the completed consent form will be returned to you.   
 
The contact details of lead Researcher are: 
Elizabeth Gargon 
Department of Biostatistics, University of Liverpool, 1st floor Duncan Building, Daulby 
Street, Liverpool, L69 3GA 
e-mail: e.gargon@liv.ac.uk 
Tel:  +44(0) 151 706 5955 
 
The contact details of my supervisor are: 
Paula Williamson  
Department of Biostatistics, University of Liverpool, 1st floor Duncan Building, Daulby 
Street, Liverpool, L69 3GA 
e-mail: prw@liv.ac.uk  
Tel:  +44(0) 151 706 4958 
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Appendix 15: Summary characteristics of interviewed COS  
 Published (n=18) 
Number of COS 
Ongoing (n=14) 
Number of COS 
TOTAL (N=32) 
Number of COS 
Methods used (not mutually exclusive) 
Systematic/literature  review  7 8 15 
Delphi 7 10 17 
Semi structured group discussion* 10 6 16 
Consensus development conference 2 0 2 
Nominal group technique  1 0 1 
Focus groups 0 3 3 
Survey 2 2 4 
Unstructured group discussion** 1 0 1 
Interviews 0 5 5 
Methods not described 1 2^ 3 
People involved  
Clinical expert (no PPI) 9 2 11 
PPI  8 12 20 
Not described  1 0 1 
Study aims  
Outcomes only 11 12 23 
Wider trial design issues  7 2^^ 9 
How to measure  
What to measure only 8 12 20 
What to measure + discussion/consideration of 
how but no recommendation 
4 n/a 4 
What + how (done together) 5 1 6 
What + how (done in two stages) 1 1 2 
Population characteristics – Age 
All  1 1 2 
Children 4 3 7 
Adults  3 10 13 
Not specified  10 0 10 
Intervention characteristics  
All  3 8 11 
Drug  4 0 4 
surgery  0 5 5 
Specific (other)  3 1 4 
Not specified  8 0 8 
Number of COS/disease category  
Clinical area where more than 5 14 11 25 
Clinical area where less than 5 4 3 7 
Funding  
Commercial  3 0 3 
Non-commercial 7 13 20 
Commercial and non-commercial  3 0 3 
No funding  1 1 2 
Not reported  4 0 4 
Plans to review/update  
Yes 1 n/a 1 
No 17 n/a 17 
Year of earliest publication  
Pre 2010 4 n/a 4 
2010-2013 14 n/a 14 
Ongoing  n/a 14 14 
 
*Descriptions included workshop, meeting, and roundtable  
** Descriptions included task force, work group, working group/party, committee, board, and panel 
^ Consensus methods, in addition to systematic review, were not known prior to interview  
^^ Part of a wider PhD  
 
323 
 
Appendix 16: Copy of publications arising from the work in this thesis  
References for the relevant articles are provided and copies included.  
 
Chapter 2  
The work contained in chapter 2 has been published in BMC Medical Research 
Methodology: 
Gargon, E., P. R. Williamson, et al. (2015). "Collating the knowledge base for core outcome 
set development: developing and appraising the search strategy for a systematic review." 
BMC Med Res Methodology 15(1): 26. Highly accessed. 
 
Chapter 3 
The work contained in chapter 3 has been published in PLoS One:  
Gargon, E., B. Gurung, et al. (2014). "Choosing important health outcomes for comparative 
effectiveness research: a systematic review." PLoS ONE 9(6): e99111. 
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party material: 
 
Gargon, E., P. R. Williamson, et al. (2015). "Collating the knowledge base 
for core outcome set development: developing and appraising the 
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DOI: 10.1186/s12874-015-0019-9 
This text box is where the unabridged thesis included the following third 
party material: 
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